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Abstract 
 
Understanding the relationship between molecule structure and function underpins both 
biochemistry and chemical biology, and has enabled the discovery of numerous agricultural, 
diagnostic and therapeutic agents. A subset of this chemical diversity is found in cysteine-rich 
proteins and peptides. By forming intra-molecular covalent disulfide bridges between their cysteine 
residues, monomeric peptides (up to about 50 amino acids in length) are able to adopt precise and 
stable globular conformations allowing interactions of high affinity with various molecular targets 
involved in the premise of specific biochemical pathways and physiological responses. 
 
The first part of this thesis work investigates the structure and function of secreted human cysteine-
rich mini-proteins. The design of a high-throughput algorithm allowed the isolation of 53 cysteine 
frameworks spread over 378 mature forms of secreted mini-proteins, from which all the metadata 
relative to these active regions were used for classifying them into 21 pharmacological families. A 
deeper analysis of the molecular targets of these cysteine-rich mini-proteins (up to 200 amino acid 
in length, containing an even number of cysteine <20 all engaged in intra-chain disulfide bridges) 
shows that they are frequently ligands for G protein- and enzyme-coupled receptors, transporters, 
extracellular enzyme inhibitors, and antimicrobial peptides. 
 
The second and third chapters rely on a large-scale analysis of the structure-activity relationships of 
cysteine-rich venom peptides, with an emphasis on molecules specifically directed toward targets of 
the nociceptive pathways. These analyses demonstrate the preference for recruitment into the 
venom of highly stable peptides with particular cysteine scaffolds often cross-braced by one or 
more disulfide bridges that shape well-defined tertiary structures such as inhibitory cysteine knots, 
Kunitz inhibitor, Kazal, or WAP domains and dictate their specificity of action. This diversity of 
disulfide-rich architectures that confers venom peptides an important stability against enzymatic 
degradation or extreme pH and temperatures, has already served as templates for designing 
molecules of diagnostic and therapeutic interests such as anti-nociceptive or anti-cancer drugs 
directed toward GABA or natriuretic receptors, as well as sodium channels. 
 
The fourth chapter describes the conception of a high-throughput bioinformatic program, called 
ConoSorter, for fast and precise de novo identification and classification of toxins produced by 
venomous marine cone snails sequenced with next-generation transcriptomic and proteomic 
platforms. This published work notably shows the efficiency and specificity of two complementary 
searching strategies based on regular expressions and profile Hidden Markov Models that allow the 
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recognition of 100% of known superfamilies and classes with a minimum species specificity of 
99%. A re-analysis of the Conus marmoreus venom duct transcriptome also allowed the discovery 
of 158 new toxin sequences (106 confirmed by mass spectrometry), as well as 13 novel gene 
superfamilies. 
 
Finally, the last chapter of this thesis describes a high-resolution interrogation of the Conus 
episcopatus venom duct, salivary gland, and radular sac transcriptomes and proteomes, supported 
by a meticulous and efficient bioinformatics methodology. This work has by far unveiled the 
highest number of conopeptides discovered in a single Conus species to date, by revealing 3,305 
novel precursor conopeptide sequences identified from transcriptomic data, 144 of which validated 
by protein mass spectrometry. In addition, we describe for the first time a large population of 
venom peptides containing the pharmacologically active C-C-CC-C-C inhibitory cysteine knot (168 
molecules) or CC-C-C (45) cysteine frameworks. We also describe six cysteine frameworks novel 
to cone snails - four of which are ubiquitous in nature, one which is highly abundant in snake C-
type lectins, and one containing 10 cysteines which is previously undescribed. These data indicate 
that sequence hypervariablity of conotoxins originates from codon usage bias at the gene level, and 
support the creation of 16 novel cone snail gene superfamilies that could be directed toward new 
classes of targets. The novel conopeptides described here are strong candidates to act as molecular 
templates for the development of diagnostic and therapeutic tools. 
 
Taken together this thesis work depicts the journey of the biodiscovery of numerous novel toxin 
sequences, some of them characterized by unique cysteine scaffolds present in pharmacologically 
active molecules, and also demonstrates the power of the transcriptome/proteome sequencing and 
matching approach for detecting low expressed proteins and potential new drug leads. 
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  Proteins are biological macromolecules built from a combination of up to 20 different L-α-amino 
acids linked by covalent peptide bonds.1 In living organisms these molecules fulfill a wide array of 
functions and are involved in all the levels of cell functioning, such as metabolism, cell signaling, 
ligand binding, DNA replication, or cell structure.1 A sequence of amino acids (primary protein 
structure) is ‘folded’ into local secondary elements like α-helices, turns or β-sheets, which often 
reflects the physicochemical properties of the side chain of each amino acid.2 As a consequence, 
proteins fold into unique three-dimensional conformations that dictate their activity. Although these 
boundaries are not well defined, it is generally accepted that large proteins, also designated as 
polypeptides, usually contain at least 150 amino acid residues, whereas small proteins made of a 
maximum of 50 to 100 amino acids are referred as peptides or sometimes as mini-proteins as well.3 
Cysteine-rich proteins and peptides 
Cysteine-rich proteins are ubiquitous in nature. They can be found across the whole phylogenetic 
spectrum, including animals, plants, bacteria, or non-cellular entities like viruses. Following the 
translation of messenger RNA (mRNA), proteins containing cysteine amino acids can form strong 
covalent intra- or inter-chain disulfide bonds between their thiol groups (-SH).4 This post-
translational modification (PTM) increases the stability of their folded structures and improves their 
resistance against protease degradation (Figure 1).5, 6  
 
 
 
Figure 1 – Disulfide bonds. When oxidized the thiol group of cysteine residues form intra- (green) or inter-molecular (blue) 
disulfide bridges. 
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A common enzyme-assisted mechanism of disulfide bridge formation is via a thiol-disulfide 
exchange reaction.7 It involves sulfhydryl-containing substrates like glutathione, and is catalyzed by 
thiol-disulfide oxidoreductases such as Protein Disulfide isomerase (PDI). It usually takes place in 
the lumen of the rough endoplasmic reticulum (RER) or the inter-membrane space of mitochondria 
in eukaryotic organisms, and in the periplasm of prokaryotic cells. Because disulfide bonds are 
unstable in reducing media such as the cytosol, most of the cysteine-rich proteins and peptides are 
found embedded in outer membranes or secreted in the extracellular environment.8 
 
Although cysteine-rich peptides are involved in numerous biological processes, they usually appear 
to act as enzyme inhibitors, hormones, growth factors, host defense molecules, or toxins, and can 
selectively interact with a broad range of molecular targets such as cell membrane receptors, 
transporters, and can also modulate ion channel activities.9 Despite providing an enhanced stability 
to protein tertiary architectures, disulfide bonds also organize discrete parts of the molecule into 
conserved structural motifs (also called super-secondary structures) that share an identical 
arrangement of secondary elements and often similar functions.10 The cysteine framework is an 
important structural feature of small cysteine-rich proteins. It is usually defined as the combination 
of two elements: the cysteine pattern describing the location of the cysteine residues along the 
sequence (the number of amino acids between these cysteines being sometimes called loop); plus 
the cysteine connectivity that informs about the precise pair of cysteines forming a bridge. 
 
Through large-scale analysis of human and venom cysteine-rich peptides, it will be shown in this 
thesis how these cysteine scaffolds are crucial for maintaining precise three-dimensional shapes in 
peptides and how they display specific active amino acid residues in an optimized orientation in 
order to efficiently interact with a broad range of molecular targets.  
Peptide toxins 
Toxins are small molecules, peptides or proteins produced by uni- and pluricellular organisms 
belonging to various taxa (bacteria, fungi, plants or animals). They are mostly used for defense, 
predation and as a deterrent for competitors. All these molecules have been naturally optimized to 
perturb homeostasis once inoculated by contact, absorption or injection into the prey or predator 
tissues. Toxins vary greatly in their mode of delivery (e.g. passive secretion of accumulated 
lipophilic alkaloids in the skin of poison dart frogs; use of elaborated envenomation organs in 
snakes, scorpions or spiders), their action mechanisms (e.g. hemotoxins that disrupt red blood cells; 
necrotoxins that cause necrosis of various cell tissues; neurotoxins that specifically target animal 
Introduction 
 4 
nervous systems), and the type of macromolecules they interact with (ligand- or enzyme coupled 
receptors, transporters, ion channels, enzymes).11-13 
 
Peptide toxins define a well-known molecular subclass in venomics. Apart from a low quantity of 
compounds such as inorganic salts, small organic molecules or high molecular weight proteins such 
as enzymes, venoms mainly contain complex and abundant mixtures of cysteine-rich bioactive 
peptides (≤ 50 amino acids) and polypeptides (≤ 150 amino acids).14 With their conserved cysteine 
scaffolds, peptide toxins are usually small in size and display compact shapes that provide high 
stability and resistance against enzymatic degradation and tissue clearance. Moreover, their striking 
structural diversity combined with their high binding affinities and functional selectivity for precise 
subtypes of heterologous receptors like G protein-coupled receptors (GPCRs),15, 16 voltage- or 
ligand-gated sodium, potassium, calcium channels17-19, transporters20-22 or enzymes23-25 expressed in 
different animal body systems makes them a source of templates of unraveled richness for 
designing pharmacological probes or system-specific human therapeutics.26, 27 
Venomous marine cone snails and conopeptides 
Predatory marine snails from the genus Conus, typically called cone snails or cone shells, are 
venomous gastropod molluscs mainly found in tropical and subtropical shallow costal waters. These 
marine invertebrates have long been of interest because of the abundance and diversity of their 
venom peptides. Cone snails have also developed advanced defense and hunting strategies by using 
an extremely coordinated venom apparatus. When waterborne chemical signals from a prey or 
predator are sensed by the osphradium, a specialized chemoreceptory organ also called siphon, the 
searching behaviour begins with the release and extension of its proboscis (Figure 2A).28, 29 A single 
dart-like radula tooth stored in the radular sac is then filled with venom, tightly held to the proboscis 
by circular muscles and loaded in its lumen (Figure 2B & 2C).30 It is only when the tip of the 
proboscis comes in contact with the target organism that the attached radula tooth is rapidly 
propelled into the prey and acts as a hypodermic needle to inject the venom.31 This radula tooth then 
serves as a harpoon to bring the captured prey to the mouth of the snail. 
 
The venom apparatus of cone snails is composed of a long winding venom duct that contains toxins 
(also referred as the venom gland) connected in its proximal extremity to a large muscular bulb that 
triggers burst contractions in order to carry the venom toward the pharynx region where the 
oesophagus, salivary gland, radular sac and proboscis meet (Figure 2B). 
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The biochemical and cellular mechanisms of venom elaboration, including synthesis, processing 
and packaging of toxins into large secretory granules, still remain unclear. However, it has been 
demonstrated that epithelial cells bordering the venom duct are most likely considered as the site of 
production of venom toxins, which are then released into the gland’s lumen by holocrine 
secretion.32, 33 Also, it has been demonstrated that some components of the venom could also be 
synthesized, though to a much lesser extent, in the salivary gland.34 The venom duct of cone snails 
is a compartmentalized tissue where certain type of toxins, as well as particular enzymes involved 
in processing (such as protein disulfide isomerases, immunoglobulin binding proteins or peptidyl-
prolyl isomerases) are expressed preferentially in discrete parts of the duct.35  
 
 
 
Differences in the histological structure and morphology between the proximal (on the bulb side) 
and distal (on the pharynx side) parts of the venom gland can be noticed.36 A study conducted by 
Marshall et al. in Conus californicus, showed that these two distinct regions are composed of an 
outermost collagenous layer of connective tissue with a basal lamina in which rests a layer of 
epithelial cells facing the lumen of the duct, tightly held together by a complex system of cellular 
connections and tight junctions.32 
The proximal part possesses a unique architecture with a collagenous layer containing a few muscle 
cells and probably a few fibroblasts on its outer surface (Figure 3). The epithelium in this part is 
well organized and displays numerous mitochondria and nuclei concentrated on the basal surface of 
Figure 2 – Schematic representations of the cone snail anatomy (A), the venom apparatus (B) with the venom duct in green, the 
radular sac in blue, and the salicary gland in red, as well as a radula (C). 
A
Foot
Eye stalks
Siphon
Shell
Proboscis
B
Venom bulb
Venom duct Radular sac
Salivary gland
Salivary ductsPharynx
Oesophagus
Proboscis
Harpoons
C
Introduction 
 6 
the epithelial cells, whereas their apical surface terminates in dense microvilli. The lumen of this 
proximal region of the duct contains only a few uncommon venom granules, as well as some cell 
debris and mitochondria fragments probably originating from the distal part. 
 
 
The distal part of the venom duct connected to the pharynx is strikingly different when compared to 
the proximal region. The dimly demarcated luminal and lateral boundaries between the large and 
columnar epithelial cells make the epithelium poorly organised (Figure 4). Unlike the proximal part, 
cells with apical microvilli rich in mitochondria are absent, whereas numerous large intracellular 
venom granules can be observed. The lumen of the distal part also contains much more cellular 
debris and venom granules then in the proximal area. 
 
 
Finally, the anterior most part joining the venom duct to the pharynx through a complex and narrow 
branching channel in the pharyngeal wall is also composed of a unique type of epithelial cell. In this 
Figure 3 - Proximal part of the venom duct 
(Marshall J. et al. – 2002). Low-power light 
micrograph showing an overall view of the duct 
in this region (left panel). A collagenous layer 
(c) covers the epithelium (ep) composed of 
large cells with prominent nuclei (n). The duct 
lumen (l) contains noncellular material. Scale 
bar is 50 µm. Transmission electron microscope 
image focusing on apical edge of the epithelial 
cells and the lumen (right panel). Large 
amounts of cellular debris (cd) in the lumen and 
mitochondrial fragments (mt) can be observed, 
as well as cross sections of cilia (arrow) and 
sparse venom granules (g). Scale bar is 1 µm. 
 
Figure 4 - Distal part of the venom duct (Marshall J. et al. – 2002). Light micrograph of the collagenous 
layer (c), epithelial cells (ep), and venom granules (g) (left panel; scale bar is 50 µm). Transmission electron 
microscope image of the basal surface of epithelial cells, with the basal lamina (bl), and collagen fibrils (c) 
(right panel; scale bar is 1 µm). Profiles of neural processes (nv) containing dense vesicles are apparent. A 
portion of a venom granule is also visible (g). 
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region of the duct, venom granules are abundantly packed in the lumen but sparse inside the 
epithelial cells. 
 
According to these observations, Marshall et al. proposed a model of venom production and 
delivery: 
1) Toxins may be biosynthesized, then packed into granules in the intracellular compartment of the 
distal epithelial cells of the venom duct. 
2) Because this epithelium appears disorganized with a very thin and almost indistinctive apical 
membrane, the granules may be further released into the lumen according to a holocrine secretion 
mechanism in view of the presence of cell debris in the lumen as well. 
3) Then, a recycling of ions and small organic molecules coming from the cell debris could take 
place in the proximal part of the duct. These solutes may be actively transported from the lumen to 
the blood stream through the epithelial cells using energy provided by the numerous mitochondria 
in this region (the apical microvilli of the proximal epithelium increasing the surface of absorption). 
 
Cone snail species can be classified according to their diet as vermivorous (or worm-hunters), 
molluscivorous (mollusc-hunters), and piscivorous (fish-hunters). As they are only able to move 
along slowly and cannot swim, they developed extremely potent venoms which allow them to hunt 
and defend against a broad range of animals including worms, molluscs, bivalves, crustacea, 
cephalopods, echiuroids, hemichordata, and fast-moving organisms like fish.37 
The venom of cone snails is rich in small peptide neurotoxins (called conotoxins or conopeptides) 
from 10 to about 35 amino acids in length, which function on the prey as fast-acting paralysing 
drugs. More than 600 different Conus species are estimated to produce between 50 and 200 
conopeptides, yielding a library of more than 70,000 pharmacologically active peptides.38 Because 
of speciation, as well as a high rate of hypermutation and a remarkable number of PTMs, only little 
overlap of conopeptides exists between species.38-40 In venom-producing cells, the coding sequence 
(CDS – region delimited by a start and a stop codon) of the mature mRNA molecule is translated 
into a precursor conopeptide composed of three distinct regions: a N-terminal ER signal peptide; a 
central pro-peptide region; the C-terminal mature toxin (although sometimes the mature region can 
be located between the signal sequence and the pro-region). The signal peptides of precursor 
conopeptides are remarkably conserved compared to the two other hypervariable regions. This 
feature is used to classify the toxins into gene superfamilies (16 empirical ones named A, D, I1, I2, 
I3, J, L, M, O1, O2, O3, P, S, T, V, and Y; 13 minor ones for those identified in early divergent 
clade species; 10 recent ones discovered in the past two years named B1, B2, B3, C, E, F, G, H, K, 
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and N)41-49. Conopeptides are further divided into secondary classes according to the number of 
disulfide bridges they form and the redundancy of their cysteine frameworks (Table 1).45, 50 
 
 
Cysteine-rich mature peptides containing at least two disulfide bonds are called conotoxins, 
whereas those without or less than two disulfide bonds are subdivided into disulfide-poor 
conopeptide groups (contulakin, conantokin, conorfamide, contryphans, conopressins).51-55 
Furthermore, conopeptides are also classified into pharmacological families according to the type of 
target they specifically interact with (Table 2).45 
 
Finally, some recently discovered conotoxins that couldn’t unambiguously be incorporated into 
known superfamilies but that share common activities, signal regions, cysteine patterns or particular 
PTMs have been included into 9 additional classes: conodipine, conohyal, conolysin, conomap, 
conomarphin, conopeptide Y, conophan, conoporin, and conotoxin-like.34, 56-62 A summary of the 
most recent classification schemes is listed in Table 3. 
Table 1 – Conopeptide cysteine frameworks. Their cysteine patterns and 
connectivities are described. 
Framework Cysteine Pattern Cysteine Connectivities
I CC-C-C I-III, II-IV
II CCC-C-C-C -
III CC-C-C-CC -
IV CC-C-C-C-C I-V, II-III, IV-VI
V CC-CC I-III, II-IV
VI/VII C-C-CC-C-C I-IV, II-V, III-VI
VIII C-C-C-C-C-C-C-C-C-C -
IX C-C-C-C-C-C I-IV, II-V, III-VI
X CC-C.[PO]C I-IV, II-III
XI C-C-CC-CC-C-C I-IV, II-VI, III-VII, V-VIII
XII C-C-C-C-CC-C-C -
XIII C-C-C-CC-C-C-C -
XIV C-C-C-C I-III, II-IV
XV C-C-CC-C-C-C-C -
XVI C-C-CC -
XVII C-C-CC-C-CC-C -
XVIII C-C-CC-CC -
XIX C-C-C-CCC-C-C-C-C -
XX C-CC-C-CC-C-C-C-C -
XXI CC-C-C-C-CC-C-C-C -
XXII C-C-C-C-C-C-C-C -
XXIII C-C-C-CC-C -
XXIV C-CC-C -
XXV C-C-C-C-CC -
XXVI C-C-C-C-CC-CC -
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Biodiscovery of conopeptides: technologies and methods employed to date 
Traditionally, isolation of conopeptides is usually carried out from crude venom obtained either by 
dissection of the duct or according to the “milking” technique (Figure 5).63 The first method 
consists of dissecting the venom duct and extracting its content by squeezing. While this method is 
commonly used and supplies large quantity of venom, the crude material extracted may contain 
many contaminants (such as unprocessed molecules or cellular debris) and further purification steps 
are required to isolate the individual toxins. In comparison, the milking procedure allows only a few 
microliters of mature venom to be obtained though at higher purity and solubility.64-66 Indeed, 
milked venom shows a more elaborate mixture than the duct contents, as the “primary venom” 
originating from the gland may be further processed during its progression through the pharynx 
where additional substances could be discharged from the salivary gland as well. The venom thus 
collected is then purified by reversed-phase high performance liquid chromatography (RP-HPLC) 
in order to isolate the conopeptides. The sequence of these may then be further deciphered using 
Edman chemistry in conjunction with tandem mass spectrometry (MS/MS).67, 68 However, recent 
fast large-scale data mining strategies employing the complementary sequencing and matching of 
venom gland transcriptome and proteome approach will be described in more details in the next 
section. 
Once the amino acid sequence of the peptide is known, larger amounts can be produced by Fmoc or 
Boc chemistry solid-phase peptide synthesis (SPPS) coupled to native chemical ligation (NCL) 
when long polypeptides are required.69, 70 Alternatively, peptides of interest can also be produced by 
recombination using heterologous overexpression systems such as bacteria, yeast, or insect cells.71 
Pharmacological Family Molecular Target
 (alpha) Nicotinic acetylcholine receptors (nAChR)
 (gamma) Neuronal pacemaker cation currents (inward cation current)
 (delta) Voltage-gated Na channels (agonist, delay inactivation)
 (epsilon) Presynaptic Ca channels or G protein-coupled presynaptic receptors
 (iota) Voltage-gated Na channels (agonist, no delayed inactivation)
 (kappa) Voltage-gated K channels (blocker)
µ (mu) Voltage-gated Na channels (antagonist, blocker)
 (rho) Alpha1-adrenoceptors (GPCR)
 (sigma) Serotonin-gated ion channels (GPCR)
 (tau) Somatostatine receptor
 (chi) Neuronal noradrenaline transporter
 (omega) Voltage-gated Ca channels (blocker)
Table 2 – Conopeptide pharmacological families. 
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Superfamily Cysteine Framework Pharmacological Family
A I, II, IV, XIV , , 
B1 - -
B2 VIII -
B3 XXIV
C - -
D XV, XX
E XXII -
F - -
G XIII -
H VI/VII -
I1 VI/VII, XI
I2 XI, XII, XIV
I3 VI/VII, XI -
J XIV , 
K XXIII -
L XIV
M I, II, III, IV, VI/VII, IX, X, XIV, XVI , , , µ
N XV -
O1 I, VI/VII, IX, XII, XIV , , , µ, 
O2 VI/VII, XIV, XV , 
O3 VI/VII -
P IX -
S VIII , 
T I, V, X, XVI , µ, , 
V XV -
Y XVII -
Divergent M---L-LTVA VI/VII, IX, XIV -
Divergent MKFPLLFISL VI/VII -
Divergent MKLCVVIVLL XIV -
Divergent MKLLLTLLLG - -
Divergent MKVAVVLLVS - -
Divergent MRCLSIFVLL XVI -
Divergent MRFLHFLIVA VI/VII -
Divergent MRFYIGLMAA I, V -
Divergent MSKLVILAVL IX -
Divergent MSTLGMTLL- IX, XIX, XXII -
Divergent MTAKATLLVL XIV -
Divergent MTFLLLLVSV IX -
Divergent MTLTFLLVVA VI/VII -
Table 3 – Conopeptide gene superfamilies. The cysteine frameworks and the pharmacological families 
encountered in each superfamilies are mentioned. Source: www.conoserver.org (15/01/2014). 
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In order to assess the potential activity of venom components, it is usual to first directly test prior to 
any purification steps the crude extracted material on specific targets expressed on isolated tissues, 
cells, cell lines, or oocytes. Then, an approach called activity guided fractionation that relies on 
screening the activity of each venom fractions (obtained by RP-HPLC, 1 or 2 dimension 
polyacrylamide gel electrophoresis – 1D/2D-PAGE) toward specific subtypes of voltage-/ligand-
gated channels, nicotinic receptors, or GPCRs, may be used to precisely identify the bioactive 
peptide. Activity assays such as binding, electrophysiology experiments or using the high-
throughput cell culture-based fluorometric imaging plate reader (FLIPR) device are usually 
performed.72, 73 
Optimization of bioactive peptides is usually engaged by first identifying the site and mode of 
interaction between the pharmacophore and the target. This step is achieved by elucidating the 
three-dimensional structure of the toxin using either nuclear magnetic resonance (NMR) 
spectroscopy or X-ray crystallography, which can be followed by in silico docking experiments. 
Knowing the nature and the location of the active amino acid residues in the sequence then guides 
the design and production of peptide analogs or mimetics with improved bioactivity. Although 
cysteine-rich peptide toxins are usually naturally resistant to proteases, extreme pH and 
temperature, their use for therapeutic purpose can be limited due to their reduced bioavailability, 
their relatively large size compared to small molecules, as well as their hydrophilicity. Nevertheless, 
these physicochemical characteristics that prevent the passive diffusion of the toxin through 
Figure 5 - Milking procedure (Hopkins C. et al. – 1995). A fish is placed in front of the 
snail until it extends its proboscis (A). The collection tube (surrogate fish) is quickly 
substituted for the fish, as the snail is about to strike. Once the snail has harpooned the 
collection tube, the harpoon is cut off (B). Assembly of the collection tube (right panel). 
The cap of a microcentrifuge tube is hollowed out and placed over a membrane with a cut 
up fish tail to seal the top of the tube. 
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hydrophobic epithelial layers such as the blood-brain barrier can be overcome with the use of 
vectors like homing-peptides (HMs) or cell-penetrating peptides (CPPs) able to transport 
macromolecular systems through cell membranes, thus improving their selectivity, efficiency and 
tolerance in vivo.74, 75 
Transcriptome/proteome sequencing and matching approach 
More and more experimental strategies designed for decrypting the sequence of protein molecules 
of therapeutic and pharmacological interest now incorporate the analysis of particular tissues or cell 
transcriptome in addition of MS/MS profiling.76, 77 The main advantage of this fast and large-scale 
approach is to bypass Edman sequencing which is time consuming, and where certain post-
translational modifications are not always detected.  
 
In venom-based drug discovery and toxin mining experiments, the complementary transcriptomic 
and proteomic approach follows this general step-wise process (Figure 6): (i) dual extraction of total 
RNA and proteins from venom-producing cells or tissues, (ii) mRNA isolation and preparation of a 
complementary DNA (cDNA) library to be sequenced (that will provide between 100,000 and 
30,000,000 cDNA reads of various length depending on the sequencing platform used), (iii) 
fractionation of protein toxins and MS/MS sequencing, (iv) in silico matching of translated cDNA 
coding sequence (CDS) isolated from the reads with the protein sequences obtained by mass 
spectrometry. 
 
However, recent advances in next-generation sequencing technologies, which can be applied at all 
three levels of the omics cascade (genomics, transcriptomics, proteomics), provide substantial 
amount of data that need to be processed and analyzed with purpose-built bioinformatics tools. The 
first issue to take into consideration after collecting the raw transcriptomic reads is the assembly of 
these fragments into contigs. Transcriptome assembly is performed in order to obtain longer 
transcripts, usually when the average read length provided by the sequencing platform (between 50 
to 350 base pair - bp) is not high enough to cover, once translated into amino acid sequence, the full 
size of the precursor toxins to be validated with proteomic data. This step can be relatively 
laborious and time consuming depending on the source organism, the availability of a reference 
genome, the complexity of the inner cell compartment (e.g. size of the transcriptome, presence of 
repetitive elements, rate of alternative splicing), as well as the sequencing strategy that has been 
used (depth, single- or paired-end reads, length of reads). In most venomics studies, the genome of 
the organism investigated is unknown. As a consequence, a de novo transcriptome assembly has to 
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be considered. It can be performed by three main categories of short read assemblers based on 
graph theory (i.e. a collection of nodes – also called vertices - linked by a set of directed edges – 
also called arcs) that use slightly different approaches: greedy algorithms, overlap-layout-consensus 
(OLC) approaches, and de Bruijn graphs. The greedy algorithm performs pairwise alignments of all 
reads, keeping the ones showing the largest overlap, before joining them to each other.78-80 The two 
previous steps are repeated until the growing contigs reach the shortest common supersequence. In 
the OLC approach, the relationships between reads are represented as an overlap graph where the 
nodes represent the reads and the edges represent pair-wise alignment of reads. In this case the 
assembly consists of finding a path along the graph that visits each nodes once (Hamiltonian cycle) 
and reconstitutes contigs.78, 81, 82 Because this approach is computationally intensive, most recent 
assemblers use de Bruijn graphs.78, 83 The reads are split into smaller sequences of fixed length k (k-
mers) that represent the vertices, and the edges represent perfect overlaps (k-1 in length) of k-mer 
suffix-to-prefix. The path thus created follows a Eulerian cycle (visits each edge exactly once) that 
corresponds to the original sequence. This approach has the effect of reducing the redundancy 
Cell / Tissue sample
Matching
TRANSCRIPTOMICS
Assembly
Total RNA
mRNA
cDNA library
Sequencing
cDNA reads
cDNA contigs
BIOINFORMATICS
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& translation
Precursor protein
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Protein extract
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Figure 6 – Transcriptome/proteome sequencing and matching approach. Total RNA and proteins are 
extracted from cell or tissue sample. After isolation of mRNA, a cDNA library is produced in order to be 
sequenced and to obtain short nucleic acid reads (depending on the length of these later and the purpose of the 
study, they can be assembled into longer contig sequences). The coding sequence of the reads/contigs are 
identified and translated in silico into precursor amino acid sequences. In parallel, individual components 
obtained by fractionation of the protein extract are isolated (reduced/alkylated and/or digested by an 
endopeptidase such as trypsin). They are then submitted to tandem mass spectrometry for sequencing. Finally, 
the peptide sequence tags obtained by MS/MS are matched to the corresponding precursor protein using a 
mass fingerprinting software. 
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encountered in short-reads data sets and significantly reducing the time needed to reconstruct de 
novo transcriptome assemblies. Today, most next-generation sequence assemblers use de Bruijn 
graphs but still lack efficiency when given highly repetitive sequences. The graph resolution is 
often aborted after a number of cycles, and no consensus sequences are generated. This issue is 
currently a main focus of the scientific community. 
 
Once the cDNA sequences have been assembled, a possible strategy would be then to isolate the 
CDSs and to directly translate these regions in silico in order to obtain amino acid sequences 
corresponding to the precursor proteins (numerous stand alone and web-based programs are 
available to achieve translation of nucleic acid sequences). It is of particular importance at this step 
to identify the precursor protein, as opposed of the mature peptide sequence, to be able to 
distinguish toxins from housekeeping proteins. Indeed, precursor proteins entering the secretory 
pathway, including toxins, are likely to contain a N-terminal signal region responsible for the 
trafficking toward the endoplasmic reticulum (ER).84, 85 Moreover, the presence of the three regions 
in the precursor proteins (signal, pro-, and mature peptides) can be used for the classification of the 
toxins. Nevertheless, the recognition of these signatures among the thousands of sequences cannot 
be achieved manually with high accuracy. In addition to the time and effort that needs to be 
invested, this approach raises the question of the phylogenetic specificities of venomous animal 
taxa, and the ability of global bioinformatics programs to accurately recognize and classify toxins 
from diverse organisms. Depending on the objective of the study, the size of the query data set and 
the nature of the endogenous precursor toxin (presence of pro-regions, length of mature peptide), 
various processing pipelines could be adopted. Despite being particularly maladapted to large-scale 
proteomic analysis (time-consuming, computationally intense, limited specificity), multiple 
sequence alignment programs, such ClustalW, or MUSCLE, have been widely used and are 
probably the easiest approach to set up.86, 87 For more accuracy, model-based programs built on 
species specific training sets could be used instead. However, because different venomous animals 
produce a variety of peptide toxins with unique sequence features, the design of “tailor-made” 
models (such as regular expressions or more flexible stochastic models like profile Hidden Markov 
Models - pHMMs) for a particular taxon are required to efficiently detect toxin from non-toxin 
sequences. 
 
Decoration of an amino acid sequence with PTMs is often necessary for the toxin to be active. Such 
modifications cannot be detected at the transcriptomic level. Therefore, integration of proteomic 
data obtained by soft ionisation mass spectrometry experiments (such as matrix assisted laser 
desorption ionization – MALDI, or electrospray ionisation – ESI) has been routinely used in 
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venomics.88 For the study of complex protein and peptide mixtures, improvements in speed 
performance, coverage, sensitivity and resolution, have been made possible by coupling mass 
spectrometers to offline (MALDI) or online (ESI) upstream RP-HPLC pre-fractionation devices 
that commonly use large pore (300Å) C18 reversed-phase stationary phase columns. 
 
A mass spectrometer itself is composed of three main parts: an ionisation source, a mass analyzer, 
and a detector.89 Proteins to be analyzed are first converted to gas-phase ionic species (by removal 
or addition of electron(s) or proton(s)), which further facilitates their motion control and detection. 
An excess of energy transferred during this step can cause the sample to break into fragments. Soft 
ionization techniques like MALDI and ESI limit the amount of this residual energy, which prevents 
fragmentation of the sample. The ions thus created then travel through magnetic and/or electric 
fields produced by the mass filter that separates the charged species based on their charge-to-mass 
(m/z) ratios and dictate their spatiotemporal trajectories. The current created by the mass-resolved 
ions is measured, amplified, and displayed as a mass spectrum by the detector. 
 
Tandem mass spectrometry (also referred as MS/MS) is widely used in protein identification, 
sequencing and elucidation of PTMs. Different configurations of tandem MS can be set up 
depending on the applications. When tandem MS is performed in space, the mass spectrometer 
components are physically distinct (e.g. quadrupole, time-of-flight – TOF – analyzers), whereas for 
tandem MS in space ions are trapped in a same compartment. Although various MS modes exist 
(precursor ion scan, product ion scan, neutral loss scan, or selected reaction monitoring), the basic 
principle of MS/MS relies first on the separation of precursor ions and selection of specific masses, 
followed by their fragmentations into product ions that will be separated again and analyzed. The 
peptide sequence tags thus generated can then be used to match translated transcriptome cDNA 
sequences or protein databases in order to identify the precursor protein. 
 
Finally, the last step of this combinatorial transcriptome/proteome approach relies on the matching 
of the data set containing the precursor toxin sequences inferred from the transcriptome with the 
MS/MS sequencing data to bring additional proof that a particular toxin is expressed at protein 
level. Matching of the peptide fragments to their parent precursor proteins can be achieved by using 
mass fingerprinting programs that perform theoretical enzymatic digestion, alkylation, and ion 
fractionation of a custom database of protein sequences (the translated transcripts in this case) in 
order to generate a theoretical mass list that will be compared to the experimental mass list 
produced by MS/MS experiments. Such program, like ABSCIEX ProteinPilotTM for instance (based 
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on the Paragon and ProGroup algorithms), also allows the identification of post-translational 
modifications of the peptide fragments based on their mass shift. 
 
 
This thesis work will start with two large-scale analyses of cysteine-rich peptides and mini-proteins 
isolated in human and venomous animals respectively. The relationship between their cysteine 
frameworks and ability to selectively bind with high affinity various types of membrane receptors, 
ion channels, transporters, and to act as extracellular enzyme inhibitors, as well as antimicrobial 
agents will be described. Special emphasis will be also given to the secondary elements, folds, and 
motifs responsible for the activity of these proteins. 
 
A third chapter will be dedicated to the analysis of the structural and functional elements of venom 
peptides able to modulate targets of the nociceptive pathways from heterologous species. With the 
recent re-focusing of pharmaceutical companies on the potential of natural substances for the design 
of human therapeutics, an overview of the currently marketed and studied venom peptides under 
clinical trials, as well as promising molecules still at the fundamental research stage will be 
presented. 
 
The last part of this thesis will show concrete examples of the transcriptome/proteome sequencing 
and matching approach conducted in venomous marine cone snails. The fourth chapter will describe 
the conception of a high-throughput bioinformatic program, called ConoSorter, designed for fast 
and precise de novo identification and classification of conotoxins sequenced from next-generation 
transcriptomic and proteomic platforms. Finally, the last chapter will demonstrate the efficiency of 
this program when applied to data obtained from state-of-the-art transcriptome sequencing 
technologies and a road map used for effective biodiscovery of new potential pharmacological hits. 
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Cysteine-rich Mini-proteins in Human Biology
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Cysteine-Rich Mini-Proteins in Human Biology 
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4072, Australia 
Abstract: Understanding the relationship between structure and function underpins both biochemistry and chemical biol-
ogy, and has enabled the discovery of numerous agricultural and therapeutic agents. Small cysteine-rich proteins, which 
form a unique set of protein frameworks and folds, are found in all living organisms and often play crucial roles as hor-
mones, growth factors, ion channel modulators and enzyme inhibitors in various biological pathways. Here we review se-
creted human cysteine-rich mini-proteins, classify them into broad families and briefly describe their structure and func-
tion. To systematically investigate this protein sub-class we designed a step-wise high throughput algorithm that is able to 
isolate the mature and active forms of human secreted cysteine-rich proteins (up to 200 amino acids in length) and extract 
their cysteine scaffolds. We limited our search to frameworks that contain an even number of cysteine residues (< 20), all 
of which are engaged in intra-molecular disulfide bonds. We found 53 different cysteine-rich frameworks spread over 378 
secreted cysteine-rich mini-proteins. Restricting our search to those that contain >5% cysteine residues led to the identifi-
cation of 22 cysteine-rich frameworks representing 21 protein families. Analysis of their molecular targets showed that 
these mini-proteins are frequently ligands for G protein- and enzyme-coupled receptors, transporters, extracellular enzyme 
inhibitors, and antimicrobial peptides. It is clear that these human secreted mini-proteins possess a wide diversity of 
frameworks and folds, some of which are conserved across the phylogenetic spectrum. Further study of these proteins will 
undoubtedly lead to insights into unresolved questions of basic biology, and the development of system-specific human 
therapeutics. 
Keywords: Cysteine framework, cysteine scaffold, cysteine-rich peptides, cysteine-rich proteins, secreted human mini-
proteins, structure-function relationship. 
1. INTRODUCTION 
 Cysteine-rich proteins are ubiquitous in nature and can be 
found in all cellular and non-cellular organisms where their 
cysteine residues form inter- and intra-chain disulfide bonds 
with other cysteine residues in proteins [1]. This post-
translational modification is of vital importance to stabilize 
the folded tertiary structures of these proteins which is gen-
erally an essential requirement for functional specificity and 
selectivity [2]. It appears that during the protein folding 
process (assumed to be driven initially by hydrophobic inter-
actions, hydrogen bonding and Van der Waals forces [3]), 
strong covalent disulfide links impose distance and angle 
constraints between the C  and S  atoms of the joined cys-
teine residues, thus stabilizing the folded form of the protein 
by reducing the entropy of its unfolded state [4]. Disulfide 
bonds may also stabilize the folded state by packing local 
clusters of hydrophobic residues [5]. 
 In eukaryotes, formation of protein disulfide bonds 
mainly occurs in the lumen of the endoplasmic reticulum 
(ER), through thiol-disulfide exchange reactions catalyzed 
by several thiol-disulfide oxidoreductases, including Protein 
Disulfide Isomerase (PDI) [6]. Because disulfide bridges are 
unstable in reducing environments like the cytosol, most of 
the cysteine-rich proteins are secreted or, if embedded in the 
cell membrane, are exposed to the oxidizing extracellular 
environment [7]. 
*Address correspondence to this author at the Institute for Molecular,  
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Fax +61 7 3346 2101; E-mail: p.alewood@imb.uq.edu.au 
 These proteins vary in size and may be part of large pro-
tein complexes, or exist as smaller monomeric forms as cys-
teine-rich peptides or mini-proteins. Such molecules play 
significant roles in various biological processes [8] and may 
act as enzyme inhibitors, hormones, autacoids, growth fac-
tors, toxins, or host defense molecules, and can maintain or 
modify cell homeostasis by selectively acting on receptors, 
channels, or other extracellular and cell surface mediators 
[9]. 
 In this review, we focus our attention on human cysteine-
rich mini-proteins, generally containing less than 100 amino 
acids, and describe their frameworks, structures and func-
tions. This class of mini-protein is already well known in the 
world of venomous and poisonous animals. Peptide toxins 
that are cysteine rich have long been of interest because of 
their small sizes and well-defined structures stabilized by 
conserved cysteine scaffolds, allowing an efficient interac-
tion and modulation of key receptors in prey or predator ho-
meostasis (for typical examples see Fig. (1)) [10,11]. Be-
cause of their structural and functional diversity, such toxins 
have long been of interest to the scientific community as 
either pharmacological probes or drug leads. Numerous stud-
ies of their 3-dimensional structures, mechanism of action, 
and functional relevance have been undertaken [12,13]. An 
interesting aspect of this molecular class is that many have 
the ability to act on a variety of heterologous receptors with 
high potency and selectivity. These peptide toxins are seen 
as a rich library of molecules with therapeutic and diagnostic 
potential as well as potent tools for the study of new phar-
macological targets [14,15]. 
Pseudonaja textilis (Eastern brown snake)
KDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA
Plasmin, Trypsin (inhibitor)
Textilinin-1
(3d65)
N
C
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NC
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CKGKGAKCSRLMYDCCTGSCRSGKC
Ca2+ channels (blocker)
Stoichactis helianthus (Sea anemone)
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K+ channels (inhibitor)
N C
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Grammostola rosea (Chilean rose tarantula)
GCLEFWWKCNPNDDKCCRPKLKCSKLFKLCNFSF
Stretch-activated channels (blocker)
Na+/K+ channels (inhibitor)
N C
M-theraphotoxin-Gr1a
(1lu8)
Leiurus quinquestriatus (Deathstalker scorpion)
MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR
Cl- channels (blocker)N C
Chlorotoxin
(1chl)
Ornithorhynchus anatinus (Duckbill platypus)
FVQHRPRDCESINGVCRHKDTVNCREIFLADCYNDEQKCCRK
Nociceptors (activator)
N
C
Defensin-like peptide-1
(1b8w)
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 Whereas cysteine-rich mini-proteins are common in the 
secretions of venomous organisms such as cone snails, scor-
pions, spiders and snakes with dozens of cysteine frame-
works already described [26,27], the presence of such 
frameworks in vertebrates and some unusual mammals such 
as the platypus [28,29] prompted us to consider how widely 
humans employed this molecular class, what they are, what 
receptors they target and whether there are functional analo-
gies with cysteine-rich toxins. To answer these questions we 
investigated the architecture of secreted human cysteine-rich 
mini-proteins including their frameworks, 3-dimensional 
structures and their mode of action where known.  
 For the purpose of this review a cysteine-rich mini-
protein is defined as a polypeptide displaying a cysteine-rich 
framework where all the cysteine residues are involved in 
intra-chain disulfide bonds and where the connectivity of all 
these amino acids is known. Thus, we exclude amino acid 
sequences containing an odd number of cysteine residues 
where usually one cysteine residue is involved in an inter-
chain disulfide bond as well as two-chain cysteine-rich mini-
proteins such as insulin and relaxin [30]. Surprisingly, we 
find that conserved human cysteine-rich frameworks are 
more abundant than anticipated, suggesting that future dis-
coveries in this field are likely. 
 To uncover human cysteine-rich frameworks we used the 
UniprotKB-SwissProt database for our target data set and 
began our query with a search for all human proteins de-
scribed in the literature and validated at the protein level [31] 
(Fig. (2)). We then used a step-wise high throughput algo-
rithm (manuscript in preparation) to select mature processed 
proteins and their associated meta-data (i.e. amino acid se-
quence, cysteine connectivity, domain(s), subcellular loca-
tion, and 3D structure references) whose sequences were less 
than 200 amino acids in length containing an even number of 
2 to 20 cysteine residues. 
 This gave a set of 378 secreted mature proteins (Table 1)
of which a large number have been extensively character-
ized. In order to avoid molecules with long inter-cysteine 
sequences (sometimes called disulfide loops), and to high-
Fig. (1). Common disulfide-rich scaffolds in peptide toxins. 
The 3D structure ( -helices, -strands, and disulfide bonds are colored respectively in blue, red and yellow) of common peptide toxins are 
represented with their name, Protein Data Bank (PDB) reference, the species of origin, the primary amino sequence showing the cysteine 
connectivity, as well as their molecular target and function. M-theraphotoxin-Gr1a [16,17], the potassium channel toxin ShK [18,19], the 
platypus defensin-like peptide-1 [20], chlorotoxin from the death stalker scorpion [21,22], the magician’s cone shell omega-conotoxin 
MVIIA [23], as well as the protease inhibitor textilinin-1 isolated from the Australian eastern brown snake [24,25], have been taken as ex-
amples. 
Human protein precursor database
(130,588)
Molecules isolated at protein state
(13,780)
Mature cysteine-rich mini-proteins
      - ≤ 200 a.a in length
      - 2 ≤ Cysteines ≤ 20
                            - all cysteines in disulfide bond(s)
(516)
Extract cysteine framework
(cysteine pattern + connectivity)
(53)
Review representative molecules
(with cysteine content > 5%)
(21 protein families / 22 different cysteine frameworks)
Mature secreted cysteine-rich mini-proteins
(378)
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light the role of the cysteine framework, a selection of se-
creted mini-proteins containing at least 5% cysteine residues 
was selected and described in detail below.  
Fig. (2). Methodology employed in the selection of human se-
creted cysteine-rich mini-proteins. 
Identification of cysteine-rich mini-proteins (supported by experi-
mental evidence for the expressed protein such as Edman sequenc-
ing, mass spectrometry, X-ray or NMR structure, or detection by 
antibodies) with cysteine-rich frameworks began with a query of 
proteins within the UniprotKBSwissProt database and the extrac-
tion of their associated meta-data (processing products, sequences, 
cysteine connectivity, domains, subcellular location, 3D structure 
references). An algorithm developed in-house to extract the proc-
essed products containing up to 200 amino acids in length, and 
containing an even number of cysteine residues between 2 and 20, 
all engaged in disulfide bond(s) was used. Numbers in italics be-
tween brackets indicate the numbers of UniprotKB-SwissProt hu-
man entries remaining after each step. The same algorithm was 
used to generate the cysteine frameworks from the mature protein 
fragments and to display the domain(s). 
 Interestingly, despite the diversity of human cysteine 
frameworks and folds uncovered as illustrated in (Table 2), 
many share similar functions. This observation led to a clas-
sification based on the molecular targets of these proteins. 
Indeed, we found that a majority of human secreted cysteine-
rich mini-proteins interact with G protein- and enzyme-
coupled receptors (GPCRs and ECRs respectively), inhibit 
transporters or extracellular enzymes or act as antimicrobial 
peptides; suggesting that the cysteine-rich sub-category of 
small human proteins warrants significant additional study 
with the potential for future discoveries in this field. The 
description of selected members from each family of small 
human cysteine-rich mini-proteins follows.  
2. CYSTEINE-RICH MINI-PROTEINS TARGETING 
GPCRs 
 GPCRs, also called 7 transmembrane receptors (7TM 
receptors), are a large family of eukaryotic cell surface re-
ceptors with more than 800 members encoded within the 
human genome [34]. Upon ligand binding, GPCRs transduce 
intracellular signal through downstream messengers that 
mediate a wide array of physiological functions. In addition, 
these receptors are of particular pharmaceutical interest, as 
30 to 40% of marketed drugs target GPCRs [35,36]. Among 
the 378 mature cysteine-rich protein sequences selected for 
this study, we found 112 mini-proteins (29.6%) targeting 
GPCRs. Representative examples are showed in Fig. (3), and 
are discussed immediately below. 
2.1. Oxytocin  
 This short cyclic nonapeptide contains 2 cysteine resi-
dues which form a single disulfide bridge (Fig. (3A & 3B)). 
Oxytocin (OT) is predominantly produced in the brain and 
has variable actions in the periphery (parturition, lactation) 
and the central nervous system (CNS) (memory, sexual be-
havior, aggression, learning, stress, but also feeding, and 
pain perception) [37,38]. OT is currently known to have only 
one receptor (OTR), a typical member of the rhodopsin-type 
(class I) GPCR family, primarily coupled to phospholipase C 
via Gq proteins [39]. It would be difficult to talk about oxyto-
cin without mentioning its homologue, arginine vasopressin 
(AVP). The two peptides share the same scaffold and only 
differ at position 3 and 8 (Ile3/Leu8 and Phe3/Arg8 for OT 
and AVP respectively) [40]. These two differences confer 
distinct functions to AVP (including vasoconstriction and 
regulation of water absorption in kidneys). In fact, AVP acts 
on three GPCRs called V1a (vasopressor), V1b (pituitary) 
and V2 (renal) involving phosphatidylinositol/calcium sec-
ond messenger system (V1a and V1b) and adenylate cy-
clase/cAMP (V2) [41]. Numerous pharmacological studies 
have also focused on the design of potent and selective ago-
nists of oxytocin and vasopressin receptors [42].  
2.2. Somatostatin 
 Somatostatin-14 (SST-14) is a mature 14 amino acid pep-
tide possessing a similar though less structured cysteine scaf-
fold than OT and AVP (Fig. (3A)). The main function of 
SST is to inhibit the secretion of major hormones in various 
bodily compartments (dopamine and noradrenaline in the 
brain; thyroid hormones T3, T4 and calcitonin, aldosterone 
and catecholamine in the adrenals; renin in kidney, insulin 
and glucagon in pancreas; as well as certain growth factors 
and cytokines) [43,44]. The five SST receptors (SSTR1-5) 
belong to the GPCR rhodopsin-like family and are involved
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Table 1. Cysteine Frameworks of Small Mature Human Proteins 
Cysteines Cysteine Pattern Cysteine Connectivity Length Ranges of Inter-Cysteine Sequences Secreted 
Protein(s) 
Domain(s) 
2 C-C I-II (0-131)C(2-73)C(0-116) 66 Ig-like (6); EF-hand (1); Gla 
(1); Thioredoxin (1). 
I-II, III-IV (0-80)C(1-73)C(1-74)C(2-71)C(1-101) 15 Ig-like (2); SH3 (2). 
I-III, II-IV (0-53)C(1-66)C(1-74)C(2-48)C(1-65) 73 Ephrin RBD (3); Transferrin-
like (1). 
C-C-C-C 
I-IV, II-III (19-57)C(3-18)C(6-16)C(3-42)C(1-120) 15 PAN (3). 
4
CC-C-C I-III, II-IV (4-17)CC(4-27)C(1-16)C(16-75) 41  
I-II, III-V, IV-VI (47)C(12)C(21)C(2)C(4)C(2)C 1  
I-II, III-VI, IV-V (7-70)C(9-10)C(16)C(61-77)C(13-16)C(7)C(4-6) 7 C-type lectin (7). 
I-III, II-IV, V-VI (5-54)C(5-7)C(4-11)C(1-10)C(1-5)C(6-8)C(1-16) 6 EGF-like (5). 
I-IV, II-III, V-VI (6)C(10)C(4)C(18)C(38)C(42)C(9) 1  
I-IV, II-V, III-VI (1-33)C(3-44)C(2-17)C(11-32)C(3-31)C(1-14)C(1-32) 8  
I-V, II-IV, III-VI (0-20)C(5-16)C(7-41)C(10-70)C(2-9)C(17-28)C(0-44) 10 Kazal-like (8). 
I-V, II-VI, III-IV (3)C(65)C(49)C(8)C(30)C(13)C(2-9) 5  
I-VI, II-III, IV-V (7)C(14)C(4)C(45)C(5)C(40)C(11) 1  
I-VI, II-IV, III-V (2-14)C(8-20)C(15-27)C(7-18)C(11-33)C(3-27)C(2-36) 4 BPTI/Kunitz inhibitor (2); 
Kringle (1). 
C-C-C-C-C-C 
I-VI, II-V, III-IV (1-27)C(2-31)C(12-41)C(10-47)C(23-36)C(5-11)C(2-11) 7 Saposin B-type (5). 
I-V, II-IV, III-VI (2-18)C(5-7)C(3-4)C(9-13)C(4-6)CC(1-40) 24  C-C-C-C-CC 
I-VI, II-IV, III-V (0-27)C(1-1)C(3-4)C(9)C(9)CC(0-3) 9  
I-II, III-IV, V-VI (3)C(6)C(46)C(115)C(16)C(7)C 1  C-C-CC-C-C 
I-IV, II-VI, III-V (5-8)C(11)C(24-28)CC(3)C(8)C(7-9) 3  
C-CC-C-C-C I-IV, II-V, III-VI (3-8)C(46)CC(44)C(5)C(1)C(42-48) 2  
C-CCC-C-C I-IV, II-VI, III-V (12)C(11)C(132)CC(3)C(8)C(21) 1  
I-III, II-IV, V-VI (7)CC(24)C(17)C(27)C(18)C(12) 1  CC-C-C-C-C 
I-IV, II-V, III-VI (3-32)CC(9-14)C(7-12)C(15)C(10-17)C(5-15) 10  
6
CC-C-C-CC I-IV, II-V, III-VI (21-22)CC(12)C(11-12)C(6)CC(20) 3 Anaphylatoxin-like (3). 
I-V, II-VI, III-VII, IV-VIII (22-56)C(13)C(10-17)C(3-6)C(3-28)C(2-13)C(15-21)C(1-
14)C(21-46) 
3 CTCK (2). 
I-VI, II-V, III-IV, VII-VIII (5)C(2)C(30)C(10)C(30)C(10)C(33)C(2)C(28) 1  
I-VI, II-VII, III-VIII, IV-V (22-24)C(13)C(17)C(6)C(6-8)C(9-11)C(9-12)C(14)C(12-23) 5  
I-VIII, II-III, IV-VII, V-VI (10)C(2)C(10)C(16)C(67)C(13)C(8)C(5)C(33) 1 C-type lectin (1). 
C-C-C-C-C-C-C-C 
I-VIII, II-VII, III-V, IV-VI (5)C(21-23)C(32-34)C(7-11)C(3)C(13)C(19-20)C(8-12)C(2-12) 8
C-C-C-C-C-C-CC I-II, III-IV, V-VII, VI-VIII (28)C(32)C(27)C(31)C(22)C(4)C(24)CC(2) 1  
C-C-C-C-CC-C-C I-VI, II-VII, III-V, IV-VIII (15-19)C(6-8)C(3-8)C(5)C(5)CC(3)C(3)C(4) 2 WAP (2). 
8
C-CC-CC-C-CC I-VIII, II-IV, III-VI, V-VII (1-6)C(2)CC(1)CC(4)C(2)CC(2) 2  
10 C-C-C-C-C-C-C-C-C-C I-II, III-IV, V-X, VI-VIII, VII-
IX 
(16)C(4)C(24)C(12)C(4)C(20)C(27)C(11)C(11)C(4)C(12) 1 Gla (1); Kringle (1). 
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(Table 1) contd…. 
Cysteines Cysteine Pattern Cysteine Connectivity Length Ranges of Inter-Cysteine Sequences Secreted 
Protein(s) 
Domain(s) 
I-IV, II-V, III-VI, VII-IX, VIII-
X
(14-16)C(7)C(6)C(8-13)C(8)C(3)C(9)C(9)C(21)C(9)C(17-27) 2  
I-V, II-VI, III-VII, IV-VIII, IX-
X
(11)C(13)C(9)C(3)C(19)C(14)C(15)C(1)C(2)C(6)C(3) 1  
I-VI, II-VII, III-VIII, IV-IX, V-
X
(18)C(13)C(9)C(3)C(18)C(2)C(13)C(18)C(1)C(2)C(58) 1 CTCK (1). 
C-C-C-C-C-C-C-CC-C I-V, II-III, IV-VI, VII-VIII, IX-
X
(2)C(2)C(5-6)C(5)C(6)C(12-20)C(3-5)C(15-18)CC(4)C(2-8) 4 UPAR/Ly6 (4). 
C-C-C-C-C-CC-C-C-C I-VII, II-V, III-IX, IV-VI, VIII-
X
(1-2)C(7-15)C(17-18)C(2)C(1)C(6-7)CC(12-13)C(8)C(13)C(7-
25) 
2
C-C-C-C-CC-C-C-C-C I-II, III-V, IV-VI, VII-X, VIII-
IX 
(31)C(26)C(12)C(15)C(25)CC(5)C(3)C(45)C(6)C(5) 1  
C-C-C-CC-CC-C-C-C I-IV, II-VII, III-VIII, V-IX, VI-
X
(6)C(2)C(17)C(2)CC(26)CC(21)C(1)C(2)C(5) 1  
I-IV, II-V, III-VII, VI-IX, VIII-
X
(6-11)C(5)C(3-4)CC(8-11)C(9)C(11-38)C(1)C(5)C(9-17)C(4-9) 4C-C-CC-C-C-C-C-C-C 
I-IV, II-VI, III-IX, V-X, VII-
VIII 
(66-70)C(6)C(6)CC(2)C(2)C(1)C(6)C(1)C(6-9)C(0-3) 2 Agouti (2). 
I-IV, II-V, III-VI, VII-XII, VIII-
IX, X-XI 
C(1)C(9)C(54-59)C(26-28)C(24)C(1-
2)C(4)C(4)C(7)C(20)C(7)C(10-19) 
4 NTR (4). 
I-VI, II-IV, III-V, VII-XII, VIII-
X, IX-XI 
(25)C(8)C(15)C(7)C(12)C(3)C(5)C(8)C(15)C(7)C(12)C(3)C(15
)
1 BPTI/Kunitz inhibitor (1). 
C-C-C-C-C-C-C-C-C-C-
C-C 
I-VI, II-VII, III-XII, IV-VIII, V-
IX, X-XI 
(1-8)C(13)C(2)C(7)C(3)C(18-
20)C(14)C(15)C(1)C(2)C(6)C(9)C(7-35) 
6
12
C-C-CC-C-C-C-C-C-C-
C-C 
I-XII, II-IV, III-XI, V-X, VI-
VIII, VII-IX 
(25)C(1)C(14)CC(5)C(8)C(17)C(5)C(4)C(1)C(6)C(19)C(1) 1  
C-C-C-C-CC-C-C-C-C-
C-C-C-C 
I-VI, II-VII, III-V, IV-VIII, IX-
XIV, X-XII, XI-XIII 
(11)C(6)C(7)C(5)C(5)CC(3)C(3)C(7)C(8)C(15)C(7)C(12)C(3)C
(6) 
1 WAP (1); BPTI/Kunitz inhibi-
tor (1). 
C-C-C-C-CC-C-C-C-C-
CC-C-C 
I-XIV, II-VI, III-V, IV-VII, 
VIII-XII, IX-XI, X-XIII 
(5)C(1)C(10)C(9)C(4)CC(10)C(11)C(9)C(9)C(4)CC(10)C(8)C(
2) 
1 P-type (1). 
C-C-C-CC-C-C-C-C-C-
C-C-C-C 
I-VIII, II-XIV, III-V, IV-XIII, 
VI-XII, VII-X, IX-XI 
(10)C(15)C(1)C(14)CC(5)C(9)C(15)C(6)C(6)C(4)C(1)C(6)C(18
)C(2) 
1
C-C-C-CC-C-C-C-C-C-
CC-C-C 
I-VIII, II-IV, III-VII, V-VI, IX-
XI, X-XIV, XII-XIII 
(9)C(2)C(7)C(5)CC(5)C(9)C(9)C(6)C(5)C(5)CC(4)C(5)C(8-9) 2  
14
C-C-CC-CC-C-C-C-C-
C-C-C-C 
I-XIII, II-IV, III-XII, V-XIV, 
VI-XI, VII-IX, VIII-X 
(24-
25)C(1)C(14)CC(4)CC(8)C(17)C(5)C(4)C(1)C(6)C(19)C(6)C 
2
C-C-C-C-CC-C-C-C-C-
C-C-CC-C-C 
I-VI, II-VII, III-V, IV-VIII, IX-
XIV, X-XV, XI-XIII, XII-XVI 
(5-9)C(7-8)C(3-7)C(5)C(5)CC(3)C(3)C(9-16)C(6-12)C(3-
8)C(5)C(5)CC(3)C(3-4)C(5-6) 
2 WAP (2). 16
C-C-C-CC-CC-C-C-C-
C-C-C-C-C-C 
I-IX, II-XV, III-V, IV-XIV, VI-
XVI, VII-XIII, VIII-XI, X-XII 
(10)C(13)C(1)C(14)CC(4)CC(8)C(10)C(6)C(6)C(4)C(1)C(6)C(
17)C(6)C(1) 
1
Total 29 53 - 378 - 
Fifty three cysteine frameworks were identified in mature secreted human mini-proteins (see introduction and Figure (2) for more details). Please note that in the last column we have 
reported the name of the domains contained in the proteins displaying a given framework, with the number in brackets representing the number of these proteins in that group. Abbre-
viations used: Ig-like, Immunoglobulin-like; Gla, gamma-carboxy-glutamate; SH, Src Homology; Ephrin RBD, Ephrin Receptor Binding Domain; PAN, Poly (A) Nuclease; EGF, 
Epidermal Growth Factor; BPTI, Bovine Pancreatic trypsin Inhibitor; CTCK, C-Terminal Cystine Knot-like; WAP, Whey Acidic Protein; UPAR/Ly6, Urokinase-type Plasminogen 
Activator Receptor/Lymphocyte antigen 6; NTR, Netrin-like; P-type, Trefoil. 
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Table 2. Fold Description and Classification of the Selected Human Cysteine-Rich Secreted Mini-Proteins 
Peptide Fold    Structural Group 
Oxytocin Cyclic    - 
Somatostatin -    - 
Interleukin-8 (CXCL8) 
RANTES (CCL5) 
Leukotactin-1 (CCL15) 
IL8-like: 3 -strands, 1 C-terminal helix (1 extra -strand
for RANTES) 
   Interleukine 8-like chemokines 
6Ckine (CCL21) -    - 
Endothelin-1 Small disufide-rich and distorted -hairpin    Endothelin-like 
C3a anaphylatoxin 4 helices with a three-helix bundle, right handed    Anaphylatoxin 
Agouti-related protein Knottin-like I: disulfide-bounded form with 1 -hairpin
and 2 adjacent disulfides 
   Agouti-like 
GPCR 
Prokineticin-2 Knottin-like II: 4 cysteines located on 4 structure ele-
ments; left-handed connections 
   Colipase-like 
Atrial natriuretic peptide Cyclic    Atrial natriuretic peptides 
Guanylin Small disulfide-closed loop    Guanylin/Heat-stable enterotoxin-like
Epidermal Growth Factor Knottin-like III: first two cysteines residues located on
one irregular/bulging structure element; -hairpin with
adjacent disulfides 
   EGF-type module Enzyme-coupled 
Receptor 
Insulin-like growth factor II Three-helix bundle, left handed    Insulin-like 
Transporter 
Inhibitor 
Hepcidin -hairpin crossed linked by 4 disulfide bridges    Antimicrobial -hairpin 
Serine protease inhibitor Kazal-type 5
Pancreatic secretory trypsin inhibitor
-hairpin and -helix disulfide-bonded to N-terminal loop    Kazal-type Serine Protease Inhibitor 
Elafin Knottin-like III: first two cysteines residues located on 
one irregular/bulging structure element 
   Elafin-like 
Secretory leukocyte protease inhibitor Trypsin-like serine proteases: barrel, closed; greek key 
(duplicated WAP domains 1 & 2, similar to elafin) 
   Eukaryotic proteases 
Bikunin BPTI-like: folded and twisted hairpin (disulfide-rich alpha
+ beta fold) 
   Small Kunitz-type inhibitors & BPTI-
like toxins 
Extracellular 
Enzyme Inhibitor 
Metalloproteinase inhibitor 1 OB-fold (barrel, closed or partly opened; greek key) with
an irregular alpha+beta subdomain in C-terminal exten-
sion 
   TIMP-like  
Liver-expressed antimicrobial peptide
2 (LEAP-2) 
-hairpin with a single turn helix    Antimicrobial -hairpin 
-defensin 1 (HNP1) 
Antimicrobial 
Peptides 
-defensin 1 (HBD1) 
Defensin-like: disulfide rich, nearly all- (three-strand -
sheet, antiparallel, strand order 132) 
   Defensin-like 
N-terminus: 4 antiparallel -strands (Greek key motif) +
2 small antiparallel -strands; 
-microseminoprotein 
C-terminus: 2 double stranded antiparallel -strands 
   - 
SLURP-1 -    - 
Miscellaneous 
Neurophysin 1 2 domains separated by 1 -helix, each containing 2-
strands -sheets (antiparallel) 
   Neurophysin II-like 
The description and the classification of the folds of the proteins discussed in the review are summed up in the table. SCOP (Structural Classification of Proteins) database [32] and 
Cheek et al. [33] classifications have been used here. 
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in complex signaling pathways. They induce multiple key 
enzyme pathways such as adenylate cyclase (via Gi1, Gi2
and Gi3 proteins), SH2 domain-containing tyrosine phos-
phatases SHP-1 and -2, the mitogen-activated protein kinase 
(MAPK) cascade, but also indirectly regulate calcium and 
potassium channels (respectively via Go2 and Gi3), along 
with the sodium/proton antiporter [45,46]. The five SSTRs 
bind SST-14 and SST-28 (the other processing product with 
a 14 amino acid extension at the N-terminus) with high af-
finities. However, the short half-life of SST in plasma has 
necessitated the design of stable and selective analogs. Inter-
estingly, the most potent hexa- and octa-peptide SST deriva-
tives (among which SMS 201-995 or “octreotide” was the 
first FDA approved analog) contain the endogenous -turn 
pharmacophore composed of residues Phe7, Trp8, Lys9 and 
Thr10 [47]. A recent derivative, a cyclohexapeptide called 
SOM-230, is an almost universal agonist showing high af-
finities for four of the five SSTRs [48]. 
2.3. Chemokines 
 This large family of cysteine-rich mini-proteins is re-
sponsible for chemotaxis [49,50]. These small secreted cyto-
kines (between 8-10 kDa) contain cysteine frameworks 
based, in most cases, on 4 cysteine residues with conserved 
positions and connectivity (CI-CIII, CII-CIV), to form a char-
acteristic Greek key shape [51]. Chemokine receptors are 
GPCRs associated with phospholipase C (PLC) and phos-
phatidylinositol (4,5)-biphosphate (PIP2) pathways, which 
trigger intracellular calcium release [52,53]. Interleukin-8 
(also called IL-8 or CXCL8) is a C-X-C motif chemokine 
with 4 cysteine residues displaying a characteristic frame-
work (a C-C-C-C cysteine pattern, with I-III, II-IV connec-
tivity) [54,55] (Fig. (3A & 3B)). It has a characteristic terti-
ary structure formed by three -strands and one C-terminal 
helix. IL-8 is an important mediator of the inflammatory and 
innate immune responses. It acts as a signal molecule that 
attracts and activates inflammatory cells at the site of in-
flammation after binding the GPCRs CXCR1 (or IL-8 recep-
tor alpha) and CXCR2 (or IL-8 receptor beta) expressed on 
their surface [56]. Mutagenesis studies have shown that the 
three amino acid residues Glu1-Leu2-Arg3 (designated as 
ELR motif, located just before the first cysteine in the 69 
amino acid mature form) are crucial for receptor binding and 
biological activity of IL-8 and other CXC chemokines [57]. 
 The overlapping affinity of various chemokines for their 
receptors is exemplified by the RANTES peptide (Regulated 
upon Activation, Normal T-cell Expressed, and Secreted or 
CCL5), a member of the CC chemokine subfamily (Fig. (3A
& 3B)). Similarly to IL-8, RANTES is a chemotactic cyto-
kine, which recruits leukocytes in inflammatory responses 
and causes the release of histamine from basophils, or acti-
vates eosinophils. It binds CCR1, but also CCR3, and pre-
dominantly CCR5 (as well as the orphan G-protein-coupled 
receptor 75 – GPR75) [58,59]. A “message-address” docking 
mechanism has been attributed to several chemokines, in 
which their core region carries an “address” function respon-
sible for receptor specificity and affinity while their N-
terminal region carries the “message” function. For RAN-
TES the message resides in residues 1-9 and induces the in-
tracellular sequestration of CCR5. Synthetic analogs of 
RANTES have been employed as preventive and curative 
anti-HIV molecules, including the amino-terminally modi-
fied PSC-RANTES which has been shown to have enhanced 
“message” activity, also driven by the Lys33 residue [60,61]. 
 Among the chemokine protein family we also find mini-
proteins containing 6 cysteine residues such as 6Ckine (or 
CCL21) and leukotactin-1 (CCL15) (Fig. (3A & 3B)). Both 
belong to the CC chemokine family and although both dis-
play an identical cysteine pattern (CC-C-C-C-C), they have 
different cysteine connectivities (I-III, II-IV, V-VI for the 
former, and I-IV, II-V, III-VI for the latter) and 6Ckine has 
slightly longer loops. CCL21 and CCL15 both induce che-
motaxis and trafficking of immune cells by acting on differ-
ent GPCRs - predominantly on CCR7 and CCR1 or CCR3 
respectively [62-65]. Interestingly, it has been demonstrated 
that six amino acids (Ser1-Asp2-Gly3-Gly4-Ala5-Gln6) in the 
N-terminal part of CCL21 might be crucial for the high af-
finity of its receptor and its activity [66]. Moreover, the N-
terminal region of CCL15 plays an important role in CCR1 
and CCR3 affinity and selectivity, as well as the carboxy-
terminal alpha helix (Gln53-Asp54-Cys55-Met56-Lys57-Lys58-
Leu59 residues in the shortest form), which is a cornerstone 
for the maintenance of its 3D-structure [67]. Interestingly, 
the third disulfide bond and the highly conserved Tyr70 do 
not appear to be involved in CCR1 function.
2.4. C3a Anaphylatoxin  
 Another cysteine-rich mini-protein with chemotactic ac-
tivity though not a chemokine is C3a anaphylatoxin. This 
pro-inflammatory polypeptide results from the proteolytic 
cleavage of complement component 3 and is also involved in 
smooth muscle contraction, cell apoptosis and lipid metabo-
lism [68-70]. C3a mediates its function by interacting with 
its receptor (C3aR) which promotes an intracellular increase 
of calcium through different G proteins and molecules from 
the signalosome depending on the cell type where the recep-
tor is expressed (phosphatidylinositol-bisphosphate-3-kinase 
gamma, protein kinase C, PLC, Akt, or MAP kinases). C3a 
anaphylatoxin is composed of 77 amino acids and contains 
the CC-C-C-CC pattern forming 3 disulfide bonds (I-IV, II- 
V, III-VI) (Fig. (3A)). The peptide forms four -helices com-
prising a right-handed helix bundle (Fig. (3B)). Structure-
activity experiments revealed that, like C5a (another member 
of the anaphylatoxin family with the highest specificity of 
action), the C3a C-terminal octapeptide region (specially the 
Leu75-Ala76-Arg77 motif) is important for triggering C3aR 
activity, whereas the 69 remaining N-terminal amino acids 
seem to contain a high affinity binding domain [71,72]. 
2.5. Endothelins 
 Among cysteine-rich peptides that target GPCRs we also 
find the endothelin (ET) family. Its three 21 amino acid con-
taining members (ET-1, ET-2, ET-3) contain four cysteine 
residues with 2 disulfide bridges (CI-CIV, CII-CIII) which sta-
bilize the overall distorted -hairpin shape (Fig. (3A & 3B)). 
ET-1, the predominant isoform and the most biologically 
relevant is considered to be the most potent and long-lasting 
vasoconstrictor known to date in humans (100 times more 
potent than noradrenaline) [73]. These stress-responsive 
regulators exert various beneficial and detrimental effects
GPCR
Peptide Receptor Type Length Disulfide Bonds Cysteine Scaffold
Oxytocin OXTR 9 1 C(4)C(3)
Somatostatin-14 SST 1-5 14 1 (2)C(10)C
Interleukin-8 (CXCL8) CXCR1/2 69 2 (3)C(1)C(24)C(15)C(22)
Endothelin-1 ET A/B 21 2 C(1)C(7)C(3)C(6)
RANTES (CCL5) CCR5 65 2 (6)CC(22)C(15)C(18)
6Ckine (CCL21) CCR7 111 3 (7)CC(24)C(17)C(27)C(18)C(12)
Leukotactin-1 (CCL15) CCR1/3 64 3 (3)CC(9)C(12)C(15)C(10)C(9)
C3a anaphylatoxin C3AR1 77 3 (21)CC(12)C(12)C(6)CC(20)
Prokineticin-2 PK-R2 102 5 (6)C(5)C(4)CC(11)C(9)C(38)C(1)C(5)C(9)C(4)
Agouti-related protein MC3/4 112 5 (66)C(6)C(6)CC(2)C(2)C(1)C(6)C(1)C(9)C(3)
A)
B)
Oxytocin
(1npo)
C-C
Endothelin-1
(1edn)
C-C-C-C
Interleukin-8
(1icw)
C-C-C-C
RANTES
(1eqt)
CC-C-C
Leukotactin-1
(2hcc)
CC-C-C-C-C
C3a anaphylatoxin
(2a73)
CC-C-C-CC
Toxin MIT1 (Black mamba)
(1IMT)
C-C-CC-C-C-C-C-C-C
AgRP (C-terminal domain)
(1hyk)
C-C-CC-C-C-C-C-C-C
N
N
N
N
N
N
N
C
C
C
C
C C C
C
N
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Fig. (3). Cysteine sca olds and 3D structures of a selection of secreted cysteine-rich mini-proteins targeting G protein-coupled recep-
tor (GPCR). 
(A) Representative members of small cysteine-rich protein families interacting with GPCRs. The name of the polypeptide and its associated 
GPCR, its length, the number of disulfide bonds and its cysteine scaffold (green bolded text indicates active sites) are listed in the table (upper 
part of the figure). (B) 3-dimensional structures of the polypeptides and their cysteine frameworks (Protein Data Bank references in brackets). 
Disulfide bonds, and lateral chain of amino acids confirmed to participate in activity/binding are represented with yellow sticks and green 
lines respectively. The N- and C-termini of the polypeptides are also represented. Some 3D structures have been replaced by their nearest 
homologue which displays the same cysteine pattern and connectivity. For example Toxin MIT1-1IMT from the black mamba for Proki-
neticin-2. 
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depending on which of the two widespread receptors, ETA
and ETB, they bind. Although the specific roles of these re-
ceptors have not been fully elucidated and often appear 
counteracting, it is generally accepted that ETA is considered 
as the “bad” receptor, as it mediates vasoconstriction and 
proliferative response on smooth muscle cells associated 
with hypertension, diabetes and other cardiovascular disease 
[74]. In contrast, ETB is referred as the “good” receptor and 
is responsible for the clearance of circulating ET-1 and 
through promotion of endothelial synthesis of vasodilators 
nitric oxide and prostaglandins. The binding of ETs to the 
pharmacologically selective ETA and non-selective ETB re-
ceptors activates an overlapping set of G proteins, producing 
an array of differential physiological responses notably 
ionotropy and chronotropy in the heart or function as hor-
mone-releasing neurotransmitters in the brain that modulate 
cardiorespiratory centers [75]. Interestingly, ET-1 is highly 
similar to the snake Atractaspis engaddensis vasoconstrictor 
sarafotoxin (SRTX) S6B, sharing more than 66% similarity 
(14 identical amino acids) while displaying identical cysteine 
framework and loop sizes with their precursors being 
cleaved by the same carboxypeptidase A [76,77]. Numerous 
structure-function studies have shown that Trp21, the two 
disulfide bridges, as well as the amino and carboxy terminal 
groups, and the carboxylic side chains of Asp8 and Glu10 are 
crucial for the high vasonconstrictor activity of ET-1 [78,79]. 
It has then been suggested that ETA recognizes the tertiary 
structure of both the amino- and carboxy- ends of the ETs, 
whereas ETB is more specific to the C-terminal segment be-
tween amino acids Glu10 and Trp21 [80]. 
2.6. Prokineticins 
 Prokineticins (PKs, also called Bv8) are found in many 
organisms (amphibians, fishes, snakes, lizards and mam-
mals), and have a broad range of functions spanning from 
angiogenesis, reproduction, neurogenesis, hypothalamic 
hormone secretions, circadian rhythm control, behavior 
modulation, hematopoiesis, to reduction of the pain thresh-
old [81]. In humans, PK-2 is 102 amino acids in length with 
a motif containing 10 cysteine residues (C-C-CC-C-C-C-C-
C-C) which are able to form 5 disulfide bonds (I-IV, II-V, 
III-VII, VI-IX, VIII-X) (Fig. (3A)). The molecule forms a 
compact colipase fold where four cysteine residues are lo-
cated on the different strands that compose two -hairpins 
(Fig. (3B)). A highly conserved N-terminal hexapeptide se-
quence across species, Ala1-Val2-Ile3-Thr4-Gly5-Ala6, is 
known to be critical for its biological activity [81]. 
2.7. ASIP/AgRP 
 Finally, among the secreted cysteine-rich mini-proteins 
targeting GPCRs, we find the Agouti Signaling Protein 
(ASIP, 110 amino acids) and its homolog the Agouti-Related 
Protein (AgRP, 112 amino acids) which unusually function 
as antagonists. The two mature neuropeptides have 32 iden-
tical residues and display, at their C-termini, the same cys-
teine scaffold containing 5 disulfide bonds (C-C-CC-C-C-C-
C-C-C; I-IV, II-VI, III-IX, V-X, VII-VIII) [82] (Fig. (3A)). 
Although both act upon the same receptor family, the mela-
nocortin receptors (MCRs) they display different antagonis-
tic functions [83,84]. ASIP is the most efficient antagonist of 
the skin-specific MC1R and influences pigmentation during 
hair growth. Alternatively, hypothalamic AgRP is involved 
in energy balance by antagonizing MC3R (body weight con-
trol) and MC4R (metabolism) in the brain, which enhances 
feeding behavior and decreases energy expenditure. The cys-
teine-rich C-terminal domains of ASIP and AgRP are very 
similar to each other, and form a partial C-Terminal Cysteine 
Knot (CTCK) domain with a knottin-like I fold (i.e. one -
hairpin and its two adjacent disulfide bridges – Fig. (3B))
[85]. In both mini-proteins, these C-terminal domains are 
necessary for receptor binding (specially Arg91-Phe92-Phe93
in mature AgRP), whereas their N-termini confer upon them 
different properties [86]. Indeed, the ASIP N-terminal do-
main promotes MCR antagonism by binding an accessory 
receptor, whereas AgRP N-terminal pro-domain negatively 
regulates the antagonistic function for its receptor. 
3. CYSTEINE-RICH MINI-PROTEINS TARGETING 
ENZYME-COUPLED RECEPTORS 
 In addition to targeting GPCRs some well-known human 
secreted cysteine-rich mini-proteins function through en-
zyme-coupled receptors.  
3.1. Natriuretic Peptides  
 The natriuretic peptide hormone family is composed of 
atrial natriuretic peptide (ANP), the brain natriuretic peptide 
(BNP) and C-type natriuretic peptide (CNP) [87,88]. In hu-
mans these peptides share 11 ientical amino acids. These 
hypotensive hormones are secreted by cardiomyocytes and 
activate natriuretic peptide receptors (NPRs) A, B, and C 
which belong to the family of guanylate cyclase-coupled 
(GC-C) receptors. The selective NPR-A and NPR-B (NPR-A 
interacting with ANP and BNP; NPR-B interacting with 
CNP preferentially) and the non-selective NPR-C mediate 
protective effects of cardiovascular physiology. All NP ma-
ture active forms contain a 17-amino acid loop bridged by an 
intramolecular disulfide bond that generates a poorly defined 
loop which is further extended by the unstructured N- and C-
termini (see ANP in Fig. (4A & 4B)). In addition, it has been 
shown that the ring and the carboxyl-terminal sequence ex-
tending from the ring structure to Ser25-Phe26-Arg27-Tyr28 are 
required for the biological activity of ANP [89]. 
3.2. Guanylins 
 It has been demonstrated that ANP can promote natriure-
sis by acting in synergy with some members of the guanylin 
peptide family [90]. This group is represented by the bacte-
rial heat-stable enterotoxins (3 disulfide bonds), guanylin 
(GN) and uroguanylin (UGN) (2 disulfide bonds), as well as 
lymphoguanylin (1 disulfide bond) which activate the same 
class of cell surface receptors, GC-C. The endogenous hu-
man guanylin and uroguanylin are two hormones which are 
synthesized in the intestine and kidney. By inducing cGMP-
dependent and independent mechanisms, they induce natri-
uresis, kaliuresis, diuresis and maintain sodium balance by 
eliminating excess of electrolytes in the urine [91,92]. GN 
and UGN are 15 and 16 amino acids in length respectively, 
differing by 8 residues and displaying 4 conserved cysteine 
residues connected in a I-III, II-IV pattern (Fig. (4A)). A 
common guanylate cyclase activation domain, Ala11-Cys12-
Enzyme-coupled Receptor
Peptide Receptor Type Length Disulfide Bonds Cysteine Scaffold
Atrial natriuretic peptide NPR-A (guanylate cyclase-coupled receptor) 28 1 (6)C(15)C(5)
Guanylin GC-C (guanylate cyclase-coupled receptor) 15 2 (3)C(2)C(4)C(2)C
Epidermal Growth Factor EGFR (receptor tyrosine kinase) 53 3 (5)C(7)C(5)C(10)C(1)C(8)C(11)
Insulin-like growth factor II
IGF-1 receptor (receptor tyrosine kinase), 
IGF-2 receptor (mannose 6-phosphate 
receptor)
67 3 (8)C(11)C(24)CC(3)C(8)C(7)
A)
B)
Atrial natriuretic peptide
(1yk0)
C-C
N
Epidermal growth factor
(1nql)
C-C-C-C-C-C
N
C
Guanylin
(1o8r)
C-C-C-C
N
C
C
Insulin-like
growth factor II
(3kr3)
C-C-CC-C-C
N
C
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Thr13-Gly14-Cys15 on one side of the GN C-terminus is also 
highly conserved across species (Fig. (4B)). Nevertheless, 
the presence of Asn9 in uroguanylin (compared to Tyr9 in 
guanylin) confers protection against proteolytic cleavage and 
inactivation by endoproteases such as chymotrypsin, which 
destabilize the active disulfide bond fold [93]. A role for the 
biological activity of the N-terminal residues adjacent to the 
first cysteine in uroguanylin has also been suggested [93]. 
3.3. Epidermal Growth Factors 
 The epidermal growth factor (EGF) protein family in-
cludes several members displaying the same cysteine 
framework (C-C-C-C-C-C, with a I-III, II-IV, V-VI connec-
tivity) [94,95]. In humans, mature peptides include EGF it-
self (53 amino acids – Fig. (4A)), epiregulin (EPR; 49 amino 
acids), transforming growth factor-  (TGF ; 50 amino acids), 
neuregulin-4 (NRG-4; 61 amino acids), heparin-binding 
EGF-like growth factor (HBEGF; 86 amino acids), and am-
phiregulin (AR; 84 amino acids). All of these ligands bind 
the EGF receptor (EGFRs) which is associated with intracel-
lular tyrosine kinase activity [96]. As illustrated in Fig. (4B), 
EGF forms a knottin-like tertiary structure in which a major 
-hairpin is linked to a minor one through cysteine bonds 
surrounding the -sheets. Moreover, a consensus sequence of 
these growth factors, known as the EGF module, forms three 
loops and is necessary for receptor binding. In humans, it is 
as follows: CX7CX2-3GlyXCX10CXCX3TyrXGlyXArgC (X 
can be any amino acid except a cysteine). It has been shown 
Fig. (4). Cysteine scaffolds and 3D structures of representative secreted cysteine-rich mini-proteins interacting with enzyme-coupled 
receptors. 
(A) A selection of members of small cysteine-rich protein families interacting with enzyme-coupled receptors. The name of the polypeptide, 
its receptor, its length, the number of disulfide bonds and its cysteine scaffold (in which the green bold parts indicates active sites) are dis-
played in the table. (B) 3-dimensional structures of the polypeptides and their cysteine frameworks (Protein Data Bank references in brack-
ets). Disulfide bonds and the lateral chain of amino acids confirmed to participate in activity/binding are represented with yellow sticks and 
green lines respectively. The N- and C-terminal ends of the polypeptides are also represented. Note: the 3D structure of the human atrial 
natriuretic peptide (1yk0) lacks the first five amino acids (SLRRS) and the last two active residues (RY). However, no equivalent sequences 
with high similarity were found in other species. 
Transporter Inhibitor
Peptide Transporter Type Length Disulfide Bonds Cysteine Scaffold
Hepcidin Ferroportin-1 25 4 (6)C(2)CC(1)CC(4)C(2)CC(2)
A)
B)
Hepcidin
(3h0t)
C-CC-CC-C-CC
N C
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that the hydrophobic Tyr13 and Tyr37 are crucial for the 
mitogenic activity of EGF [97]. 
3.4. Insulin-Like Growth Factors 
 Finally, we have the insulin-like growth factor (IGF) 
axis. This complex communication system is responsible for 
cell survival, proliferation and growth, and is composed of 
two ligands (IGF-1 and IGF-2), three cell surface receptors 
(insulin receptor, the “physiologic” receptor tyrosine kinase 
IGF-1R, and the “clearance” mannose 6-phosphate IGF-2R), 
six binding proteins (IGFBP1-6), and IGFBP proteases 
[98,99]. IGF-1 and IGF-2, also called somatomedin C and A, 
respectively, are 55% identical and contain 4 distinct do-
mains (B, C, A and D from N- to C-terminus, with A and B 
being similar to those in mature insulin). IGFs also share a 
common cysteine framework composed of 3 disulfide bonds 
(C-C-CC-C-C; I-IV, II-VI, III-V), as well as a characteristic 
left-handed helix bundle fold (Fig. (4A & 4B)). An early 
structure-function study suggested that IGF-1 interacts with 
IGF-1R through its C-terminal region [100]. More recent 
data indicates that the hydrophobic residues Glu6, Leu8,
Thr16, Phe19, Asp52, and Leu53 of human IGF-2 are responsi-
ble for binding to IGF-2R with the single Thr16 residue being 
responsible for the specificity of binding to IGF-2R and not 
IGF-1R) [101,102] (Fig. (4B)). 
4. TRANSPORTER INHIBITORS 
4.1. Hepcidin 
 To the best of our knowledge the only secreted cysteine-
rich mini-protein interacting with a transporter in humans is 
hepcidin (also called Liver-Expressed Antimicrobial Peptide 
1, LEAP-1 because of its anti-bacterial and anti-fungal prop-
erties [103]). This 25 amino acid peptide forms a tight -
hairpin structure stabilized by 4 disulfide bonds and a com-
pact cysteine pattern (C-CC-CC-C-CC, connected as I-VIII, 
II-IV, III-VI, V-VII) [104] (Fig. (5A & 5B)). By inhibiting 
the ferroportin exporter in enterocytes, hepcidin is described 
as an important regulator of iron metabolism [105,106]. In-
deed, the peptide binds to an extracellular loop of ferroportin 
and triggers the internalization and lysosomal degradation of 
the transporter. Hepcidin also presents as an inactive 20 
amino acid form, lacking the N-terminal region of the active 
peptide. In addition, recent work has shown that the highly 
conserved His3, Phe4 and Ile6 in the N-terminal domain are 
essential for its inhibitory activity [107] 
5. EXTRACELLULAR ENZYME INHIBITORS 
 We identified 39 molecules (10.3%) acting as inhibitors 
of diverse extracellular enzymes and describe representatives 
of several typical domains. 
5.1. Kazal Domain-containing Mini-proteins 
 The Kazal family (family of peptidase inhibitor I1) be-
longs to the serine protease inhibitor family [108] with the 
characteristic Kazal domains that form a small -hairpin and 
an -helix in the C-terminal region linked to the N-terminus 
end by one or two disulfide bonds [109]. A typical example 
is the serine protease inhibitor Kazal-type 5 (SPINK5, also 
called LEKTI for lympho-epithelial Kazal-type-related in-
hibitor). This multi-domain protein undergoes a proteolytic 
activation cascade by furin, leading to the release of 15 indi-
vidual domains (D1-15) [110]. The mature fragments allow a 
rapid and tight control of epithelial enzymatic activity by 
inhibition of specific serine proteases such as the kallikreins 
(KLKs 5, 7, 14) involved in desquamation [111]. D-2 and D-
Fig. (5). Cysteine scaffold and 3D structure of hepcidin, a secreted cysteine-rich peptide inhibiting ferroportin transporter. 
Hepcidin target, length, disulfide bonds and cysteine framework (in which the green bold part indicates an active site) are reported in Table 
(A). Hepcidin 3-dimensional structure (3h0t) and its cysteine connectivity (B). Disulfide bonds, and lateral chain of amino acids confirmed to 
participate in activity/binding are represented with yellow sticks and green  lines respectively. The N- and C-terminal ends of the peptide are 
also shown. 
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15 contain the characteristic Kazal motif (X6CX12-
13CX7CX10CX2CX17CX2; CI-CV, CII-CIV, CIII-CVI), which is 
conserved in Kazal-type related inhibitors. The remaining 
domains exhibit a Kazal-type related motif containing 2 di-
sulfide bridges (CI-CIV, CII-CIII – Fig. (6A)) where the disul-
fide bonds create a rigid reactive center loop that mimics the 
substrate and traps the target protease [112] (Fig. (6B)). With 
the exception of D-1, all of the 4 cysteine-containing do-
mains possess an arginine located in P1 (according to 
Schechter and Berger nomenclature of cleavage sites [113]), 
which predicts activity against trypsin-like serine proteases 
[112]. 
 Another example is the pancreatic secretory trypsin in-
hibitor (PSTI, also known as SPINK1 or TATI for Tumor-
Associated Trypsin Inhibitor). This 56 amino acid peptide 
contains only one Kazal domain (Fig. (6A & 6B)). PSTI is a 
versatile molecule also displaying growth hormone function 
(by interacting with EGFR) and is potentially able to down- 
regulate autophagy [114]. The Lys18 and Ile19 residues, lo-
cated in the second disulfide loop comprise the active site of 
the mature peptide and serve as a specific target substrate for 
trypsin, where trypsin and PSTI create a stable complex by 
covalently linking the catalytic serine with the lysine residue 
of the inhibitor. 
5.2. WAP-type Four Disulfide Core Domain-containing 
Mini-proteins 
 Another domain which is conserved in some small se-
creted protease inhibitors is the whey acidic protein-type 
four-disulfide core domain (WAP-4-DSC or WFDC) [115]. 
Composed of about 50 residues, this motif contains 8 con-
served cysteine residues which form 4 disulfide bonds. To 
illustrate the importance of this domain, we wish to highlight 
two functionally complementary and pleiotropic mini-
proteins from the chelionanin family (family I17 / clan IP 
[108]): elafin (or skin-derived antileukoproteinase, SKALP) 
and the secretory leukocyte protease inhibitor (SLPI, also 
called antileukoproteinase). Primarily regarded as potent 
serine protease inhibitors with differential specificities of 
action, the mucosal elafin and SLPI proteins also sustain 
homeostatic and host defense functions by acting as antimi-
crobials and immunomodulators, for which their similar 
WFDC domains play an undeniable role [116,117]. Elafin, a 
processing product of trappin-2 protein precursor, contains a 
unique inhibitory C-terminal WAP domain that shares about 
40 % sequence identity with the two WFDC domains that 
compose the “boomerang-like shape” of SLPI (Fig. (6A & 
6B)). Elafin and the SLPI WFDC domains are very similar, 
with a -hairpin locked by disulfide bonds between a -
strand and an -turn. The inhibitory/binding loop of elafin 
has been identified between Leu20 and Leu26 where Ala24
(second inter-cysteine sequence) has been characterized as 
the P1 residue [118]. Moreover, it has been shown that oxi-
dation of Met25 decreased its affinity for target proteases 
[119]. Similarly, it has been demonstrated that the SLPI C-
terminal WFDC domain constitutes the protease-inhibitory 
region (where the binding occurs via Leu72 acting as the P1 
active site residue), whereas the first domain appears to be 
involved in stabilization of the complex enzyme-inhibitor 
[120,121]. As for elafin the oxidized Met73 also decreases the 
inhibitory ability of SLPI. The divergence in target specific-
ity of elafin and SLPI could be thus explained by the extra 
WFDC domain in the latter, as well as the differences in 
their electrostatic surface potentials [116]. 
5.3. Kunitz/BPTI Domain-containing Mini-proteins 
 Other serine protease inhibitors mediate their actions via 
the alpha/beta fold of Kunitz domain(s). The Kunitz/bovine 
pancreatic trypsin inhibitor - BPTI or aprotinin is a classical 
member of the Kunitz family [122]). -1-micro-globulin/ 
bikunin precursor protein (AMBP) is processed into -1-
microglobulin (3 cysteines/1 bond), and inter-alpha-trypsin 
inhibitor light chain or bikunin (6 disulfide bonds) [123]. 
The mature bikunin glycoprotein belongs to the family I2 
(animal-type Kunitz) protease inhibitor and contains 2 tan-
dem Kunitz-type inhibitory domains (CI-CVI, CII-CIV, CIII-
CV) characterized by two -helices and four -strands folded 
into twisted hairpins which are responsible for the binding to 
the target enzymes [124] (Fig. (6A & 6B)). Bikunin is part of 
protein-glycosaminoglycan-protein complex and plays an 
important anti-inflammatory and anti-apoptotic activities by 
inhibiting a broad spectrum a serine proteases [125]. Based 
on sequence homology with rat, a portion of bikunin could 
be further processed into smaller trypstatin-like peptides, 
which would contain only one Kunitz domain [126]. 
5.4. Metalloproteinase Inhibitors 
 Another interesting cysteine-rich family is the tissue in-
hibitor of metalloproteinase family which contains 4 mem-
bers (TIMP-1, -2, -3, and -4). Human metalloproteinases 
(MMPs) form a group of 23 zinc-dependent endopeptidases 
responsible for the degradation of the extracellular matrix 
(ECM) leading to tissue remodeling, and adaptation 
[127,128]. By inhibiting these enzymes, the ubiquitous 
TIMPs restrict the breakdown of ECM, thus maintaining 
tissue turnover and homeostasis. However, other studies 
have revealed the pleiotropic aspect of TIMPs and their in-
volvement in cell growth, differentiation and migration, as 
well as angiogenesis, apoptosis and synaptic plasticity 
[129,130]. Under physiological conditions the TIMP N- ter-
minus (3 disulfide: CI-CIV, CII-CV, CIII-CVI) mediates MMP 
proteolysis whereas its C-terminal segment (3 disulfides: 
CVII-CXII, CVIII-CIX, CX-CXI) interacts with cell surface recep-
tors and initiates intracellular signaling [127,131,132] (Fig. 
(6A)). The different folds of these two domains could ex-
plain this functional divergence. Indeed, the overall molecule 
adopts an oligonucleotide/oligosaccharide-binding fold (OB-
fold) with an opened barrel in the N-terminus domain and an 
irregular  and  rich tertiary structure in the C-terminal end 
(Fig. (6B)). Interactions between TIMPs and MMPs usually 
occur through the first five residues of the N-terminus (Cys1-
Thr2-Cys3-Val4-Pro5 in TIMP-1) and the residues before CIV
(Met66-Glu67-Ser68-Val69-Cys70 in TIMP-1) [127] (Fig. (6B)). 
Cys1 (I) and Cys70 (IV) are connected to each other and cre-
ate the ridge which lies above the catalytic Zn2+ site of the 
enzyme, and displaces the water molecule needed for peptide 
bond hydrolysis. Thr2 interacts with the S1’ specificity 
pocket of MMP, whereas residues Cys3-Val4-Pro5 interact 
with the active S’2 to S’4 subsites and Ser68 and Val69 inter-
act with S2 and S3 of MMP. As a consequence, TIMP’s C-
terminal domain would likely play a role in the stabilization 
of the enzyme-inhibitor complex. 
Peptide Enzyme Type Length Disulfide Bonds Cysteine Scaffold
Serine protease 
inhibitor Kazal-type 5 
(Kazal-like domain 1)
 KLK5/7/14, Trypsin 
(serine proteases) 39 2 (2)C(13)C(18)C(2)C
Pancreatic secretory 
trypsin inhibitor
Trypsin (serine 
protease) 56 3 (8)C(6)C(7)C(10)C(2)C(17)C
Elafin
Neutrophile Elastase, 
Proteinase-3 (serine 
proteases)
57 4 (15)C(6)C(8)C(5)C(5)CC(3)C(3)C(4)
Metalloproteinase 
inhibitor 1
MMP-1/-2/-3/-7/-8/-9/-
10/-11/-12/-13/-16 
(Matrix 
MetalloProteinase)
184 6 C(1)C(9)C(56)C(28)C(24)C(2)C(4)C(4)C(7)C(20)C(7)C(10)
 Bikunin (Inter-alpha-
trypsin inhibitor light 
chain)
Trypsin, Chymotrysin, 
Kallikrein, Elastase, 
Cathepsin, Plasmin 
(serine proteases)
147 6 (25)C(8)C(15)C(7)C(12)C(3)C(5)C(8)C(15)C(7)C(12)C(3)C(15)
Secretory leukocyte 
protease inhibitor
Neutrophile Elastase, 
Trypsin, 
Chymotrypsin, 
Chymase, Cathepsin G
107 8 (9)C(7)C(7)C(5)C(5)CC(3)C(3)C(16)C(6)C(8)C(5)C(5)CC(3)C(3)C(6)
Extracellular Enzyme Inhibitors
A)
B)
Pancreatic secretory
trypsin inhibitor
(1cgj)
C-C-C-C-C-C
Elafin
(1fle)
C-C-C-C-CC-C-C
Serine protease inhibitor
Kazal type-5
(1uuc)
C-C-C-C
Metalloproteinase inhibitor 1
(1uea)
C-C-C-C-C-C-C-C-C-C-C-C
Bikunin
(1bik)
C-C-C-C-C-C-C-C-C-C-C-C
SLPI (WAP domain 2)
(2z7f)
C-C-C-C-CC-C-C-C-C-C-C-CC-C-C
N
N
N
N
N
N
C
C
C
C
C
C
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Fig. (6). Cysteine scaffolds and 3D structures of secreted mini-proteins inhibiting extracellular enzymes, and containing characteristic 
inhibitory domains. 
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(Legend Fig. 6) contd…. 
Kazal, Kunitz, WAP or metalloproteinase domain-containing proteins inhibiting extracellular enzymes (A). The name of the polypeptide, its 
target, length, as well as the number of disulfide bonds plus its cysteine scaffold (in which the green bold parts indicates active sites) are listed 
in the table.  3-dimensional structures of the polypeptides and their cysteine frameworks (Protein Data Bank references in brackets) (B). Di-
sulfide bonds, and lateral chain of amino acids confirmed to participate in activity/binding are represented with yellow sticks and green lines 
respectively. This 3D structure of human pancreatic secretory trypsin inhibitor (1cgj) replaces the two active Lys18-Ile19 residues with 
Leu18-Glu19. For clarity only the 3D structure of the second WAP domain of secretory leukocyte protease inhibitor (SLPI) is represented 
(dotted lines) as it is this particular region that confers activity to the protein and because the first WAP domain is identical.
6. ANTIMICROBIAL PEPTIDES 
6.1. LEAP-2 
 From the analysis of human blood ultrafiltrate, Krause et
al. discovered LEAP-2, a mature 40 amino acid cationic pep-
tide, which revealed common structural characteristics with 
other antimicrobial peptides (multiple disulfide bonds, ex-
cess of positively charged residues, a basic cluster Arg29-
Lys30-Arg31-Arg32, and an acidic segment Asp19-Asp20-Ser21-
Glu22) [133,134]. Although its physiological role has not 
been elucidated it has been confirmed in vitro that LEAP-2 
possesses dose-dependent antibacterial activities against sev-
eral Gram-positive bacteria probably due to membrane per-
meabilisation [135]. According to this same study, its two 
disulfide bonds (CI-CIII, CII-CIV) may not be essential for 
activity (Fig. (7A)). However, LEAP-2 secondary structures 
may be crucial for its antimicrobial activity and membrane 
affinity (Fig. (7B)), as the reduced form of the peptide exhib-
its equal or greater efficiency against bacteria than the 
bonded scaffold [135,136]. Truncation experiments have 
demonstrated that the hydrophobic N-terminal domain and 
the cationic core region (composed of a -hairpin and a 
3(10)-helix, stabilized by disulfide and hydrogen bonds) are 
essential for electrostatic membrane binding. 
6.2. Defensins 
 Cysteine-rich defensins also form an important line of 
defense in the innate (antibiotic activity) and adaptive im-
mune system (chemotaxis) [134,137-139]. In human, there 
are 6 -defensins (human neutrophil peptides or HNP1-4 
expressed in neutrophil granules, plus HD5-6 from Paneth 
cells of the small intestine), as well as 4 -defensins (HBD1-
4 secreted by mucosal epithelia), classified according to their 
cysteine connectivities [138]. Human -defensins are 29 to 
33 residues in length, with a consensus sequence (X0-
2CXCRX2-3CX3EX3GXCX3GX5CCX0-3) composed of 3 di-
sulfide bonds (CI-CVI, CII-CIV, CIII-CV – Fig. (7A)). -
defensins contain 36 to 50 amino acids and display a consen-
sus sequence (X4-10CX6CX2-3CX7GXCX5-6CCX1-14) with 3 
disulfide bridges (CI-CV, CII-CIV, CIII-CVI – Fig. (7A)). De-
fensin disulfide bonds stabilize their predominant three 
twisted antiparallel -sheets (Fig. (7B)) and the peptides ex-
ert their antimicrobial action by the “carpet-wormhole” 
model [138]. Like most antimicrobial peptides, defensins are 
amphipathic molecules containing clusters of cationic resi-
dues and hydrophobic amino acid side chains. This chemical 
feature allows them to interact respectively with negatively 
charged and hydrophobic membrane phospholipids head and 
fatty acid chain of the pathogen, which increases membrane 
permeability and allows defensins to form oligomers which 
form pores. A recent study of -defensins highlights the im-
portance of the cationic arginine residues (XnRXnRRXnR 
for HNP1-3; XnRXnRXnRXnRXnR for HNP-5) for weakly 
binding anionic patches of the pathogen/host cell surface 
(phospholipids or glycocalix) [139]. Similar to LEAP-2 it 
has also been demonstrated that the reduction of the disulfide 
bonds in HBD-1 improves antimicrobial activity [140]. In 
addition, this study shows the involvement of the 7 residues 
of C-terminal domain in HBD-1 (Gly30-Lys31-Ala32-Lys33-
Cys34-Cys35-Lys36) in antimicrobial activity. 
7. MISCELLANEOUS CYSTEINE-RICH MINI-
PROTEINS 
 Here we describe some well-known endogenous human 
cysteine-rich proteins for which the precise functions and/or 
targets have only been partially defined. 
7.1. -Microseminoprotein 
-microseminoprotein, also called PSP94 or inhibin, is a 
10.7kDa cysteine-rich protein produced by epithelial cells of 
the prostate gland, and considered as a putative prostate can-
cer biomarker [141]. PSP94 has been shown to control the 
level of follicle-stimulating hormone, and to regulate sperm 
function [142]. It also inhibits tumor growth by forming het-
erodimers notably with the cysteine-rich secretory proteins 
(CRISPs) -3/-9, immunoglobulins and the laminin receptor 
37LRP [143]. The PSP94 monomer comprises two domains 
linked together by a disulfide bond (CIII-CIX) (Fig. (8A & 
8B)) [143]. The N-terminal domain (Ser1 – Trp52) contains 
three disulfide bonds holding together two groups of four 
and two antiparallel -strands that form a Greek key motif 
and a flap on top respectively. The C-terminal domain (Gln53
– Ile94) contains the last disulfide bridge linking one of the 
two double-stranded antiparallel -sheets. The arrangement 
of these last strands is unusual and gives rise to a new fold 
where the N- and C-terminal amino acids face each other and 
interact via a hydrogen bond.  
7.2. SLURP-1 
 Secreted Ly-6/uPAR-related protein 1 (SLURP-1) is a 
small hormone-like peptide, mainly known as an autocrine 
and paracrine allosteric ligand of epithelial nicotinic acetyl-
choline receptor (nAchR), which shows agonistic activity on 
7 nAchR subtype in the presence of Ach in vitro [144,145]. 
Moreover, SLURP-1 has been recently shown to be involved 
in cholinergic pain modulation in rodents [146]. Human 
SLURP-1 was the first mammalian member of the secreted 
Ly-6/uPAR subfamily isolated [147]. This protein family 
shares at least one Ly-6/uPAR domain(s) characterized by 
conserved cysteine residues and disulfide bond connectivity 
(C-C-C-C-C-C-C-CC-C connected as I-V, II-III, IV-VI, VII-
Antimicrobial Peptides
Peptide Target Length Disulfide Bonds Cysteine Scaffold
Liver-expressed antimicrobial peptide 2 
(LEAP-2) Bacteria 40 2 (16)C(5)C(4)C(4)C(7)
!-defensin 1 (HNP1) Microbial cell membrane 30 3 (1)C(1)C(4)C(9)C(9)CC
"-defensin 1 (HBD1) Microbial cell membrane 36 3 (4)C(6)C(4)C(9)C(6)CC(1)
A)
B)
LEAP-2
(2l1q)
C-C-C-C
α-defensin 1
(3hj2)
C-C-C-C-CC
β-defensin 1
(2nls)
C-C-C-C-CC
N
N
N
C
C
C
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VIII, IX-X). Two subfamilies can be distinguished: the GPI-
anchored glycoproteins, such as LYNX-1 (Ly-6/neurotoxin-
like protein 1) that act on nAchR [148]; and the secreted 
single domain members lacking the GPI anchor comprising 
the 82 amino acid SLURP-1 (Fig. (8A)), as well as some 
homologous snake and frogs cytotoxins such as the black 
mamba muscarinic toxin alpha, the cobra toxin CM2a, the 
krait neurotoxins, and the African clawed frog xenoxin-1 
[147]. No NMR or crystal structures of the mini-protein or of 
its close homologs have been determined. 
7.3. Neurophysins 
 Originally thought to be solely carriers for oxytocin and 
vasopressin, neurophysins (NP I and II respectively) have 
since been shown to act as folding and sorting chaperones 
necessary for the trafficking of the prohormones from the ER 
to the secretory granules [149,150]. Moreover, neurophysins 
may indirectly modulate the activity and affinity of endopep-
tidases responsible for the cleavage and maturation of their 
respective hormone-neurophysin precursors [151]. The se-
quences of NPs are highly conserved across species. They 
contain two similar N- and a C-terminal domains, each con-
taining an identical cysteine framework (C-C-CC-C-C, 
linked as II-IV, III-VII, V-VI and IX-XI, X-XIV, XII-XIII 
for N- and C-terminal regions respectively), linking a short 
hinge region with the N-terminal domain containing an extra 
disulfide bond (I-VIII, Figs. (8A & 8B)). It has been shown 
that the NP binding pocket (made by the disulfides CI-CVIII,
CIII-CVII, as well as the Cys21-Phe22-Gly23-Pro24 backbone 
and the side chains of Pro24, Glu47 and Asn48) interacts with 
the first three N-terminal residues of the hormones through a 
salt bridge [149]. The disulfide bond CI-CVIII is also crucial 
for the overall stability of the peptide [152] and the hormone 
sorting mechanism is also driven by NP dimerization and 
aggregation [153].  
8. CONCLUSIONS 
 Here we have reviewed a suite of secreted cysteine-rich 
human mini-proteins, and highlighted the relationship be-
tween particular frameworks, their biochemical properties 
and the roles these proteins play in various physiological 
systems. Surprisingly, despite the fact that we employed very 
conservative criteria, our in-house algorithm revealed a 
minimum of 53 different frameworks in 378 distinct human 
Fig. (7). Cysteine scaffolds and 3D structures of representative secreted cysteine-rich antimicrobial peptides. 
Selection of a member of small cysteine-rich LEAP and defensin antimicrobial peptides (A). The name of the polypeptide, its target, length, 
as well as the number of disulfide bonds plus its cysteine scaffold (in which the green bold parts indicates active sites) are listed in the table. 
3-dimensional structures of the peptides and their cysteine frameworks (Protein Data Bank references in brackets) (B). Disulfide bonds, and 
lateral chain of amino acids confirmed to participate in activity/interaction with microorganisms are represented with yellow sticks and green 
lines respectively. The N- and C-terminal ends of the polypeptides are represented as well. 
Miscellaneous
Peptide Target Length Disulfide Bonds Cysteine Scaffold
!-microseminoprotein CRISP-3/-9, Ig, 37LRP 94 5 (1)C(15)C(18)C(2)C(1)C(6)CC(13)C(8)C(13)C(7)
SLURP-1 "7 nAchR 82 5 (3)C(2)C(8)C(5)C(6)C(22)C(3)C(15)CC(4)C(4)
Neurophysin 1 Oxytocin (carrier) 94 7 (9)C(2)C(7)C(5)CC(5)C(9)C(9)C(6)C(5)C(5)CC(4)C(5)C(9)
A)
B)
β-microseminoprotein
(3ix0)
N C
C-C-C-C-C-CC-C-C-C
Neurophysin 1 (bovine)
(1l5c)
C-C-C-CC-C-C-C-C-C-CC-C-C
N
C
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cysteine-rich proteins. This alone strongly suggests that cys-
teine-frameworks play an important role in human biology, a 
claim which is further strengthened by the observation that a 
selection of these mini-proteins have pleiotropic effects, by 
acting as GPCRs activators (except for the antagonist mem-
bers of the Agouti protein family containing a C-terminal 
cysteine knot domain), enzyme-coupled receptor activators, 
transporter inhibitors as well as antimicrobial peptides. In-
triguingly, we also identified a set of proteins with defined 
cysteine frameworks whose functions are not completely 
elucidated, many of which, however, appear to be involved 
in hormone regulation, processing and trafficking. 
 Although the range of cysteine connectivities we have 
described here are relatively diverse, most individual frame-
works are highly conserved among protein families and often 
across heterologous species, suggesting that these protein 
scaffolds are subject to significant evolutionary pressure to 
be maintained. Interestingly, there are also examples of par-
ticular disulfide bridges with unique and important functions, 
including those described above in LEAP-2 and the defensin 
antimicrobial peptides. This highlights the importance of 
both the individual amino acid residues and the folds – it is 
the combination of these two facets that makes these cys-
teine-rich structures of such profound biological signifi-
cance. 
 It is likely that the number of secreted cysteine-rich hu-
man mini-proteins far exceeds what we have described here. 
Indeed, there have been a number of reports indicating that 
there is a wide diversity of largely uncharacterized small 
proteins encoded within the human transcriptome (particu-
larly within 3' untranslated regions), many of which are 
likely to have cysteine frameworks [154,155]. Indeed, our 
analysis did not find any small cysteine-rich ion channel 
modulators (only the SLURP/Lynx family), nor any proteins 
with the ubiquitous inhibitory cysteine knot [156] (C-C-CC-
C-C; I-IV, II-V, III-VI) which is abundant in animal toxins 
Fig. (8). Cysteine scaffolds and 3D structures of human cysteine-rich mini-proteins with diverse targets. 
Peptide name, target, length, number of disulfide bonds and cysteine frameworks (green bold characters indicate active sites) are listed in 
table A. The available 3D structures of -microseminoprotein and bovine neurophysin I show -helices (blue), - sheets (red), disulfide 
bonds (yellow sticks) and amino acid side chains involved in activity (green lines) (B). As the 3D structure of human neurophysin is not 
available we have shown its bovine counterpart. Human and bovine neurophysin I share 85% sequence homology, with the same number of 
amino acids, as well as the same cysteine framework and disulfide loop sizes. 
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and a plethora of other organisms. We suspect that these and 
other frameworks will be revealed by the current explosion 
in high-throughput RNA and protein analysis tools, and that 
further study of cysteine-rich mini-proteins will shed light on 
human physiology and the design of agents to address 
physiological and pathological imbalance. 
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2.1 Introduction 
2.1.1 Venom Peptides 
Animal venoms are heterogenous composite secretions designed for predatory and defensive 
purposes. Their function is to disrupt homeostasis in target organisms following a traumatic 
injection of the venom by use of specialized envenomation apparatus. Venoms usually contain 
inorganic salts, small organic molecules, as well as a broad range of high molecular weight proteins 
including enzymes. However, the most abundant class of molecules found in these secretions are 
cysteine-rich bioactive peptides (≤ 50 amino acids) and polypeptides (≤ 150 amino acids). 
 
In recent decades, peptide toxins have taken centre stage because of their modest size and compact 
structure which is often stabilized by conserved disulfide-rich scaffolds that provide 
physicochemical resistance against enzymatic degradation and tissue clearance. Moreover, their 
remarkable structural and functional diversity make them an abundant source of templates that can 
be used as pharmacological probes or for the design of therapeutic agents.1,2 Indeed, most venom 
peptides have the ability to selectively modulate heterologous receptors or ion channels with high 
potency or inhibit enzymes that mediate key biochemical processes. 
 
Small, disulfide-rich secreted proteins are found across the phylogenetic spectrum. Recently, the 
range of disulfide-rich peptide frameworks was described for humans, which is surprisingly the 
most extensively surveyed organism to date.3 In contrast, the diversity of disulfide scaffolds present 
in venom peptides isolated from venomous animals such as snakes, scorpions, spiders, cone snails, 
or even unexpected mammals like the duck-billed platypus, has never been surveyed but rather only 
reported in case-by-case studies.4-7 
 2.1.2 Disulfide Frameworks: Structural Skeletons Sustaining Bioactivity 
Venom peptides can dramatically vary in size, ranging from the small bromoheptapeptide Im 
isolated from the cone snail Conus imperialis 8 to the 14–18 kDa phospholipase A2 (PLA2) enzymes 
found in a variety of snake venoms.9 The most conserved structural feature of these peptides is the 
presence of intra-chain disulfide bonds that stabilise their tertiary structure; even 
bromoheptapeptide Im contains a single disulfide bond. Disulfide bonds stabilise folded proteins via 
a combination of effects, including: (i) an unfavourable reduction in conformational entropy of the 
unfolded state, thereby destabilizing the unfolded state relative to the native state; (ii) a favorable 
increase in enthalpy of the folded state through induction of favorable local interactions (e.g., by 
facilitating the packing of a cluster of hydrophobic residues), thereby stabilizing the folded state 
relative to the denatured state; (iii) protection of the folded protein from proteolytic degradation; 
(iv) in some cases, a decrease in the propensity of the protein to aggregate.10 
 
We will show in this chapter that only a limited number of disulfide frameworks and three-
dimensional (3D) folds are found among more than 2,000 mature venom mini-proteins reported to 
date. The structural stability imparted by the disulfide bridges, which allows venom peptides to 
reach their site of action when delivered into prey or predators, is not the only reason for their 
remarkable efficiency. The disulfide framework directs the three-dimensional fold of these peptides 
to such an extent that there is extreme hypervariability of the non-cysteine residues, which allows 
the most selective and potent venom peptides to be selected through the course of evolution. The 
combined structural and functional properties of venom peptides directed toward heterologous 
receptors such as G-protein coupled receptors (GPCRs),11,12 voltage- and ligand-gated sodium, 
potassium, calcium and chloride channels,13-16 transporters,17-19 or specific subtypes of enzymes20-22 
makes them a source of molecular ligands of unparalleled richness.1,2,23,24 
 
2.2 Diversity of Disulfide Scaffolds and Tertiary Structures 
In this chapter we define a disulfide-rich mini-protein as a peptide or polypeptide up to about 150 
amino acid residues in length displaying a cysteine-rich framework where all the cysteine residues 
are involved in intra-chain disulfide bonds and where all their connectivities are known. Thus, for 
the purposes of this analysis, we discarded amino acid sequences containing an odd number of 
cysteine residues (where often one cysteine residue is involved in an inter-chain disulfide bond), as 
well as polymeric disulfide-rich mini-proteins such as insulin for instance. 
 
In this chapter, particular attention will be devoted to peptide toxins elaborated by venomous 
animals with an emphasis related to their secondary structure, 3D fold, and function. 
 2.2.1 Overview of Framework Richness 
To present the mosaic of the diverse frameworks of disulfide-rich venom peptides we surveyed the 
UniProtKB-SwissProt and TrEMBL databases and retained only proteins that were isolated at the 
protein level and located exclusively in extracellular compartments (Figure 2.1).25 We then used a 
high-throughput algorithm developed in-house to select only the mature region of proteins and their 
associated meta-data (i.e. amino acid sequence, cysteine connectivity, domain(s), subcellular 
location, and 3D structure references). We then used PLA2 from Pseudonaja textilis, one of the 
longest venom polypeptides, as a reference (with a 5% tolerance threshold) to retain sequences less 
than 162 residues long, and displaying an even number of 2 to 16 cysteine residues. By selecting 
proteins with at least 9% cysteine content in order to highlight the role of the cysteine framework 
and to avoid molecules with long inter-cysteine sequences, we obtained a set of 2,022 secreted 
mature proteins. A final sorting of these peptides and polypeptides according to their taxonomic 
affiliation gave rise to 31 different groups. The great majority of these hits belong to venomous 
eumetazoans from diverse taxa such as marine invertebrates (cone snails, sea anemones, stingrays, 
octopus), arthropods (centipedes, hymenopterans, spiders, scorpions), reptiles (snakes, lizards), and 
mammals (platypus). Interestingly, despite the broad diversity of disulfide frameworks uncovered, 
as illustrated in Table 2.1, many belong to defined protein families sharing similar folds or 
structural motifs. This observation has led us to describe, in the first part of this chapter, protein 
groups from different taxa characterized by identical domains and clusters of secondary structures. 
In the second part, we focus on venom peptides with unique disulfide frameworks that tend to be 
taxon-specific.  
 
2.2.2 Consensus Architectures of Venom Peptides 
In this section we will review some typical disulfide frameworks found in peptides isolated from 
animal venoms. We will explain how the disulfide scaffolds are used to stabilize these molecules in 
a compact and well-defined form by describing the shapes and secondary structures usually 
encountered. We will also briefly describe how the active residues (i.e., the peptide 
pharmacophores), when known, are displayed on the 3D framework. 
 
2.2.2.1 Inhibitor cystine knot toxins 
The inhibitor cystine knot (ICK) motif,26 also known as a “knottin” fold, 27 is particularly abundant 
in spider-venom peptides,28,29 although it can also be found in venom peptides from predatory 
marine cone snails and scorpions.16,30 The ICK motif is composed of six cysteine residues 
distributed in a C–C–CC–C–C pattern, in which the thiol groups of CI–CIV, CII–CV, and CIII–CVI 
form three distinct disulfide bonds (Figure 2.2A–C).31 The CI–CIV and CII–CV disulfide bonds and 
   
Figure 2.1 - Pipeline for the selection of secreted cysteine-rich peptides. (A) The UniProtKB/SWISS-PROT and 
TrEMBL databases were searched for entries supported by proteomic evidence (based on Edman sequencing, mass 
spectrometry, X-ray or NMR structure, as well as detection by antibodies) and isolated from any extracellular 
compartment. A step-wise algorithm was designed for retaining only mature fragments from the parent precursor 
proteins, extracting their cysteine-framework and their related meta-data (sequences, domains, 3D structure 
references, structural homologies, phylogenetic groups). The PLA2 enzyme from Pseudonaja textilis was used as a 
reference to apply length and cysteine-content thresholds in our query (for more flexibility we added a 5% window 
in the selection criteria). Thus, we selected monomeric proteins up to 162 residues in length with an even number of 
2 to 16 cysteine residues engaged in intra-chain disulfide bonds and with an overall cysteine content of at least 9%. 
(B) Histogram showing the taxonomic distribution of protein hits that were generated using this pipeline. 
Table 2.1 - Cysteine-frameworks of venom peptides. 86 different cysteine frameworks were identified among venom peptides and polypeptides (see Figure 2.1 for details about the selection process). 
Cysteine-frameworks are displayed according to the number of cysteines, cysteine pattern and their connectivities. Taxa of the proteins containing such cysteine scaffold are listed along with the 
numbers of family members. The number of residues found between each pair of cysteine residues is shown in parentheses. The number of three-dimensional structures resolved per taxon are also listed 
in the table. Finally, as a comparison, we also reported the presence of the isolated cysteine-frameworks in humans by tick marks in the final column.	  
#	  
Cysteines	  
#	  
Disulfide	  
Bond(s)	  
Cysteine	  Pattern	   Cysteine	  Connectivity	   Taxon	   Inter-­‐cysteine	  Length	  
#	  
Toxins
/Taxon	  
#	  3D	  
Structure(s)	   Human?	  
2	   1	   C-­‐C	   I-­‐II	  
Actinopterygii	   (0-­‐5)C(4-­‐15)C(0-­‐3)	   23	   -­‐	  
✓ 
Amphibia	   (0-­‐14)C(4-­‐15)C(0-­‐4)	   48	   -­‐	  
Batoida	   C(4)C(3)	   1	   -­‐	  
Brachycera	   (8)C(2)C(4)	   3	   -­‐	  
Colubridea	   (3-­‐8)C(3-­‐10)C(4-­‐9)	   5	   -­‐	  
Conus	   (0-­‐4)C(4-­‐5)C(0-­‐3)	   15	   4	  
Decapoda	   (2)C(5)C	   1	   -­‐	  
Dytrisia	   (2)C(5)C	   1	   1	  
Eutheria	   (0-­‐5)C(4-­‐15)C(0-­‐3)	   19	   4	  
Hemiptera	   (10)C(6)C(3)	   1	   1	  
Lumbricina	   C(4)C(3)	   1	   -­‐	  
Monotrema	   C(4)C(3)	   1	   -­‐	  
Octopidadae	   C(4)C(3)	   1	   -­‐	  
Panpulmonata	   C(4)C(3)	   1	   -­‐	  
Selachii	   (0-­‐6)C(4-­‐15)C(0-­‐5)	   8	   -­‐	  
4	   2	   C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐IV	  
Actinaria	   (6)C(2)C(8)C(5)C(3)	   1	   -­‐	  
✓ Colubridea	   (2)C(11)C(6)C(16)C(2)	   1	   -­‐	  Conus	   (2-­‐6)C(3-­‐10)C(1-­‐10)C(1-­‐3)C(0-­‐1)	   2	   1	  
Eutheria	   (3-­‐16)C(2-­‐5)C(4)C(2-­‐4)C(0-­‐7)	   6	   4	  
Scorpiones	   (10)C(5)C(5)C(5)C(7)	   2	   2	  
4	   2	   C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐III	  
Aranea	   (1)C(3)C(4)C(3)C(3)	   1	   1	  
✓ Colubridea	   C(1)C(7)C(3)C(6-­‐10)	   4	   1	  Conus	   (5-­‐6)C(3)C(11)C(3)C(1)	   6	   -­‐	  
Eutheria	   (5)C(1)C(4)C(1)C(1-­‐3)	   4	   3	  
Scorpiones	   (1-­‐5)C(3-­‐5)C(5-­‐9)C(3)C(0-­‐6)	   16	   6	  
4	   2	   C-­‐C-­‐CC	   I-­‐III,	  II-­‐IV	   Conus	   (1)C(1)C(5)CC	   1	   1	     
4	  
2	  
C-­‐C-­‐CC	   I-­‐IV,	  II-­‐III	  
Conus	   (1-­‐2)C(1-­‐3)C(4-­‐6)CC(0-­‐2)	   3	   -­‐	     
	  	   Terebridae	   (1)C(2)C(4)CC	   1	   -­‐	  
4	   2	   CC-­‐C-­‐C	   I-­‐III,	  II-­‐IV	   Conus	   (0-­‐4)CC(3-­‐4)C(3-­‐7)C(0-­‐2)	   50	   19	   ✓ 
4	   2	   CC-­‐C-­‐C	   I-­‐IV,	  II-­‐III	   Conus	   (0-­‐3)CC(4)C(2-­‐3)C	   9	   3	     
4	   2	   CC-­‐CC	   I-­‐III,	  II-­‐IV	   Conus	   (0-­‐21)CC(4-­‐6)CC(0-­‐4)	   25	   1	     
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐IV,	  V-­‐VI	  
Actinaria	   (5)C(8)C(5)C(10)C(1)C(8)C(5)	   1	   -­‐	   ✓ 
Eutheria	   (7)C(7)C(4)C(10)C(1)C(8)C(7)	   3	   1	  
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐V,	  IV-­‐VI	   Aranea	   (2-­‐3)C(3)C(8-­‐9)C(4-­‐7)C(5)C(4)C(3)	   34	   1	     
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐III,	  V-­‐VI	   Scorpiones	   (2)C(4)C(3)C(9)C(4)C(1)C(3)	   1	   -­‐	   ✓ 
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI	  
Acari	   (3)C(6)C(3)C(9)C(7)C(1)C(3)	   2	   -­‐	    Aranea	   (2-­‐3)C(3)C(8-­‐13)C(7-­‐11)C(4-­‐5)C(4)C(3)	   5	   1	  
Brachycera	   (2-­‐12)C(6-­‐12)C(3)C(9)C(4-­‐5)C(1)C(2)	   7	   3	  
Conus	   (1-­‐5)C(3-­‐4)C(5)C(2-­‐3)C(1)C(4)C(4)	   5	   1	   ✓ Dytrisia	   (6)C(10)C(3)C(9)C(7)C(1)C(1-­‐2)	   4	   2	  
Hemiptera	   (2)C(16)C(3)C(9)C(4)C(1)C(2)	   2	   -­‐	  
Scorpiones	   (1-­‐28)C(2-­‐9)C(2-­‐3)C(5-­‐11)C(3-­‐8)C(1-­‐2)C(0-­‐11)	   115	   34	  
Terebridae	   (4)C(4)C(5)C(3)C(1)C(12)C(2)	   1	   -­‐	  
Turridae	   (2-­‐6)C(4)C(4)C(3)C(1-­‐3)C(6-­‐10)C(2-­‐4)	   3	   -­‐	  
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐IV,	  III-­‐VI	  
Actinopterygii	   (11)C(8)C(7)C(10)C(2)C(17)C	   1	   -­‐	  
✓ 
Amphibia	   (5)C(7)C(7)C(10)C(2)C(21)C	   2	   -­‐	  
Aranea	   (5)C(15)C(2)C(6)C(3)C(8)C(5)	   3	   1	  
Brachycera	   (2)C(3)C(7)C(17)C(6)C(14)C(1)	   1	   -­‐	  
Dytrisia	   (13)C(3)C(2)C(12)C(3)C(10)C(13)	   2	   -­‐	  
Eutheria	   (6-­‐13)C(6-­‐9)C(7)C(10)C(2)C(17)C(0-­‐8)	   14	   5	  
Scorpiones	   (1)C(4)C(3)C(8)C(3)C(1)C(2-­‐3)	   2	   1	  
6	   3	   C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐VI,	  II-­‐IV,	  III-­‐V	  
Actinaria	   (1-­‐7)C(6-­‐8)C(4-­‐15)C(7-­‐10)C(3-­‐12)C(2-­‐3)C(0-­‐7)	   17	   3	  
✓ Aranea	   (3)C(8)C(13)C(7)C(12)C(3)C(3)	   1	   1	  Colubridea	   (1-­‐6)C(8-­‐9)C(15)C(7)C(12)C(3)C(2-­‐10)	   33	   7	  
Eutheria	   (4-­‐6)C(8)C(15)C(7)C(12)C(3)C(3-­‐9)	   5	   1	  
Panpulmonata	   (6)C(8)C(15)C(7)C(12)C(3)C(1)	   1	   -­‐	  
Scyphozoa	   (2)C(8)C(6)C(13)C(3)C(2)C	   1	   1	  
6	   3	   C-­‐C-­‐C-­‐C-­‐CC	   I-­‐V,	  II-­‐IV,	  III-­‐VI	  
Actinaria	   (2-­‐4)C(1)C(14-­‐21)C(6-­‐9)C(6-­‐9)CC(1-­‐5)	   35	   6	   ✓ Colubridea	   (3)C(6)C(6-­‐7)C(11)C(5)CC(4-­‐8)	   12	   1	  
Eutheria	   (4-­‐10)C(6)C(4)C(9)C(6)CC(1-­‐4)	   20	   4	  
Monotrema	   (8)C(6)C(7)C(7)C(6)CC(2)	   2	   2	  
6	   3	   C-­‐C-­‐C-­‐C-­‐CC	   I-­‐VI,	  II-­‐IV,	  III-­‐V	  
Colubridea	   (1)C(17)C(22)C(1)C(6)CC(7)	   1	   -­‐	   ✓ 
Eutheria	   (0-­‐36)C(1)C(3-­‐5)C(9)C(6-­‐9)CC(0-­‐3)	   46	   13	  
6	   3	   C-­‐C-­‐C-­‐CC-­‐C	   I-­‐II,	  III-­‐IV,	  V-­‐VI	   Conus	   (3)C(6)C(3)C(9)CC(14)C(1-­‐2)	   2	   1	     
6	   3	   C-­‐C-­‐CC-­‐C-­‐C	   I-­‐III,	  II-­‐V,	  IV-­‐VI	   Aranea	   (1)C(6)C(6)CC(19)C(2)C(1)	   1	   -­‐	     
Conus	   (3)C(6)C(6)CC(4)C(3)C(1)	   1	   -­‐	  
Dytrisia	   (5-­‐9)C(3)C(9)CC(10)C(5-­‐6)C(1-­‐3)	   2	   -­‐	  
6	   3	   C-­‐C-­‐CC-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI	  
Aranea	   (0-­‐6)C(4-­‐6)C(4-­‐9)CC(2-­‐10)C(3-­‐14)C(1-­‐16)	   227	   28	  
  Brachycera	   (10)C(6)C(5)CC(3)C(6)C(2)	   1	   -­‐	  Conus	   (0-­‐6)C(2-­‐7)C(2-­‐9)CC(2-­‐9)C(3-­‐10)C(0-­‐7)	   78	   14	  
Hemiptera	   (4-­‐5)C(6)C(6)CC(4-­‐5)C(6)C(1-­‐3)	   3	   2	  
Scorpiones	   (1-­‐4)C(6)C(5)CC(3-­‐5)C(8-­‐10)C(1-­‐6)	   4	   2	  
Terebridae	   (2-­‐10)C(2-­‐5)C(3-­‐5)CC(4-­‐16)C(2-­‐10)C(1-­‐3)	   3	   -­‐	  
6	   3	   CC-­‐C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐V,	  IV-­‐VI	   Conus	   (0-­‐1)CC(6)C(2)C(1)C(3)C(0-­‐5)	   3	   -­‐	     
6	   3	   CC-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI	   Eutheria	   (3)CC(9)C(12)C(15)C(10)C(9)	   1	   1	   ✓ 
6	   3	   CC-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐III,	  IV-­‐VI	   Conus	   (1)CC(7)C(2)C(1)C(6-­‐7)C(2-­‐6)	   2	   2	     
6	   3	   CC-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐IV,	  III-­‐VI	   Actinaria	   (2)CC(1)C(4)C(5)C(4)C(5)	   1	   1	     
6	   3	   CC-­‐C-­‐C-­‐CC	   I-­‐IV,	  II-­‐V,	  III-­‐VI	   Conus	   (1-­‐3)CC(3-­‐6)C(4-­‐9)C(1-­‐5)CC(0-­‐3)	   17	   6	   ✓ 
6	   3	   CC-­‐C-­‐C-­‐CC	   I-­‐V,	  II-­‐IV,	  III-­‐VI	   Conus	   (0-­‐2)CC(4)C(1-­‐5)C(1)CC(0-­‐4)	   12	   1	     
6	   3	   CC-­‐C-­‐C-­‐CC	   I-­‐VI,	  II-­‐IV,	  III-­‐V	   Conus	   (0-­‐3)CC(2-­‐4)C(2-­‐4)C(2-­‐3)CC(0-­‐2)	   20	   -­‐	     
6	   3	   CCC-­‐C-­‐C-­‐C	   I-­‐VI,	  II-­‐IV,	  III-­‐V	   Conus	   (1-­‐7)CCC(3)C(3-­‐5)C(2-­‐3)C(0-­‐1)	   2	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐II,	  III-­‐VI,	  IV-­‐VII,	  V-­‐VIII	   Scorpiones	   (1)C(2)C(4)C(5)C(3)C(10)C(4)C(1)C(2)	   4	   1	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐VII,	  IV-­‐V,	  VI-­‐VIII	   Aranea	   (3)C(3)C(8)C(4)C(1)C(10)C(5)C(4)C(3)	   2	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI,	  VII-­‐VIII	   Scorpiones	   (12)C(9)C(3)C(10)C(11)C(1)C(10)C(7)C(1)	   1	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐IV,	  III-­‐VIII,	  VI-­‐VII	   Dytrisia	   (2)C(10)C(3)C(8)C(7)C(1)C(11)C(5)C	   1	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐IV,	  VII-­‐VIII	   Scorpiones	   (2)C(5)C(3)C(5)C(4)C(4)C(1)C(2)C(0-­‐1)	   3	   2	     
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐VII,	  IV-­‐VIII	   Scorpiones	   (2-­‐6)C(5)C(3)C(4-­‐5)C(4)C(4)C(1)C(2-­‐3)C(0-­‐2)	   8	   6	   ✓ 
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐VIII,	  II-­‐V,	  III-­‐VI,	  IV-­‐VII	   Brachycera	   (1)C(8)C(7)C(3)C(9)C(5)C(1)C(2)C	   1	   1	     
Scorpiones	   (9-­‐12)C(3)C(3-­‐9)C(3)C(8-­‐11)C(4-­‐9)C(1)C(13-­‐17)C(0-­‐4)	   167	   28	  
8	   4	   C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C	   I-­‐III,	  II-­‐IV,	  V-­‐VI,	  VII-­‐VIII	  
Amphibia	   (2)C(13)C(6)C(12)C(5)C(14)CC(4)C(2)	   3	   -­‐	     
Colubridea	   (2)C(8-­‐16)C(4-­‐6)C(13-­‐20)C(1-­‐3)C(5-­‐11)CC(2-­‐5)C(0-­‐8)	   165	   34	  
8	   4	   C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C	   I-­‐III,	  II-­‐VI,	  IV-­‐VII,	  V-­‐VIII	   Conus	   (2)C(7)C(4)C(1)C(8)CC(4)C(5)C(6)	   2	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C	   I-­‐VI,	  II-­‐VII,	  III-­‐V,	  IV-­‐VIII	  
Colubridea	   (6-­‐9)C(7-­‐12)C(3)C(5)C(5)CC(3)C(3-­‐4)C(5-­‐7)	   2	   2	   ✓ 
Eutheria	   (15)C(6)C(8)C(5)C(5)CC(3)C(3)C(4)	   1	   1	  
8	   4	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐VII,	  V-­‐VIII	   Scorpiones	   (0-­‐15)C(2-­‐10)C(3-­‐10)C(2-­‐10)CC(3-­‐9)C(1-­‐4)C(1-­‐19)C(0-­‐8)	   34	   6	     
8	   4	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐VIII,	  IV-­‐VII	   Aranea	   C(7)C(3)C(1)CC(5)C(12)C(26)C(1)	   2	   -­‐	     
8	   4	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VII,	  III-­‐VI,	  IV-­‐VIII	   Aranea	   (1)C(10)C(3)C(1)CC(5)C(8)C(28)C(8)	   1	   -­‐	     
8	   4	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI,	  VII-­‐VIII	   Aranea	   C(6)C(5)CC(3)C(5-­‐6)C(4-­‐6)C(3)C(2-­‐3)	   4	   -­‐	     
8	   4	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VIII,	  VI-­‐VII	   Aranea	   (1-­‐11)C(4-­‐7)C(4-­‐10)CC(4-­‐13)C(1)C(4-­‐16)C(1)C(1-­‐30)	   49	   8	     
8	   4	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐VIII,	  V-­‐VII	   Aranea	   (2)C(6)C(7)CC(2)C(1)C(15)C(1)C(4)	   2	   -­‐	     
8	   4	   C-­‐C-­‐CC-­‐CC-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐VII,	  V-­‐VIII	   Conus	   (0-­‐4)C(6)C(5)CC(1-­‐5)CC(3-­‐7)C(3-­‐10)C(3-­‐8)	   10	   1	     
8	   4	   C-­‐C-­‐CC-­‐CC-­‐C-­‐C	   I-­‐VI,	  II-­‐VII,	  III-­‐IV,	  V-­‐VIII	  
Aranea	   (2-­‐3)C(6)C(2)CC(1)CC(4)C(9-­‐10)C(3-­‐5)	   4	   1	     
Conus	   (2)C(6)C(5)CC(3)CC(2)C(3)C(4)	   1	   1	  
8	   4	   C-­‐C-­‐CCC-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐VII,	  V-­‐VIII	   Aranea	   C(6)C(5)CCC(3)C(10)C(10-­‐11)C(0-­‐2)	   7	   3	     
8	   4	   C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐VII,	  V-­‐VIII	   Colubridea	   (0-­‐6)C(4)CC(2)C(8)C(9-­‐11)C(4)C(1)C(5-­‐11)	   16	   3	     
8	   4	   C-­‐CC-­‐CC-­‐C-­‐CC	   I-­‐VIII,	  II-­‐IV,	  III-­‐VI,	  V-­‐VII	  
Actinopterygii	   (1)C(2)CC(1)CC(5)C(2)CC(2)	   1	   1	   ✓ 
Eutheria	   (1-­‐6)C(2)CC(1)CC(4)C(2)CC(2)	   3	   2	  
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐VII,	  IV-­‐VIII,	  IX-­‐X	   Eutheria	   (11)C(13)C(9)C(3)C(19)C(14)C(15)C(1)C(2)C(6)C(3)	   1	   -­‐	   ✓ 
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐VI,	  II-­‐VII,	  III-­‐VIII,	  IV-­‐IX,	  V-­‐X	   Conus	   (1)C(3)C(4)C(3)C(1)C(5)C(1)C(10)C(1)C(1)C(1)	   1	   -­‐	   ✓ 
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐CC	   I-­‐X,	  II-­‐IX,	  III-­‐VI,	  IV-­‐VII,	  V-­‐VIII	   Eutheria	   (31)C(11)C(8)C(1)C(3)C(10)C(1)C(1)C(9)CC(3)	   1	   -­‐	     
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C	   I-­‐III,	  II-­‐VI,	  IV-­‐V,	  VII-­‐VIII,	  IX-­‐X	   Colubridea	   (2)C(9-­‐12)C(5-­‐6)C(4-­‐5)C(3)C(10)C(3)C(10-­‐11)CC(4)C(2-­‐18)	   46	   8	     
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C	   I-­‐V,	  II-­‐III,	  IV-­‐VI,	  VII-­‐VIII,	  IX-­‐X	  
Colubridea	   (2-­‐9)C(2)C(4-­‐7)C(5-­‐7)C(6)C(14-­‐20)C(3)C(9-­‐11)CC(4)C(1-­‐3)	   27	   8	   ✓ 
Eutheria	   (2)C(2)C(6-­‐8)C(5-­‐6)C(6-­‐7)C(12-­‐22)C(2-­‐5)C(15-­‐17)CC(4-­‐5)C(3-­‐8)	   5	   1	  
10	   5	   C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C	   I-­‐VII,	  II-­‐V,	  III-­‐IX,	  IV-­‐VI,	  VIII-­‐X	  
Colubridea	   (1)C(15-­‐17)C(19)C(2)C(1)C(6)CC(11)C(8)C(13)C(2)	   2	   -­‐	   ✓ Eutheria	   (1-­‐2)C(7-­‐15)C(17-­‐18)C(2)C(1)C(6-­‐7)CC(12-­‐13)C(8)C(13)C(7-­‐25)	   4	   2	  
Loliginidae	   (1)C(19)C(18)C(2)C(1)C(6)CC(13)C(6)C(12)C(3)	   1	   -­‐	  
10	   5	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐VII,	  IV-­‐IX,	  VIII-­‐X	   Aranea	   (3)C(6)C(3)C(1)CC(4)C(1)C(24)C(1)C(11)C(5)	   2	   -­‐	     
10	   5	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐VI,	  III-­‐X,	  IV-­‐IX,	  VII-­‐VIII	   Aranea	   (0-­‐3)C(6)C(3)C(1)CC(4-­‐5)C(1)C(3-­‐11)C(1)C(8-­‐16)C(0-­‐6)	   13	   -­‐	     
10	   5	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐XII,	  IX-­‐VI,	  III-­‐X,	  IV-­‐IX,	  VII-­‐VIII	   Aranea	   (1)C(6)C(6)C(1)CC(5)C(1)C(9)C(1)C(11)C(3)	   1	   -­‐	     
10	   5	   C-­‐C-­‐C-­‐CC-­‐CC-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VII,	  III-­‐VIII,	  V-­‐IX,	  VI-­‐X	  
Actinopterygii	   (10)C(2)C(16-­‐17)C(2)CC(26)CC(18-­‐20)C(1)C(2)C(5)	   4	   -­‐	   ✓ Amphibia	   (10)C(2)C(18)C(2)CC(26)CC(21)C(1)C(2)C(5)	   1	   -­‐	  
Eutheria	   (4-­‐10)C(2)C(17)C(2)CC(26)CC(21)C(1)C(2)C(5)	   11	   1	  
10	   5	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VII,	  VI-­‐IX,	  VIII-­‐X	  
Amphibia	   (6)C(5)C(4)CC(11)C(9)C(17)C(1)C(5)C(8)C(1)	   4	   1	   ✓ Aranea	   (2-­‐7)C(4-­‐5)C(4)CC(7-­‐8)C(9)C(12-­‐15)C(1)C(5)C(5-­‐6)C(3-­‐5)	   8	   -­‐	  
Colubridea	   (6)C(5)C(4)CC(11)C(9)C(17)C(1)C(5)C(9)C(4)	   1	   1	  
Decapoda	   (2)C(6)C(4)CC(11)C(9)C(15)C(1)C(5)C(6)C(13)	   1	   -­‐	  
Eutheria	   (6-­‐11)C(5)C(3-­‐4)CC(10-­‐11)C(9)C(11-­‐38)C(1)C(5)C(9-­‐17)C(4-­‐9)	   7	   1	  
10	   5	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VIII,	  VI-­‐VII,	  IX-­‐X	   Aranea	   (1)C(6)C(5)CC(13)C(1)C(6)C(1)C(3)C(3)C	   1	   -­‐	     
10	   5	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐IX,	  V-­‐VIII,	  VII-­‐X	   Aranea	   (2)C(6)C(6)CC(2)C(2)C(1)C(7)C(1)C(6)C(3)	   1	   -­‐	     
10	   5	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐IV,	  II-­‐VI,	  III-­‐IX,	  V-­‐X,	  VII-­‐VIII	  
Aranea	   (2-­‐3)C(6)C(5)CC(2)C(2)C(1)C(6-­‐7)C(1)C(6-­‐8)C(1-­‐2)	   6	   -­‐	   ✓ 
Eutheria	   (65-­‐70)C(6)C(6)CC(2)C(2)C(1)C(6)C(1)C(6-­‐9)C(0-­‐3)	   2	   1	  
10	   5	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐CC-­‐C	   I-­‐V,	  II-­‐III,	  IV-­‐VI,	  VII-­‐VIII,	  IX-­‐X	   Colubridea	   (2)C(2)C(9)CC(6)C(26)C(3)C(13)CC(4)C(7)	   2	   -­‐	     
12	   6	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C	  
I-­‐V,	  II-­‐IV,	  III-­‐VI,	  VII-­‐XI,	  VIII-­‐X,	  IX-­‐XII	  
Eutheria	   (7-­‐15)C(11)C(7)C(10)C(2)C(17)C(3)C(6)C(7)C(10)C(2)C(17)C(0-­‐3)	   8	   -­‐	     
Hemiptera	   (5)C(1)C(7)C(10)C(3)C(16)C(8)C(2)C(8)C(10)C(3)C(16)C(2)	   1	   1	  
12	   6	   C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐VI,	  II-­‐IV,	  III-­‐V,	  VII-­‐XII,	  VIII-­‐X,	  IX-­‐XI	  
Acari	   (5-­‐9)C(8)C(14-­‐15)C(7)C(12)C(3)C(10-­‐17)C(8)C(15)C(7)C(12)C(3)C(1-­‐3)	   3	   1	   ✓ 
Eutheria	   (4-­‐6)C(8)C(15)C(7)C(12)C(3)C(5)C(8)C(15)C(7)C(12)C(3)C(12)	   2	   -­‐	  
12	   6	  
C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C	   I-­‐VI,	  II-­‐VII,	  III-­‐XII,	  IV-­‐VIII,	  V-­‐IX,	  X-­‐XI	  
Actinopterygii	  
(1-­‐5)C(13)C(2)C(7)C(3)C(18-­‐20)C(14)C(15)C(1)C(2)C(6)C(9-­‐11)C(6-­‐
21)	   8	   -­‐	   ✓ Amphibia	   (0-­‐3)C(13)C(2)C(7)C(3)C(18)C(14)C(15)C(1)C(2)C(6)C(9)C(5-­‐7)	   2	   -­‐	  
Eutheria	   (0-­‐10)C(13)C(2)C(7)C(3)C(18-­‐20)C(14)C(15)C(1)C(2)C(6)C(9)C(7-­‐11)	   17	   2	  
12	   6	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C	  
I-­‐V,	  II-­‐VII,	  III-­‐XI,	  IV-­‐X,	  VI-­‐XII,	  VIII-­‐IX	   Aranea	   (1)C(6)C(3)C(1)CC(1)C(3)C(1)C(13)C(1)C(7)C(6)C(3)	   1	   -­‐	     
12	   6	  
C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C	   I-­‐XII,	  IX-­‐VI,	  III-­‐X,	  IV-­‐IX,	  VII-­‐VIII,	  XI-­‐XII	   Aranea	   (1)C(6)C(6)C(1)CC(5)C(1)C(10)C(1)C(11)C(6)C(7)C(9)	   2	   -­‐	  
  
12	   6	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C	  
I-­‐VII,	  II-­‐IV,	  III-­‐XII,	  V-­‐XI,	  VI-­‐IX,	  VIII-­‐X	   Actinaria	   (10)C(15)C(14)CC(5)C(6)C(17)C(3)C(6)C(4)C(1)C(6)C(12)	   1	   -­‐	     
12	   6	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐XII,	  II-­‐IV,	  III-­‐XI,	  V-­‐X,	  VI-­‐VIII,	  VII-­‐IX	  
Actinaria	   (24)C(1)C(14)CC(5)C(11)C(16)C(8)C(4)C(1)C(6)C(17)C	   1	   1	   ✓ 
Eutheria	   (25)C(1)C(14)CC(5)C(8)C(17)C(5)C(4)C(1)C(6)C(19)C(1)	   1	   -­‐	  
12	   6	   C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C	   I-­‐IV,	  II-­‐V,	  III-­‐VI,	  VII-­‐X,	  VIII-­‐XI,	  IX-­‐XII	   Aranea	   (1)C(6)C(5)CC(6)C(7)C(12)C(6)C(5)CC(4)C(7)C(8)	   1	   -­‐	     
12	   6	   C-­‐C-­‐CC-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C	   I-­‐III,	  II-­‐IV,	  V-­‐VIII,	  VI-­‐XI,	  VII-­‐IX,	  X-­‐XII	   Colubridea	   (0-­‐8)C(1)C(6)CC(4)C(7)C(4)CC(2)C(8)C(10-­‐11)C(6)C(5-­‐7)	   35	   4	     
12	   6	   C-­‐C-­‐CC-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C	   I-­‐V,	  II-­‐IV,	  III-­‐IX,	  VI-­‐VIII,	  VII-­‐XI,	  X-­‐XII	   Colubridea	   (3)C(1)C(6)CC(4)C(7)C(4)CC(2)C(8)C(11)C(6)C(6)	   1	   1	     
12	   6	   C-­‐C-­‐CC-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	   I-­‐XI,	  II-­‐IV,	  III-­‐X,	  V-­‐XII,	  VI-­‐IX,	  VII-­‐VIII	   Colubridea	   (25)C(1)C(14)CC(4)CC(24)C(10)C(1)C(6)C(19)C(6)C	   3	   -­‐	     
14	   7	   C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C	  
I-­‐VI,	  II-­‐VII,	  III-­‐V,	  IV-­‐VIII,	  IX-­‐XIV,	  X-­‐XII,	  
XI-­‐XIII	  
Eutheria	   (11)C(6)C(7)C(5)C(5)CC(3)C(3)C(7)C(8)C(15)C(7)C(12)C(3)C(6-­‐7)	   2	   -­‐	   ✓ 
14	   7	  
C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐
CC-­‐C-­‐C	  
I-­‐XIV,	  II-­‐VI,	  III-­‐V,	  IV-­‐VII,	  VIII-­‐XII,	  IX-­‐
XI,	  X-­‐XIII	   Eutheria	   (5)C(1)C(10)C(9)C(4)CC(10)C(11)C(9)C(9)C(4)CC(10)C(8)C(2)	   2	   1	  
✓ 
14	   7	   C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐CC-­‐C-­‐
C-­‐C-­‐C	  
I-­‐IV,	  II-­‐VII,	  III-­‐VI,	  V-­‐XI,	  VIII-­‐X,	  IX-­‐XIII,	  
XII-­‐XIV	  
Colubridea	   (4)C(10)C(1)C(5)C(3)CC(4)C(7)C(4)CC(2)C(8)C(11)C(6)C(4)	   1	   -­‐	     
14	   7	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	  
I-­‐V,	  II-­‐VI,	  III-­‐X,	  IV-­‐IX,	  VII-­‐VIII,	  XI-­‐XII,	  
XIII-­‐XIV	   Aranea	   (1-­‐2)C(6)C(6)C(1)CC(5)C(1)C(9)C(1)C(11)C(5)C(5-­‐12)C(3)C(4)C(0-­‐4)	   2	   -­‐	  
  
14	   7	  
C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C	  
I-­‐V,	  II-­‐VI,	  III-­‐X,	  IV-­‐IX,	  VII-­‐VIII,	  XI-­‐XIII,	  
XII-­‐XIV	   Aranea	   (5)C(6)C(6)C(1)CC(5)C(1)C(6)C(1)C(11)C(5)C(10)C(3)C(3)C(1)	   2	   -­‐	  
  
14	   7	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C	  
I-­‐VIII,	  II-­‐XIV,	  III-­‐V,	  IV-­‐XIII,	  VI-­‐XII,	  VII-­‐
X,	  IX-­‐XI	  
Colubridea	   (10)C(13-­‐15)C(1)C(13-­‐14)CC(5)C(8-­‐9)C(10-­‐15)C(5-­‐8)C(5-­‐
6)C(4)C(1)C(6)C(17-­‐20)C(0-­‐3)	  
74	   20	   ✓ 
Eutheria	   (8-­‐10)C(15)C(1)C(14)CC(5)C(9)C(15)C(6)C(6)C(4)C(1)C(6)C(17-­‐18)C(0-­‐2)	   8	   3	  
14	   7	   C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C	  
I-­‐VIII,	  II-­‐IV,	  III-­‐VII,	  V-­‐VI,	  IX-­‐XI,	  X-­‐XIV,	  
XII-­‐XIII	  
Conus	   (5)C(2)C(4)C(5)CC(4)C(9)C(9)C(6)C(11)C(5)CC(4)C(5)C(1)	   1	   -­‐	   ✓ 
Eutheria	   (6-­‐9)C(2)C(7)C(5)CC(5)C(9)C(9)C(6)C(5)C(5)CC(4)C(5)C(7-­‐10)	   8	   1	  
14	   7	  
C-­‐C-­‐CC-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C	  
I-­‐XIII,	  II-­‐IV,	  III-­‐XII,	  V-­‐XIV,	  VI-­‐XI,	  VII-­‐
IX,	  VIII-­‐X	  
Colubridea	  
(24-­‐25)C(1)C(13-­‐15)CC(4)CC(6)C(16-­‐19)C(4-­‐6)C(3-­‐4)C(1)C(6)C(17-­‐
20)C(5-­‐7)C	   153	   42	   ✓ 
Eutheria	   (24)C(1)C(14)CC(4)CC(8)C(17)C(5)C(4)C(1)C(6)C(19)C(6)C	   2	   -­‐	  
16	   8	   C-­‐C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C-­‐C-­‐C	  
I-­‐X,	  II-­‐III,	  IV-­‐XVI,	  V-­‐VII,	  VI-­‐XV,	  VIII-­‐
XIV,	  IX-­‐XII,	  XI-­‐XIII	  
Colubridea	   (18)C(3)C(3)C(7)C(1)C(14)CC(5)C(9)C(15)C(6)C(6)C(4)C(1)C(6)C(18)
C(1)	  
1	   -­‐	     
16	   8	  
C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐C-­‐C-­‐C-­‐C	  
I-­‐X,	  II-­‐XVI,	  III-­‐VI,	  IV-­‐VII,	  V-­‐XV,	  VIII-­‐
XIV,	  IX-­‐XII,	  XI-­‐XIII	   Colubridea	  
(10)C(14)C(1)C(1)C(11)CC(3)C(1)C(9)C(10)C(6)C(6)C(4)C(1)C(6)C(18
)C(1)	   1	   1	  
  
16	   8	   C-­‐C-­‐C-­‐C-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐
C-­‐CC-­‐C-­‐C	  
I-­‐VI,	  II-­‐VII,	  III-­‐V,	  IV-­‐VIII,	  IX-­‐XIV,	  X-­‐XV,	  
XI-­‐XIII,	  XII-­‐XVI	  
Eutheria	   (5-­‐14)C(7-­‐10)C(2-­‐7)C(5)C(5)CC(3-­‐4)C(3)C(9-­‐17)C(6-­‐12)C(3-­‐
8)C(5)C(5)CC(3)C(3-­‐4)C(5-­‐14)	  
7	   2	   ✓ 
16	   8	   C-­‐C-­‐C-­‐CC-­‐CC-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C-­‐C	  
I-­‐IX,	  II-­‐XV,	  III-­‐V,	  IV-­‐XIV,	  VI-­‐XVI,	  VII-­‐
XIII,	  VIII-­‐XI,	  X-­‐XII	   Eutheria	  
(10)C(13)C(1)C(14)CC(4)CC(8)C(10)C(6)C(6)C(4)C(1)C(6)C(17)C(6)C(
1)	   1	   -­‐	  
✓ 
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 the intervening sections of the peptide backbone form a ring that is bisected by the third disulfide 
bridge (Figure 2.2B), resulting in four hypervariable inter-cystine loops (Figure 2.2A). This 
"knotted" architecture confers on ICK peptides quite remarkable thermodynamic stability and 
resistance to proteases.29 The four peptides described below illustrate the core ICK architecture and 
how it can be elaborated with additional disulfide bonds. 
 
 
ω-Conotoxin MVIIA (Figure 2.2D) is a 25-residue peptide from the venom of the cone snail Conus 
magus. A synthetic version of this peptide is marketed under the trade name ziconitide as an 
analgesic drug for the treatment of intractable chronic pain.32 (See Chapter 9 for more details.) 
Figure 2.2 - Venom peptides containing an inhibitor cystine knot motif. (A) Structure of the spider-venom peptide ω-
hexatoxin-Hv1a (pdb code 1axh)172 with the three disulfide bonds that form the ICK motif highlighted in red and green. The 
disulfide bridges result in four intercystine loops, with the final loop emanating from the C-terminal β sheet (β strands shown 
in blue). (B) The CysI-CysIV and CysII–CysV disulfide bonds in ω-hexatoxin-Hv1a (shown in green) and the intervening 
sections of the peptide backbone (shown in grey) form a closed loop that is bisected by the CysIII–CysVI disulfide bond. (C) 
Topology of the ICK motif, which comprises an antiparallel β sheet stabilised by a cystine knot. β strands are shown in blue 
and the six cysteine residues that form the cystine knot are labeled I–VI. The β sheet comprises two mandatory C-terminal β 
strands (shown in blue) that house CysV and CysVI, and a third N-terminal β strand (shown in translucent blue) that 
encompasses CysII is sometimes present. The two “outer” disulfide bonds are shown in green and the “inner” disulfide bridge 
that bisects the cystine-knot loop is shown in red. (D–G) Amino acid sequence and ribbon representations of the three 
dimensional structure of the ICK toxins ω-conotoxin MVIIA (D), huwentoxin IV (E), psalmotoxin 1 (F), and δ-hexatoxin-
Hv1a (G). In these images and all subsequent structures shown in this chapter, α helices, β strands, and disulfide bonds are 
shown in blue, red, and yellow, respectively. Residues that have been experimentally demonstrated to be critical for toxin 
function are highlighted in green in the amino acid sequence and their side chains are displayed in the 3D structures. The N- 
and C-termini are labelled, PDB accession numbers are indicated in parentheses, and the source organism and molecular 
target are indicated. Cysteine connectivities are shown above the primary structures. (nh2) indicates that the C-terminus is 
amidated. 
 MVIIA contains an ICK motif supported by a triple-stranded β-sheet involving residues Ala6–Cys8 
(β strand 1), Cys20–Arg21 (β strand 2), and Lys24–Cys25 (β strand 1).33,34 MVIIA exerts its anti-
nociceptive action by potently and selectively inhibiting the voltage-gated calcium (Cav) channel 
Cav2.2 via an interaction mediated largely by residues Arg10 and Arg21 in loops 2 and 4, 
respectively.35,36 
 
Huwentoxin IV from the venom of the Chinese tarantula Haplopelma schmidti also contains an ICK 
motif (Figure 2.2E). Its 3D structure is very similar to that of ω-conotoxin MVIIA with two 
antiparallel β-strands connected by a loop that contains the positively charged Arg26 residue that is 
essential for inhibition of the human voltage-gated sodium (NaV) channel NaV1.7.37-39 Loss-of-
function mutations in the gene encoding this channel lead to a congenital insensitivity pain,40 
without any other sensory deficits except anosmia,41,42 and consequently this channel is considered 
an excellent analgesic target.43-46 Thus, there is much interest in the potential of this class of spider-
venom-derived ICK toxins as potential analgesics drugs.46,47  
 
Psalmotoxin 1 (π-theraphotoxin-Pc1a or PcTx1; Figure 2.2F) is a 40-residue peptide isolated from 
the venom of the Trinidad chevron tarantula Psalmopoeus cambridgei. It is a potent and selective 
inhibitor (IC50 ~ 0.5 nM) of acid sensing ion channel (ASIC) 1a.48,49 The structure of PcTx1 is 
dominated by a β-hairpin (Leu21 to Lys35) made of two antiparallel β-strands (Leu21–Trp24 and 
Val32–Lys35), plus a single turn of 310 helix in the second loop (His14–Asp16), and a β-turn in the 
third loop (Cys18–Leu21).48,49 The overall structure of PcTx1 is stabilized by a typical ICK 
framework. PcTx1 is currently in preclinical studies for treatment of chronic pain50 and stroke.51 
 
δ-Hexatoxin-Hv1a (δ-HXTX-Hv1a; Figure 2.2G) from the Blue Mountains funnel-web spider 
Hadronyche versuta is a member of the lethal δ-hexatoxin family that is responsible for deaths from 
envenomation by this family of spiders. δ-HXTX-Hv1a slows down inactivation of insect and  
vertebrate NaV channels and causes a hyperpolarizing shift in the voltage-dependence of 
activation13. This induces spontaneous repetitive firing and prolongation of action potentials which 
results in neurotransmitter release from somatic and autonomic nerve endings.13 In humans, this 
leads to a severe envenomation syndrome that includes lachrymation, salivation, skeletal muscle 
fasciculation, sweating, nausea, vomiting, diarrhoea, pulmonary oedema, disturbances in 
respiration, blood pressure and heart rate, followed by severe hypotension and respiratory or 
circulatory failure. 52 
 
 δ-HXTX-Hv1a is a 42-residue peptide with a cysteine framework comprising eight cysteine 
residues that form a C–C–CCC–C–C–C pattern with a unique triplet of consecutive cysteine 
residues.53 The eight cysteine residues are engaged in four disulfide bonds with CI–CIV, CII–CVI, 
CIII–CVII, CV–CVIII connectivity.52 Although, the cysteine pattern is unique, δ-HXTX-Hv1a is 
simply a variant ICK toxin in which an additional disulfide bond has been added to stabilise an 
extended C-terminal region. Three of the four disulfide bonds in δ-ACTX-Hv1a (Cys1–Cys15, 
Cys8–Cys20 and Cys14–Cys31) form a classical ICK motif in which the Cys14–Cys31 disulfide 
bond passes through a 14-residue ring formed by the peptide backbone and the Cys1–Cys15 and 
Cys8–Cys20 disulfide bonds.52 The core ICK region contains a classical three-stranded β-sheet 
comprising Asn6–Trp7 (β strand 1), Met18–Val21 (β strand 2), and Ser30–Ser33 (β strand 3) 
(Figure 2.2E). The C-terminal region beyond the last Cys residue of the ICK core is unusually long 
and forms several turns of 310 helix (residue Ile35–Lys41) (Figure 2.2E). The fourth, atypical 
disulfide bond between the C-terminal Cys42 residue and Cys16 in the ICK core region effectively 
acts as a molecular staple that limits the flexibility of the C-terminal helical extension.52 
 
δ-HXTX-Hv1a is an example of the way in which ICK toxins are commonly elaborated via the 
addition of non-core disulfide bonds. There are numerous examples of ICK toxins in which an 
extended β-hairpin loop (loop 4; see Figure 2.2A) is held in place by an additional disulfide bond 
positioned at the tip of the β strands; examples included the spider-venom peptides Aps III54, ω-
agatoxin IVA55, and δ-palutoxin IT2.56 In some cases, more exotic disulfide bonds are present, such 
as the vicinal disulfide bridge found in loop 2 of κ-HXTX-Hv1c,57 which is essential for its high-
affinity block of insect calcium-activated potassium (KCa) channels. 58,59 Since the disulfide bonds 
strongly direct the 3D fold of ICK toxins, they are very permissive to sequence variations in the 
intercystine loops. As a result, ICK toxins have evolved to target a wide range of ion channels and 
receptors, including CaV, Kv, NaV, and KCa, channels, ASICs, transient receptor potential (TRP) 
channels, and P2X3 receptors. Moreover, this sequence plasticity has enabled ICK toxins to serve 
as templates for the design of diagnostic agents and drugs in which residues in the intercystine 
loops have been substituted in order to optimize bioavailability or bioactivitiy.60-62 
 
Two-disulfide toxins with a knottin-like fold have also been described in spiders and scorpions.63 In 
this fold, denoted a disulfide-directed β-hairpin (DDH),57 the N-terminal CysI–CysIV disulfide bond 
found in knottins is absent. At this stage, there is conflicting evidence about whether the ICK fold is 
derived from the DDH fold by addition of a disulfide bond (making the DDH fold the plesiotypic 
state) or vice versa.57,63,64 
 
 2.2.2.2 BPTI/Kunitz Inhibitor Domain 
The Kunitz/BPTI (Bovine Pancreatic Trypsin Inhibitor) family are a ubiquitous group of cysteine-
rich proteinase inhibitors.65 Members of this family contain a conserved cysteine framework (C–C–
C–C–C–C pattern with connectivity CI–CVI, CII–CIV, CIII–CV) and a consensus α/β fold, called the 
Kunitz domain, responsible for their protease inhibitory activity, mainly against serine proteases 
such as trypsin, chymotrypsin, cathepsin, and plasmin.66,67 Kunitz domain peptides have been 
recruited into a number of animal venoms. For example, the Kunitz-type proteinase inhibitor SHPI-
1 isolated from the sea anemone Stoichactis helianthus (Figure 2.3A),68-70, κ-theraphotoxin-Hh1a 
(also called huwentoxin-11; Figure 2.3B) from the venom of the Chinese bird spider,71, and 
calcicludin from the venom of the Eastern green mamba snake (Figure 2.3C)72,73 all contain a 
Kunitz domain. 
 
 
They share a similar elongated structural organization with an α-helix in their C-terminal region 
connected to one of the two (SHPI-1, calcicludin) or three (huwentoxin-11) central β-strands, as 
well as to the N-terminal extremity of the toxin through the CI–CVI and CIII–CV disulfide bonds. The 
Figure 2.3 - Venom peptides containing a BPTI/Kunitz inhibitor motifs. Shown on the left are the 3D structures of (A) SHPI-
1, (B) huwentoxin-11, and (C) calcicludin. The N- and C-termini are labelled and PDB accession numbers are indicated in 
parentheses. The primary structure of these peptides along with their disulfide framework, source organism, and molecular 
function are shown in the right panels of the figure. 
 remaining disulfide bridge CII–CIV stabilizes the flexible portion of the toxin located at the opposite 
side of the linked N- and C-termini. In SHPI-1 and huwentoxin-11 the key pharmacophoric Arg and 
Lys residues are located in the first and second loop, respectively.71,74 However, although these 
three peptide toxins have a similar 3D structure, they have different specificities of action. While 
SHPI-1 appears to be primarily a protease inhibitor (acting on vertebrate trypsin and 
chymotrypsin),74 huwentoxin-11 also strongly inhibits the Kv1.1 channel,71,75 and calcicludin 
inhibits CaV1 (L-type) calcium channels with an IC50 in the nanomolar range.72 This observation 
highlights the importance of hypervariablity in the protein primary structure and the difficulty of 
predicting the function of venom peptides based solely on structural homology. 
 
2.2.2.3 Kazal-Like Domain 
Another clan of proteolytic enzyme inhibitors is the Kazal family. According to the MEROPS 
database,76 members of this family of peptidase inhibitor I1 contain one or multiple consensus 
Kazal domain(s) in reference to the pancreatic secretory trypsin inhibitor SPINK1 originally 
discovered by Kazal et al. in 1948.77 This domain contains a conserved cysteine framework (C–C–
C–C–C–C pattern) with disulfide connectivity CI–CV, CII–CIV, CIII–CVI as compared to the CI–CVI, 
CII–CIV, CIII–CV connectivity in the Kunitz domain protease inhibitors and CI–CIV, CII–CV, and CIII–
CVI connectivity in ICK toxins. The consensus core of the Kazal domain usually consists of an α-
helix and a small β-hairpin cross-linked by two disulfide bonds.78 As Kazal domain-containing 
mini-proteins can be found in many divergent species, this characteristic structure is also present in 
venom peptides like rhodniin, an extremely potent inhibitor of thrombin (Figure 2.4). 
 
 
Figure 2.4 - The Kazal domains of rhodniin from the assassin bug Rhodnius prolixus. 3D structure of rhodniin. The N- 
and C-termini are labelled and the PDB accession number is indicated in parentheses. The primary structure of the peptide 
along with the source organism and molecular target and shown below the 3D structure.  
 This 103-residue (11 kDa) polypeptide was isolated from the assassin bug Rhodnius prolixus and it 
is presumed to be expressed in the saliva of this blood-feeding insect in order to prevent blood 
clotting and thus allow prolonged feeding.79 Homologs are present in many other triatomine bugs. 
Rhodniin contains N- and C-terminal Kazal domains separated by an acidic linker. The 2.6 Å 
resolution crystal structure of a rhodniin/bovine α-thrombin complex revealed the dominant role of 
the disc-shaped N-terminal rhodniin domain in the interaction with thrombin.80 The N-terminal 
domain residues Pro9, His10, Ala11, Leu12, His13 and Arg14 interact with the active-site cleft of 
thrombin, whereas the C-terminal domain interacts with the fibrinogen recognition exosite mainly 
through electrostatic interactions. 
 
2.2.2.4 WAP Domain 
The four-disulfide whey acidic protein (WAP)-type core domain (also called WAP-4-DSC or 
WFDC)81 is particularly conserved in the subclass of small-secreted cysteine-rich mini-proteins like 
elafin or the secretory leukocyte protease inhibitor SLPI for instance, that play important roles in 
host defense as antimicrobials and immunomodulators.82,83 Two snake venom peptides belonging to 
the waprin family, nawaprin from the black-necked spitting cobra Naja nigricollis (Figure 2.5A) 
and omwaprin-a from the inland taipan Oxyuranus microlepidotus (Figure 2.5B), contain a single 
WAP domain and have similar functions.84,85 These two peptides are of similar length (51 and 50 
residues, respectively, which is characteristic of WAP domains), and they have the same eight-
cysteine scaffold (C–C–C–C–CC–C–C pattern with disulfide connectivity CI–CVI, CII–CVII, CIII–CV, 
CIV–CVIII), as well as identical secondary structures and tertiary folds. Nawaprin and omwaprin-a 
possess an overall flat shape with a spiral backbone organized in one outer and one inner segment 
stabilized by the four disulfide bridges.84 The outer part contains only a small 310 helix connected to 
the inner segment that comprises an antiparallel β-sheet. Interestingly, whereas only hypothetical 
specificities of action have been formulated for nawaprin, it has been demonstrated that contrary to 
elafin and SLPI, omwaprin-a selectively targets its bactericidal activity against certain species of 
Gram-positive bacteria (Bacillus megaterium and Staphylococcus warneri) by causing membrane 
disruption in a dose-dependent manner; in contrast, it is non-toxic to mice.85 Moreover, the same 
study revealed that the structure and disulfide scaffold of omwaprin-a are essential for sustaining 
the function of the toxin, as witnessed by the complete loss of activity upon reduction and 
alkylation of the cysteine residues, even with its six N-terminal pharmacophoric residues still 
present.
  
2.2.2.5 SXC Motif 
The six-cysteine SXC or ShKT motif is found in diverse organisms such as mammals,86,87 the 
nematode Caenorhabditis elegans,88 and cnidarians (sea anemones and jellyfish). The Kv channel 
blocker ShK from the Caribbean sea anemone Stichodactyla helianthus (Figure 2.6A), and aurelin 
from the moon jellyfish Aurelia aurita (Figure 2.6B) illustrate this diversity. Both peptide toxins 
contain a unique SXC motif comprising six cysteines arranged in a C–C–C–C–C–C pattern with 
disulfide connectivity CI–CVI, CII–CIV, CIII–CV.89-91 The disulfide-rich SXC domain is an all-α motif 
with two short α-helices linked to portions of the peptide backbone via two disulfide bonds.91-93 The 
third disulfide bond (CI–CVI) links the N- and C-terminal regions of the toxin. The 40-residue 
aurelin peptide has moderate antibacterial activity against Gram-positive Listeria monocytogenes 
and Gram-negative Escherichia coli.91 In contrast, ShK (35 residues, 4.05 kDa) potently inhibits 
human Kv1.3 (IC50 ≈ 10–100 pM). This channel is a therapeutic target for autoimmune disease 
because of its upregulation in effector memory T cells. ShK-186, a derivative of ShK with 
improved stability and selectivity for Kv1.3, recently passed Phase Ia clinical trials for treatment of 
multiple sclerosis (see Chapter 10 for further details). 
Figure 2.5 - WAP domains of two members of the waprin family. Left panels show the 3D structures of (A) nawaprin 
determined using NMR spectroscopy, and (B) omwaprin-a determined using X-ray crystallography. The N- and C-termini are 
labelled and PDB accession numbers are indicated in parentheses. Right panels show the primary structure and disulfide 
framework of these peptides and list the source organism and molecular function. 
  
2.2.2.6 PLA2 
PLA2 enzymes are found in almost all living entities from bacteria to mammals. They are essential 
hydrolytic enzymes involved in various physiological processes such as lipid metabolism,94 signal 
transduction,95 and host defense.96 In the world of venomous animals, secreted Ca2+-dependent 
PLA2s are particularly abundant in snake, bee and wasp venoms. PLA2s are at the edge between 
polypeptides and proteins, being larger than most venom peptides, and functionally viable as 
monomers or homo- or heterodimers. We have chosen to illustrate a subtype of secretory PLA2s 
using three different snake venom mini-proteins: the acidic PLA2 5 isolated from the venom of the 
cobra Naja sagittifera (Figure 2.7A), the basic PLA2 notexin from the common tiger snake Notechis 
scutatus scutatus (Figure 2.7B), and ammodytoxin A from the Western sand viper Vipera 
ammodytes ammodytes (Figure 2.7C). These toxins are 118–122 residues in length, and they have 
different cysteine frameworks. PLA2 5 from N. sagittifera contains 16 cysteine residues disposed in 
a C-C-C-C-CC-C-C-C-C-C-C-C-C-C-C pattern with disulfide connectivity CICX, CIICXVI, CIIICVI, 
CIVCVII, CVCXV, CVIIICXIV, CIXCXII, CXICXIII.97 Notexin has 14 cysteine residues (C-C-C-CC-C-C-C-
C-C-C-C-C-C) that form seven disulfide bridges (CICVIII, CIICXIV, CIIICV, CIVCXIII, CVICXII, CVIICX, 
CIXCXI).98 Ammodytoxin A also has 14 cysteine residues, although their disposition (C-C-CC-CC--
Figure 2.6 - The SXC folds of ShK and aurelin. Left panels show the 3D structures of 
(A) ShK and (B) aurelin. The N- and C-termini are labelled and PDB accession 
numbers are indicated in parentheses. Right panels show the primary structure and 
disulfide framework of these peptides and list the source organism and molecular 
function. 
 C-C-C-C-C-C-C-C) and disulfide connectivity (CICXIII, CIICIV, CIIICXII, CVCXIV, CVICXI, CVIICIX, 
CVIIICX) are not the same as notexin.99 Despite their different primary structure (~28% identity) and 
cysteine frameworks, these three members of the PLA2 family share identical secondary elements 
and very similar overall 3D architectures. They all display a central core comprised of three long α-
helices flanked by a small β-hairpin on the side, as well as two short helical turns in the C-terminal 
region, with the numerous disulfide bridges stabilizing the compact structure.97,99,100 Apart from 
exerting classical PLA2 hydrolytic activities on the 2-acyl groups in 3-sn-phosphoglycerides, 
notexin and ammodytoxin A are also able to increase the release of acetylcholine (ACh) at 
neuromusclar junctions via a mechanism that remains to be precisely elucidated.100-105 
 
 
2.2.3 Taxon-Specific Disulfide Frameworks 
In the second part of this chapter, we will focus on unique disulfide frameworks that are only found 
in specific animal taxa, and describe the 3D architecture of these venom peptides. 
 
Figure 2.7 - Structure of PLA2 enzymes from snake venoms. The 3D structures of (A) acidic PLA2 5, (B) notexin, and (C) 
ammodytoxin A are shown at the top of the figure. The N- and C-termini are labelled and PDB accession numbers are 
indicated in parentheses. (D) Primary structure and disulfide framework of these PLA2 enzymes. The source organism and 
molecular function are indicated. 
 2.2.3.1 Neurotoxin III Fold in Sea Anemones (Order Actinaria) 
The first taxon-specific disulfide framework we will discuss is found in neurotoxin III (ATX III), a 
27-residue peptide isolated from the Mediterranean snakelocks sea anemone Anemonia sulcata. 
ATX III contains six cysteine residues that form a CC–C–C–C–C pattern and are organized into 
three disulfide bonds (CI–CV, CII–CIV, CIII–CVI; Figure 2.8).106-108 ATX III is devoid of any regular 
secondary structure; rather, the 3D structure determined using NMR spectroscopy109 revealed a 
compact architecture containing two distorted type I β-turns (Cys6–Gly9 and Trp8–Cys11), two 
inverse γ-turns (Pro12–Gly14 and Gln15–Cys17), and two other chain reversals that enable ATX III 
to adopt an overall globular and twisted fold. ATX III slows inactivation of NaV channels in 
crayfish giant axons.110 However there have been no investigations into structure-activity 
relationships of the toxin. 
 
 
 
2.2.3.2 Snakes (Order Squamates) 
2.2.3.2.1 Snake Three-Finger Toxins 
The three-finger toxins (3FTs) are a snake-specific disulfide-rich peptide family characterized by a 
conserved three-dimensional fold and disulfide framework.111 All 3FTs contain four conserved 
disulfide bridges in their core region, but extra disulfide bonds are sometimes present.112 The 
typical fold of 3FTs is comprised of three β-stranded loops, symbolized as fingers, which stretch 
and diverge from a single globular and hydrophobic cysteine-rich core region comprising the four 
conserved disulfide bonds.113,114 Despite their common three-dimensional topology, 3FTs have 
diverse pharmacology with toxins from this family capable of targeting nicotinic acetylcholine 
receptors (nAChRs), muscarinic acetylcholine receptors (mAChRs), acetylcholinesterase, CaV 
Figure 2.8 - Structure of the sea anemone peptide neurotoxin III. Left panel shows the 
3D structure of neurotoxin III determined using NMR spectroscopy. The N- and C-termini 
are labelled and the PDB accession number is indicated in parentheses. Right panel shows 
the primary structure and disulfide framework of neurotoxin III and lists the source 
organism and molecular function. Note the lack of regular secondary structure.  
 channels, adrenergic receptors, and ASICs.111,115,116 3FTs have been used extensively as molecular 
probes for studying the pharmacology and tissue/cellular distribution of nAChRs.117-119  
 
α-Elapitoxin-Nk2a (Figure 2.9A) is a typical 3FT isolated from the venom of the monocled cobra 
Naja kaouthia. This 71-residue peptide contains 10 cysteine residues (C–C–C–C–C–C–C–CC–C 
pattern) that form five disulfide bonds with connectivity CI–CIII, CII–CVI, CIV–CV, CVII–CVIII, CIX–
CX).120-122 α-Elapitoxin-Nk2a contains the three loops typically found in 3FTs plus two distorted 
right-handed helical turns at the tip of loop II, stabilized by the fifth disulfide bond CIV–CV.121 The 
monomeric form of the toxin binds selectively and with high affinity to muscle and neuronal α7 
nAChR, thereby triggering paralysis in envenomated prey.123-125 Loop II of α-elapitoxin-Nk2a, 
which is stabilized by the extra disulfide bond and contains the helical turns, is crucial for high 
affinity interaction of the toxin with the α7 nAChR.126-128 
 
2.2.3.2.2 Snake Disintegrins 
The 3FTs display diverse pharmacology on a conserved structural scaffold. In contrast, members of 
the viper-specific disintegrin protein family share a similar function, namely inhibition of platelet 
aggregation and integrin-dependent cell adhesion, but they encompass a wider range of folds than 
the 3FTs.129,130 To illustrate this structural diversity we will discuss three disintegrins that exhibit 
different disulfide scaffolds and 3D folds: jarastatin from the South American pit viper Bothrops 
jararaca (Figure 2.9B), triflavin from the venom of Protobothrops flavoviridis (Figure 2.9C), a 
viper endemic to the Ryukyu islands of Japan, and obstutatin from the Asian blunt-nosed viper 
Macrovipera lebetina obtusa (Figure 2.9D). Jarastatin and triflavin are medium-sized disintegrins, 
with 73 and 70 residues respectively, and they contain six disulfide bonds,131-133 whereas obstustatin 
is smaller (41 residues) and contains only four disulfide bridges.134,135 Jarastatin and triflavin have 
identical cysteine patterns (C–C–CC–C–C–CC–C–C–C–C) but different cysteine connectivities 
(CI–CIII, CII–CIV, CV–CVIII, CVI–CXI, CVII–CIX, CX–CXII and CI–CV, CII–CIV, CIII–CIX, CVI–CVIII, 
CVII–CXI, CX–CXII respectively). Obtustatin has only eight cysteine residues (C–CC–C–C–C–C–C 
pattern) with connectivity CI–CIV, CII–CVI, CIII–CVII, CV–CVIII. The 3D structures of these toxins 
(note that the jarastatin structure is a theoretical model produced in silico) reveal different overall 
shapes and a lack of major secondary structure elements. Triflavin adopts an elongated and rigid 
structure characterized by a series of turns and two short regions composed of antiparallel β-
strands.136 This anti-aggregant agent inhibits the interaction between fibrinogen and platelets by 
binding to the glycoprotein IIb-IIIa receptor on the platelet surface.131 Obtustatin has a compact 
globular shape comprised almost exclusively of turns without any regular secondary structure.135 
 Obtustatin potently and selectively inhibits the α1/β1 integrin via a triad of loop residues (Lys21-
Thr22-Ser23) that differs from the usual disintegrin Arg-Gly-Asp pharmacophore motif.137 
 
 
Figure 2.9 - 3FTs and disintegrins from snake venom. Left panels show the 3D structures of (A) α-elapitoxin-Nk2a (X-
ray; PDB 1ctx), (B) jarastatin (model; PDB 2inh), (C) triflavin (X-ray; PDB 1j2l), and (D) obtustatin (NMR; PDB 1mpz). 
The N- and C-termini are labelled and PDB accession numbers are indicated in parentheses. Right panels show the primary 
structure and disulfide framework of these peptides and indicate the source organism and molecular function. 
 2.2.3.3 Marine Cone Snails (Genus Conus) 
Several toxins found in the venom of marine cone snails from the genus Conus display unique 
cysteine scaffolds. We exemplify such peptides with descriptions of ι-conotoxin RXIA, α-conotoxin 
PIVA, and ε-conotoxin TxVA. 
 
2.2.3.3.1 ι-Conotoxins 
ι-Conotoxin RXIA was first discovered in the venom of the piscivorous (fish-hunting) rayed cone 
snail Conus radiatus 138 (Figure 2.10A). ι-Conotoxin RXIA contains 46 residues with eight 
cysteines arranged in an atypical framework (C–C–CC–CC–C–C pattern with disulfide connectivity 
CI–CIV, CII–CVI, CIII–CVII, CV–CVIII).139 ι-conotoxin RXIA has numerous post-translational 
modifications (PTMs) in addition to the four disulfide bonds, including hydroxyproline at positions 
2, 11 and 29 and an unusual D-Phe as the third last residue.139,140 The 3D structure of ι-conotoxin 
RXIA comprises a series of turns and two antiparallel β-strands in a compact globular region 
stabilized by the four disulfide bonds, as well as a long flexible C-terminal tail.139 
Electrophysiology experiments revealed that ι-conotoxin RXIA is an excitatory peptide that 
agonises frog and mouse NaV1.2, NaV1.6 and NaV1.7 channels (NaV1.6 > NaV1.2 > NaV1.7) by 
shifting the voltage-dependence of activation to more hyperpolarised potentials.139,141 Mutation of 
the D-Phe residue to L-Phe caused a two-fold reduction in affinity towards NaV1.6 and a two-fold 
faster off-rate, as well as a complete inactivity on NaV1.2, indicating that this PTM contributes 
significantly to toxin activity.139,141 
 
2.2.3.3.2 α-Conotoxins 
α-Conotoxin PIVA from the piscivorous purple cone Conus purpurascens is a typical α-conotoxin 
that displays a taxon-specific cysteine framework (Figure 2.10B). This short, 25-residue 
conopeptide contains six cysteine residues (CC–C–C–C–C) that form three disulfide bonds (CI–CV, 
CII–CIII, CIV–CVI).142 Like ι-conotoxin RXIA, it is also rich in PTMs, with hydroxyprolines at 
positions 7, 13, and 20 as well as an amidated C-terminus. Han et al. described the overall shape of 
α-conotoxin PIVA as an “iron” in which the external and highly charged hydrophilic Ser15–Arg19 
segment is the “handle”, while the rest of the toxin forms the “bottom plate”.143 α-Conotoxin PIVA 
does not contain significant secondary structure, with the exception of a single turn of a 310 helix 
formed by residues Ser21–Gly24. Like most α-conotoxins, α-conotoxin PIVA inhibits postsynaptic 
nAChRs, particularly the α1/β1/γ/δ subtype.144 
  
2.2.3.3.3 ε-Conotoxins 
ε-Conotoxin TxVA from the venom of the molluscivorus cone snail Conus textile (Figure 2.10C) is 
a very short 13-residue peptide with a unique cysteine pattern composed of two tandem cysteines 
(CC–CC) with disulfide connectivity CI–CIII, CII–CIV. TxVA is replete with PTMs, including γ-
carboxyglutamate at positions 1 and 4, bromotryptophan at position 7, a glycosylated threonine at 
position 10, and hydroxyproline at the C-terminus.145-147 It is the prototypic member of the T-
superfamily of conotoxins that is defined by the presence of two tandem cysteines separated by 4–7 
residues.148 The side chains of the two γ-carboxyglutamate residues create an electronegative patch 
Figure 2.10 - Taxon-specific disulfide frameworks from cone snail venom. Left panels show the 3D structures of (A) ι-
conotoxin RXIA, (B) α-conotoxin PIVA, and (C) ε-conotoxin TxVA. The N- and C-termini are labelled and PDB accession 
numbers are indicated in parentheses. Right panels show the primary structure and disulfide framework of these peptides and 
indicate the source organism and molecular function. PTMs are indicated as follows O = hydroxyproline; f = D-Phe; (Gla) = 
γ-carboxyglutamate; (BTr) = bromotryptophan; (gTr) = glycosylated threonine; (nh2) = amidated C-terminus. 
 extending outward from a cavernous cleft.146 On the C-terminal face of the peptide, the 
glycosylated Thr10 and Hyp13 confine a cluster of hydrophobic residues around the brominated 
Trp7 in the constrained intercysteine region.146 It has been suggested that TxVA might target 
presynaptic CaV channels or GPCRs based on the fact that it causes a reduction of calcium influx 
and neurotransmitter release in Aplysia cholinergic synapses.146 However, no unequivocal target has 
been defined for any member of the T-superfamily with the exception of τ-CnVA, from the 
piscivorous cone snail Conus consors, which was recently shown to be a micromolar antagonist of 
the somatostatin sst3 receptor.148 
 
2.2.3.4 CSα/β Toxins in Scorpions (Order Scorpiones) 
Scorpions and centipedes are the oldest terrestrial venomous taxa, with the oldest scorpion fossils 
dating back 430 million years to the Silurian period.2 Although they inhabit a diverse range of 
habitats, they are far less speciose than their closest venomous relatives, the spiders, with ~1,750 
extant species.2 Scorpion venoms are dominated by so-called cysteine stabilised α/β (CSα/β) toxins 
that are evolutionarily derived from CSα/β defensins, innate-immunity-related antimicrobial 
peptides that are found in plants, fungi, nematodes, and arthropods.149,150 It was recently 
demonstrated that only a modest number of mutations are required to convert a CSα/β defensin into 
a neurotoxin.151 Most CSα/β scorpion toxins target Kv or NaV channels.150 The core cysteine 
framework of CSα/β scorpion toxins is the C–C–C–C–C–C pattern found in CSα/β defensins, but 
many toxins are elaborated with additional disulfide bonds, as outlined in the examples below. 
  
2.2.3.4.1 Butantoxin (α-KTx12.1) 
The potassium channel toxin α-KTx12.1, also called butantoxin or TsTX-IV, was first isolated from 
the venom of the Brazilian yellow scorpion Tityus serrulatus (Figure 2.11A).152 This 40-residue 
peptide contains a cysteine framework composed of eight cysteine residues (C–C–C–C–C–C–C–C) 
with disulfide connectivity CI–CII, CIII–CVI, CIV–CVII, CV–CVIII).153,154 The CIII–CVI, CIV–CVII, and 
CV–CVIII disulfide bonds constitute the core disulfide framework found in CSα/β defensins, with the 
N-terminal CI–CII disulfide being an elaboration of the core fold. Butantoxin is a typical CSα/β 
toxin in which an α-helix is nestled on face of a β-hairpin, with this core fold stabilized by the CIII-
CVI, CIV-CVII and CV-CVIII disulfide bonds.153,155,156 The remaining N-terminal CI–CII disulfide 
bridge is unique to this toxin and does not appear to confer additional stability.153 Butantoxin blocks 
high-conductance KCa channels and inhibits Shaker Kv channels with low affinity.152 Preliminary 
SAR studies revealed that His28 is important for interaction with its molecular targets.155 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.4.2 Maurotoxin (α-KTx6.2) 
α-KTx6.2, also known as maurotoxin (Figure 2.11B), from the venom of the chactoid scorpion 
Scorpio maurus palmatus is a 34-residue peptide comprising an 8-cysteine scaffold (C–C–C–C–C–
C–C–C) with disulfide connectivity CI–CV, CII–CVI, CIII–CIV, CVII–CVIII.157-161 The CI–CV, CII–CVI, 
and CIII–CIV disulfide bonds constitute the core disulfide framework found in CSα/β defensins, with 
the C-terminal CVII–CVIII disulfide being an elaboration of the core fold. The core CSα/β fold is 
Figure 2.11 - The scorpion-specific CSα /β  framework. Left panels show the 3D structures of (A) 
butantoxin, (B) maurotoxin, and (C) chlorotoxin. The N- and C-termini are labelled and PDB 
accession numbers are indicated in parentheses. Right panels show the primary structure and 
disulfide framework of these peptides and indicate the source organism and molecular function. Note 
that all three peptides exhibit a core CSα/β defensin fold consisting of an α-helix on one face of a 2- 
or 3-stranded antiparallel β-sheet. 
 comprised of a single α-helix (Ser6–Gln16) abutting a two-stranded antiparallel β-sheet (β-strands 
Lys23–Asn26 and Ser28–Cys31).161 Maurotoxin can block the Shaker B channel as well as Kv1.1 
(IC50 = 45 nM), Kv1.2 (IC50 = 0.8 nM), and Kv1.3 (IC50 = 180 nM) channels with high 
affinity.158,159,162  
 
2.2.3.4.3 Chlorotoxin 
Chlorotoxin is a 36-residue CSα/β toxin isolated from the venom of the Egyptian scorpion Leiurus 
quinquestriatus quinquestriatus. It contains eight cysteine residues distributed in a C–C–C–CC–C–
C–C pattern with disulfide connectivity CI–CIV, CII–CVI, CIII–CVII, CV–CVIII.163,164 In this case, the 
CII–CVI, CIII–CVII, and CV–CVIII disulfide bonds constitute the core disulfide framework found in 
CSα/β defensins, with the N-terminal CI–CIV disulfide being an elaboration of the core fold. 
Relative to the classic CSα/β defensin fold, chlorotoxin contains an additional N-terminal β-strand, 
which leads to the formation of a three-stranded antiparallel β-sheet, and the extra disulfide bond 
links this additional β-strand to the α-helix (Figure 2.11C).164 Chlorotoxin induces paralysis in 
crayfish and cockroaches and inhibits small conductance chloride channels isolated from rat 
epithelia and brain.163,165 Chlorotoxin selectively binds to gliomas (a type of malignant brain 
cancer) and inhibits glioma cell invasion by virtue of interactions with annexin A2 and matrix 
metalloproteinase-2 on the cell surface.166,167 Moreover, it was recently reported that chlorotoxin is 
capable of permeating the human blood-brain barrier.168 A chlorotoxin conjugate is currently in 
clinical trials as an imaging agent for intraoperative visualization of cancer foci.169-171 
 
2.3 Discussion 
In this chapter we have provided an overview of the broad diversity of structures encountered in 
secreted venom peptides. In the majority of these small proteins, the three-dimensional architecture 
is maintained by precise and often elaborate disulfide-rich scaffolds. As well as providing stability 
and in many cases resistance to proteases, these rigid disulfide frameworks allow pharmacophoric 
amino acid side chains to be displayed in precise spatial orientations, thereby optimising the 
interaction between these venom peptides and their molecular targets. Moreover, the disulfide 
bonds often direct the three-dimensional architecture of these peptides to such an extent that the 
inter-cystine loops are highly permissive to mutations, thereby facilitating the evolution of new 
toxic functions on the same 3D scaffold. The consequence of this is that a single scaffold, such as 
the ICK motif, can support a wide range of pharmacological activities that aid the process of 
envenomation. In summary, the disulfide-rich scaffolds found in venom peptides provide stability, 
resistance to proteases, and they facilitate the evolution of high affinity binding and diverse 
pharmacology, traits that make these peptides ideal candidates for drug discovery programs. 
 We found that 86 disulfide frameworks account for the 2,022 secreted cysteine-rich peptides and 
polypeptides reported to date. Although some of these disulfide scaffolds are found in 
taxonomically diverse venomous animals (e.g. the ICK, Kunitz, Kazal, WAP, SXC and PLA2 
folds), other scaffolds such as snake 3FTs, scorpion CSα/β toxins, and α-conotoxins are found only 
in specific taxa. The diversity of cysteine-rich venom peptides is certain to exceed what is currently 
known, as only a very small percentage of venomous taxa (<1%) has been examined to date. 
Advances in transcriptomic and proteomic analyses of venoms, which are discussed in Chapter 3, 
are rapidly transforming the field and are likely to lead to the discovery of many new disulfide-rich 
scaffolds in hitherto unstudied venomous animals. 
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7.1 Introduction
7.1.1 Peptide Toxins
Toxins are engineered molecules of choice for numerous uni- and multicellular
organisms, from bacteria to plants and animals. They are used for defence,
predation and competitor deterrence by acting as endogenous drugs that can
disturb homeostasis and induce a wide variety of pathophysiological conditions
by contact, absorption or injection into the soft tissue of animals.1
Non-peptide toxins are mainly produced as secondary metabolites and
notably include phycotoxins produced by prokaryotic or eukaryotic microalgae
like cyanobacteria, dinoflagellates, diatoms, haptophytes and raphydo-
phytes.2–4 Among the most studied molecules of this group are the neurotoxic
azaspiracids;5 domoic acid, a glutamate receptor agonist;6,7 okadaic acid which
inhibits serine/threonine protein phosphatases 1 and 2A;8 ciguatoxins
and brevetoxins, which activate voltage-gated sodium (NaV) channels;
9–11 and
saxitoxins, which block NaV channels.
12 Tetrodotoxin, another potent and
selective NaV channel blocker, is produced by symbiotic bacteria.
13 The
accumulation of guanidinium toxins in pufferfish and filter-feeding bivalves can
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lead to severe food poisoning after consumption by humans. Plants also
produce a broad range of non-peptide phytotoxins that are a proven source of
pharmaceutical drugs including alkaloids (vinblastine, vincristine,14 cocaine,15
morphine,16 ephedrine,17 codeine18), terpenes such as taxol (diterpene)19 or
salicin (glucoside)20 for instance, and phenolic compounds including furan-
ocoumarin, lignins and tannins.21,22 Finally, non-peptide toxins can also be
found to a lesser extent in animals such as poison dart frogs that accumulate
lipophilic alkaloids such as batrachotoxin and epibatine. These molecules are
of particular interest because of their antinociceptive properties resulting
from their interaction with NaV channels and nicotinic acetylcholine receptors
(nAChRs).23–27
Conversely, peptide toxins generally constitute the main components of most
animal venoms, with non-elapid snakes being the exception. These highly
efficient secretions, sometimes considered as an evolved saliva,28 can only be
administered via specialised envenomation organs with sharp body features
that facilitate a traumatic subcutaneous, intramuscular or intravenous mode of
delivery into prey or predators. The composition of venom is generally highly
complex, comprising an array of salts, small molecules, bioactive peptide
toxins, and various enzymes, leading to a broad range of molecular interactions
in envenomed prey and predators across the phylogenetic spectrum.29
In this chapter, particular attention will be devoted to peptide toxins that can
be elaborated by venomous eumetazoa from diverse taxa across marine
invertebrates (marine cone snails, sea anemones, stingrays), centipedes, insects
(ants, bees, wasps), arachnids (spiders, scorpions), reptiles (snakes, lizards) and
mammals (platypus), with an emphasis relating to their structure and function.
We also briefly describe the technologies and methods employed to date for the
characterisation and elaboration of peptide toxins. Finally, we examine the
pharmacological diversity of peptide toxins with potential antinociceptive activity.
7.1.2 Bioactive Peptide Toxins: Therapeutic and Diagnostic
Potential
Despite their variable size (10–90 amino acid residues), most venom peptides
have a high cysteine content which enables them to form specific disulfide
bonds that provide them with a high level of thermodynamic stability as well as
resistance to proteases. It appears that conserved cysteine patterns and
disulfide-bond connectivities with only a limited number of folds are found
among the venom peptides of probably several thousands of different
venomous animal species. However, the remarkable hypervariability of their
primary structures and accompanying post-translational modifications (PTMs)
make venom peptides molecular ligands of unparalleled richness. In addition,
their high selectivity and potency towards key receptors, channels, transporters
or enzymes of crucial biochemical signalling pathways involved in organism
homeostasis make them an unrivalled and unexplored source of leads for the
development of molecules with therapeutic and diagnostic potential.30–32
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The modes of action of venom peptides are broad. They may act on different
body systems (circulatory, lymphatic, muscular, nervous, endocrine, immune,
respiratory) and target specific tissues. At the molecular level, venom peptides
are directed towards a large repertoire of target receptors. Indeed, they have
been shown to selectively modulate the activity of precise subtypes of
enzymes,33–35 voltage- and ligand-gated sodium, potassium, calcium or chloride
channels,36–38 transporters,39–41 and G-protein coupled receptors (GPCRs).42,43
Some venom peptides form pores in cell membranes, enabling them to exhibit
cytolytic or antimicrobial activities.44–48
7.1.3 Discovery and Characterisation of Peptide Toxins
Isolation of peptide toxins is usually carried out from crude venom obtained by
either dissection or milking. The first method consists of dissecting the venom
glands from the animal and subsequently extracting its contents via organic
aqueous mixed solvents. This method is commonly used, but the crude material
extracted contains many components and further purification steps are generally
required to isolate the individual toxins. The milking procedure yields anywhere
from a few microlitres of venom from venomous arthropods to millilitre
quantities from larger snakes, and is commonly restricted to the larger animals.
Subsequent isolation of pure peptide toxins is then generally achieved using
reversed-phase HPLC (RP-HPLC) followed by sequence determination using
Edman chemistry in conjunction with tandem mass spectrometry.49,50 Modern
strategies are now taking a faster and complementary approach by integrating
venom-gland transcriptomes with Edman sequencing and tandem mass spec-
trometry.51,52 Once a partial peptide sequence has been obtained using either of
the latter two techniques, a search of the transcriptomic data usually reveals the
sequence of the entire transcript encoding the peptide of interest, and in many
cases the sequence of paralogues as well.
Only rarely is sufficient native peptide available for complete structural,
functional, and in vivo characterisation. However, once the amino acid
sequence of the peptide has been determined, it can be produced using synthetic
or recombinant techniques.53 Production of venom peptides may be technically
challenging because of the large number of specific disulfide bonds; thus, a
toxin with three or four disulfide bonds is theoretically capable of forming 15 or
105 different disulfide-bond isomers, respectively. Longer polypeptide toxins
can be accessed by coupling solid-phase peptide synthesis (SPPS) with native
chemical ligation (NCL)54 where the high cysteine content actually increases
the efficiency of chemical synthesis.
Venom peptides can also be produced by overexpression in bacteria, yeast or
insect cells.53 Recombinant protein production is generally less time- and cost-
effective than SPPS but when optimised enables facile site-directed mutagenesis
for structure–activity relationship (SAR) studies and isotopic labelling for
multidimensional NMR studies. This approach generally precludes the intro-
duction of PTMs found in the native toxin and is limited to genetically-encoded
L-amino acids.
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In order to assess the potential activities within the venom it is usual to test
the crude material directly on isolated tissues, cells, cell lines, or oocytes
expressing specific targets at their surface. Activity-guided fractionation may
then be performed to precisely identify the bioactive peptidic components. Each
fraction separated by RP-HPLC or via some other chromatographic technique
is then individually tested for its activity on particular receptors, transporters,
or channels. Classical activity assays comprise binding and electrophysiology
experiments on various targets such as voltage- and ligand-gated channels,
nicotinic receptors, and GPCRs.
7.1.4 Optimisation of Peptide Toxins: from Candidates to Drug
Leads
Determination of the three-dimensional structure of an active peptide toxin
using NMR spectroscopy or X-ray crystallography often gives precise
information about its potential pharmacophore and mode of interaction with
its target, which may be further examined by in silico docking studies. As a
consequence, the precise location of the residues involved in target binding can
be used to guide the elucidation of SAR and the design of analogues with
enhanced properties for system-specific human therapeutics.
We mentioned earlier that venom peptides are perfectly designed to accomplish
their natural task. The formation of disulfide bonds and other PTMs not only
facilitates the formation of a highly stable tertiary structure necessary for optimal
potency and activity, but in many cases also provides resistance against extremes
of pH and temperature as well as proteases that are present in the circulatory
system and tissues of target organisms. However, these natural structural
advantages are not always favourable for therapeutic purposes. Venom peptides
may also have reduced bioavailability and can be subject to limitations due to
their large size and hydrophilic nature, which prevent passive diffusion through
hydrophobic epithelial layers including the blood–brain barrier. Nevertheless, if
required, vectors such as homing peptides (HMs) or cell-penetrating peptides
(CPPs) are able to deliver macromolecular cargoes across cell membranes, thus
improving their selectivity, efficiency and tolerance in vivo.55,56
7.2 Pharmacology of Peptide Toxins in the Modulation
of Nociception
Because of their ample structural diversity, venom peptides are directed
towards a broad range of heterologous molecular targets, including soluble and
membrane proteins. The proof of concept of the therapeutic utilisation of
peptides isolated from animal venoms was demonstrated some time ago with
the commercialisation of drugs for the treatment of various human patho-
physiological conditions (see Table 7.1).
In the remaining part of this chapter we review selected well-characterised
peptide toxins that are already available on the market for pain management,
as well as molecules considered as future potential antinociceptive drugs
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undergoing advanced and early-stage clinical trials. Finally we will describe
some structural and functional aspects of molecules still at the preclinical
research phase.
7.2.1 Marketed Toxin Analogue Drug: Ziconotide
To our knowledge, the only venom peptide approved for clinical use in the
treatment of acute pain is ziconotide, the non-opioid synthetic equivalent of
o-conotoxin MVIIA (hereafter called MVIIA), sold under the name Prialt by
Azur Pharma.57 Isolation of native o-conotoxin MVIIA from the venom of the
piscivorus cone snail Conus magus was first reported in 1982 by McIntosh
et al.58 The mature peptide contains 25 residues with an amidated
C-terminus.59,60 MVIIA contains six cysteine residues arranged in a
C(6)C(6)CC(3)C(4)C pattern, with the number between parentheses repre-
senting the number of non-cysteine amino acids within each of the four inter-
cystine loops. The cysteine residues are connected in I-IV, II-V, III-VI pattern
that forms an inhibitor cystine knot (ICK) motif (Figure 7.1).61 The ICK or
‘knottin’ fold, which is abundant in the venom of some animals, especially
spiders,62 is of particular interest for drug design because it confers
thermodynamic and biological stability, most importantly resistance to
proteases.63 The three-dimensional structure of MVIIA is composed of a triple-
stranded b-sheet segment involving residues Ala6-Lys7-Cys8 (b strand 1),
Cys20-Arg21 (b strand 2), and Lys24-Cys25 (b strand 1).64,65
The pharmacologically active o-conotoxins show potential analgesic
properties because of their ability to inhibit, with high potency and selectivity,
different subtypes of mammalian voltage-gated calcium (CaV) channels that are
Figure 7.1 o-Conotoxin MVIIA (ziconotide). The three-dimensional structure (PDB
accession code 1MVI) of ziconotide from the magician’s cone Conus
magus is shown in the left panel. b-Strands and disulfide bonds are
shown in red and yellow, respectively, and pharmacophore residues are
highlighted in green. The N- and C-termini are labelled. In the amino acid
sequence of the toxin shown on the right, cysteine residues are bold,
pharmacophore residues are highlighted in bold green font, and the
disulfide connectivity is shown as black lines above the sequence.
Conotoxin MVIIA is a selective blocker of CaV2.2 channels. ‘nh2’
indicates C-terminal amidation.
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expressed in sensory neurons of ascending pain pathways, particularly the
neuronal P/Q-type (CaV2.1) and N-type (CaV2.2) channels.
66,67 It has been
reported that o-conotoxins bind preferentially the S5–S6 linker of domain III
in the external vestibule of the channels.68 Moreover, the kinetics and affinity of
o-conotoxin/CaV2.2 interactions were suggested to be driven by intracellular
domains of the human channel as well.69,70 Mutagenesis experiments have
determined the critical role played by the conserved Tyr13 and Lys2 basic
residues in o-conotoxin that facilitate high-affinity binding to CaV2.2.
71–74
In the case of ziconotide, the toxin isB10 000-fold more selective for N-type
over P/Q-type CaV channels and it appears to bind irreversibly to the former.
75
The channel affinity of MVIIA seems to be driven also by Arg21 in the fourth
loop of the toxin, whereas Arg10 in the second loop may be responsible for
channel subtype selectivity.76 Though ziconotide is a potent and selective CaV
channel antagonist that avoids the opiate side effects of addiction and
tolerance, its intrathecal route of administration and dose-limiting neurological
side effects on the central and peripheral nervous system influence its thera-
peutic index and limit its clinical use. Indeed, intrathecal ziconotide may cause
dizziness, nystagmus, confusion, abnormal gait, somnolence, speech difficulties,
amblyopia, ataxia, amnesia or abnormal thought processes.77
7.2.2 Venom Peptides in Clinical Trials
7.2.2.1 o-conotoxin CVID
Another o-conotoxin called CVID or leconotide was isolated from the crude
venom of the piscivorous Conus catus by assay-guided fractionation and gene
cloning.75 The peptide completed a Phase 2 clinical trial with AMRAD and is
being commercialised by CNSBio as NMED-160. CVID contains 27 residues
with an amidated C-terminus and six cysteine residues arranged in a
C(6)C(6)CC(3)C(6)C pattern. This relatively hydrophilic knottin peptide has
three disulfide bonds (I–IV, II–V, III–VI) linked in the same way as MVIIA.78
However, a unique characteristic of the fold comes from the presence of two
hydrogen bonds (from the backbone amide protons of Lys10 and Leu11)
between the second and fourth loops, which leads to a unique orientation of
loop 4 and which may provide an entropic advantage for binding to the target
channel. In contrast to ziconotide, CVID is able to inhibit neurotransmitter
release from the preganglionic cholinergic neurons innervating the rat
submandibular ganglia, which is usually resistant to selective antagonists of
CaV1, CaV2.1, CaV2.2, and CaV3 channels.
79 To date, CVID (together with its
CVIE and CVIF isoforms) is the most selective o-conotoxin for CaV2.2 over
CaV2.1 channels (100-fold more selective than MVIIA).
75 In addition,
compared to MVIIA, CVID has better in vitro reversibility, a faster onset/offset
of action, and sustains antinociception with a better therapeutic index
(E 5-fold) with no significant cardiovascular side effects.80–82 These differences
may be due to the fact that although CVID possesses the conserved Tyr13
residue essential for binding (inhibition of the rat brain CaV2.1 channel is
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reduced by 400-fold with a [Y13F]CVID analogue),79 it lacks the Arg21 residue
located in loop 4 of MVIIA and utilises instead an exposed Val24 for interaction
with its target,75 as well as Lys10 which is considered to be the preferred residue
for inhibition of resistant-type calcium channel and neurotransmitter release in
presynaptic neuronal ends.79 These structural and functional differences
compared to ziconotide suggest that CVID might make potentially a more
effective and safer analgesic agent following systemic administration.
7.2.2.2 Contulakin-G
An interesting venom peptide directed to an unusual target for cone snail
toxins is contulakin-G. Contulakin-G underwent a small Phase 2a clinical
trial with Cognetix as CGX-1160. This 16-residue glycopeptide is devoid of
cysteine residues, is N-terminally blocked by a pyroglutamic acid, and is
O-glyclosylated on Thr10 (disaccharide b-D-Galp-(1-3)-a-D-GalpNAc-(1-).83
Interestingly, the unmodified native toxin can be chemically synthesised and
mammalian uridine diphospho-N-acetyl-D-galactosamine:polypeptide N-acetyl-
galactos-aminyltransferase T1 (EC 2.4.1.41) can be used to efficiently and
specifically transfer GalNAc to Thr10 of the peptide.84,85
The C-terminal part of contulakin-G closely resembles some members of the
neurotensin neurotransmitter family such as bovine hypothalamus neurotensin,
porcine spinal cord neuromedin N, Xenopus laevis xenopsin and human gastric
mucosa xenin with identities of 66%, 83%, 66% and 66% respectively.83
Contulakin-G has agonistic properties against cloned human neurotensin
receptor (NTR)1, rat NTR1 and NTR2, as well as mouse NTR3, with slightly
lower binding affinities than the endogenous neurotensins. The presence of the
glycan at position 10 strongly enhances binding to the neurotensin GPCRs.
Moreover, in vivo injection of contulakin-G induces the same sluggishness in mice
as neurotensin. Recent preclinical trials revealed that, although its mechanism of
action is still unknown, contulakin-G is a potent antinociceptive when delivered
intrathecally with no observable motor or cardiovascular side effects in acute pain
models in rats (formalin test) and dogs (thermal skin twitch model).86 As a
consequence, contulakin-G optimisation could lead to a promising therapeutic
candidate and may provide an alternative to opioid spinal analgesics.
7.2.2.3 w-conotoxin MrIA
w-Conotoxin MrIA was isolated from the venom of the molluscivorous marble
cone Conus marmoreus.87 The stable pyroglutamate analogue is currently
undergoing a Phase 2b double-blind clinical trial under the name Xen2174 with
Xenome Ltd.41 This short 13-residue peptide displays a compact cysteine
pattern, (3)CC(4)C(2)C, with disulfide bonds defined by a ‘ribbon’ connectivity
(I–IV, II–III) (Figure 7.2).88 The disulfide-bond connectivity combined with the
length of the intercystine loops and the presence of a hydroxyproline residue
located prior to the last cysteine make w-conotoxins structurally unique. The
two-loop MrIA toxin adopts a b-hairpin structure with close N- and C-terminal
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ends stabilised by the hydrophobic interaction of Val3 and hydroxyproline at
position 12. The three-dimensional structure also shows a flexible g-turn made
by residues Gly6-Tyr7-Lys8.88
MrIA is a reversible and selective inhibitor of the noradrenaline (norepi-
nephrine) transporter (NET), where it acts in a non-competitive or allosteric
manner.89 The Na1- and Cl–-dependent NET, one of the main mechanisms of
elimination of noradrenaline from chemical synapses, is an important thera-
peutic target for various neurological disorders. Also, given the role of
noradrenaline and multiple antidepressants targeting NET in antinociception,
this transporter has significant potential as a target for pain management.90–92
MrIA shows considerable selectivity for NET over other members of the
monoamine neurotransmitter transporter family such as dopamine and
serotonin transporters.93 SAR experiments identified the region starting from
the g-turn up to the C-terminus as the active site of MrIA responsible for its
interaction with NET, highlighting the crucial role of the Tyr7-Lys8-Leu9 and
His11 residues located in the second intercystine loop.93,94 Interestingly, several
analogues containing non-natural amino acid residues, while enhancing affinity
for NET, also produced undesirable side effects or had reduced efficacy in a rat
neuropathic pain model.94
7.2.3 Venom Peptides in Preclinical Trials
7.2.3.1 m-conotoxin MrVIB
Voltage-gated sodium (NaV) channels are expressed at high levels in nociceptive
neurons.95,96 Numerous peptide toxins isolated from the venom of spiders
(theraphotoxins, thomitoxins, hexatoxins, ctenitoxin), scorpions (a and b
toxins), or cone snails (m- and d-conotoxins) have been demonstrated to be
efficient inhibitors of NaV channels involved in pain pathways.
67,97,98 Their low
Figure 7.2 w-Conotoxin MrIA. Left panel shows the three-dimensional structure of
the cone snail venom peptide w-conotoxin MrIA (PDB accession code
2JL5). b-strands and disulfide bonds are coloured red and yellow,
respectively, and the side chains of pharmacophore residues are high-
lighted in green. The right panel shows the primary structure with disulfide
connectivity shown as black lines and residues responsible for interaction
with the norepinephrine transporter (NET) highlighted in bold green font.
O, hydroxyproline.
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specificity for NaV channels has made most of these ligands unsuitable leads for
drug design. However, recent studies have indicated that NaV1.7 and NaV1.8
subtype-selective inhibitors could have therapeutic potential.99,100
m-Conotoxin MrVIB (hereafter called MrVIB) is a 31-residue venom
peptide from the marine cone snail Conus marmoreus that has analgesic
potential due to its ability to inhibit subtypes of NaV channels. MrVIB was
licenced to Cognetix under the name CGX-1002. It contains a large number of
non-polar residues as well as six cysteine residues arranged in an ICK motif
(1)C(6)C(9)CC(4)C(4)C(1) (Figure 7.3).101,102 Recent advances in regioselective
synthesis using selenocysteine residues has allowed a more facile production of
synthetic MrVIB and determination of its three-dimensional structure.103,104
The toxin displays a hydrophobic surface with two short b-strands comprising
Ile24-Cys25 and Cys30-Val31. MrVIB is a potent and selective NaV channel
inhibitor with a preference for the neuronal NaV1.8 subtype and skeletal muscle
NaV1.4 subtype over other NaV channel subtypes. In rat dorsal root ganglion
(DRG) neurons, MrVIB blocks TTX-resistant NaV1.8 (IC50E98 nM)
4100-fold more potently than NaV1.9 (IC50E1.1 mM), and about 10-fold more
potently than TTX-sensitive NaV1.1, NaV1.2, NaV1.3, NaV1.6 and Nav1.7
channels (IC50E1 mM).
105 For NaV subtypes expressed heterologously in
Xenopus oocytes, MrVIB inhibits human NaV1.8 channels (IC50E102 nM)
with a 10-fold higher potency than for rat NaV1.2 and NaV1.3 and human
NaV1.5 and NaV1.7 (IC50E1 mM).
105 Another study reported selective
inhibition of NaV1.4 with an IC50 of 222 nM.
105 When tested in vivo, MrVIB
showed a significant reduction of allodynia and hyperalgesia in rat pain models
after intrathecal injection.105 Synthetic MrVIB also has potent and long-lasting
antinociceptive activity in local anaesthetic and postincision allodynia
assays.106 Importantly, MrVIB did not show significant motor side effects and
it has a greater therapeutic index than non-selective NaV channel antagonists
such as lidocaine (lignocaine).105
Figure 7.3 m-Conotoxin MrVIB. The tertiary and primary structures of Conus
marmoreusMrVIB are shown in the left and right panels, respectively. The
three-dimensional structure of the toxin (PDB accession code 1RMK,
with b-sheets and disulfide bonds coloured red and yellow, respectively)
reveals an ICK fold.
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7.2.3.2 a-conotoxin Vc1A
The a-conotoxin family represents the largest and most diverse group of
conopeptides characterised to date. They are selective antagonists of nicotinic
acetylcholine receptors (nAChRs) expressed in muscle and neuronal cells, and
are considered to be one of the best sources of potential leads for nAChR-based
therapeutics.67,107
a-Conotoxin Vc1A (hereafter called Vc1a) is a small endogenous 16-residue
peptide initially identified at the nucleic acid level by a PCR-RACE screen of
cDNA from the venom duct of the cone snail Conus victoria.108 It contains two
disulfide bonds (I–III, II–IV) that form two loops containing four and seven
amino acid residues with the pattern (1)CC(4)C(7) (Figure 7.4).109 Vc1a
possesses 4-hydroxyproline and g-carboxyglutamate PTMs at positions 6 and
14 respectively, as well as being C-terminally amidated.110 The main secondary
structural elements are a small a-helix spanning Pro6–Asp11 and a type I b-turn
at the N-terminus.109
Synthetic Vc1.1 without the PTMs at positions 6 and 14 originally received
attention because, contrary to its endogenous isoform, it demonstrated pain
relief and suppressed the vascular responses to sensory nerve C-fibre activation
in rat,108 as well as antagonistic effect in unmyelinated human axons.111
Initially it was thought that Vc1.1 was primarily selective for a3-containing
nAchR subtypes (a3b2 IC50E7.3 mM, and a3b4 IC50E4.2 mM).
109 However, it
has since been reported that Vc1.1 has 100-fold higher affinity for the a9a10
nAchR subtype, a potential therapeutic target for pain management.112–114
In order to explain Vc1.1 potency and selectivity towards the a9a10 nAchR
subtype, SAR investigations were performed.115 An extensive panel of point
mutants revealed that the proline residues have key roles in maintenance of the
active conformation (Pro13) and receptor binding (Pro6). Also, the importance
Figure 7.4 a-Conotoxin Vc1.1. Left panel shows the three-dimensional fold (PDB
accession code 2H8S) of Vc1.1, a synthetic variant of wild-type conotoxin
Vc1A. Disulfide bonds and a-helix are coloured yellow and blue,
respectively. The side chains of pharmacophore residues are highlighted
in green. Contrary to its native isoform, Vc1.1 inhibits nicotinic acetyl-
choline receptor (nAChR) with high potency. Vc1.1 contains a C-terminal
amidation (nh2) but lacks the two other native PTMs (hydroxyproline and
g-carboxylic glutamic acid).
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of residues 5–7 as well as 11–15 defined, as in most a-conotoxins, a conserved
hydrophobic patch in the first loop and a more variable cluster in the second
loop responsible for binding and subtype selectivity respectively.
Finally, experiments performed in vivo in two models of peripheral neuro-
pathy of the rat sciatic nerve demonstrated that Vc1.1 was not only able to
induce analgesia when injected intramuscularly near the site of injury but also
accelerated the recovery of damaged neurons.116 To overcome the generally
short biological half-lives specific to a-conotoxins as well as their poor activity
when administered orally, Clark et al. designed a cyclic Vc1.1 mimetic that
shows improved in vivo stability, enhanced activity and specificity, as well as
oral availability.117
7.2.3.3 Psalmotoxin 1
Acid-sensing ion channels (ASICs) are proton-gated sodium channels formed
by the homomeric or heteromeric association of three subunits (ASIC1a, 1b,
2a, 2b, 3, or 4). ASICs are members of the epithelial sodium channel/degenerin
family of ion channels but they are distinguished by their restriction to
chordates, their predominantly neuronal distribution, and their activation by
decreases in extracellular pH.118 ASICs have been demonstrated to play crucial
functions in nociceptive pathways and are thus considered potential therapeutic
targets for the treatment of chronic inflammatory pain.119–121
The first toxin discovered and characterised as an inhibitor of ASICs is
psalmotoxin 1 (p-theraphotoxin-Pc1a or PcTx1), a 40-residue peptide isolated
from the venom of the South American tarantula Psalmopoeus cambridgei.122
The toxin is undergoing preclinical trials for treatment of chronic pain under
the name THA 901 by Theralpha (www.theralpha.com). Several three-
dimensional solution structures have been determined for this toxin.123,124 The
three disulfide bonds form an ICK scaffold and the most detailed structure
available reveals a predominant b-hairpin (from Leu21 to Lys35) composed of
two antiparallel b-strands (Leu21–Trp24 and Val32–Lys35) (Figure 7.5).124
Minor secondary structures are also present with a 310 helix in the second
loop (His14–Asp16), as well as a b-turn in the third loop (Cys18–Leu21). Wild-
type, synthetic, and recombinant forms of PcTx1 rapidly and reversibly block
ASIC1a homomers with an IC50 of B0.5 nM.
122,124 In contrast, PcTx1 does
not inhibit homomeric ASIC1b or ASIC2a channels, nor heteromeric
ASIC1a/ASIC3 or ASIC1a/ASIC2a channels. In addition, the voltage-gated
potassium (KV) channels KV2.1, KV2.2, KV4.2, and KV4.3 are insensitive to
PcTx1.122 The selectivity of the toxin is supported by its ability to efficiently
inhibit only the more slowly inactivating native proton-gated currents in rat
DRGs (IC50¼ 0.7 nM).122 When tested in vivo, intrathecal PcTx1 was shown to
be more efficient than morphine in rodent models of acute pain.125
Several different studies that used mutagenesis and in silico docking
approaches were used to define the PcTx1 pharmacophore.124,126,127 It has been
suggested that PcTx1 may bind to the acidic pocket of ASIC1a via its b-hairpin
structure in loop 4, and more precisely through the interaction of Trp24, Arg26,
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Arg27 and Arg28 residues (the co-substitution of Trp24 and Arg27 to Ala led to a
150-fold decrease of inhibition). Presumably, the arginine residues are able to
mimic the persistent activation by protons that trigger the steady-state desen-
sitisation of ASIC1a. Recently, Baconguis I. et al. described the X-ray crystal
structures of the chicken ASIC1a complex with PcTx1 at high and low pH.128
They confirm the importance of the arginine-rich hairpin that makes polar
interactions in the acidic pocket of the channel, and particularly the
involvement of Arg26 and Arg27 in the establishment of hydrogen bonds with
residues located in the thumb (also anchored by the aromatic interaction of
Trp24) and palm domains of adjacent channel subunits respectively. Two
different expression systems (Drosophila melanogaster S2 cells and Escherichia
coli)123,124 have been used to produce recombinant toxin, with the latter system
producing considerably higher yields.124
7.2.3.4 Mambalgin-1 and -2
Diochot et al. recently described two new three-finger toxins isolated from the
venom of the black mamba Dendroaspis polylepis polylepis.129 The 57-residue
mambalgin-1 and mambalgin-2 isopeptides cause potent, rapid, and reversible
analgesic effects by inhibiting ASICs expressed in central and peripheral
neurons. They contain eight cysteine residues that form four intramolecular
disulfide bonds with I–III, II–IV, V–VI and VII–VIII connectivity. The two
isoforms differ by a single residue at position 4. A homology model of
mambalgin-1 suggests that the toxin forms a triple-stranded b-sheet that
connects loops II and III, as well as a short double-stranded b-sheet forming
loop I. These three loops emerging from the disulfide-rich core of mambalgin-1
enable its classification as a three-finger toxin.130
Figure 7.5 Psalmotoxin 1 (p-theraphotoxin-Pc1a). Psalmotoxin 1 was isolated from
the venom of the Trinidad chevron tarantula Psalmopoeus cambridgei. Its
three-dimensional structure (left panel; PDB accession code 2KNI) reveals
a 310-helix (blue), b-strands (red) and three disulfide bonds (yellow). The
side chains of the pharmacophore residues responsible for activity on
ASIC1a are highlighted in green. The amino acid sequence of the toxin
(right panel) shows the typical disulfide framework found in the ICK
motif. Pharmacophore residues are highlighted in bold green font.
Peptide Therapeutics from Venomous Creatures 231
Mambalgin inhibits ASIC subtypes in both the central and peripheral
pain pathways. These toxins block rat homomeric ASIC1a, heteromeric
ASIC1a/ASIC2a (naloxone-insensitive analgesia) and heteromeric
ASIC1a/ASIC2b subtypes, targets that are abundantly expressed in the
CNS.131–134 Mambalgins also inhibit human homomeric ASIC1b and
heteromeric ASIC1a/ASIC1b channels specifically expressed by sensory
neurons.135 These peptides have been also proposed to act as gating modifier
toxins by binding to the closed and/or inactivated state of the channels and
thereby modifying their affinity for protons. Consequently they inhibit native
ASIC currents by reducing the response of the channels to acidic pH. These
peptides are analgesic in rodent models of acute and inflammatory pain, with
potency similar to that of morphine, but unlike other three-finger toxins they
do not cause behavioural neurotoxicity upon central injection in mice.
Theralpha is currently conducting preclinical trials with mambalgin-1 under
the name THA 904.
7.2.3.5 APETx2
A selective inhibitor of ASIC3 known as APETx2 was isolated by
activity-guided fractionation of venom from the sea anemone Anthopleura
elegantissima.136 Theralpha is currently conducting preclinical trials with
APETx2 (under the name THA 902) for treatment of chronic inflammatory
pain. This toxin has received particular interest as ASIC3 is considered
to be a potential analgesic target being predominantly expressed in
nociceptors.137,138
APETx2 is a highly cationic peptide consisting of 42 residues. The six
cysteine residues are linked to form three disulfide bonds with I–V, II–IV, III–
VI connectivity; the compact disulfide-rich core has the sequence pattern
(3)C(1)C(13)C(9)C(6)CC(4) (Figure 7.6).136 The three-dimensional structure of
APETx2 determined using NMR spectroscopy reveals a central four-stranded
b-sheet linked together by type I and type-II00 b-turns; the N- and C-termini, as
well as a long loop including residues from Phe15 to Thr27, emerge from one end
of this disulfide-rich core.139 APETx2 selectively blocks homomeric rat ASIC3
channels expressed in Xenopus oocytes with an IC50 of 63 nM; it is 3-fold less
active on homomeric human ASIC3 channels transfected in COS cells
(IC50¼ 175 nM).136 APETx2 also inhibits heteromeric ASIC2b/3 channels
(IC50¼ 117 nM) and to a lesser extent heteromeric ASIC1a/3 channels
(IC50¼ 2 mM) and ASIC1b/3 channels (IC50¼ 0.9 mM) when transfected in
COS cells.136 APETx2 has very little activity towards NaV and KV channels,
with the highest activity reported against NaV1.8 (IC50E2.6 mM).
140
With its unusual target specificity and selectivity compared to other venoms
peptides,141 APETx2 is a valuable pharmacological tool for the study of ASICs
and a promising template for the design of a pain therapeutics directed
against ASIC3.
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7.2.3.6 Hannalgesin
Hannalgesin, also called CM-11 or long neurotoxin OH-55, was isolated from
the venom of the world’s longest venomous snake, the king cobra Ophiophagus
hannah,142 as well as cloning via a venom-gland cDNA library.143 Hannalgesin
is an a-neurotoxin containing 72 residues and 5 disulfide bonds (the connec-
tivity of the cysteines has been inferred by homology as I–III, II–VI, IV–V,
VII–VIII, IX–X). To our knowledge, the three-dimensional structure of the
toxin has not been published to date, but the cysteine pattern suggests that
hannalgesin would adopt a three-finger toxin fold. Hannalgesin produces a
dose-dependent, long-lasting analgesia with 2700-fold higher potency than
morphine when assessed with the hot-plate test in rats.144 However, the same
study revealed that this neurotoxin could be toxic for rodents by causing
neurological deficits and proconvulsant effects. The biochemical mechanism of
action of hannalgesin is not yet fully elucidated. Nevertheless, it has been
shown that the toxin significantly increases nitric oxide synthase activity, and
the analgesic effect of hannalgesin is strongly reduced by inhibition of this
enzyme.145 Hannalgesin also causes relaxation of precontracted rat annococ-
cygeus muscle.146 Together, these observations suggest that hannalgesin causes
analgesia by an unknown mechanism involving nitric oxide release that may
stimulate guanylate cyclase and thus formation of GMPc. In addition, the
analgesic effect of the neurotoxin was blocked by naloxone, suggesting its
potential interaction with opioid receptors.144 Recently, Kini et al. claimed that
they identified the pharmacophore of hannalgesin,130 using a ‘proline bracket’
method,147 located in the C-terminal end of the peptide (unpublished data).
They also reported the synthesis of a short peptide from this region of hann-
algesin that showed selective analgesia in vivo without neurotoxicity (patented
Figure 7.6 Toxin APETx2. Left panel shows the three-dimensional structure (PDB
accession code 1WXN) of APETx2 secreted from nematocysts of the sea
anemone Anthopleura elegantissima. Turns, b-strands and disulfide bonds
are coloured blue, red and yellow, respectively. APETx2 displays a
cysteine scaffold defined by a C-C-C-C-CC pattern with I–V, II–IV, III–
VI disulfide connectivity (shown as black lines in the primary structure on
the right panel). APETx2 is a highly selective inhibitor of acid-sensing ion
channel 3 (ASIC3).
Peptide Therapeutics from Venomous Creatures 233
data).148 The short active peptide is currently undergoing preclinical trials with
Theralpha under the name THA 903.
7.2.4 Venom Peptides Targeting Nociceptive Receptors
7.2.4.1 GABAB Receptor Agonists
7.2.4.1.1 a-Conotoxin RgIA. CaV2.1 channels in peripheral neurons are a
proven target for the treatment of chronic neuropathic pain.149–151 Recent
studies have revealed that some a-conotoxins such as Vc1.1 (discussed
previously), RgIA, PeIa and AuIB might mediate their potent analgesic effect
by acting as agonists of presynaptic GABAB receptors, thereby leading to an
indirect inhibition of CaV2.1 channels and a consequent decrease in neuro-
transmitter release.43,152–155 Although the precise mechanism of their analgesic
effects has not been fully determined, it has been suggested that these toxins
interact with the GABAB receptor via an allosteric binding site.
114
RgIA contains 13 residues and, like other a-conotoxins, it contains four
cysteine residues with a I–III, II–IV connectivity (Figure 7.7). The three-
dimensional structure is comprised of a type I b-turn followed by a 310 helix and
a type VIII b-turn.156
7.2.4.2 Natriuretic Peptide Receptor Ligand
7.2.4.2.1 Taipan Natriuretic Peptide TNP-c. Natriuretic peptides (NPs) are
found in many animals, where they exert hypotensive and vasodilator
activities.157,158 Recent studies have suggested that natriuretic peptides may
also be involved in the regulation of pain sensitivity, although the biochemical
mechanisms have not yet been fully elucidated.159–161 Natriuretic peptides
contain a single disulfide bond leading to a ring-shaped structure extended by
a C-terminal tail. Three natriuretic peptides (TNP-a, TNP-b and TNP-c) have
been isolated from the venom of the taipan snake Oxyuranus microlepidotus.162
They are highly similar to other NP family members within the loop region
but contain an unusual C-terminal tail. TNP-c, the only active isoform long of
39 amino acids, has a 17-membered ring structure prolonged by a 14-
amino-acid C-terminal tail. TNP-c is able to trigger full relaxation of precon-
tracted rat aorta through type-C natriuretic peptide receptor (NPR-C) and
type-A guanylate cyclase (GC-A) mediated mechanisms.162
7.2.4.3 Sodium Channel Peptides
Several peptide toxins from the venom of theraphosid spiders (commonly
known as tarantulas) have useful properties that make them interesting
candidates for the design of new analgesics.62 First, like most spider toxins
these peptides contain an ICK motif (like Prialt) that confers thermodynamic
stability and resistance to proteases. Second, these toxins act as allosteric
modulators or ‘gating modifiers’;98 thus, they are more likely to exhibit subtype
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selectivity than small molecules that bind to the highly conserved pore of the
channel.
7.2.4.3.1 ProTx-II. To date, the most potent blocker of human NaV1.7
(IC50E0.3 nM) is ProTx-II isolated from the venom of the green velvet
tarantula Thrixopelma pruriens (see ArachnoServer entry at www.arach-
noserver.org/toxincard.html?id¼ 414).62 This 30-residue peptide contains 6
cysteine residues arranged in an ICK motif. The disulfide bond framework
provides a rigid peptide backbone that forms four loops.163 ProTx-II is clas-
sified as a gating modifier because of its ability to shift the voltage
dependence of activation to more positive potentials. It has been proposed
that it inhibits activation and inactivation of human NaV1.7, which is highly
expressed in nociceptive neurons95,100 by interacting with the positively
charged S4 segments in the voltage sensors of channel domains II and IV
that sense membrane depolarisation and induce channel gating (and thus
triggers action potentials).164 ProTx-II also inhibits other sodium channel
subtypes (NaV1.2, NaV1.3, NaV1.5, NaV1.6 and NaV1.8) but with an
approximate 100-fold lower potency than NaV1.7. Although the binding sites
of the toxin on NaV channels still remain to be precisely determined, it has
been suggested that ProTx-II acts by trapping the voltage sensor of NaV
channel domain II in the resting state, impeding outward gating movement
of the IIS4 transmembrane segment of the channel and reduces maximum
activation of sodium conductance.165 ProTx-II itself shows no potential as a
therapeutic as it is lethal to rats when injected intravenously at 1.0mg kg1
(although doses of 0.01 and 0.1mg kg1 are well tolerated) or by intrathecal
administration at 0.1mg/kg. Moreover, the toxin was not efficacious in
rodent models of acute and inflammatory pain when administered intra-
venously at 0.01 or 0.1mg kg1 or intrathecally at 0.001 or 0.01mg kg1.
The latter intrathecal dose transiently reduced muscle tone and impaired
Figure 7.7 a-Conotoxin RgIA. Left panel shows the tertiary structure of a-conotoxin
RgIA isolated from Conus regius. Helices and disulfide bonds are coloured
blue and yellow, respectively. RgIA is a potent inhibitor of the a9a10
nicotinic acetylcholine receptor (nAChR) with agonistic activity on the
GABAB receptor. The disulfide connectivities are shown as black lines in
the primary structure on the right.
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motor function even though systemic levels at 4 hours after toxin adminis-
tration were below the level of detection (3 nM).
7.2.4.3.2 Huwentoxin-IV. Huwentoxin-IV (HWTX-IV) is also a gating
modifier of NaV channels (see ArachnoServer entry at www.arachnoserver.org/
toxincard.html?id=332). This 35-residue peptide isolated from the venom of
the Chinese bird spider Haplopelma schmidti has a compact three-dimensional
architecture stabilised by three disulfide bonds that form an ICK motif
(Figure 7.8).166 HWTX-IV potently blocks human NaV1.7 (IC50B23nM) by
interacting with the voltage sensor in domain II (DII).167 It traps the DII
voltage sensor in the closed state and inhibits channel activation by interacting
with five critical residues located in the S1-S2 linker (Glu753), the extracellular
part of S3 (Glu811, Leu814, Asp816), and the S3-S4 linker (Glu818) of DII.166–168
It has also been proposed that the positively charged Arg26 residue in the
fourth intercystine loop of HWTX-IV may play an important role in the
channel binding. In contrast with ProTx-II, HWTX-IV does not partition into
artificial phospholipid bilayers.169
7.2.4.3.3 m-Conotoxin PIIIA. In contrast to the gating modifiers from
spider venoms, the m-conotoxins block the pore of NaV channels (see
ArachnoServer entry at www.arachnoserver.org/toxincard.html?id=332). The
sequence of m-conotoxin PIIIA was deduced from mRNA isolated from the
cells lining the venom duct of Conus purpurascens.170 This 22-residue peptide
is highly basic and contains three post-translationally modified residues (one
pyroglutamate and two hydroxyprolines at positions 1, 8, and 18
respectively, as well as an amidated C-terminus). The CC-C-C-CC cysteine
framework, with I–IV, II–V, III–VI connectivity, is the same as found in
many m-conotoxins (Figure 7.9). The disulfide bonds form three distinct
Figure 7.8 Huwentoxin-IV (m-theraphotoxin-Hh2a). Left panel shows the three-
dimensional structure of the spider huwentoxin-IV (PDB accession code
1MB6). Disulfide bonds and b-strands are coloured yellow and red,
respectively. The side chain of the functionally important arginine 26
residue is highlighted in green. The right panel shows the amino acid
sequence of the toxin highlighting the disulfide connectivity (black lines)
and functionally important arginine residue (bold green font). ‘nh2’
indicates C-terminal amidation.
236 Chapter 7
loops and constrict the overall globular shape of PIIIA, where consecutive
turns are found over the N-terminal end with a distorted helix from Ser13 up
to the C-terminus.171 PIIIA specifically inhibits tetrodotoxin-sensitive NaV
channels. Although the toxin strongly inhibits the skeletal muscle NaV1.4
channel (IC50E41 nM), it also blocks the neuronal NaV1.2 subtype with
lower potency (IC50E690 nM).
172 PIIIA-mediated inhibition occurs via
binding to the so-called sodium channel neurotoxin receptor site 1 which
blocks flow of sodium ions through the pore.173 Residues Arg14 and Lys17
(and to a lesser extent Arg12 and Arg20) face deep into the vestibule of the
channel pore.174 With Arg14 positioned in the permeation pathway, PIIIA
causes steric and/or electrostatic occlusion of the channel pore.175
Replacement of His19 by Gln increases the selectivity of PIIIA for NaV1.4
over NaV1.2,
175 suggesting that His19, which is highly conserved among
m-conotoxins, increases selectivity for the neuronal subtype. Interestingly, a
recent study demonstrated that PIIIA isoforms with different cysteine
connectivity (i.e., without changes in the primary structure) can be more
potent blockers of NaV1.4.
176
7.3 Future Prospects and Outlook
As a consequence of their ability to efficiently and selectively target specific
subtypes of receptors, transporters or ion channels in mammals, venom
peptides have been recognised as particularly useful probes for in vitro and
in vivo pharmacological studies, as well as an unrivalled source of potential
candidates and molecular templates for therapeutic applications. As an
example, the 500 species within the genus Conus have been estimated to
elaborate more than 50 000 conopeptides, of which only B0.1% have been
pharmacologically characterised to date. Scorpions comprise about 1,750
extant species that are thought to produce B100,000 unique peptides.177
Figure 7.9 m-Conotoxin PIIIA. Left panel shows the three-dimensional structure of
conotoxin PIIIA (PDB accession code 1R9I), a selective blocker of NaV1.4
isolated from the cone snail Conus purpurascens. Disulfide bonds and
helices are coloured yellow and blue, respectively. The side chains of
pharmacophore residues are highlighted in green. The right panel shows
the amino acid sequence of the toxin, highlighting the disulfide connec-
tivities (black lines), pharmacophore residues (bold green font), and PTMs
(nh2, C-terminal amidation; O, hydroxyproline; Z, pyroglutamic acid).
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Spiders (B44,000 species) might produce more than 10 million active
peptides.178 As a consequence of this substantial molecular diversity, and also
because a vast majority of this subclass of natural products has been designed
to act on the nervous systems of prey or predators, venom peptides have
attracted great interest for the development of therapeutic agents dedicated to
the modulation of nociception.
Increasing efforts to identify and optimise toxin pharmacophores, coupled
with the development of peptidomimetics, will provide novel molecules with
improved therapeutic indices that might provide new drugs for the treatment
of pain.
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ConoSorter: a High-throughput Bioinformatic Algorithm 
for Large-scale Identification and Classification 
of Conopeptides
Lavergne et al. BMC Genomics 2013, 14:708
http://www.biomedcentral.com/1471-2164/14/708METHODOLOGY ARTICLE Open AccessSystematic interrogation of the Conus marmoreus
venom duct transcriptome with ConoSorter
reveals 158 novel conotoxins and 13 new gene
superfamilies
Vincent Lavergne1, Sébastien Dutertre1, Ai-hua Jin1, Richard J Lewis1, Ryan J Taft2* and Paul F Alewood1*Abstract
Background: Conopeptides, often generically referred to as conotoxins, are small neurotoxins found in the venom
of predatory marine cone snails. These molecules are highly stable and are able to efficiently and selectively interact
with a wide variety of heterologous receptors and channels, making them valuable pharmacological probes and
potential drug leads. Recent advances in next-generation RNA sequencing and high-throughput proteomics have
led to the generation of large data sets that require purpose-built and dedicated bioinformatics tools for efficient
data mining.
Results: Here we describe ConoSorter, an algorithm that categorizes cDNA or protein sequences into conopeptide
superfamilies and classes based on their signal, pro- and mature region sequence composition. ConoSorter also
catalogues key sequence characteristics (including relative sequence frequency, length, number of cysteines, N-
terminal hydrophobicity, sequence similarity score) and automatically searches the ConoServer database for known
precursor sequences, facilitating identification of known and novel conopeptides. When applied to ConoServer and
UniProtKB/Swiss-Prot databases, ConoSorter is able to recognize 100% of known conotoxin superfamilies and
classes with a minimum species specificity of 99%. As a proof of concept, we performed a reanalysis of Conus
marmoreus venom duct transcriptome and (i) correctly classified all sequences previously annotated, (ii) identified
158 novel precursor conopeptide transcripts, 106 of which were confirmed by protein mass spectrometry, and (iii)
identified another 13 novel conotoxin gene superfamilies.
Conclusions: Taken together, these findings indicate that ConoSorter is not only capable of robust classification of
known conopeptides from large RNA data sets, but can also facilitate de novo identification of conopeptides which
may have pharmaceutical importance.
Keywords: ConoSorter, Cone snail, Venomics, Transcriptome, Proteome, Conopeptides, ConotoxinsBackground
Venomous marine cone snails have evolved a broad array
of peptide toxins, called conopeptides, for prey capture and
defense. These small bioactive compounds selectively act
on a wide variety of receptors and channels in the central
and peripheral nervous systems [1-4]. These vast, mostly
untapped, natural toxin libraries provide potent tools for* Correspondence: r.taft@imb.uq.edu.au; p.alewood@imb.uq.edu.au
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reproduction in any medium, provided the orstudying the properties of these targets and have become a
platform for the discovery of new pharmaceuticals [5-8].
Only ~2% of the estimated >70,000 venom peptides
expressed by the genus Conus have been sequenced to
date [9].
In the apical secretory cells lining the long convoluted
venom duct [10,11] (and likely to a much lesser extent the
salivary glands [12]), mature mRNA is translated to precur-
sor conopeptides which are generally composed of three
distinct regions: a N-terminal endoplasmic reticulum (ER)
signal sequence, a central pro-peptide region, and the C-al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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signal sequence, conopeptides are currently classified into
16 empirical gene superfamilies (A, D, I1, I2, I3, J, L, M,
O1, O2, O3, P, S, T, V, Y), and 13 minor families for those
identified in early divergent clade species [13-16]. In
addition, 10 new superfamilies have been discovered in the
past two years - B1 [17], B2 [18], B3 [19], C [17], E [18], F
[18], G [20], H [18], K [21], N [18]. Conopeptides can also
be further divided into secondary classes based on the
number of disulfide bonds they can contain - disulfide-rich
conopeptides containing at least 2 disulfide bonds are col-
loquially known as conotoxins, whereas those with none or
one disulfide bond are called disulfide-poor conopeptides
[22] - or the cysteine patterns in the mature region of
disulfide-rich conopeptides [14]. Although amino acid con-
servation in the pro- and mature regions of conopeptides
from the same superfamily is much lower than for the ER
signal sequence (Figure 1 and Additional file 1: Figure S1),
consensus cysteine patterns and connectivities are often
highly conserved (although not always specific to a gene
superfamily) and may be linked to particular pharmaco-
logical families [14].
Recent studies have reported the existence of new
conopeptides, which do not clearly belong to any of the
previous annotated superfamilies but share common
pharmacological targets. Although some show conserved
signal regions, cysteine motifs or specific post-translational
modifications, these conotoxins have been incorporated
into 14 additional classes [14] called conantokin [23],
conodipine [24], conohyal [25], conolysin [26], conomap
[27], conomarphin [28], conopeptide Y [29], conophan
[30], conoporin [31], conopressin [32], conorfamide [33],
conotoxin-like [12], contryphan [34] and contulakin [35].
Advances in high-throughput sequencing technologies,
combined with directed studies of venom producing cells
[36-39], have resulted in a data deluge which requires ded-
icated tools for the analysis and classification of cono-
peptide sequences. ConoServer, a specialized database
dedicated to conopeptides [22], implemented a web-based
tool (ConoPrec) that guides gene superfamily assignment
of precursor toxins by the recognition of a limited number
of known cleavage sites (or protease specificities) and a
sequence similarity search based on existing conopeptide
superfamilies [16]. However, the limitations of this program
include the restriction to known conopeptide motifs, as
well as a requirement that the query precursor sequences
contain the signal region, which is rarely the case as most
conopeptide screening is conducted on milked venom or
dissected venom gland that almost exclusively contains
mature protein products. Another web-based program,
ConoDictor, overcomes the issue of missing signal regions
by using three independent sets of models built from sig-
nal, pro- and mature regions of conopeptides respectively
[40,41]. However, this tool only accepts selected aminoacid sequences as input, only classifies conopeptides into
the main superfamilies, does not provide any data quanti-
tation, and perhaps most importantly, cannot facilitate the
discovery of new conopeptide families. Both ConoPrec and
ConoDictor are limited in their ability to handle large
transcriptomic or proteomic datasets, and therefore are
unlikely to fill the need for large-scale analysis of cone
snail transcriptomes or proteomes.
Here we describe ConoSorter, a program able to classify
conopeptides into superfamilies and classes from either
protein sequences or RNA sequencing data. ConoSorter
has been designed to recognize all currently annotated
gene superfamilies and classes. Regular expression sequen-
ce searches are complemented by a profile Hidden Markov
Model (pHMM) analysis allowing the classification of
conotoxins that may be only distantly related to well-
established conopeptide groups. ConoSorter also reports
key sequence characteristics (including relative sequence
frequency, length, number of cysteine residues, N-terminal
hydrophobicity, sequence similarity score) and automatic-
ally searches the ConoServer database for known precursor
sequences, which facilitates clear and precise identification
of known and novel conopeptides and their associated
families. ConoSorter allows an investigator to efficiently
deal with the thousands of sequences produced by high-
throughput sequencing methods in a rapid and accurate
manner.
Results
Identification and classification of known conopeptides
To assess if ConoSorter can accurately classify conopeptides
into superfamilies and classes we performed two initial con-
trol experiments - analysis of the ConoServer cone snail
toxin database and an analysis of the universal UniProtKB/
Swiss-Prot protein database [22,42].
The ConoServer database contains 5,449 entries of
complete or partial conopeptide sequences. We emplo-
yed 36.85% (2,008 sequences) of the ConoServer entries
in the development of our training set, and here sought
to assess the accuracy of both the regular expression and
pHMM approaches described above to hierarchically
classify the entire suite of ConoServer sequences into
superfamily and class. We found that the regular expres-
sion analysis was able to classify 100% of well-defined
ConoServer sequence regions (i.e. those that do not dis-
play undetermined amino acids) for which the gene
superfamily or class have been previously assigned. This
approach also assigned a superfamily to 1,228 sequences,
and a class to 42 others, which were not previously
classified. ConoSorter failed to confidently classify a total
of only ~440 sequences, all of which are derived from
patents and synthetic constructs that contain one or
more undetermined amino acids, or are sequences for
which supportive data regarding their classification are
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Figure 1 Amino acid diversity in conopeptides. The position-specific diversity of amino acid for each conopeptide regions (ER signal in red,
pro- in green, and mature region in purple) belonging to the 4 largest gene superfamilies A, M, O1 and T (the remaining superfamilies are
presented in Additional file 1: Figure S1). The true diversity of order 2 (or inverse Simpson index, 1/λ) have been calculated according to the
following equation in order to take into account the amino acid richness R, their average proportional abundance pi, as well as the variability of
sequence lengths for each regions: 1=λ ¼ 1=
XR
i¼1
p2i . For each amino acid position, a color gradient applies to the diversity index (from 0 in light
to higher values in darker color).
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level of accuracy.
Analysis of the ConoServer entries with pHMMs showed
true positive recognition rates of 99.25% for superfamily (9
instances of conopeptide region annotation conflict, plus 3
false positives out of 1,609 complete sequences with anno-
tated superfamilies), and 99.60% for class (7 conflicts, plus 4
patent sequences with undetermined amino acids counted
as false positives out of 2,750 sequences with known classes)
using the HMMER hmmscan script with the default E-value
cutoff at 10. This approach was also able to confidently as-
sign 1,153 sequences into superfamilies and 32 into classes,
which had previously lacked annotation.
In the second experiment, the ability of ConoSorter to
distinguish between Conus peptide toxins and other pro-
teins from various organisms has been assessed by
screening the entire UniProtKB/Swiss-Prot database.
Using the version released on June 2013 we examined a
total of 540,261 protein sequences isolated from 12,988
cellular and non-cellular species. Table 1 reports the
specificity S calculated at 7 E-value cutoffs (10 – default
threshold, 1, 0.1, 0.01, 10-3, 10-4 and 10-5) according to
the following equation:
S ¼ True Negatives
True Negativesþ False Positivesð Þ
where True Negatives = N – True Positives (with N = total
number of input sequences, and True Positives = numberTable 1 Species specificity of conopeptide models
E-value cutoff Superfamily Class
S (%) False + (%) S (%) False + (%)
≤10 99.19 0.81 99.25 0.75
≤1 99.31 0.69 99.35 0.66
≤0.1 99.42 0.58 99.46 0.55
≤0.01 99.56 0.44 99.57 0.43
≤10-3 99.81 0.19 99.81 0.19
≤10-4 99.90 0.10 99.90 0.10
≤10-5 99.94 0.06 99.93 0.07
The species specificity, S (expressed in %), of the conopeptide models has
been assessed on UniProtKB/Swiss-Prot database (540,261 sequences in total
spread over 12,988 species) at different total E-value thresholds. Percentages
of specificity and false positive rates (“False +”, expressed in %) are reported
for the classification by gene superfamily, and by class.of conopeptide matches), and False Positives = the number
of non-Conus species matches plus the number of non-
conopeptides Conus matches.
At all E-value thresholds ConoSorter was able to confi-
dently identify and classify conopeptides (Table 1). Of the
540,261 amino acid sequences referenced in the UniProtKB/
Swiss-Prot database, ConoSorter, using an E-value of 10-5,
was able to classify 879 peptide toxins from the genus Conus
with an annotated superfamily (specificity of 99.94%) with
only 345 false positives (p-value = 0.06%) isolated from other
organisms. Similarly, ConoSorter was able to classify 894
conopeptides with an annotated class (specificity of 99.93%)
with only 393 false positives (p-value = 0.07%).
Analysis of Conus marmoreus venom duct transcriptome
The results presented above indicate that ConoSorter is
capable of identifying conopeptides at high specificity and
sensitivity, and, even when the dataset being analyzed os-
tensibly includes all known proteins, accurately assigning
the appropriate superfamily and class. We next sought to
use ConoSorter’s regular expression and pHMMs searches
to ascertain if it was possible to identify novel conopeptides,
superfamilies and classes in a previously interrogated RNA-
seq dataset.
Dutertre et al. have recently performed an analysis of the
C. marmoreus venom duct transcriptome, which principally
relied on serial BLAST homology searches [18]. They
reported 30 full conopeptides precursor sequences (i.e.
those beginning with a methionine residue and finishing by
a stop codon) that had been previously characterized in this
species. A total of 75 novel conopeptides were also identi-
fied which were assigned to 8 known gene superfamilies.
Thirteen of these were classified, based on the high conser-
vation of their signal sequences, into 5 new superfamilies
dubbed B2, E, F, H, and N.
We re-examined this medium-throughput 454 sequen-
cing data (179,843 cDNA sequences) with ConoSorter,
and identified 4,307,681 putative precursor protein se-
quences derived from all possible translations of these
sequences into six reading frames (see ConoSorter pipeline
in Methods), which were analyzed hierarchically using the
regular expressions and pHMMs described above to assign
sequences to superfamily, class or ‘unknown’. This led to
the identification of 72% (106/146) of annotated complete
Conus marmoreus precursor conopeptides, including all
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analysis (two incomplete conotoxins, named Mr8.1 and
Mr11.3 precursors, did not encode a methionine and thus
were discarded). Moreover, 17 novel isoforms of known
Conus marmoreus precursor conopeptides (Mr1.1, con-
omarphin Mr1, conomarphin Mr2, contryphan M, cMrVIA,
CMrX, and MrIA precursors) were identified and assigned
the correct superfamily or class based on the signal, pro-,
and mature regions. These conopeptides were confirmed by
a tandem mass spectrometry (MS/MS) analysis of the
milked venom, in which we were able to identify their corre-
sponding mature sequences (Additional file 2: Table S1).
ConoSorter was also able to assign known gene super-
families to 125 novel full-length precursor conopeptides
(Figure 2, Additional file 3: Figure S2, Additional file 4:
Table S2). Using the C. marmoreus milked venom mass
spectrometry data, and employing the methods Dutertre
et al. used to match the MS data to putative novel
conopeptides (e.g. restricting ProteinPilot results to
those with a confidence threshold of at least 99%)
[18], we were able to validate protein fragments ofFigure 2 New conopeptide precursors isolated from the venom duct
full-length precursor conopeptides inferred from mRNA data, and detected
regions without conflict (isoforms of these sequences can be found in Add
alignment shows the amino acid conservation specifically in the N-termina
are). Partial sequences in bold characters correspond to the peptide fragme
Numbers listed after conopeptide names indicate the sequence frequency
of full-length precursors, as well as post-translational modifications (PTMs) c86 of the novel conopeptide precursors (Figure 2,
Additional file 3: Figure S2, Additional file 4: Table S2).
Milked venom almost exclusively contains mature peptide
toxins, which was reflected in the coverage of the mature
peptide fragments compared to the full-length precursor
conopeptide sequences (Figure 2).
ConoSorter also identified 33 additional precursor cono-
peptides which, despite showing conserved amino acids and
high hydrophobicity in the signal region, could not be classi-
fied into known superfamilies (Figure 3, Additional file 4:
Table S2, Additional file 5: Table S3). Among these new pre-
cursors, 20 peptide fragments were identified in milked
venom MS data (validation rate of ~60%). Based on their
conservation, and their similarities with known superfamilies,
we propose classifying these 33 precursor conopeptides into
13 new gene superfamilies - H2, I4, M2, N2, O4, Q, R, U, W,
X, Y2, Y3, and Z. The names of these new groups have been
taken from (i) the 6 available letters of the alphabet used to
name the currently known superfamilies – Q, R, U, W, X, Z,
or (ii) the names of the superfamily which they are the most
similar to, and from which a number has been appended.transcriptome of Conus marmoreus and MS/MS coverage. New
with ConoSorter simultaneously in the signal, pro-, and mature
itional file 3: Figure S2). For each known superfamily, the sequence
l signal region (the deeper color the more conserved the amino acids
nts isolated by MS/MS analysis of C. marmoreus milked venom.
in the input data. DNA Data Bank of Japan (DDBJ) accession numbers
alculated by ProteinPilot 4.0 are provided in Additional file 4: Table S2.
Figure 3 (See legend on next page.)
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Figure 3 New superfamilies of conopeptides. Top panel shows an identity cladogram in which signal sequences of conopeptides matching
only pro- and mature regions (in grey) have been aligned with consensus signal regions of known superfamilies (in red). Percentage value
between brackets following the superfamily name measures the intraspecific conservation of members populating this family (the “*” symbol
means that only one sequence is part of the family). Bottom panel shows the 33 new precursor sequences spread over the 13 new superfamilies.
Red rectangles enclose the signal sequences determined with SignalP 4.0. The number following the precursor name is the precursor sequence
frequency among the input data set. Bold partial sequences represent the peptide fragments retrieved by MS/MS sequencing of milked venom.
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Additional file 5: Table S3). The signal sequences of these 13
new groups of conopeptides show high intrinsic identity
rates from 82.6% to 100% (as a comparison, the lowest intra-
specific conservation percentages known are 58.1%, 65.0% or
69.1% between members of the well established I2, L and P
superfamilies). In addition, we find that the integration of
these new distinct and well-defined superfamilies in the
current classification does not interfere with the established
superfamily classifications - for example, identity rates are as
low as 0.2% between the new W group and the empirical I3
superfamily (Additional file 5: Table S3). ConoSorter also
assigned non-conotoxin classes to 4 conomarphin and 2
contryphan precursor sequences (data not shown).
Discussion
Many studies have reported the existence of intraspecific
variations in the venom content of distinct Conus individ-
uals belonging to the same species [43-46]. Reanalysis of
the venom gland transcriptome of one Conus marmoreus
individual revealed that ConoSorter was able to identify
72% of the annotated and complete known precursor
conopeptides previously isolated in this species, and also
led to the discovery of 158 new precursor conopeptides,
67.1% of which were validated in a matched MS/MS
dataset. Interestingly, we observed that the overall number
of C. marmoreus precursor conopeptides found to date is
comparable to the number Conus species can theoretically
produce [9]. Further investigation of the novel sequences
identified by ConoSorter also allowed us to define 13 new
superfamilies of conopeptides, which we have classified as
H2, I4, M2, N2, O4, Q, R, U, W, X, Y2, Y3, and Z based
on their intraspecific conservation rates and identity to
established superfamilies. We note that in all new precur-
sor sequences we were able to detect putative pro-peptide
cleavage sites (usually positively charged amino acids like
KR, LR or QR for instance), located just before the mature
regions, an observation that is consistent with mass spec-
trometry data and supports the reliability of the matching
between the venom duct transcriptome and the proteome
of milked venom.
In this reanalysis we were able to retrieve 106 of the 146
known Conus marmoreus precursor sequences. A manual
investigation of the 40 conopeptide sequences ConoSorter
failed to identify in this analysis and the 454 RNA-seq data,
revealed two likely sources of error: (i) 454 sequencingerrors, particularly those associated with homopolymers
(which has been extensively documented [47]), and (ii) lack
of congruence between the RNA-seq data read length and
the length of the encoded conopeptides. Indeed, although
conopeptide precursors are relatively short polypeptides,
their average length is nonetheless ~70 amino acids (~210
nucleotides), there are those, including CalMKLL-1 and −2
conotoxin precursors from Conus californicus, that are 131
amino acids in length. The average length of a high quality
RNA-seq read in this dataset was 317.93 bases, indicating
that failure to detect known conotoxins could be improved
with longer reads. We suspect that further work in this
field will take advantage of platforms offering up to 2 ×
300 bp nucleotide reads, which not only allow for impro-
ved detection of conotoxins but may also facilitate de novo
assembly of the Conus transcriptome.
Conclusions
In this article we present ConoSorter, a high-throughput
standalone program that implements regular expressions
and pHMMs for large-scale identification and classifica-
tion of precursor conopeptides into gene superfamilies
and classes based on the ER signal, pro-, and mature
conopeptide regions generated from raw next-generation
transcriptomic or proteomic data. ConoSorter also gener-
ates a set of relevant additional information - frequency of
protein sequences, length, number of cysteine residues,
hydrophobicity rate of N-terminal region, similarity to
known conopeptides - that allows the user to assess the
reliability and relevance of the results and aids the identifi-
cation of new conopeptide superfamilies and classes.
When applied to ConoServer and UniProtKB/Swiss-Prot
databases, ConoSorter is able to recognize 100% of known
conotoxin superfamilies and classes with a minimum spe-
cies specificity of 99%. We also performed a reanalysis of
Conus marmoreus venom duct transcriptome and (i) cor-
rectly classified all sequences previously annotated, (ii) re-
trieved 106 of the 146 precursor conopeptides known in
this species, (iii) assigned the correct classification to 17
novel precursor toxin isoforms, (iv) identified 158 novel
precursor conopeptide transcripts, 106 of which were con-
firmed by protein mass spectrometry, and (v) identified an-
other 13 novel conotoxin gene superfamilies called here
H2, I4, M2, N2, O4, Q, R, U, W, X, Y2, Y3, and Z.
Overall, ConoSorter provides a fully automated, accur-
ate and easy-to-use tool for the analysis of large quantities
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quences, which could contribute to the acceleration of the
discovery of new bioactive molecules.
Methods
Training set
Query data are compared to known conopeptide se-
quences using regular expressions and pHMMs. The
conopeptides sequences used to build these reference
models were obtained from the latest updates of the
ConoServer (27/05/2013) and UniProtKB (06/2013)
databases. These databases contain complete or partial
wild type precursor and mature toxin sequences, isolated
either as conotoxin genes, transcripts, or proteins, as
well as artificially synthesized peptides. For the training
set, only full-length endogenous precursor and mature
conopeptides isolated at the protein level, or sequences
from a superfamily where all members were annotated
at the gene/DNA level, were used. Synthetic constructs
and patented sequences with undetermined amino acids
have not been included in the training set. A total of
2,008 sequences were used – 1,390 conopeptide super-
family sequences and 1,931 for their classes (a high pro-
portion of which overlap). For each superfamily and
class the signal, pro- and mature regions, which are used
for the region-specific queries described below, were
identified (Table 2). A total of 1,435 signal, 2,391 pro-,
and 3,187 mature fragments were retrieved after discar-
ding sequences with undetermined amino acids and
duplicate regions coming from both the precursor and
mature forms of the same conopeptide.
Each conopeptide region was aligned using ClustalW
(BLOSUM cost matrix; gap open and extension penalties
of 10 and 0.1 respectively) in order to generate clusters of
closely related sequences and establish consensus subsets
that best describe each superfamily and class. Signal
conopeptide regions showed high conservation rates
(from 61.4% to 100% identity). Sequence variability was
higher in pro-region groups, and CD-hit [48], MEME
[49], or BLASTCLUST [50] failed to produce reliable se-
quence clusters. Sequences were therefore manually cu-
rated until at least 40% pairwise identity was reached.
Mature region sequence clusters were initially generated
by analysis of the cysteine frameworks using a previously
published in-house algorithm [51], which resulted in over-
all sequence conservation comparable to pro-regions.
These clusters of sequences sorted by (i) superfamily, (ii)
class, (iii) conopeptide signal, pro-, and mature regions
and (iv) similarity were then used as templates for the cre-
ation of regular expressions. We produced 436 distinct
models for superfamily classification (75, 165 and 196 for
signal, pro-, and mature regions respectively) and 341
class models (40, 91, and 210 for signal, pro, and mature
regions respectively). The number of clusters containingsequences with the highest rate of similarity and/or groups
with unique sequence for each superfamily and class are
summarized in Table 2.
The second sequence analysis approach implemented by
ConoSorter is based on pHMMs. The sequence clusters
described above used to create the regular expressions for
each conopeptide superfamily / class have been used to
build these models. Aligned clusters of sequences were
converted to Stockholm format and the pHMMs were gen-
erated with hmmbuild from HMMER 3.0 package [52-54].
These conopeptide-specific profiles have then been conca-
tenated to one single HMM database flat file, which has
been subsequently compressed and indexed by using
hmmpress from the same package.
ConoSorter pipeline
The ConoSorter algorithm treats either cDNA or protein
sequences according to a hierarchical step-wise process
outlined in Figure 4. First, raw cDNA sequences are trans-
lated into all 6 reading frames. In order to obtain full-
length precursor proteins, amino acid sequences delimited
by a methionine and a stop codon are trimmed from the
rest of the string and analysed. These sequences are
submitted to a “rigid” Boolean search for signal / pro- /
mature regions with high identity to known conopeptide
superfamilies and classes using the regular expressions de-
scribed above. The sequences are classified into (i) known
superfamilies and/or classes, or (ii) sequences that did not
return a match. For the first group, a score is given for
each of the 3 regions independently - 1 if there is a match,
0 otherwise. Total scores for superfamilies and classes are
then generated by simple addition of each region’s score.
Instances in which there is conflict in the identification
between distinct regions of the same sequence (i.e. the sig-
nal, pro- and/or mature regions have matches to different
superfamilies) are also identified. The group of sequences
that did not return matches to known superfamilies and
classes is submitted to a more flexible stochastic search
using the conopeptide-specific pHMMs described above
and hmmscan script from the HMMER 3.0 package
(hmmscan, like many other matching programs, use a de-
fault E-value threshold of 10). Total scores for superfam-
ilies and classes are then calculated as the product of the
E-values of the 3 independent regions.
Two separate sets of results are thus obtained, one for
those with clear similarity to known superfamilies and
classes and one for those that are potentially novel,
which are stored in tabulated files called “Regex.tab” and
“pHMM.tab”, respectively. We note that if a sequence
has been assigned to a superfamily and/or a class based
on the ER signal region, the amino acids before its spe-
cific signal motif are trimmed. The number of sequence
(s) identical to a hit in the original input data set is
reported, as well as the hit length, its cysteine content,
Table 2 Training set used to build regular expression and pHMMs models
Signal Pro-region Mature
Total clusters Unique seq. Total seq. Total clusters Unique seq. Total seq. Total clusters Unique seq. Total seq.
A 3 - 77 21 6 136 23 6 195
B1 2 1 8 2 - 13 7 3 13
B2 1 1 1 1 1 1 1 1 1
B3 1 1 1 - - - 1 1 1
C 1 - 3 2 - 4 2 - 4
D 1 - 10 3 1 21 5 1 30
E 1 1 1 - - - 1 1 1
F 1 1 1 1 1 1 1 1 1
G 1 1 1 1 1 1 1 1 1
H 1 - 2 3 2 5 4 2 7
I1 3 1 12 5 4 13 8 2 48
I2 2 - 31 14 6 32 12 5 50
I3 1 - 4 3 2 7 2 - 8
J 1 - 8 2 1 5 2 - 11
K 1 1 1 1 1 1 1 - 3
L 4 2 10 5 2 10 5 2 11
M 6 2 152 16 5 263 34 16 267
N 1 - 2 1 - 3 1 - 3
O1 14 3 198 20 7 292 32 4 437
O2 4 1 50 15 6 75 12 6 81
O3 1 - 16 7 5 21 3 1 26
P 2 1 6 5 3 7 3 1 12
S 4 3 7 3 - 9 5 1 14
T 3 - 79 18 10 112 12 6 138
V 1 - 2 1 - 2 1 - 2
Y 1 1 1 1 1 1 1 1 1
M—L-LTVA 1 - 5 2 1 8 4 2 8
MKFPLLFISL 1 1 1 1 1 1 1 1 1
MKLCVVIVLL 1 - 2 1 1 1 1 - 3
MKLLLTLLLG 1 1 1 - - - - - -
MKVAVVLLVS 1 1 1 - - - - - -
MRCLSIFVLL 1 - 2 1 1 1 1 1 1
MRFLHFLIVA 1 1 1 1 1 1 1 1 1
MRFYIGLMAA 1 - 2 1 - 3 1 - 4
MSKLVILAVL 1 1 1 1 1 1 1 1 1
MSTLGMTLL- 1 - 5 3 2 5 3 1 5
MTAKATLLVL 1 1 1 1 1 1 1 1 1
MTFLLLLVSV 1 1 1 1 1 1 1 1 1
MTLTFLLVVA 1 1 1 1 1 1 1 1 1
Conantokin 2 1 8 2 - 13 4 1 19
Conodipine - - - - - - 2 2 2
Conohyal 1 - 2 - - - 2 2 2
Conolysin - - - - - - 1 - 2
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Table 2 Training set used to build regular expression and pHMMs models (Continued)
Conomap - - - - - - 1 1 1
Conomarphin 1 - 2 1 - 2 1 - 4
Conopeptide Y 1 1 1 1 1 1 1 - 2
Conophan - - - - - - 1 - 2
Conoporin 1 1 1 - - - 1 1 1
Conopressin 1 1 1 - - - 1 - 6
Conorfamide - - - - - - 1 - 2
Conotoxin 29 4 697 84 14 1,299 189 87 1,730
Conotoxin-like 1 - 2 1 1 1 1 - 2
Contryphan 2 1 10 1 - 13 2 1 15
Contulakin 1 - 3 1 - 3 2 1 4
For each gene superfamilies and classes the table shows the total number of clusters (containing conopeptides with high sequence similarities), unique
sequences, and total sequences in the ER signal, pro- and mature regions.
Lavergne et al. BMC Genomics 2013, 14:708 Page 10 of 12
http://www.biomedcentral.com/1471-2164/14/708and the percentage of hydrophobic residue in the N-
terminal region of the sequence which is a hallmark for
most newly synthesized proteins likely destined toward the
secretory pathway. Finally, ConoSorter searches ConoServer
database for previously described precursor conopeptide
sequences.
Analysis of the mRNA pool isolated from Conus
marmoreus venom gland
The analysis of Conus marmoreus venom duct RNA se-
quencing data has recently been performed [18]. Briefly,Figure 4 Program pipeline. The approach used in ConoSorter is
divided into 4 steps: 1) translation of raw cDNA into amino acid
sequences and formatting (input protein sequences can also be
used directly with the corresponding command line argument); 2)
independent searching for conopeptides superfamilies and classes
using regular expressions; 3) matching pHMMs with unclassified
sequence data set that didn’t provide hits with regular expressions;
4) calculation of additional sequence information (for details see
“Methods” section).mRNAs were sequenced with a Roche 454 pyrosequencer,
and corresponding conopeptide sequences were identified
by a BLAST homology search. To confirm the existence of
new conopeptides, peptides isolated from C. marmoreus
milked venom were sequenced by MS and matched to the
conopeptide transcripts.
Here, we perform a reanalysis of this data using
ConoSorter, as described above, with the addition of a
number of computational steps to confidently identify
novel conotoxin superfamilies and classes. Specifically,
ConoSorter hits displaying matches only for the pro-
and mature regions, as well as containing at least 60%
hydrophobic amino acid in their N-terminal region
were selected. This cutoff was chosen based on an ana-
lysis of all ConoServer conopeptide sequences with
unique and complete signal regions - 644 in total, with
a length and number of hydrophobic amino acids being
21.28 and 15.83 on average respectively (74.56% hydro-
phobicity with a standard deviation σ=6.59, and a mini-
mum of 52.00%). These selected sequences were
submitted to SignalP 4.0 in order to select sequences
with a defined signal region [55]. Using these signal
peptides, and those from annotated superfamilies, we
then built a similarity matrix to ascertain the minimal
intraspecific and maximal interspecific identity rates
within and between known superfamilies (Additional
file 5: Table S3). We submitted the isolated signal re-
gions to the CD-hit clustering program by applying an
identity cut-off of 75.00%. Signal sequences of the se-
lected hits showing a similarity rate ≥75.00% were clus-
tered. As an internal control we queried all empirical
superfamilies and found that I2, L, P, M, I1, O1 families
have an intraspecific conservation rate well below this
threshold with 58.10%, 65.00%, 69.10%, 69.30%, 73.60%
and 73.70% identity, respectively (Additional file 5:
Table S3). Clusters displaying a maximum of 53.3%
identity with any known superfamily were considered a
Lavergne et al. BMC Genomics 2013, 14:708 Page 11 of 12
http://www.biomedcentral.com/1471-2164/14/708putative novel superfamily. Signal regions of members
of known and newly defined superfamilies were aligned
using ClustalW in order to create a consensus identity
cladogram. This analysis was also performed using
MUSCLE algorithm, and showed a deviation of ±0.17%
from the ClustalW results. Validation of novel cono-
peptides was performed using the previously published
MS/MS data [18].Availability of supporting data
ConoSorter is licensed under the GNU General Public
License version 3 (GPLv3) and freely available at http://
sourceforge.net/p/conosorter.Additional files
Additional file 1: Figure S1. Amino acid diversity in conopeptides. The
position-specific inverse Simpson index, 1/λ, of amino acid for the ER
signal (red), pro- (green), and mature (purple) conopeptide regions of the
remaining gene superfamilie. For each amino acid position, a color
gradient applies to the diversity index (from 0 in light to higher values in
darker color).
Additional file 2: Table S1. New isoforms of known Conus marmoreus
precursor conopeptides. New isoforms of conopeptide precursors
previously discovered in Conus marmoreus inferred from their known
mature region (in blue). Peptide fragment coverage obtained by mass
spectrometry analysis of the milked venom is represented in bold. The
frequency of the sequence present in the mRNA pool, as well as the
superfamily of the precursor conopeptide are also indicated in the table.
Additional file 3: Figure S2. Isoforms of new precursor conopeptides
classified into known superfamilies
Additional file 4: Table S2. New precursor sequences found in Conus
marmoreus. Their names, DDBJ accession numbers, and post-translational
modifications of the peptide fragments (bold) generated by ProteinPilot
4.0 are mentioned in the above table.
Additional file 5: Table S3. Similarity matrix of known and new
conopeptide gene superfamilies. Known and new superfamilies are
highlighted in red and grey respectively. Number between brackets
following the superfamily name represents the conservation index of its
members.
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Additional le 1: Figure S1. Amino acid diversity in conopeptides. The position-specic inverse
Simpson index, 1/λ, of amino acid for the ER signal (red), pro- (green), and mature (purple)
conopeptide regions of the remaining gene superfamilies. For each amino acid position, a color
gradient applies to the diversity index (from 0 in light to higher values in darker color).
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Additional le 1: Figure S1(continued)
Additional le 2: Table S1. New isoforms of known Conus marmoreus precursor conopeptides. New isoforms of conopeptide precursors
previously discovered in Conus marmoreus inferred from their known mature region (in blue). Peptide fragment coverage obtained by mass
spectrometry analysis of the milked venom is represented in bold. The frequency of the sequence present in the mRNA pool, as well as the
superfamily of the precursor conopeptide are also indicated in the table.
Additional file 2:  Table S1 
 
Name Freq. Sequence Superfamily 
New_Mr1.1_precursor 2 MSTVFLLVVLATTVVSFTSDRASDGRKAAAKDKASDLVALTVKGCCSHPACSVNNPDICG A 
New_conomarphin_Mr1_precursor_1 1 MSKLGVVLCIFLVLFPMATLQLDGDQTADHHADQRGQDLTEQQRNSKRVLKKRDWEYHAHPKPNSFWTLV M 
New_conomarphin_Mr1_precursor_2 2 MSKLGVVLCIFLVLFPMATLQLDGDQTADRHADQRGQDLTEQHRNLKRVLKKRDWEYHAHPKPNSFWTLV M 
New_conomarphin_Mr1_precursor_3 1 MSKLGVVLCIFLVLFPMATLQLDGDQTADRHADQRGQDLTEQQRNSKRVLKKRDWEYHAHPKPNSFWTLVERHQAGYSRTVVV M 
New_conomarphin_Mr2_precursor 1 MSKLGVVLCIFLVLFPMATLQLDGDQTADRHADQRGQDLTEQHQNLKRVLKKRDWVNHAHPQPNSIWSLV M 
New_contryphan_M_precursor_1 1 MGKLTILVLVAAILLSTQVMVQDDRDQPADRNAVPRDDNPGRARRKRMKVLNESECPWHPWCG O2 
New_contryphan_M_precursor_2 1 MGKLTILVLVAAVLLSTQAWFKGDRDQPADRNAVPRDDNPGRARRKRMKVLNESECPWHPWCG O2 
New_cMrVIA_precursor 1 MRCLPVLIILLLLTASAPGVVVLPKTEDDVPMSSVYGNGKSILRGILRRVCCGYKLCHPC T 
New_CMrX_precursor_1 1 MRCLPVLIILLLLTASAPGVDVLPKTEDDVPLSSVYGNGKSILRGILRKGICCGVSFCYPCLTSMKGNDFG T 
New_CMrX_precursor_2 2 MRCLPVLIILLLLTASAPGVDVLPKTEDDVSLSSVYGNGKSILRGILRKGICCGVSFCYPC T 
New_CMrX_precursor_3 1 MRCLPVLIILLLLTASAPGVDVLPKTEGDVPLSSVYGNGKSILRGILRKGICCGVSFCYPC T 
New_MrIA_precursor_1 1 MRCLPVLIILLLLIASAPGVVVLPKTEDDVPMSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
New_MrIA_precursor_2 3 MRCLPVLIILLLLTASAAGVVVLPKTEDDVPMSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
New_MrIA_precursor_3 2 MRCLPVLIILLLLTASALGVVVLPKTEDDVPMSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
New_MrIA_precursor_4 1 MRCLPVLIILLLLTASAPDVVVLPKTEDDVPMSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
New_MrIA_precursor_5 5 MRCLPVLIILLLLTASAPGVDVLPKTEDDVPLSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
New_MrIA_precursor_6 1 MRCLPVLIILLLLTASAPGVVVLPKTEDDVPLSSVYGNGKSILRGILRNGVCCGYKLCHPC T 
 
 
New isoforms of conopeptide precursors previously discovered in Conus marmoreus inferred from their known mature region (in blue). Peptide fragment coverage obtained 
by mass spectrometry analysis of the milked venom is represented in bold. The frequency of the sequence present in the mRNA pool, as well as the superfamily of the 
precursor conopeptide are also indicated in the table. 
I2 Superfamily
Mr_precursor_041      4       
Mr_precursor_047     11       
Mr_precursor_046      6       
Mr_precursor_045      2       
Mr_precursor_044      2       
Mr_precursor_043      2       
Mr_precursor_042      1      
Mr_precursor_050      1       
Mr_precursor_049      2       
Mr_precursor_048      1       
M Superfamily
Mr_precursor_058      1       
Mr_precursor_059      1       
Mr_precursor_060      1       
Mr_precursor_061      2       
Mr_precursor_062      1       
Mr_precursor_063      2       
Mr_precursor_064      3       
Mr_precursor_065      1       
Mr_precursor_066      1       
Mr_precursor_067      1       
Mr_precursor_068      1       
Mr_precursor_069      1       
Mr_precursor_070      1       
Mr_precursor_071      1       
Mr_precursor_072      1       
Mr_precursor_073      1       
Mr_precursor_074      1       
Mr_precursor_075      1       
Mr_precursor_076      1       
Mr_precursor_077      1       
Mr_precursor_078      1       
Mr_precursor_079      1       
Mr_precursor_080      2       
Mr_precursor_081      1       
Mr_precursor_082      1       
Mr_precursor_083      2       
Mr_precursor_084      2       
Mr_precursor_085      1       
Mr_precursor_086      1       
Mr_precursor_087      2       
Mr_precursor_088      1       
Mr_precursor_057      1       
Mr_precursor_056      6       
Mr_precursor_055      8       
Mr_precursor_054     41       
Mr_precursor_053      1       
Mr_precursor_052      1       
Mr_precursor_051      1       
O1 Superfamily
Mr_precursor_090      2       
Mr_precursor_091      1       
Mr_precursor_092      1       
Mr_precursor_093      1       
Mr_precursor_094      1       
Mr_precursor_095      1       
Mr_precursor_096      1       
Mr_precursor_097      1       
Mr_precursor_098      1       
Mr_precursor_099      1       
Mr_precursor_100      1       
Mr_precursor_101      1       
Mr_precursor_102      1       
Mr_precursor_103      1       
Mr_precursor_104      1       
Mr_precursor_105      1       
Mr_precursor_106      4       
Mr_precursor_107      1       
Mr_precursor_108      1       
Mr_precursor_109      1       
Mr_precursor_110      1       
Mr_precursor_111      1       
Mr_precursor_112      1       
Mr_precursor_113      1       
Mr_precursor_114      1       
Mr_precursor_115      1       
Mr_precursor_116      1       
Mr_precursor_117      1       
Mr_precursor_118      1       
Mr_precursor_119      5       
Mr_precursor_120      2       
Mr_precursor_121      6       
Mr_precursor_089      1       
O2 Superfamily
Mr_precursor_123      1       
Mr_precursor_122      1       
T Superfamily
Mr_precursor_124      3       
Mr_precursor_125      2       
Additional le 3: Figure S2. Isoforms of new precursor conopeptides classied into known
superfamilies.
Additional file 4: Table S2 
!
Name DDBJ Acc. # Post-translational Modification(s) 
Mr_precursor_001 AB850695  
Mr_precursor_002 AB850696  
Mr_precursor_003 AB850697  
Mr_precursor_004 AB850698  
Mr_precursor_005 AB850699  
Mr_precursor_006 AB850700  
Mr_precursor_007 AB850701  
Mr_precursor_008 AB850702 Oxidation(H)@54. 
Mr_precursor_009 AB850703  
Mr_precursor_010 AB850704  
Mr_precursor_011 AB850705 Oxidation(C)@59; Oxidation(H)@60; Oxidation(C)@63; Sulfo(Y)@64; Oxidation(C)@66. 
Mr_precursor_012 AB850706  
Mr_precursor_013 AB850707  
Mr_precursor_014 AB850708  
Mr_precursor_015 AB850709  
Mr_precursor_016 AB850710  
Mr_precursor_017 AB850711 Oxidation(C)@89; Oxidation(H)@90; Oxidation(C)@93; Sulfo(Y)@94; Oxidation(C)@96. 
Mr_precursor_018 AB850712  
Mr_precursor_019 AB850713  
Mr_precursor_020 AB850714 Oxidation(D)@49; Oxidation(P)@52; Oxidation(P)@57; Oxidation(C)@60; Oxidation(C)@63; Oxidation(C)@64. 
Mr_precursor_021 AB850715  
Mr_precursor_022 AB850716 Deamidated(Q)@49; Deamidated(N)@53; Oxidation(C)@58; Oxidation(P)@59; Carboxy(E)@62; Oxidation(C)@63; Deamidated(Q)@66; Deamidated(Q)@68. 
Mr_precursor_023 AB850717  
Mr_precursor_024 AB850718 Deamidated(N)@27. 
Mr_precursor_025 AB850719  
Mr_precursor_026 AB850720  
Mr_precursor_027 AB850721 Bromo(W)@76; Bromo(W)@80. 
Mr_precursor_028 AB850722 Oxidation(P)@78. 
Mr_precursor_029 AB850723  
Mr_precursor_030 AB850724  
Mr_precursor_031 AB850725  
Additional le 4: Table S2. New precursor sequences found in Conus marmoreus. Their names, DDBJ accession numbers, and post-translational
modications of the peptide fragments (bold) generated by ProteinPilot 4.0 are mentioned in the above table.
Additional le 4: Table S2 (continued)
Mr_precursor_032 AB850726  
Mr_precursor_033 AB850727  
Mr_precursor_034 AB850728 Oxidation(C)@56; Deamidated(Q)@61; Oxidation(W)@66; Oxidation(P)@69; Oxidation(C)@73. 
Mr_precursor_035 AB850729  
Mr_precursor_036 AB850730  
Mr_precursor_037 AB850731 Carboxy(E)@60. 
Mr_precursor_038 AB850732  
Mr_precursor_039 AB850733 Oxidation(M)@67. 
Mr_precursor_040 AB850734 Deamidated(N)@65; Oxidation(C)@67; Oxidation(C)@68; Deamidated(R)@71; Deamidated(Q)@72; Oxidation(C)@73. 
Mr_precursor_041 AB850735  
Mr_precursor_042 AB850736  
Mr_precursor_043 AB850737  
Mr_precursor_044 AB850738  
Mr_precursor_045 AB850739  
Mr_precursor_046 AB850740  
Mr_precursor_047 AB850741  
Mr_precursor_048 AB850742  
Mr_precursor_049 AB850743  
Mr_precursor_050 AB850744  
Mr_precursor_051 AB850745 Oxidation(C)@53; Oxidation(H)@54; Oxidation(W)@57. 
Mr_precursor_052 AB850746  
Mr_precursor_053 AB850747 Oxidation(H)@54. 
Mr_precursor_054 AB850748 Oxidation(H)@54. 
Mr_precursor_055 AB850749  
Mr_precursor_056 AB850750  
Mr_precursor_057 AB850751 Oxidation(C)@59; Oxidation(H)@60; Oxidation(C)@63; Sulfo(Y)@64; Oxidation(C)@66. 
Mr_precursor_058 AB850752 Oxidation(H)@54. 
Mr_precursor_059 AB850753 Oxidation(H)@54. 
Mr_precursor_060 AB850754  
Mr_precursor_061 AB850755  
Mr_precursor_062 AB850756  
Mr_precursor_063 AB850757  
Mr_precursor_064 AB850758  
Mr_precursor_065 AB850759  
Additional le 4: Table S2 (continued)
Mr_precursor_066 AB850760  
Mr_precursor_067 AB850761  
Mr_precursor_068 AB850762  
Mr_precursor_069 AB850763  
Mr_precursor_070 AB850764 Oxidation(C)@59; Oxidation(H)@60; Oxidation(C)@63; Sulfo(Y)@64; Oxidation(C)@66. 
Mr_precursor_071 AB850765  
Mr_precursor_072 AB850766  
Mr_precursor_073 AB850767  
Mr_precursor_074 AB850768  
Mr_precursor_075 AB850769 Oxidation(H)@54. 
Mr_precursor_076 AB850770 Oxidation(H)@54. 
Mr_precursor_077 AB850771 Oxidation(H)@54. 
Mr_precursor_078 AB850772 Oxidation(H)@53. 
Mr_precursor_079 AB850773 Oxidation(H)@54. 
Mr_precursor_080 AB850774 Oxidation(H)@54. 
Mr_precursor_081 AB850775  
Mr_precursor_082 AB850776 Oxidation(H)@56. 
Mr_precursor_083 AB850777 Oxidation(H)@57. 
Mr_precursor_084 AB850778 Oxidation(H)@60. 
Mr_precursor_085 AB850779 Deamidated(R)@49; Oxidation(C)@51; Oxidation(C)@55; Bromo(H)@60; Oxidation(P)@61; Oxidation(C)@62. 
Mr_precursor_086 AB850780 Oxidation(P)@52; Deamidated(N)@61; Oxidation(P)@62. 
Mr_precursor_087 AB850781 Deamidated(R)@57; Oxidation(P)@62; Oxidation(C)@63; Oxidation(C)@64; Oxidation(W)@65. 
Mr_precursor_088 AB850782 Oxidation(H)@60. 
Mr_precursor_089 AB850783  
Mr_precursor_090 AB850784  
Mr_precursor_091 AB850785  
Mr_precursor_092 AB850786  
Mr_precursor_093 AB850787 Oxidation(M)@58; Deamidated(N)@63. 
Mr_precursor_094 AB850788 Deamidated(N)@27. 
Mr_precursor_095 AB850789  
Mr_precursor_096 AB850790  
Mr_precursor_097 AB850791 Deamidated(N)@27; Deamidated(N)@31. 
Mr_precursor_098 AB850792  
Mr_precursor_099 AB850793 Deamidated(N)@27. 
Additional le 4: Table S2 (continued)
Mr_precursor_100 AB850794  
Mr_precursor_101 AB850795  
Mr_precursor_102 AB850796  
Mr_precursor_103 AB850797  
Mr_precursor_104 AB850798  
Mr_precursor_105 AB850799  
Mr_precursor_106 AB850800  
Mr_precursor_107 AB850801  
Mr_precursor_108 AB850802  
Mr_precursor_109 AB850803 Bromo(W)@76; Bromo(W)@80. 
Mr_precursor_110 AB850804  
Mr_precursor_111 AB850805  
Mr_precursor_112 AB850806  
Mr_precursor_113 AB850807  
Mr_precursor_114 AB850808  
Mr_precursor_115 AB850809  
Mr_precursor_116 AB850810  
Mr_precursor_117 AB850811  
Mr_precursor_118 AB850812  
Mr_precursor_119 AB850813  
Mr_precursor_120 AB850814  
Mr_precursor_121 AB850815  
Mr_precursor_122 AB850816 Oxidation(C)@56; Deamidated(Q)@61; Oxidation(W)@66; Oxidation(P)@69; Oxidation(C)@73. 
Mr_precursor_123 AB850817  
Mr_precursor_124 AB850818  
Mr_precursor_125 AB850819 Deamidated(Q)@56; Oxidation(M)@65. 
Mr_precursor_126 AB850820 Deamidated(R)@46; Oxidation(C)@47; Oxidation(C)@48; Oxidation(H)@49; Bromo(W)@50; Oxidation(W)@50; Deamidated(N)@51; Oxidation(W)@52; Oxidation(C)@53; Oxidation(C)@59; Oxidation(C)@60. 
Mr_precursor_127 AB850821  
Mr_precursor_128 AB850822  
Mr_precursor_129 AB850823 Deamidated(Q)@58; Deamidated(Q)@63; Deamidated(Q)@66; Oxidation(C)@68. 
Mr_precursor_130 AB850824 Deamidated(Q)@58; Deamidated(Q)@63; Deamidated(Q)@66; Oxidation(C)@68. 
Mr_precursor_131 AB850825  
Mr_precursor_132 AB850826 Deamidated(N)@21; Deamidated(N)@25. 
Mr_precursor_133 AB850827  
Additional le 4: Table S2 (continued)
Mr_precursor_134 AB850828  
Mr_precursor_135 AB850829  
Mr_precursor_136 AB850830  
Mr_precursor_137 AB850831 Oxidation(P)@20; Deamidated(N)@22; Deamidated(N)@26; Oxidation(M)@53; Deamidated(N)@58. 
Mr_precursor_138 AB850832 Oxidation(P)@20; Deamidated(N)@22; Deamidated(N)@26; Oxidation(M)@53; Deamidated(N)@58. 
Mr_precursor_139 AB850833 Deamidated(N)@22. 
Mr_precursor_140 AB850834 Deamidated(N)@22; Deamidated(N)@26. 
Mr_precursor_141 AB850835  
Mr_precursor_142 AB850836 Oxidation(P)@73. 
Mr_precursor_143 AB850837  
Mr_precursor_144 AB850838  
Mr_precursor_145 AB850839  
Mr_precursor_146 AB850840  
Mr_precursor_147 AB850841  
Mr_precursor_148 AB850842  
Mr_precursor_149 AB850843  
Mr_precursor_150 AB850844 Oxidation(P)@90. 
Mr_precursor_151 AB850845  
Mr_precursor_152 AB850846  
Mr_precursor_153 AB850847  
Mr_precursor_154 AB850848  
Mr_precursor_155 AB850849 Sulfo(Y)@16. 
Mr_precursor_156 AB850850 Sulfo(Y)@16. 
Mr_precursor_157 AB850851  
Mr_precursor_158 AB850852  
New_Mr1.1_precursor AB850863  
New_conomarphin_Mr1_precursor_1 AB850857 Oxidation(H)@58; Oxidation(H)@60; Oxidation(P)@61; Oxidation(P)@63; Oxidation(N)@64; Deamidated(N)@64; Oxidation(W)@67. 
New_conomarphin_Mr1_precursor_2 AB850858 Oxidation(H)@58; Oxidation(H)@60; Oxidation(P)@61; Oxidation(P)@63; Oxidation(N)@64; Deamidated(N)@64; Oxidation(W)@67. 
New_conomarphin_Mr1_precursor_3 AB850859 Oxidation(H)@58; Oxidation(H)@60; Oxidation(P)@61; Oxidation(P)@63; Oxidation(N)@64; Deamidated(N)@64; Oxidation(W)@67. 
New_conomarphin_Mr2_precursor AB850860 Deamidated(N)@57; Oxidation(P)@61; Oxidation(P)@63; Deamidated(N)@64. 
New_contryphan_M_precursor_1 AB850861  
New_contryphan_M_precursor_2 AB850862 Deamidated(N)@52. 
New_cMrVIA_precursor AB850853  
Additional le 4: Table S2 (continued)
New_CMrX_precursor_1 AB850854 Oxidation(P)@5; Oxidation(P)@60; Oxidation(C)@61. 
New_CMrX_precursor_2 AB850855  
New_CMrX_precursor_3 AB850856  
New_MrIA_precursor_1 AB850864 Oxidation(P)@5; Oxidation(P)@31; Oxidation(M)@32; Deamidated(N)@38; Deamidated(N)@49; Oxidation(C)@52; Oxidation(C)@58; Oxidation(P)@60; Oxidation(C)@61. 
New_MrIA_precursor_2 AB850865  
New_MrIA_precursor_3 AB850866  
New_MrIA_precursor_4 AB850867  
New_MrIA_precursor_5 AB850868  
New_MrIA_precursor_6 AB850869  
!
New precursor sequences found in Conus marmoreus.  Their names, DNA Data Bank of Japan (DDBJ) accession numbers, and post-translational modifications of the 
peptide fragments (bold) generated by ProteinPilot4 are mentioned in the above table. 
Additional le 5: Table S3. Similarity matrix of known and new conopeptide gene superfamilies. Known and new superfamilies are highlighted in
red and grey respectively. Number between brackets following the superfamily name represents the conservation index of its members.
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Abstract  
Cone snails are predatory marine gastropods characterised by a sophisticated venom apparatus 
responsible for the biosynthesis of toxin peptides that are able to potently and selectively interact 
with heterologous ion channels and receptors. Approximately 1,900 conotoxins from an estimated 
number of >70,000 bioactive peptides have been identified in the genus Conus to date. Here we 
describe a high-resolution interrogation of the transcriptomes and proteomes of the Conus 
episcopatus venom duct, salivary gland, and radular sac. This unveiled the highest number of 
conopeptides discovered in a single Conus specimen to date with 3,305 novel precursor 
conopeptide sequences identified from the transcriptomic data (144 of which were validated by 
protein mass spectrometry) spread over 9 gene superfamilies. In addition, we describe a large 
population of venom peptides containing the pharmacologically active C-C-CC-C-C inhibitory 
cysteine knot motif (168 molecules) and CC-C-C (45) cysteine frameworks. We also describe six 
cysteine-rich frameworks novel to cone snails:  four of which are ubiquitous in nature, one which is 
highly abundant in snake C-type lectins, and one containing 10 cysteine residues which is 
previously undescribed. The data indicates that sequence hypervariablity of conotoxins originates 
from codon usage bias at the gene level, and supports the creation of 16 novel cone snail gene 
superfamilies that could be directed toward new pharmacological classes and subsequently for the 
development of diagnostic tools and therapeutic agents. 
 
Significance statement 
Venomous marine cone snails have evolved complex mixtures of fast-acting paralytic peptide 
toxins for prey capture and defense. These cysteine-rich conopeptides (also referred as conotoxins) 
can alter the function of specific subtypes of heterologous nicotinic acetylcholine receptors, sodium, 
calcium, potassium or serotonin-gated ion channels, as well as noradrenaline transporters. Deep 
sequencing of the transcriptome from a single cone snail coupled to extensive proteomic analysis of 
Conus episcopatus, revealed for the first time thousands of new conotoxins, some of which contain 
well-known cysteine motifs present in FDA-approved peptides or currently in clinical trials that 
might provide valuable structure-activity relationship information, as well as new subtype selective 
ligands. We also identified new cysteine scaffolds likely to unveil unique peptide architectures with 
as yet unknown pharmacological properties.  
  
Introduction 
 Cone snails are venomous marine gastropod molluscs from the genus Conus (family Conidae), 
with more than 600 species known to date (1). Over the last  ~30 million years, these species have 
evolved sophisticated predatory and defense strategies with the elaboration of a highly organized 
envenomation machinery (2). The Bishop’s cone Conus episcopatus, like most of its congeners, is 
usually found in shallow water of lagoons and ocean sides of coral reefs from the Indo-Pacific 
region, and is known to feed exclusively on molluscs (3). Its venom apparatus is responsible for the 
biosynthesis and maturation of short peptide neurotoxins called conopeptides that, once injected in 
the prey or predator (fish, molluscs, or worms), act as fast acting paralytics. When the cone snail 
senses waterborne chemical signals via a specialized chemoreceptory organ (called a siphon or 
osphradium), searching behaviour begins with the release and extension of the proboscis where, in 
its lumen, a single dart-like radula tooth is tightly held by circular muscles and filled with venom 
that has been loaded from the radular sac (RS) (Fig. 1A) (4-6). It is only when the tip of the 
proboscis comes in contact with the target that the radula is rapidly propelled into the prey and acts 
like a hypodermic needle to inject the venom (7). This radula tooth then serves as a harpoon to 
bring the captured prey back to the mouth of the snail (Fig. 1C).  
 
 
The biochemical and cellular mechanisms of venom production, including its synthesis, processing 
and packaging of toxins inside secretory granules are poorly described. Nevertheless, it has been 
Fig. 1 – Cone snail anatomy and venom apparatus. Schemas illustrating the macroscopic anatomy of a cone snail (A), its 
venom apparatus organization (B) with the venom duct, the radular sac, and the salivary system highlighted in green, blue and 
red respectively. An enlarged representation of a single dart radula stored in the radular sac that will be filled with venom and 
loaded in the proboscis is also shown (C).	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demonstrated that epithelial cells bordering the venom duct (VD) are the most likely site of 
conopeptide production, which are then released into the gland’s lumen through a holocrine 
secretion process (Fig. 1B) (8). The venom duct also shows a functional compartmentalization 
where specific cabals of conopeptides, as well as particular enzymes involved in processing (such 
as protein disulfide isomerases, immunoglobulin binding proteins or peptidyl-prolyl isomerases) are 
preferentially expressed in particular regions of the duct (9, 10).  The muscular venom bulb and the 
burst contractions it triggers only serves for the circulation of the venom inside the duct up to the 
pharynx, where conopeptides may undergo molecular sorting and maturation (11). In addition, it 
has been suggested that certain conopeptides could, to a much lesser extent, be specifically 
expressed by the salivary gland (SG) (12). 
To compensate for their limited mobility, cone snails have developed an efficient venom delivery 
system along with a vast library of structurally diverse bioactive peptides for prey capture and 
defense (13). Mature and active conopeptides are typically between 10 to 35 amino acids in length, 
most often stabilized by conserved cysteine mediated disulfide connectivities (14). They are able to 
selectively modulate specific subtypes of voltage- or ligand-gated transporters, receptors and ion 
channels expressed in organisms broadly distributed along the phylogenetic spectrum (13). 
Moreover, as a result of speciation, a high rate of hypermutations, and a remarkable number of post-
translational modifications, little overlap of conopeptides from between conus species has been 
observed (15, 16). This has led to estimates >70,000 of pharmacologically active peptides expressed 
by the genus Conus, though less than 1% have been characterised to date (17). 
Cone snail toxins are considered a source of unrivalled richness of potential pharmacological agents 
with diagnostic and therapeutic interests for the treatment of human neuropathic pain, epilepsy, 
cardiac infarction, and neurological diseases (13). As described in Table 1, 25 cysteine patterns 
have been reported in cone snail venom to date (8 of which with known disulfide bond 
connectivities) (18). Although cysteine bridges always improve the stability of the conotoxin and 
provide resistance to enzymatic degradation, some cysteine frameworks associated with particular 
loop lengths are more conserved than others in bioactive conopeptides. For instance, ω-conotoxin 
MVIIA (C(6)C(6)CC(3)C(4)C), the only FDA-approved venom peptide mimetic, which is 
marketed under the name Prialt (19) and ω-conotoxin CVID (C(6)C(6)CC(3)C(6)C), which is 
undergoing phase II clinical trials (20) both contain a rare inhibitory cysteine knot (ICK) motif 
named framework VI/VII among the genus Conus (where cysteines are disposed as a C-C-CC-C-C 
pattern and branched as I-IV, II-V, III-VI). Also, conotoxins with framework I, such as χ-conotoxin 
MrIA (currently in a Phase II clinical trial) which display a (3)CC(4)C(2)C arrangement with a I-
III, II-IV connectivity  scaffold, are important drug leads (21). In addition other cysteine 
conopeptides like contulakin-G (phase II) (22), and conantokin-G (phase II) (23) which do not 
contain disulfide bonds also show potent activity.  
 
 
 
The precursor form of conopeptides are composed of three distinct regions: a highly conserved N-
terminal endoplasmic reticulum (ER) signal region (used to classify the toxins into gene 
superfamilies), a central pro-region, and a hypervariable mature region characterised by conserved 
cysteine patterns and connectivities (24, 25). Bioactive mature conopeptides are also classified into 
pharmacological families according to their molecular target. Despite a weak correlation between 
gene superfamilies and pharmacological properties, some functional redundancy among members 
of a same superfamily exists (26). To date, 16 empirical gene superfamilies (designated as A, D, I1, 
Table 1 – Conotoxin cysteine frameworks. Each framework is defined as the combination of a 
cysteine pattern in which the cysteine residues are connected to form specific disulfide bonds 
(source: ConoServer website – 07/02/2014).  
Framework Cysteine Pattern Cysteine Connectivities
I CC-C-C I-III, II-IV
II CCC-C-C-C -
III CC-C-C-CC -
IV CC-C-C-C-C I-V, II-III, IV-VI
V CC-CC I-III, II-IV
VI/VII C-C-CC-C-C I-IV, II-V, III-VI
VIII C-C-C-C-C-C-C-C-C-C -
IX C-C-C-C-C-C I-IV, II-V, III-VI
X CC-C.[PO]C I-IV, II-III
XI C-C-CC-CC-C-C I-IV, II-VI, III-VII, V-VIII
XII C-C-C-C-CC-C-C -
XIII C-C-C-CC-C-C-C -
XIV C-C-C-C I-III, II-IV
XV C-C-CC-C-C-C-C -
XVI C-C-CC -
XVII C-C-CC-C-CC-C -
XVIII C-C-CC-CC -
XIX C-C-C-CCC-C-C-C-C -
XX C-CC-C-CC-C-C-C-C -
XXI CC-C-C-C-CC-C-C-C -
XXII C-C-C-C-C-C-C-C -
XXIII C-C-C-CC-C -
XXIV C-CC-C -
XXV C-C-C-C-CC -
XXVI C-C-C-C-CC-CC -
I2, I3, J, L, M, O1, O2, O3, P, S, T, V, Y) have been annotated (24), plus 31 novel superfamilies 
discovered during the past two years (27-33). 
Recent advances in next-generation sequencing technologies have facilitated rapid and accurate 
matched transcriptomic and proteomic profiling of both model and non-model organisms (28, 34-
36). Here we present a deep analysis of the transcriptomes and proteomes of the three main 
compartments of Conus episcopatus venom apparatus: the venom duct, the salivary gland and the 
radular sac. Using ConoSorter (30), we separated newly identified conopeptide sequences from 
those previously characterised and classified them into gene superfamilies. We also investigated 
their cysteine patterns and report many new toxins with ICK and CC-C-C motifs, which are 
considered as strong candidates for drug design. Moreover, we report 5 cysteine arrangements novel 
to cone snails, as well as 1 pattern previously undescribed. We also propose the creation of 16 new 
gene superfamilies and explain the hypervariability of conotoxin sequences by the existence of a 
codon usage bias at the gene level. 
 
Results 
RNA prep & cDNA library sequencing 
The lysis of the venom duct, radular sac, and salivary gland of a single Conus episcopatus specimen 
provided 401 ng/µl, 314 ng/µl, and 73 ng/µl of total RNA respectively. Interestingly, the initial 
qualitative controls of these samples performed with a 2100 Bioanalyzer revealed a lack of 
ribosomal 28S peak along with a strong and sharp 18S band suggesting that RNA integrity was 
suitable for library preparation. This observation of missing 28S rRNA was originally called “the 
hidden break” by H. Ishikawa (37), and has been since observed in the sea slugs Aplysia (38), 
insects (39) or nematode parasites (40). To our knowledge this is the first time it has been reported 
for cone snails. Subsequent to mRNA isolation and generation of sequence libraries with the 
TruSeq® Stranded mRNA Sample preparation kit (Illumina Inc) we obtained inserts at 
concentrations of 12,461.6 pM (VD), 2,119.9 pM (RS), 803.6 pM (SG) with average sizes of 445 
base pair (bp) (VD), 462 bp (RS), and 431 bp (SG) before preparing the samples for sequencing.  
Next-generation MiSeq sequencing gave rise to average numbers of reads (between forward and 
reverse strands) of 20,885,730 (N50forward = 244, N50reverse = 251, N90forward = N90reverse = 301), 
29,187,419 (N50forward = 248, N50reverse = 293, N90forward = N90reverse = 301) and 31,725,853 
(N50forward = 239, N50reverse = 300, N90forward = N90reverse = 301) for VD, RS, and SG respectively 
(Table 2). Filtering of sequences showing an average Phred+33 quality score >30 and merging of 
paired-end reads led to a decrease in number of 15.45% (N50 = 230, N90 = 438), 21.94% (N50 = 
215, N90 = 441), and 36.94% (N50 = 165, N90 = 358) for VD, RS, and SG respectively.
 Table 2 – The numbers of cDNA sequences from the venom duct (A), radular sac (B), and salivary gland (C), as well as length interval, average length, N50, N75 and N90 values, %GC and %N 
calculated after the sequencing (raw reads), trimming and merging steps are reported in the table. The same metrics and alignment rates of the merged/unmerged reads back to the contigs have been 
calculated after using 4 different assembly algorithms for the venom duct (the two programs leading to the highest number of conopeptide hits have been used for RS and SG thereafter). The number of 
conopeptides hits ≥ 40 amino acid long and containing ≥ 60% hydrophobic residues in their N-terminal region (separated into known ones, showing superfamily matches in both signal, pro-, and 
mature regions – score 3, in pro- and mature regions – score 2, and from known classes) revealed after analysis of the merged and unmerged reads, as well as contigs with ConoSorter are also listed. 
Finally, for every compartment, the last column reports the overall number of these conopeptides with a defined signal peptide after discarding duplicates between samples. 	  
A
Raw%Forward%
Read%R1
Raw%Reverse%
Read%R2
Trimmed%
Paired%R1
Trimmed%
Paired%R2
Trimmed%
Unpaired%R1
Trimmed%
Unpaired%R2
Merged%
R1/R2
Unmerged%
R1
Unmerged%
R2 CLC%Contigs SOAP%Contigs% Oases%Contigs Trinity%Contigs%
Total%Conopeptides%
(Signal+)
20,890,920 20,880,539 18,074,096 18,065,546 2,441,661 88,418 17,659,352 2,864,734 511,428 132,719 46,926 30,354 114,771 ,
35,301 35,301 35,301 35,301 25,301 37,301 35,592 25,301 37,301 100,7,392 102,5,385 101,29,853 101,5,747 ,
209 211 200 200 249 216 215 256 281 341 408 761 370 ,
244 251 223 223 281 300 230 289 301 418 424 1,038 478 ,
300 301 300 300 300 301 346 300 301 727 586 1,890 881 ,
301 301 301 301 301 301 438 301 301 1,379 851 3,060 1,466 ,
37.44% 38.03% 37.43% 37.77% 38.06% 37.31% 37.60% 37.68% 36.99% 38.89 38.41 38.63 38.96 ,
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00 0.00 0.53 0.00 ,
Unaligned , , , , , , , , , 1,929,698/(9.17%) 4,990,672/(23.72%) 6,391,985/(30.39%) 2,661,102/(12.65%) ,
Aligned%1%time , , , , , , , , , 3,131,033/(14.88%) 7,817,417/(37.16%) 2,642,840/(12.56%) 13,667,816/(64.97%) ,
Aligned%>1%time , , , , , , , , , 15,974,783/(75.94%) 8,227,425/(39.11%) 12,000,689/(57.05%) 4,706,596/(22.37%) ,
%%Overall%Alignment , , , , , , , , , 90.83% 76.28% 69.61% 87.35% ,
Known%Conopeptide%precursors , , , , , , 6 6 2 1 2 2 1 6
New%ConopeptideISuperfam%score%3 , , , , , , 2,061 2,629 1,117 28 20 16 9 3,381
New%ConopeptideISuperfam%score%2 , , , , , , 822 1,323 158 6 1 3 2 1,375
New%ConoPeptideIClass , , , , , , 2 7 0 0 0 0 0 1
B
Raw%Forward%
Read%R1
Raw%Reverse%
Read%R2
Trimmed%
Paired%R1
Trimmed%
Paired%R2
Trimmed%
Unpaired%R1
Trimmed%
Unpaired%R2
Merged%
R1/R2
Unmerged%
R1
Unmerged%
R2 CLC%Contigs SOAP%Contigs%
Total%Conopeptides%
(Signal+)
29,442,459 28,932,379 24,022,117 23,771,144 4,914,281 124,625 22,782,581 6,166,372 1,324,521 138,284 171,378 ,
35,301 35,301 35,301 35,301 35,301 35,301 35,592 35,301 35,301 100,5,386 36,5,385 ,
206 209 193 192 253 194 204 262 288 258 206 ,
248 293 215 213 274 300 215 286 301 301 237 ,
300 301 300 300 300 301 345 300 301 543 396 ,
301 301 301 301 301 301 441 301 301 979 665 ,
32.90% 33.47% 32.86% 32.83% 32.98% 34.28% 32.60% 33.11% 33.95% 36.67 36.56 ,
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00 0.00 ,
Unaligned , , , , , , , , , 2,442,768/(8.07%) 3,059,630/(10.11%) ,
Aligned%1%time , , , , , , , , , 6,345,989/(20.96%) 26,196,313/(86.53%) ,
Aligned%>1%time , , , , , , , , , 21,484,717/(70.97%) 1,017,531/(3.36%) ,
Overall%Alignment , , , , , , , , , 91.93% 89.89% ,
Known%Conopeptide%precursors , , , , , , 1 1 0 1 1 3
New%ConopeptideISuperfam%score%3 , , , , , , 10 13 6 8 3 23
New%ConopeptideISuperfam%score%2 , , , , , , 1 1 0 2 2 3
New%ConoPeptideIClass , , , , , , 0 0 0 0 0 0
C
Raw%Forward%
Read%R1
Raw%Reverse%
Read%R2
Trimmed%
Paired%R1
Trimmed%
Paired%R2
Trimmed%
Unpaired%R1
Trimmed%
Unpaired%R2
Merged%
R1/R2
Unmerged%
R1
Unmerged%
R2 CLC%Contigs SOAP%Contigs%
Total%Conopeptides%
(Signal+)
32,701,009 30,750,697 22,459,176 21,967,596 9,505,550 140,249 20,005,743 2,454,298 2,174,305 147,817 200,077 ,
35,301 35,301 35,301 35,301 23,301 35,301 35,592 51,301 45,301 100,5,386 32,3,646 ,
200 205 174 171 250 163 164 299 299 249 186 ,
239 300 181 177 269 165 165 300 301 305 200 ,
300 301 300 300 300 301 213 301 301 544 381 ,
301 301 301 301 301 301 358 301 301 928 644 ,
33.08% 34.58% 33.03% 33.18% 32.99% 34.44% 32.84% 33.33% 34.21% 36.30 36.28 ,
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00 0.00 ,
Unaligned , , , , , , , , , 2,291,585/(9.30%) 2,965,621/(12.04%) ,
Aligned%1%time , , , , , , , , , 5,781,946/(23.47%)/ 2,1529,858/(87.40%)/ ,
Aligned%>1%time , , , , , , , , , 16,560,815/(67.23%) 138,867/(0.56%) ,
Overall%Alignment , , , , , , , , , 90.70% 87.96% ,
Known%Conopeptide%precursors , , , , , , 1 1 0 1 0 2
New%ConopeptideISuperfam%score%3 , , , , , , 0 0 0 3 2 5
New%ConopeptideISuperfam%score%2 , , , , , , 0 0 0 0 0 0
New%ConoPeptideIClass , , , , , , 0 0 4 0 0 1
Reads&to&Contigs&Mapping
ConoSorter&Hits
ConoSorter&Hits
Reads&to&Contigs&Mapping
ConoSorter&Hits
Reads&to&Contigs&Mapping
%N
%GC
N90
N75
N50
Average%Length
Length%Interval
Total%Sequences
%N
%GC
N90
N75
Sample
N50
Average%Length
Sample
Length%Interval
Total%Sequences
Sample
%N
%GC
N90
N75
N50
Average%Length
Length%Interval
Total%Sequences
Merged, as well as unmerged forward/reverse reads sequenced from the venom duct were submitted 
to 4 different de novo assemblers. Trinity, CLC, SOAPdenovo-Trans, and Oases produced contigs 
of 5,747 (N50 = 478, N90 = 1,466), 7,392 (N50 = 418, N90 = 1,379), 5,385 (N50 = 424, N90 = 
851) and 29,853 bp long (N50 = 1,038, N90 = 3,060) respectively. Mapping the reads to the contigs 
with Bowtie2 algorithm provided overall alignment rates of 87.35% with Trinity, 90.83% with 
CLC, 76.28% with SOAPdenovo-Trans, and 69.61% with Oases. Based on these metrics we chose 
to use only CLC and SOAPdenovo-Trans programs for the assemblies of the merged and unmerged 
reads obtained from RS and SG. RS contigs produced with SOAPdenovo-Trans and CLC were up 
to 5,385 bp (N50 = 237, N90 = 665) and 5,386 bp in length (N50 = 301, N90 = 979). Reads showed 
an overall alignment rate of 89.89% and 91.93% respectively. SG contigs obtained with 
SOAPdenovo-Trans and CLC were 3,646 (N50 = 200, N90 = 644) and 5,386 in length (N50 = 305, 
N90 = 928). Reads showed an overall alignment rate of 87.96% and 90.70% respectively. Despite 
these excellent quality metric values, the number of conopeptide hits identified after submitting the 
contigs to ConoSorter remained very low compared to the direct analysis of the reads (10 to 100 
times lower). 
 
Protein fractionation 
In order to validate putative novel conopeptides, we simultaneously investigated the proteomes of 
the venom duct, radular sac and salivary gland. Protein fractions of each tissue were fractionated by 
HPLC, 1D-, and 2D-PAGE giving rise to a total of 300 fractions that were then analysed by LC-
MSMS (Fig. 2). Reverse phase HPLC revealed complex qualitative protein mixtures in the venom 
gland of C. episcopatus, compared to the protein contents of the radular sac and salivary gland (Fig. 
2A, 2B, 2C and 2D). Also we can see that, from a quantitative point of view, the venom gland 
contains mainly small proteins and peptides (<28kDa; Fig. 2E) whereas the major components of 
the radular sac and salivary gland have a mass >28kDa, with only very low amount of small 
proteins <14kDa. Separation of the proteins from the venom duct by 2D PAGE also revealed 3 
main groups of proteins (Fig. 2F). A large patch of small molecular weight proteins with low 
isoelectric point (pI) (bottom left), a intermediate group of middle size proteins of pI comprised 
between 5 and 7, as well as a more diffused group of peptides with high pI (bottom right). 
 
New precursor conopeptides 
ConoSorter was able to identify 2 of the 4 full-length conopeptide precursors currently known in 
Conus episcopatus (EpI - Sequence 124 from patent US 6797808; GenBank: AR584835 - and 
Ep11.1 (41) precursors). The program also identified Pn10.1 and TxMMSK-02 precursors 
previously isolated from the related molluscivorous species Conus pennaceus and Conus textile 
respectively (42).  We were also able to detect 133 novel precursor forms of known mature toxin 
regions. Indeed, 84 new precursor sequences of Conus magnificus µ-MfVIA (43), 27 of Conus 
Episcopatus Ep6.1 (US Patent Application 20020173449), 10 of Conus pennaceus Pn5.1 precursor 
conotoxin (42), 7 of Conus omaria Om6.5 toxin (also called PnVIB in Conus pennaceus) (44), and 
5 of Conus pennaceus PnMRCL-012 (42)  mature conotoxin regions have been deciphered (Fig. S1, 
Table S1A). 
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Fig. 2 – Protein fractionations. Proteins from the venom gland were first separated into <30kDa and >30kDa samples, 
then fractionated by reverse-phase HPLC (A and B respectively). Proteins from the radular sac and the salivary gland 
were also separated by RP-HPLC (C and D respectively). Total raw and reduced protein extracts have been separated by 
1D-PAGE and revealed with Coomassie blue (E). Finally, raw proteins extracted from the venom gland have been 
separated by 2D-PAGE and revealed with Coomassie blue (F). The fraction (HPLC) and spot (gels) numbers that refer to 
MS fragments (Table S1) are also mentioned.	  	  
In addition to these known toxins, ConoSorter annotated at the highest score (i.e. simultaneously the 
ER signal, pro-, and mature regions) 3,303 novel precursor conopeptide sequences in VD, as well as 
25 in RS and 6 in SG (all of them are at least 40 amino acids in length, and contain ≥60% 
hydrophobic residues in their N-terminal region – see Material and Methods section). Among these, 
3,303 (100.00%,) 22 (88.00%), and 5 (83.33%) sequences isolated from VD, RS and SG, 
respectively, displayed well-defined signal regions using the SignalP algorithm and were retained 
for further analysis. The overall distribution of peptides across the three different compartments 
revealed that 99.19% originate from the venom duct compared to 0.66% from the radular sac and 
0.15% from the salivary gland. In the venom duct a majority of conopeptides belong to the T 
superfamily (2,356 toxins – 76.78%), followed by members of the O1 (333 – 10.08%), and the S 
(199 – 6.02%) superfamilies (Fig. 3). 
 
 
Fig. 3 – Number of precursor conopeptides per gene superfamilies and compartment (VD, RS, and SG in red, 
green, and purple respectively). These toxin precursors all contain a signal peptide and have been classified with 
ConoSorter at the highest score (matching the signal, pro-, and mature regions without conflicts). 
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Interestingly, we observed that all the precursor conopeptides isolated from RS (n=22) and SG 
(n=5) were also found in the VD, except for 2 lowly expressed T superfamily RS sequences 
(present only once each in the original RS data set and named RS_sup3_seq22 & 23) that were only 
detected in this tissue (RS_sup3_seq22 is 96.88% identical to VD_sup3_seq3057; RS_sup3_seq23 
shares 98.44% similarity with VD_sup_seq1412) (Table 3). Also, we observed that the conotoxins 
found in all 3 compartments of the venom apparatus were highly expressed in the venom gland at 
the transcriptomic level (belonging to the top 0.70% of the most expressed toxin transcripts). 
 
 
A detailed examination of the similarity between venom duct precursor conopeptides with the CD-
HIT clustering algorithm (45) revealed 401 “parent” precursor sequences (defined as the longest 
protein sequence present in a cluster of similar sequences) and a ratio of 1 parent for 7.24 
“variants”, when a minimum similarity threshold between parent and a putative sequence variant of 
96% was applied (Fig. S2). Multiple similarity cut-offs were tested (from 93% to 100%). An 
optimal similarity limit of 96% corresponds to the upper edge of a smooth increase in number of 
parent precursor, just before an increase of 54.59% (883) parent sequences with an average of 2.74 
variants per parent, which seemed to us of poor biological consistency regarding the size of the data 
set (3,303 sequences) and the hypervariable nature of conopeptide pro- and mature sequences. As 
an internal control, we observed that each parent conopeptides and their associated variants 
belonged to the same gene superfamily and class. Moreover, the mapping of MS peptide fragments 
to this transcriptomic data allowed us to identify (at a confidence ≥99%) 40 (9.98%) these parent 
toxins expressed at the protein level in VD (Table S1B). 
  
Table 3 – Precursor conopeptides expressed in the 3 compartments of the venom apparatus. Their names, sequences (signal 
peptide in red, and mature toxin in blue with its cysteines in bold grey), frequency in their respective data set, superfamily and 
cysteine pattern (name of the known cone snail cysteine framework sharing the same motif between brackets) are also listed. The 
bottom part of the table shows the 2 precursor conotoxins RS_sup3_seq22 & 23 found only in the radular sac.along with their 
associated venom duct conopeptides sharing the most similarity with them (96.88% and 98.44% respectively). 	  
Name Precursor+Sequence Tissue+(frequency) Superfamily Cysteine+Pattern
VD_sup3_seq41;-RS_sup3_seq1;-SG_sup3_seq1 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIALTIKGCCSDPRCNMNNPDYCG VD-(1,465);-RS-(1);-SG-(1) A CCACAC-(I)
VD_sup3_seq240;-RS_sup3_seq3 MKLTCMIIIAVLFLTAWTFATADDTRNGLENLFSKAHHEMKNPEASKLNKRCIPQFDPCDMLRHTCCQGLCVLIACL VD-(239);-RS-(1) O1 CACACCACAC-(VI/VII)
VD_sup3_seq396;-RS_sup3_seq4;-SG_sup3_seq2 MKLTCMMIVAVLFLTAWTFATADDPRDGLGNLFSKTQHEMKNPEASKLNKRCKAENELCDIITQNCCGGMCFLICIEIPE VD-(1,469);-RS-(2);-SG-(2) O1 CACACCACAC-(VI/VII)
VD_sup3_seq494;-RS_sup3_seq5 MKLTCMMIVAVLFLTAWTFATADDPRNGLGNLFSNVHHEMKNPEDSKLDKKCLGFGEACLMFYSDCCSFCVGAVCL VD-(1,106);-RS-(3) O1 CACACCACAC-(VI/VII)
VD_sup3_seq553;-SG_sup3_seq3;-RS_sup3_seq7 MKLTCMMIVAVLFLTAWTLVTADDSGDGLENLFSKEHHEMKNPEASKLNKRCVPYEGPCNWLTQNCCSGNICFIFFCL VD-(140);-RS-(2);-SG-(2) O1 CACACCACAC-(VI/VII)
VD_sup3_seq604;-RS_sup3_seq8 MMKLTCMMIVAVLFLTAWTLVTADDSGDGLENLFSKEHHEMKNPEASKLNKRCVPYEGPCNWLTQNCCSGNICFIFFCL VD-(159);-RS-(4) O1 CACACCACAC-(VI/VII)
VD_sup3_seq698;-RS_sup3_seq9 MMSKLGAMFVLLLLFTLASSQEKGDVQAGKTQKSDFYRTLTRSARGCTMSCAFQNNICQGTCHCSGSTNC VD-(1);-RS-(1) S CACACACACAC-(IX)
VD_sup3_seq716;-SG_sup3_seq5;-RS_sup3_seq10 MMSKLGAMFVLLLLFTLASSQEKGDVQAGKTQKSDFYRTLTRSARGCTMSCAFQNNICQGTCHCSGSTNCYCASGHHNTGCGCACTN VD-(1,738);-RS-(1);-SG-(1) S CACACACACACACACACAC-(VIII)
VD_sup3_seq1004;-RS_sup3_seq11 MRCLPFFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTLQTLLNKRFCCPYFECC VD-(14);-RS-(1) T CCACC-(V)
VD_sup3_seq1233;-RS_sup3_seq12 MRCLPVFVFLLLLIASTPSVDALLKTKDDMPLASFRDNVKRILQTRSTEECCPFIVGCCVLL VD-(1,178);-RS-(1) T CCACC-(V)
VD_sup3_seq1411;-RS_sup3_seq13 MRCLPVFVILLLLIASAPSVDALPKTKDDMSLASFHDNAKRTLQILSNKRYCCVYDYSCCLSWG VD-(492);-RS-(2) T CCACC-(V)
VD_sup3_seq1599;-RS_sup3_seq14 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRILQVLESKRNCCRLQVCCG VD-(64,413);-RS-(3) T CCACC-(V)
VD_sup3_seq1969;-RS_sup3_seq15 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQIRLVDTRCCPSQPCCRFG VD-(19,998);-RS-(2) T CCACC-(V)
VD_sup3_seq2124;-RS_sup3_seq16 MRCLPVFVILLLLIASAPSVGARPKTKDDIPQASFQDNAKRILQVLESKRNCCRLQVCCG VD-(7);-RS-(1) T CCACC-(V)
VD_sup3_seq2282;-RS_sup3_seq17 MRCLPVFVILLLLIASTPNVDARPKTKDDMPLASFHDDAKRILQILQDRNGCCIAGDCCG VD-(21,042);-RS-(2) T CCACC-(V)
VD_sup3_seq2632;-RS_sup3_seq18 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTLQTLLNKRFCCPYFACC VD-(20);-RS-(1) T CCACC-(V)
VD_sup3_seq2639;-RS_sup3_seq19;-SG_sup3_seq4 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTLQTLLNKRFCCPYFECC VD-(22,097);-RS-(11);-SG-(3) T CCACC-(V)
VD_sup3_seq2698;-RS_sup3_seq20 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTLQTLLNKRFCCQYFECC VD-(7,139);-RS-(3) T CCACC-(V)
VD_sup3_seq3041;-RS_sup3_seq21 MRCLPVFVILLLLSASAPSVDVRPKAKDDMPLASFHDNPLQIRLVDTRCCPSQPCCRFG VD-(2);-RS-(1) T CCACC-(V)
VD_sup3_seq163;-RS_sup3_seq2 MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCHKSCCRSTCTFPCLIPGKRAKLREFFRQR VD-(4,524);-RS-(1) I2 CACACCACCACAC-(XI)
RS_sup3_seq22 MRCLPVLIILLLLTASGPSVDAKVHLKTKGDGPLSSFRDNAKSTLQRLQDKSTCCGYRMCVPCG RS-(1) T CCACAC-(I)
VD_sup3_seq3057 MRCLPVFVILLLLTASGPSVDAKVHLKTKGDGPLSSFRDNAKSTLQRLQDKSTCCGYRMCVPCGYPA VD-(1) T CCACAC-(I)
RS_sup3_seq23 MRCRPVFVILLLLIASAPSVDALPKTKDDMSLASFHDNAKRTLQILSNKRYCCVYDYSCCLSWG RS-(1) T CCACC-(V)
VD_sup_seq1412 MRCLPVFVILLLLIASAPSVDALPKTKDDMSLASFHDNAKRTLQILSNKRYCCVYDYSCCLSWGSRKLTLDETPANCPRM VD-(1) T CCACCAC
Cysteine patterns in mature conotoxins 
We examined the diversity of cysteine arrangements in the mature region of the novel precursor 
conopeptides (parents and variants) containing well-delimited signal, pro-, and mature regions. 
After isolating and discarding duplicate mature regions (see Material and Method section), we 
identified 1,450 unique cysteine-rich mature toxins (with ≥4 cysteines) among which 1,241 
(85.59%) contained an even number of cysteines (4 cysteines: 882 sequences; 6: 197; 8: 95; 10: 67), 
and 209 (14.41%) containing an odd number of cysteines (5:145; 7: 36; 9: 27; 11: 1). 
Among toxins with an even number of cysteines, 9 patterns known in cone snails were represented 
(Fig. 4A): 45 toxins with a CC-C-C cysteine motif (referred as framework I in cone snails; 20 
toxins supported by MS evidence – Table S1C), 834 peptides containing a CC-CC pattern 
(framework V; 43 MS fragments – Table S1C), 3 mature regions displaying a C-C-C-C cysteine 
disposition, 6 toxins with a CC-C-C-CC motif (framework III; 9 MS fragments – Table S1C), 168 
peptides showing a C-C-CC-C-C pattern (framework VI/VII; 17 MS fragments – Table S1C), 6 
molecules with a C-C-C-C-C-C arrangement, 77 mature fragments showing a C-C-CC-CC-C-C 
framework (framework XI; 15 MS fragments – Table S1C), 15 toxins with a C-C-C-C-C-C-C-C 
pattern, and 66 peptides with a C-C-C-C-C-C-C-C-C-C motif (framework VIII; 1 MS fragment – 
Table S1C). 
We then focused specifically on mature toxins containing the VI/VII pattern, which when 
complemented by a I-IV, II-V, III-VI cysteine connectivity, forms the well-known ICK fold present 
in numerous drug leads, including the FDA-approved Ziconotide (19). A total of 166 (98.81%) 
peptides belong to the O1 superfamily compare to 2 (1.19%) classified in the O2 superfamily (a 
total of 563 mature conopeptides with the VI/VII frameworks are currently known, among which 
the majority belongs to the O1 superfamily - 68.56% -, O2 - 10.66% -, and O3  - 5.68% - 
superfamilies). All of these toxins contain 6 residues with the general loop formula for these 
sequences being (0-16)C(6)C(5-9)CC(2-4)C(3-4)C(0-43) with 9 different internal loop 
combinations (i.e. regardless of the number of residues before and after the first and last cysteines 
respectively) being represented in our data (Fig. 4B; Fig. S3; Table S1C). Interestingly, we 
observed that a group of new sequences (VD_sup3_seq298, VD_sup3_seq299, VD_sup3_seq301, 
VD_sup3_seq311, VD_sup3_seq323, VD_sup3_seq325, and VD_sup3_seq615) all share 97% 
identity with the Conus magnificus MfVIA conotoxin that specifically targets voltage-gated sodium 
channels (43). 
We also investigated mature conotoxins containing the cysteine framework I, which is found in the 
norepinephrine transporter inhibitor Conus marmoreus χ-conotoxin MrIA ((3)CC(4)C(2)C which is 
currently in a Phase IIb clinical trial (46). We observed that 31 (68.89%) and 14 (31.11%) of the 
members of this subgroup belong to the A and T superfamilies, respectively (309 mature conotoxins 
containing framework I are known to date, with the most populated groups being the A - 54.05% -, 
M - 3.24% -, and T - 1.29% - superfamilies). The general loop formula for these toxins is (1-
24)CC(4-5)C(2-13)C(0-35) with 5 different loop length arrangements (Fig. 4C; Fig. S4; Table 
S1C). We also observed that the highest similarity rate (73%) is shared between the sequence we 
called here VD_sup3_seq3055 and the known patented TxId conotoxin isolated from Conus textile 
(47). 
 
 
Fig. 4 – Distribution of cysteine patterns and loop combinations in frameworks VI/VII and I. Top 
panel shows a mosaic plot displaying the number of mature toxins per superfamily and known cysteine 
pattern (A). Bottom panel shows the number of mature toxins containing the cone snail VI/VII (C-C-CC-
C-C) and I (CC-C-C) cysteine patterns classified per loop formula in (B) and (C) respectively. 
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In addition, we found 6 new cone snail cysteine patterns in 21 low-expressed mature conotoxins (7 
– 33.33% - have been identified at protein level; Table 4, Table S1D). After scanning the entire 
UniProtKB-Swissprot database (541,954 entries) and extracting the cysteine framework of all the 
mature proteins listed, we observed that 4 of these patterns (CC-C-CC-C, CC-CC-C-C, CC-CC-CC, 
and CC-CC-C-C-C-C) have been found in 558 mature proteins isolated from 292 species across the 
phylogenetic spectrum. A fifth pattern (CC-C-C-C-C-C-C) has been found in 19 snake heteromeric 
C-type lectins. Intriguingly, we also identified a novel pattern with 10 cysteines that has never been 
observed in any organism: CC-CC-CC-CC-C-C. 
 
 
 
Definition of new cone snail gene superfamilies 
Recently, we reported 13 new gene superfamilies in Conus marmoreus (30). Here we used the same 
approach to define novel superfamilies in Conus episcopatus. Briefly, ConoSorter hits showing 
matches for their pro- and mature regions only (but not the signal peptide) were submitted to 
SignalP 4.1 algorithm and CD-HIT. The isolated signal regions showing identity rates of ≥75.00% 
were grouped into clusters. We then built a similarity matrix incorporating clusters of complete 
signal regions of all known gene superfamilies in order to define the maximal identity score 
between these groups. Batch pairwise alignments (with BALIGN program (48)) between 
unclassified signal peptides and those for which a superfamily has been previously assigned were 
Table 4 – New precursor conopeptide sequences with mature regions containing new cone snail cysteine patterns. Signal 
and mature regions are highlighted in red and blue respectively with cysteines in bold grey. The number and arrangement of the 
cysteines in the mature region, as well as the frequency of the precursor sequences in the cDNA library, and the superfamily to 
which they have been assigned are mentioned in the table. Cysteine patterns also found in non-Conus organisms are illustrated 
with a representative sequence (framed) displaying the corresponding cysteine connectivities	  
interchain
performed. When all new signal regions from a same cluster shared ≤53.30% global identity with 
the signal regions of any known superfamilies, the cluster was considered a putative novel 
superfamily. 
We investigated 1,311 signal regions derived from the ConoSorter analysis, that were grouped into 
105 clusters with a minimum identity cut-off ≥75.00%. We found that 39 toxin signal peptides (10 
precursor toxins – 25.64% - retrieved in the proteome; Table S1E), belonging to 16 clusters, 
showed an identity rate ≤53.30% compared to the conopeptide signal sequences of known 
superfamilies. These 16 new groups defined putative new superfamilies and have been called SF-
Epi 1-16 (Fig. 5). 
 
 
 
Codon usage bias 
To investigate the codon variability of the mRNA transcribed into precursor conopeptides, we 
selected all the cDNA sequences (8,715) encoding toxins identified with ConoSorter (Fig. 6). By 
analyzing the relative synonymous codon usage (RSCU) we observed that nucleotide triplets coding 
Fig. 5 – The 16 new gene superfamilies of conopeptides. The member(s) of these new groups (called SF-Epi 1 to 16) have 
been aligned using BLOSUM62 cost matrix (the darker the color, the more conserved the amino acids). The number of 
sequences present in the original cDNA library (second column), their maximal identity percentage (third column) compared to 
the closest known conopeptide (name and superfamily between brackets), as well as their signal region (delimited by red lines) 
are mentioned. 
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for leucine and serine residues are most subject to variability. The CTG (Leu) and TCT (Ser) 
codons were found to be expressed more frequently than expected with RSCU values of 3.01 and 
2.84 respectively. In contrast, TTA (Leu) and CGG (Arg) are less frequent than expected in the 
sequences investigated with RSCU values as low as 0.05 and 0.06 respectively. Also, the 2 codons 
encoding the cysteine amino acids TGT and TGC presented only a moderate bias with RSCU 
values of 0.57 and 1.43 respectively. 
 
 
 
 
Discussion 
In this article we describe a deep analysis of matched transcriptomes and proteomes from the 
venom duct, the radular sac, and the salivary gland of the venomous mollusk hunter Conus 
episcopatus. Analysis of the venom duct transcriptome with ConoSorter allowed us to retrieve 4 
known precursor conopeptides, 5 new precursor forms of known mature conotoxins, and 401 novel 
parent conopeptides (40 of which were validated by MS/MS) along with 2,902 sequence variants. 
These novel conopeptides were classified into known cone snail gene superfamilies including T 
(76.78%), O1 (10.08%), and S (6.02%)), which suggests that the components of Conus episcopatus 
venom might be directed toward a broad range of pharmacological targets (conopeptides belonging 
to these gene superfamilies are known to interact on 10 over the 12 pharmacological classes) (25). 
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Fig. 6 – Codon usage bias. A sample of 8,715 cDNA sequences encoding precursor conopeptides were investigated for codon 
usage bias. The Relative Synonymous Codon Usage (RSCU) is plotted for each nucleotide triplet. It represents the observed 
frequency of a codon divided by the expected frequency if no bias would be observed, and is given by the following equation: ! !!"!#$!×𝑁, where n, frequency of a particular codon; total, frequency of all the codons coding for a same amino acid, and N, the 
number of codon(s) for that amino acid. When no codon usage bias is observed the RSCU value is equal to 1 (green bars).  If 
RSCU >1 the codon is used more frequently than expected (red bars). To the opposite, if RSCU <1 the codon is used less 
frequently than expected (grey bars). 
We isolated 1,450 mature conotoxin regions with an even number between 4 and 10 cysteines, and 
were able to identify 9 known cone snail cysteine patterns or frameworks. These included 168 with 
ICK (17 of which retrieved at protein level) and 45 (20 retrieved at protein level) with CC-C-C 
motifs, respectively. Moreover, we revealed 6 novel cysteine motifs previously unknown in cone 
snails distributed over 21 conotoxin transcripts (7 validated by MS/MS). Four of these motifs were 
found in proteins ubiquitous in nature (CC-C-CC-C, CC-CC-C-C, CC-CC-CC, and CC-CC-C-C-C-
C) fulfilling a broad range of functions (enzymes, membrane receptors, DNA-binding elements, 
transforming or transcription factors for instance), one which is highly represented in snake C-type 
lectins (CC-C-C-C-C-C-C), which modulate platelet aggregation or the coagulation cascade, as well 
as one that consists of 10 cysteines that has never been described before (CC-CC-CC-CC-C-C). The 
elucidation of these new cysteine patterns in cone snails reveals the extraordinary potential of 
Conus venoms for finding small cysteine-rich peptides with pharmacological properties either 
previously described in other organisms and animals such as the ability to antagonize integrin 
receptors like snake C-type lectins which have provided lead structures for the design of 
antimetastatic and antiangiogenic drugs (49). We have also provided evidence to support the 
creation of 16 novel gene superfamilies, called SF-Epi 1-16, defined by the original signal peptide 
of 39 new toxins (13 of them were expressed in the proteome), which could lead to new subclasses 
of toxins directed towards new pharmacological targets with potential diagnostic or therapeutic 
interest for human health or provide novel insights into their molecular evolution. 
Finally, we studied the codon usage bias of all the cDNA sequences encoding conopeptides 
identified with ConoSorter and showed that the codons CTG (Leu) and TCT (Ser) were 
overexpressed, whereas TTA (Leu) and CGG (Arg) showed a negative bias, which could explain 
the preference for certain codons to be translated more accurately and/or efficiently, and provide  
support for the molecular evolution or selection mechanism of conotoxins (49). 
During the past decade, several studies focusing only on cone snail venom duct (50-55) or salivary 
gland (12, 50-55) transcriptomes have been released in the literature. More recently, transcriptome 
analyses have been complemented by MS proteome profiling of dissected and/or milked venom in 
order to discover larger numbers of toxins or to bring the proof of the expression of specific 
conopeptide transcripts at protein level (28, 29, 56-58). All of these case studies employed ROCHE 
454 next-generation sequencing platform for sequencing the transcriptomes, and used the overall set 
of reads obtained without applying any quality filtering. As it is known that the Illumina sequencing 
strategy usually provides a higher number of reads of superior quality to ROCHE devices 
(particularly for long reads), the risk of homopolymer-associated and single-base call errors should 
be taken into consideration in order to only report high quality conopeptide transcript sequences, 
particularly when proteomic data are not shown (59). In addition, the great majority of these studies 
performed global homology BLAST searches of publically available databases for detecting 
conopeptide sequences from the cDNA libraries and to classify them into gene superfamilies 
(except for Biggs et al. who used an expressed sequence tags strategy). Because BLAST homology 
searching approaches can match any regions of the putative conopeptide sequences, the accuracy of 
superfamily assignment become weaker and only favors the discovery of closely related toxin 
compared to known ones. By using these approaches no more than a hundred (47 on average) of 
full-length precursor conopeptide sequences have been deciphered in each study. 
By using one small single Conus episcopatus specimen, we demonstrate here that only small 
amounts of RNA and protein, isolated for the first time in the three compartments of the cone snail 
venom apparatus, and analyzed with the most recent transcriptome and proteome sequencing 
technologies coupled to extensive bioinformatics processing, could provide sufficient material for 
efficient data mining. Illumina 2 x 300 bp strand-specific paired-end transcriptome sequencing 
strategy provided sufficient high quality cDNA of suitable length to uncover what is by far the 
highest number of conotoxin transcripts from a single species reported in the literature to date (28, 
55, 58). Similar results obtained from de novo read assemblies performed with 4 different 
algorithms also pointed out that the task still remains delicate for non-model organisms like cone 
snails when a good quality reference genome is unavailable. Despite excellent quality metric values 
(average length of contigs, N50 value, alignment rate of reads to contigs), the number of 
conopeptide hits remained very low compared to the direct analysis of the reads (10 to 100 times 
lower). In our opinion, this limitation may highlight the importance of choosing the right k-mer 
value, which can be difficult to determine for transcriptomes due to the variation of mRNA 
expression levels and the lack of dedicated bioinformatics tools specific to transcriptomes. As a 
consequence, choosing an uncertain k-mer value introduces the risk of obtaining only few long 
contigs (for high k-mer values) or numerous shorter contigs with contents distant from the 
endogenous nucleic acid molecules (for low k-mer values). Although the latter approach is 
generally recommended when using de novo assemblers, the high conservation of signal regions in 
conotoxins, as well as the high rate of sequence variants with similar pro- and/or mature regions 
supported by a relatively low codon bias would amplify the number of nucleic acid repetitions 
leading to incorrect assemblies. 
The only two comparable Conus transcriptome/proteome matching experiments conducted by 
Dutertre et al., as well as Jin et al. with the proprietary ProteinPilot program provided mapping 
rates of peptide sequence tags to the transcripts of 57% (43 MS/MS fragments mapped to 75 new 
full-length conopeptide transcripts) and 60% (29 MS/MS fragments matching 48 transcripts) 
respectively. Although we managed to map more peptide fragments to conopeptide transcripts (146 
in total), this step still needs optimisation. The low number of protein fragments matched against 
the transcripts could be explained by three factors. First, the MiSeq Illumina device allows 
sequencing many more molecules (up to a mono-molecular level) with much higher sensitivity and 
depth than Roche pyrosequencer or the current mass spectrometers for which enrichment of protein 
samples, when possible, is needed in order to detect low expressed proteins. Second, the possibility 
of amplifying cDNA molecules by PCR during library preparation prior to transcriptome 
sequencing allows detection of very low expressed transcripts as opposed to traditional protein 
isolation and purification methods. Also, the current proteomic technologies are only able to 
sequence short pieces of digested proteins, which lead to an enrichment of identical peptide 
fragments originating from similar proteins, thus making impossible the distinction between their 
respective parent proteins. As a consequence, the use of the ProteinPilot program dedicated to 
precisely assign one protein fragment (MSMS) to its parent sequence (transcript) with the highest 
confidence threshold (i.e. the lowest false discovery rate) shows some limitations when matching 
short MSMS fragments to a reference database containing numerous long translated precursor 
conopeptide transcripts with a high rate of similarity. Indeed, as the vast majority of precursor toxin 
sequences deciphered from the transcriptome only differ by punctual mutations, short identical 
MSMS sequence fragments originating from similar proteins should be found in multiple precursor 
isoforms. However, when the maximum confidence threshold (≥99%) is applied, we observed an 
important drop in number of matches (~70% on average) and sequence coverage (~80%) compared 
to lower cut-offs because of the grouping strategy used by the program. 
In conclusion we demonstrate that the transcriptome/proteome sequencing and matching approach 
applied to the three main compartments of C. episcopatus venom apparatus allowed us to decipher 
the sequences and to accurately classify numerous new conopeptides containing various cysteine 
arrangements, among which some potential new bioactive peptides with the ICK cysteine pattern 
known to be present in several drug leads. 
 
Material & Methods 
Specimen collection, total RNA and protein isolation 
One specimen of Conus episcopatus measuring 4cm in the antero-posterior axis was collected on 
the reef of Lady Musgrave island (Queensland – Australia), and then kept alive for 6 months in a 
seawater tank exposed to a 12:12 light cycle at a room temperature of 25˚C. Dissections of the 
venom duct VD (19 cm in length for 35.75 mg), radular sac RS (14.50 mg) and salivary gland SG 
(3.20 mg) have been performed on ice in sterile conditions under a binocular magnifier. Total RNA, 
DNA and proteins from the three systems of the venom apparatus have been isolated using TRIzol 
reagent (Life Technologies) according to the manufacturer protocol. 
 
  
Messenger RNA isolation and cDNA library preparation 
Complementary DNA (cDNA) libraries have been prepared using a TruSeq Stranded mRNA 
Sample Preparation Kit (Illumina) following the manufacturer protocol. For each organ, 1µg of total 
RNA extract have been used as starting material. Purification of poly-A mRNA molecules has been 
done using oligo-dT coated magnetic beads followed by a 2 minutes fragmentation at 94˚C for 
optimal insert sizes, clustering and sequencing. Priming of purified mRNA followed by first and 
second strands cDNA synthesis, 3’ end adenylation, adapter ligation, as well as enrichment of the 
obtained DNA fragments were performed prior controlling the quality and validating 1:50, 1:30 
diluted, and undiluted libraries using a 2100 Bioanalyzer instrument (Agilent Techonolgies) and 
high sensitivity DNA chips. 
 
Transcriptome sequencing 
Indexed cDNA libraries have been sequenced with a next-generation MiSeq Benchtop Sequencer 
(Illumina) based on 2 x 300 bp strand-specific runs. 4nM (VD and RS), and 2nM (SG) libraries of 
NaOH-denatured DNA were prepared with the corresponding MiSeq reagent kit by following the 
manufacturer guidelines in order to obtain final concentrations of 7pM (VD) and 12pM (RS and 
SG).   
 
Bioinformatics processing of transcriptome sequencing data 
Analysis of the raw sequenced reads have been done using FastQC algorithm (60). Paired-end read 
data sets have been trimmed from universal and indexed adaptor sequences used during library 
preparation with Trimmomatic-0.30 program (61). Trimming of these unwanted sequences has been 
performed with the ‘palindrome’ approach allowing seed matches a maximum of 2 mismatches, as 
well as alignment score thresholds of 30 (i.e. requiring a match of about 50 bases) and 10 (about 17 
bases) for paired- and single-end reads respectively. An average quality score threshold per read of 
30 has been also choose according to FastQC analysis report (Illumina 1.9 sequencing data display 
Phred+33 quality score encoding, which is logarithmically proportional to error probabilities (62). 
As a consequence, a Phred score of 30 is equivalent to a probability of 1 incorrect base call over 
1000 – or 99.9% base call accuracy). Trimmed overlapping paired-end read data sets have then 
been merged with FLASh software tool (minimum overlap: 10; maximum overlap: 65; maximum 
mismatch density: 0.25) (63). To assess the accuracy of the merging process, PANDAseq algorithm 
has also been used and gave similar number of merged paired-end reads (64). For each 
compartment of the venom apparatus, unpaired reads were grouped separately into a forward read 
R1 and reverse R2 groups. Moreover, with the purpose of capturing full-length messenger 
transcripts with the highest fidelity to Conus episcopatus endogenous ones without knowing the 
references genomes, VD merged paired-end and unmerged reads have also been concatenated and 
submitted to 4 different de novo assemblers: Trinity de novo assembler using Haas BJ. et al. 
protocol (65, 66); SOAPdenovo-Trans version 1.03 (http://soap.genomics.org.cn/SOAPdenovo-
Trans.html) (maximum read length: 301, read length cutoff: 300, average insert size: 200, both 
contig and scaffold assembly, minimum map length: 32), Oases 0.2.8 (67) (minimum k:15, 
maximum k: 41, insert length: 200, coverage cutoff: 3x, edge fraction cutoff: 10%, scaffold 
filtering: 4, minimum transfrag length: 200); CLC Genomics Workbench software (minimum 
contig length: 200). To assess the assembly quality, reads were mapped back to contigs using 
Bowtie2 algorithm (68). Based on the efficiency of the assembly and the number of conopeptides 
found from VD contigs, we chose to retain the best two assemblers for processing of RS and SG 
data sets. 
Merged reads and contigs have then been submitted independently to ConoSorter, an in-house 
developed algorithm based on complementary regular expression and profile Hidden Markov 
Models (pHMMs) searching strategies, for detecting precursor conopeptide sequences and 
classifying them into cone snail gene superfamilies and classes (30). Conopeptides annotated 
simultaneously in the ER signal, pro-, and mature regions (score 3), and in the pro-, and mature 
regions only (score 2) have been dispatched into two separate groups. Hits from both groups were 
then filtered according to their length (at least 40 amino acids, taking as references the shortest 
known to date 44 amino acid long precursor conotoxins displaying well-defined signal, pro- and 
mature regions, Sr5.5 and SrVA precursors isolated from Conus spurius (69)), and hydrophobicity 
rate of their N-terminal region (greater or equal to 60%, knowing that the average conopeptide 
signal region hydrophobicity is 74.56% with a standard deviation σ=6.59, and a minimum of 
52.00% (30)). The selected sequences displaying a conopeptide match in the pro- and mature but 
not in the signal region have then been submitted to SignalP 4.1 algorithm (70). Only sequences 
characterised by the presence of a defined signal region cleavage site have been kept. Milking 
molluscivorous Conus episcopatus specimen to decipher mature toxin sequences is not achievable 
because of their small sizes and restrictive diet. Therefore, the selected sequences have then been 
submitted to ProP 1.0 in order to detect potential proprotein convertase cleavage sites and delimit 
the boundaries between the pro- and mature regions (71). In addition we searched the isolated 
mature peptide for two exopeptidases cleavage sites known in mollusks as carboxypeptidase E and 
peptidylglycine α-amidating monooxygenase that cleave C-terminal lysines and arginines, or 
glycine respectively (72, 73). In addition, we controlled the order of occurrence of the pro- and 
mature regions (usually from N- to C-terminus, although some mature toxins can be located 
between the signal and pro-regions) by investigating the cysteine content of the said mature part 
(e.g. if one region contains an even number of cysteines compared to a second one that doesn’t 
contain any, the former is likely to be the mature region compared to the later pro-region). The 
mature toxins thus isolated (before and after C-terminal enzymatic cleavage) and their cysteine 
pattern have been searched against ConoServer and UniProtKB-SwissProt databases in order to 
distinguish known and new precursor forms of known conotoxins as well as known and potential 
new cysteine frameworks.  
 
Protein fractionation and preparation for mass spectrometry (MS) analysis 
Proteins extracted from the venom duct (1,360 µg – mass inferred from three consecutive 
measurements performed with a NanoDrop 1000 spectrophotometer) have been freeze-dried and 
resuspended in Milli-Q purified water to a concentration of 10 µg.ul-1. The solution has then been 
filtered using Amicon Ultra 30kDa spin filter tubes (Merck Millipore). The two size segregated VD 
protein solutions obtained (containing solutes >30kDa and <30kDa) have been independently 
fractionated using a Shimadzu Prominence HPLC system equipped with an analytical C18 2.1 x 
250 mm Vydac Everest column (particle size: 5 µm, pore size: 300 Å - Grace). A 0-100% buffer 
B/A linear gradient flowing at a rate of 1%.min-1 have been applied (buffer A: 0.05% trifluoroacetic 
acid - aq; buffer B: 0.043% trifluoroacetic acid / 90% acetonitrile - aq). The eluent was monitored 
using a dual wavelength UV detector set to 214 and 280 nm and fractions collected from the 214 
nm trace. The same treatments have been applied to the RS and SG protein extracts except for the 
freeze-drying and size filtering steps in order to limit the loss of proteins that have been isolated in 
lower amounts (682 µg and 245 µg respectively). Each HPLC fractions have been dried and 
resuspended in 1M ammonium carbonate pH11. Reduction and alkylation of protein cysteine 
residues have been carried out in a solution containing 97.5% (v/v) acetomitrile / 2% iodoethanol 
(alkylating agent) / 0.5% triethylphosphine (reducing agent) and incubated at 37˚C for 60 minutes 
as described in Hale JE. et al. protocol (74). Dry protein samples have been reconstituted in100mM 
ammonium bicarbonate pH8.5 and digested with trypsin from porcine pancreas (Sigma proteomics 
grade) overnight at 37˚C. Prior to MS sequencing, pH adjustment has been made using a 0.1% 
formic acid solution. 
Protein extracted from the venom duct, radular sac, and salivary gland have also been separated by 
one dimension polyacrelamide gel electrophoresis (1D-PAGE) under denaturing conditions with 
sodium dodecyl sulfate (SDS) using Novex Bolt system and sample buffers (Life Technologies). 
VD (80 µg), RS (50 µg), and SG (20 µg) raw and reduced protein extracts have been loaded on a 4-
12% acrylamide gel. Venom duct proteins have also been separated by 2D-PAGE using a linear pH 
3-10 immobilized pH gradient strip (BioRad) for the first dimension and a 4-12% acrylamide gel 
for the second dimension. After separation, the major bands/spots revealed with Coomassie blue 
have been excised, destained and dehydrated followed by in-gel tryptic digestion. Individual 
band/spot have been reduced with 10mM dithiothreitol in a 50mM ammonium bicarbonate solution 
for 1h at 37˚C, and reduced with 50mM iodoacetamide in 50mM ammonium bicarbonate for 1h in 
the dark at room temperature. Reduced/alkylated protein solutions have then been digested with 
trypsin (1:4 [0.02% trypsin in 1mM HCl] / 40mM ammonium bicarbonate pH8) on ice for 20 
minutes then overnight at 37˚C. For extracting the reduced / alkylated peptide fragments, gel pieces 
have been suspended in a 5% formic acid / 50% acetonitrile solution, sonicated for 10min, and 
incubated 60min at room temperature. 
 
Protein sequencing 
The reduced / alkylated trypsin digests originating from both HPLC, 1D and 2D SDS-PAGE 
separations were sequenced by shotgun liquid chromatography coupled to electrospray ionization 
tandem mass spectrometry (LC-ESI-MSMS). Low abundant protein fraction digests obtained from 
HPLC and 2D-PAGE were submitted to a Shimadzu nano HPLC system in series with the hybrid 
quadrupole time-of-flight (TOF) mass spectrometer ABSciexTripleTof 5600 system equipped with 
a NanoSpray ionisation source. Equal amount (10 µl) of peptide fragment solutions were injected 
for product ion MS/MS analysis using information dependent acquisition (IDA) experiments. The 
LC separation was achieved using a nano C18 150 mm x 75 µm Agilent Zorbax column (particle 
size: 3.5 µm) at a linear 2% B (90% acetonitrile / 0.1% formic acid –aq).min-1 gradient with a flow 
rate of 0.3 µl.min-1 over 30 minutes. One full scan of the mass range (350-1,800 Da) followed by 
multiple tandem mass spectra was applied using a rolling collision energy relative to the m/z ratio 
and charge state of the precursor ion up to a maximum of 80 eV. The duration of the full scan mass 
spectrometry was set to 30 minutes with 2.3 seconds per cycle (total cycles: 783). A maximum 
number of 20 candidate ions were monitored per cycle with an ion tolerance threshold set to 100 
mDa. Former target ions were excluded for a period of 8 seconds in order to exclude isotopes 
within a ±4 Da window. 
The same devices were used for the digest extracted from 1D SDS-PAGE except a micro 1.8µm 
2.1x100mm LC column was used (Agilent ZORBAX 300 SB-C18), flow rate of 180uL/min 
directly into the DuoSpray ionization source. For these samples the MS/MS method has also been 
adjusted accordingly (scan duration: 14 min; cycle time: 1.25 seconds for a total of 672 cycles; 
maximum number of candidate ions per cycle: 10 spectra; no exclusion of former target ions was 
applied). Data were acquired with the proprietary Analyst TF 1.6 software.  
 
MSMS data analysis and transcriptome matching 
Raw MSMS sequencing data have been submitted to the peptide mass fingerprinting program 
ProteinPilot™ 4.0 (ABSciex) for mapping peptide fragments, using the proprietary tandem 
Paragon™ and ProGroup™ algorithms (confidence threshold ≥ 99%), against selected precursor 
conopeptide hits identified and classified with ConoSorter. 
 
Codon usage bias 
Differences in the frequency of occurrence of cDNA synonymous codons (also called Relative 
Synonymous Codon Usage or RSCU) have been measured by using GCUA program (75). The 
cDNA sequences of all the ConoSorter hits classified at the highest score were used. After 
discarding duplicates, a sample of 8,715 unique cDNA sequences were analysed for calculating the 
cumulative codon and amino acid usages. 
 
Acknowledgements  
V.L acknowledges the provision of an Institute for Molecular Bioscience (IMB) Postgraduate 
Award and support from a National Health and Medical Research Council (NHMRC) Program 
grant [569927]. 
 
References 
1. Bouchet P & Gofas S (2013) World Register of Marine Species. 
2. Duda TF, Jr. & Kohn AJ (2005) Species-level phylogeography and evolutionary history of 
the hyperdiverse marine gastropod genus Conus. Molecular phylogenetics and evolution 
34(2):257-272. 
3. Rockel D, Korn W, & Kohn AJ (1995) Manual of the living Conidae (Verlag Christa 
Hemmen, Germany). 
4. Freeman SE, Turner RJ, & Silva SR (1974) The venom and venom apparatus of the marine 
gastropod Conus striatus Linne. Toxicon : official journal of the International Society on 
Toxinology 12(6):587-592. 
5. J. KA (1956) Piscivorous gastropods of the genus Conus. Proceedings of the National 
Academy of Sciences 42(3):168-171. 
6. Spengler HA & Kohn AJ (1995) Comparative external morphology of the Conus 
osphradium (Mollusca: Gastropoda). Journal of Zoology 235(3):439-453. 
7. Schulz JR, Norton AG, & Gilly WF (2004) The projectile tooth of a fish-hunting cone snail: 
Conus catus injects venom into fish prey using a high-speed ballistic mechanism. The 
Biological bulletin 207(2):77-79. 
8. Marshall J, et al. (2002) Anatomical correlates of venom production in Conus californicus. 
The Biological bulletin 203(1):27-41. 
9. Endean R & Duchemin C (1967) The venom apparatus of Conus magus. Toxicon : official 
journal of the International Society on Toxinology 4(4):275-284. 
10. Garrett JE, Buczek O, Watkins M, Olivera BM, & Bulaj G (2005) Biochemical and gene 
expression analyses of conotoxins in Conus textile venom ducts. Biochemical and 
biophysical research communications 328(1):362-367. 
11. Safavi-Hemami H, Young ND, Williamson NA, & Purcell AW (2010) Proteomic 
interrogation of venom delivery in marine cone snails: novel insights into the role of the 
venom bulb. Journal of proteome research 9(11):5610-5619. 
12. Biggs JS, Olivera BM, & Kantor YI (2008) Alpha-conopeptides specifically expressed in 
the salivary gland of Conus pulicarius. Toxicon : official journal of the International Society 
on Toxinology 52(1):101-105. 
13. Lewis RJ, Dutertre S, Vetter I, & Christie MJ (2012) Conus venom peptide pharmacology. 
Pharmacological reviews 64(2):259-298. 
14. Schroeder CI & Craik DJ (2012) Therapeutic potential of conopeptides. Future medicinal 
chemistry 4(10):1243-1255. 
15. Terlau H & Olivera BM (2004) Conus venoms: a rich source of novel ion channel-targeted 
peptides. Physiological reviews 84(1):41-68. 
16. Craig AG, Bandyopadhyay P, & Olivera BM (1999) Post-translationally modified 
neuropeptides from Conus venoms. European journal of biochemistry / FEBS 264(2):271-
275. 
17. Olivera BM (2006) Conus peptides: biodiversity-based discovery and exogenomics. The 
Journal of biological chemistry 281(42):31173-31177. 
18. Anonymous (2014) Nomenclature of cone snail cysteine frameworks. 
19. Wermeling DP (2005) Ziconotide, an intrathecally administered N-type calcium channel 
antagonist for the treatment of chronic pain. Pharmacotherapy 25(8):1084-1094. 
20. Kolosov A, Aurini L, Williams ED, Cooke I, & Goodchild CS (2011) Intravenous injection 
of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a 
rat model of bone cancer pain. Pain medicine (Malden, Mass.) 12(6):923-941. 
21. Brust A, et al. (2009) chi-Conopeptide pharmacophore development: toward a novel class of 
norepinephrine transporter inhibitor (Xen2174) for pain. Journal of medicinal chemistry 
52(22):6991-7002. 
22. Allen JW, et al. (2007) An assessment of the antinociceptive efficacy of intrathecal and 
epidural contulakin-G in rats and dogs. Anesthesia and analgesia 104(6):1505-1513, table of 
contents. 
23. Teichert RW, et al. (2007) Novel conantokins from Conus parius venom are specific 
antagonists of N-methyl-D-aspartate receptors. The Journal of biological chemistry 
282(51):36905-36913. 
24. Espiritu DJ, et al. (2001) Venomous cone snails: molecular phylogeny and the generation of 
toxin diversity. Toxicon : official journal of the International Society on Toxinology 
39(12):1899-1916. 
25. Kaas Q, Yu R, Jin AH, Dutertre S, & Craik DJ (2012) ConoServer: updated content, 
knowledge, and discovery tools in the conopeptide database. Nucleic acids research 
40(Database issue):D325-330. 
26. Kaas Q, Westermann JC, & Craik DJ (2010) Conopeptide characterization and 
classifications: an analysis using ConoServer. Toxicon : official journal of the International 
Society on Toxinology 55(8):1491-1509. 
27. Aguilar MB, et al. (2013) Precursor De13.1 from Conus delessertii defines the novel G gene 
superfamily. Peptides 41:17-20. 
28. Dutertre S, et al. (2013) Deep venomics reveals the mechanism for expanded peptide 
diversity in cone snail venom. Molecular & cellular proteomics : MCP 12(2):312-329. 
29. Jin AH, et al. (2013) Transcriptomic messiness in the venom duct of Conus miles 
contributes to conotoxin diversity. Molecular & cellular proteomics : MCP. 
30. Lavergne V, et al. (2013) Systematic interrogation of the Conus marmoreus venom duct 
transcriptome with ConoSorter reveals 158 novel conotoxins and 13 new gene 
superfamilies. BMC genomics 14(1):708. 
31. Luo S, et al. (2013) A novel inhibitor of alpha9alpha10 nicotinic acetylcholine receptors 
from Conus vexillum delineates a new conotoxin superfamily. PloS one 8(1):e54648. 
32. Puillandre N, Koua D, Favreau P, Olivera BM, & Stocklin R (2012) Molecular phylogeny, 
classification and evolution of conopeptides. Journal of molecular evolution 74(5-6):297-
309. 
33. Ye M, et al. (2012) A helical conotoxin from Conus imperialis has a novel cysteine 
framework and defines a new superfamily. The Journal of biological chemistry 
287(18):14973-14983. 
34. Liu ZC, et al. (2012) Venomic and transcriptomic analysis of centipede Scolopendra 
subspinipes dehaani. Journal of proteome research 11(12):6197-6212. 
35. Valdez-Velazquez LL, Quintero-Hernandez V, Romero-Gutierrez MT, Coronas FI, & 
Possani LD (2013) Mass fingerprinting of the venom and transcriptome of venom gland of 
scorpion Centruroides tecomanus. PloS one 8(6):e66486. 
36. Margres MJ, Aronow K, Loyacano J, & Rokyta DR (2013) The venom-gland transcriptome 
of the eastern coral snake (Micrurus fulvius) reveals high venom complexity in the 
intragenomic evolution of venoms. BMC genomics 14:531. 
37. Ishikawa H (1977) Evolution of ribosomal RNA. Comparative biochemistry and physiology. 
B, Comparative biochemistry 58(1):1-7. 
38. Hernandez AI, et al. (2009) Poly-(ADP-ribose) polymerase-1 is necessary for long-term 
facilitation in Aplysia. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 29(30):9553-9562. 
39. Fujiwara H & Ishikawa H (1986) Molecular mechanism of introduction of the hidden break 
into the 28S rRNA of insects: implication based on structural studies. Nucleic acids 
research 14(16):6393-6401. 
40. Zarlenga DS & Dame JB (1992) The identification and characterization of a break within 
the large subunit ribosomal RNA of Trichinella spiralis: comparison of gap sequences 
within the genus. Molecular and biochemical parasitology 51(2):281-289. 
41. Buczek O, et al. (2005) Characterization of D-amino-acid-containing excitatory conotoxins 
and redefinition of the I-conotoxin superfamily. The FEBS journal 272(16):4178-4188. 
42. Conticello SG, et al. (2001) Mechanisms for evolving hypervariability: the case of 
conopeptides. Molecular biology and evolution 18(2):120-131. 
43. Vetter I, et al. (2012) Isolation, characterization and total regioselective synthesis of the 
novel muO-conotoxin MfVIA from Conus magnificus that targets voltage-gated sodium 
channels. Biochemical pharmacology 84(4):540-548. 
44. Kits KS, et al. (1996) Novel omega-conotoxins block dihydropyridine-insensitive high 
voltage-activated calcium channels in molluscan neurons. Journal of neurochemistry 
67(5):2155-2163. 
45. Fu L, Niu B, Zhu Z, Wu S, & Li W (2012) CD-HIT: accelerated for clustering the next-
generation sequencing data. Bioinformatics (Oxford, England) 28(23):3150-3152. 
46. Lewis RJ (2012) Discovery and development of the chi-conopeptide class of analgesic 
peptides. Toxicon : official journal of the International Society on Toxinology 59(4):524-
528. 
47. Bhatia S, et al. (2012) Constrained de novo sequencing of conotoxins. Journal of proteome 
research 11(8):4191-4200. 
48. Aygün E, Oommen BJ, & Cataltepe Z (2010) Peptide classification using optimal and 
information theoretic syntactic modeling. Pattern Recognition 43(11):3891-3899. 
49. Arlinghaus FT & Eble JA (2012) C-type lectin-like proteins from snake venoms. Toxicon : 
official journal of the International Society on Toxinology 60(4):512-519. 
50. Remigio EA & Duda TF, Jr. (2008) Evolution of ecological specialization and venom of a 
predatory marine gastropod. Molecular ecology 17(4):1156-1162. 
51. Hu H, Bandyopadhyay PK, Olivera BM, & Yandell M (2011) Characterization of the Conus 
bullatus genome and its venom-duct transcriptome. BMC genomics 12:60. 
52. Terrat Y, et al. (2012) High-resolution picture of a venom gland transcriptome: case study 
with the marine snail Conus consors. Toxicon : official journal of the International Society 
on Toxinology 59(1):34-46. 
53. Hu H, Bandyopadhyay PK, Olivera BM, & Yandell M (2012) Elucidation of the molecular 
envenomation strategy of the cone snail Conus geographus through transcriptome 
sequencing of its venom duct. BMC genomics 13:284. 
54. Lluisma AO, Milash BA, Moore B, Olivera BM, & Bandyopadhyay PK (2012) Novel 
venom peptides from the cone snail Conus pulicarius discovered through next-generation 
sequencing of its venom duct transcriptome. Marine genomics 5:43-51. 
55. Robinson SD, et al. (2014) Diversity of Conotoxin Gene Superfamilies in the Venomous 
Snail, Conus victoriae. PloS one 9(2):e87648. 
56. Violette A, et al. (2012) Large-scale discovery of conopeptides and conoproteins in the 
injectable venom of a fish-hunting cone snail using a combined proteomic and 
transcriptomic approach. Journal of proteomics 75(17):5215-5225. 
57. Violette A, et al. (2012) Recruitment of glycosyl hydrolase proteins in a cone snail 
venomous arsenal: further insights into biomolecular features of Conus venoms. Marine 
drugs 10(2):258-280. 
58. Safavi-Hemami H, et al. (2014) Combined proteomic and transcriptomic interrogation of the 
venom gland of Conus geographus uncovers novel components and functional 
compartmentalization. Molecular & cellular proteomics : MCP. 
59. Luo C, Tsementzi D, Kyrpides N, Read T, & Konstantinidis KT (2012) Direct comparisons 
of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA 
sample. PloS one 7(2):e30087. 
60. Bioinformatics B (FastQC: a quality control tool for high throughput sequence data. 
61. Lohse M, et al. (2012) RobiNA: a user-friendly, integrated software solution for RNA-Seq-
based transcriptomics. Nucleic acids research 40(Web Server issue):W622-627. 
62. Ewing B & Green P (1998) Base-calling of automated sequencer traces using phred. II. 
Error probabilities. Genome research 8(3):186-194. 
63. Magoc T & Salzberg SL (2011) FLASH: fast length adjustment of short reads to improve 
genome assemblies. Bioinformatics (Oxford, England) 27(21):2957-2963. 
64. Masella AP, Bartram AK, Truszkowski JM, Brown DG, & Neufeld JD (2012) PANDAseq: 
paired-end assembler for illumina sequences. BMC bioinformatics 13:31. 
65. Grabherr MG, et al. (2011) Full-length transcriptome assembly from RNA-Seq data without 
a reference genome. Nature biotechnology 29(7):644-652. 
66. Haas BJ, et al. (2013) De novo transcript sequence reconstruction from RNA-seq using the 
Trinity platform for reference generation and analysis. Nature protocols 8(8):1494-1512. 
67. Schulz MH, Zerbino DR, Vingron M, & Birney E (2012) Oases: robust de novo RNA-seq 
assembly across the dynamic range of expression levels. Bioinformatics (Oxford, England) 
28(8):1086-1092. 
68. Langmead B & Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nature 
methods 9(4):357-359. 
69. Zamora-Bustillos R, Aguilar MB, Falcon A, & Heimer de la Cotera EP (2009) 
Identification, by RT-PCR, of four novel T-1-superfamily conotoxins from the vermivorous 
snail Conus spurius from the Gulf of Mexico. Peptides 30(8):1396-1404. 
70. Petersen TN, Brunak S, von Heijne G, & Nielsen H (2011) SignalP 4.0: discriminating 
signal peptides from transmembrane regions. Nature methods 8(10):785-786. 
71. Duckert P, Brunak S, & Blom N (2004) Prediction of proprotein convertase cleavage sites. 
Protein engineering, design & selection : PEDS 17(1):107-112. 
72. Fan X & Nagle GT (1996) Molecular cloning of Aplysia neuronal cDNAs that encode 
carboxypeptidases related to mammalian prohormone processing enzymes. DNA and cell 
biology 15(11):937-945. 
73. Fan X, Spijker S, Akalal DB, & Nagle GT (2000) Neuropeptide amidation: cloning of a 
bifunctional alpha-amidating enzyme from Aplysia. Brain research. Molecular brain 
research 82(1-2):25-34. 
74. Hale JE, Butler JP, Gelfanova V, You JS, & Knierman MD (2004) A simplified procedure 
for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion 
and mass spectral analysis. Analytical biochemistry 333(1):174-181. 
75. McInerney JO (1998) GCUA: general codon usage analysis. Bioinformatics (Oxford, 
England) 14(4):372-373. 
 
  
Supplementary figures 
 
Fig. S1 – New precursor forms of known mature conotoxins. Alignment of the known (framed) and novel sequences is shown in 
the figure (low to high amino acid conservation are represented from light to darker colors). 
 
 
 
RDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
M FV LVNVIM TC-VIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
M FSIQII ECCLIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MLKLTCMMIIAVLFLTAWTFVIA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMKLTCMLIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCRMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTRMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MNLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTA LTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DNSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTA CTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMVIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFLKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVIA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIA LLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNELANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMANDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMM FIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLSCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTARTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMK DPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSSNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDHEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFW TAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLVLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LA DHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLKCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTTWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MKLTCMLIIA LLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMM LIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIISVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDS EASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIA ELFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MKLMCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MKLTCMMIIAVLFLTAWTFVMA DDFNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSSDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPGASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA EDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTFMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFFTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEAAK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MIIAVPFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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RDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
M FV LVNVIM TC-VIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
M FSIQII ECCLIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MLKLTCMMIIAVLFLTAWTFVIA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMKLTCMLIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCRMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTRMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MNLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTA LTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DNSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTA CTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMVIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFLKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVIA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIA LLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNELANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MKLTCMMIVAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWI FVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSSDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPGASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA EDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTFMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFFTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEAAK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMLIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MKLTCMMIIAVLFLTAWTVVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
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MMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIVVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMISAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MM FIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MM FIAVLFLTAWTFVMA DDSNNV LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFLTAWTFVMA DDSNNG LANR FSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAGLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMG DPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFLTSWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRN EMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MTIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MI FISVLFLTAWTFVMA DDSNNG PANHFSKSRDEMEDPEASKVEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFFTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MMIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LGKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWI FVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEKEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTYVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIVVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
M FIAVLFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTFVMA DDSNNG LANYFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTFVMAVDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVLFLTAWTFVMA DDSNNELANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MIIAVPFLTAWTFVMA DDSNNG LANHFSKSRDEMEDPEASK LEKRRDCQEKWEYCIV PI LG FVYCCPG LI CG PFVCV
MfVIA
VD_sup2_seq469
VD_sup2_seq462
VD_sup2_seq624
VD_sup3_seq590
VD_sup3_seq592
VD_sup2_seq600
VD_sup2_seq602
VD_sup3_seq614
VD_sup2_seq183
VD_sup3_seq336
VD_sup3_seq279
VD_sup3_seq578
VD_sup3_seq293
VD_sup3_seq287
VD_sup3_seq277
VD_sup3_seq291
VD_sup3_seq338
VD_sup3_seq267
VD_sup3_seq230
VD_sup3_seq280
VD_sup3_seq329
VD_sup3_seq334
VD_sup3_seq294
VD_sup2_seq575
VD_sup3_seq341
VD_sup3_seq292
VD_sup2_seq562
VD_sup3_seq340
VD_sup2_seq574
VD_sup3_seq264
VD_sup3_seq575
VD_sup3_seq342
VD_sup3_seq328
VD_sup3_seq276
VD_sup2_seq576
VD_sup3_seq224
VD_sup3_seq281
VD_sup2_seq974
VD_sup2_seq573
VD_sup3_seq286
VD_sup3_seq288
VD_sup3_seq545
VD_sup3_seq282
VD_sup3_seq330
VD_sup3_seq327
VD_sup3_seq337
VD_sup2_seq112
VD_sup2_seq182
VD_sup3_seq295
VD_sup3_seq265
VD_sup3_seq339
VD_sup3_seq335
VD_sup3_seq283
VD_sup3_seq278
VD_sup2_seq513
VD_sup3_seq315
VD_sup3_seq331
VD_sup2_seq111
VD_sup2_seq440
VD_sup2_seq659
VD_sup2_seq5
VD_sup2_seq678
VD_sup2_seq679
VD_sup2_seq191
VD_sup2_seq645
VD_sup2_seq674
VD_sup2_seq660
VD_sup2_seq672
VD_sup2_seq677
VD_sup2_seq673
VD_sup2_seq327
VD_sup2_seq493
VD_sup2_seq661
VD_sup2_seq192
VD_sup2_seq495
VD_sup2_seq497
VD_sup2_seq507
VD_sup2_seq511
VD_sup2_seq4
VD_sup2_seq456
VD_sup2_seq504
VD_sup2_seq506
VD_sup2_seq496
VD_sup2_seq508
MK LTCVVIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN LEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MMK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAA LFS TAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MN LTCMM FVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEYSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVA ELFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMM FVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LEN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEVKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAWK FA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFASA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAWI FA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKS PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LGKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TS DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTYMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MN LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIGAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK FDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAR TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LM CMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMRN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MK LTCMMIVAV LFLTAWA FA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MM FVAV LFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MMIVV LLFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MIVVV LFFTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
MIVAV PFLTAW TFA TA DDPRNG LGN LFSNV HHEMKN PEDSK LDKK CLG FG EA CLM LYS DCCS YCVA LV CL
Ep6.1_precursor
VD_sup3_seq596
VD_sup2_seq577
VD_sup3_seq613
VD_sup3_seq529
VD_sup3_seq344
VD_sup3_seq273
VD_sup3_seq472
VD_sup3_seq532
VD_sup2_seq184
VD_sup3_seq354
VD_sup3_seq353
VD_sup3_seq530
VD_sup3_seq524
VD_sup3_seq541
VD_sup3_seq583
VD_sup3_seq619
VD_sup2_seq571
VD_sup3_seq351
VD_sup3_seq507
VD_sup3_seq227
RS_sup3_seq6
VD_sup3_seq531
VD_sup2_seq585
VD_sup2_seq656
VD_sup2_seq686
VD_sup2_seq530
VD_sup2_seq527
MK LTCVMIVAV LFLTAW TFV TAV PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MMK LTYIMIVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MK LS YMM LVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MK LTCMMIVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MK LTYMMIVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MMIVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MIVSV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
MIVAV LFLTAW TVV TAI PHSSNA LEN LYLKAR HEM EN PEASK LN TR DDDCEPPGN FCGMIKIG PPCCSGW CFFA CA
Om6.5_precursor
VD_sup3_seq611
VD_sup2_seq564
VD_sup3_seq563
VD_sup3_seq588
VD_sup2_seq193
VD_sup2_seq529
VD_sup2_seq175
MR CLPV FVI LLLLIAS TPSVNAR PK TK D--- LAS FHDNAKR TQHI FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR TQHVVWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNA TR TQHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNA ER TQHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR THHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR TEHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKRN QHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR TK HV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNA QR TQHV FWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR TQHV LWSKRN CCI YENW CCEWI
MR CLPV FVI LLLLIAS TPSVNAR PK TK DDMS LAS FHDNAKR TQHV FRSKRN CCI YENW CCEWI
Pn5.1_precursor
VD_sup3_seq2951
VD_sup3_seq2956
VD_sup3_seq2910
VD_sup3_seq2913
VD_sup3_seq2912
VD_sup3_seq2911
VD_sup3_seq2914
VD_sup3_seq2955
VD_sup3_seq2950
VD_sup3_seq2917
M HCLSV FVI LLLLTASA PSV DA QPK TEDGV LLSS FR DNA ER TLQK LWN HAR DW CDPCPWG
MR CLPV LII LLLLTASG PSI EAR PK TEDGV LLSS FR DNA ER TLQK LWN FAR DW CDPCPWG
M FFFLV LII LLLLTASG PSI EA LPK TEDGV LLSS FR DNA ER TLQK LWNSAR DW CDPCPWG
MR CLPV LII LLLLTASG PSI EAR PK TEDGV LLSS FR DNA ER TLQK LWNNAR DW CDPCPWG
MR CLPV LII LLLLTASG PSI EAR PK TEDGV LLSS FR DNA ER TLQK LWNN ER DW CDPCPWG
MR CLPV LII LLLLTASG PSI EAR PK TEDGV LLSS FR DNA ER TLQK LW DYAR DW CDPCPWG
PnMRCL-012
VD_sup3_seq3200
VD_sup2_seq454
VD_sup3_seq3201
VD_sup3_seq3202
VD_sup3_seq3198
Mature Region
Fig. S2 – Average number of parent and variant precursors as a function of their similarity rate. The line plot in red shows the 
variation of the number of parent conopeptide precursors when different similarity thresholds were applied.  The bar chart in green 
represents the average number of variants per parent sequence (and the corresponding standard error of the mean represented by grey 
vertical bars) for different similarity thresholds. 
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Fig. S3 – New mature conopeptides containing the cysteine pattern VI/VII (C-C-CC-C-C). Sequences are grouped according to 
their internal loop formula and have been aligned using BLOSUM62 cost matrix. Conserved cysteine amino acids are framed in red. 
 
 
 
  
C(6)C(5)CC(3)C(3)C
C(6)C(6)CC(2)C(4)C
C(6)C(6)CC(3)C(3)C
C(6)C(6)CC(3)C(4)C
C(6)C(6)CC(5)C(4)C
C(6)C(8)CC(3)C(3)C
C(6)C(9)CC(4)C(4)C
C(6)C(6)CC(2)C(3)C
C(6)C(9)CC(3)C(3)C
Fig. S3 (continued) 
 
 
 
C(6)C(5)CC(3)C(3)C
C(6)C(6)CC(2)C(4)C
C(6)C(6)CC(3)C(3)C
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C(6)C(9)CC(3)C(3)C
Fig. S4 – New mature conopeptides containing the cysteine pattern I (CC-C-C). Sequences are grouped according to their 
internal loop formula and have been aligned using BLOSUM62 cost matrix. Conserved cysteine amino acids are framed in red. 
 
 
 
CC(4)C(7)C
CC(4)C(2)C
CC(4)C(13)C
CC(5)C(4)C
CC(5)C(6)C
Supplementary table 
 
Table S1 – Proteome to transcriptome mapping. MS peptide sequence tags mapped (at the maximum confidence threshold ≥ 99%) to known precursor conopeptides (A), new precursor conopeptides 
classified into known gene superfamilies (B), forming new gene superfamilies (C), with cysteine patterns known in cone snails (D), and containing new cysteine patterns (E). The name, precursor 
sequence (MS fragment in bold; mature region underlined), cDNA frequency, gene superfamily, fraction or spot number where the peptide fragment has been isolated from, post-translational 
modifications, as well as LC and MS metrics are listed. 
 
 
  
A
Sequence'Name Sequence cDNA'Frequency Gene'Superfamily Fraction'/'Spot Modification dMass Theor'MW Prec'm/z Prec'MW Theor'm/z Theor'z Sc Spectrum Time Precursor'Signal Precursor'Elution
Ep11.1_precursor MKLCVTFLLILVILPSVTGEKSSKRTLSGAALRGDWGMCSGI
GQGCGQDSNCCGDMCCYGQICAMTFAACGP
3091 I1 Fig.C2ACfractionC54 K0.0428284 1255.514893 628.7647 1255.557739 628.7861328 2 14 1.1.1.2585.4 16.1191 8709 16.1243
EpI_precursor MFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIALTIKGCC
SDPRCNMNNPDYCG
185 A Fig.C2ACfractionC43 K0.0150174 1455.862305 486.2947 1455.877319 486.2997131 3 14 1.1.1.2895.6 18.8895 2944 18.782
MfVIA
MKLMCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRDCQEKWEYCIVPILGFVYCCPGLICGPF
VCV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
B
Sequence'Name Sequence cDNA'Frequency Gene'Superfamily Fraction'/'Spot Modification dMass Theor'MW Prec'm/z Prec'MW Theor'm/z Theor'z Sc Spectrum Time Precursor'Signal Precursor'Elution
VD_sup3_seq8 MFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIALTIKGCC
SDPRCNMNNPDYCSIIRKAKDK
1 A Fig.C2ACfractionC44 K0.0135406 1171.667725 586.8411 1171.681274 586.8479004 2 15 1.1.1.2763.10 19.7275 10932 19.7061
VD_sup3_seq40
MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCASYYLSALSSVELYDQTTEMS 1 A Fig.C2ACfractionC45 K0.00545909 1299.770752 434.2642 1299.776245 434.2660217 3 13 1.1.1.2564.7 19.2171 9136 19.1538
VD_sup3_seq41 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1465 A Fig.C2ACfractionC43 K0.0150174 1455.862305 486.2947 1455.877319 486.2997131 3 14 1.1.1.2895.6 18.8895 2944 18.782
VD_sup3_seq43 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCGQNLNKNMRSVCSNKIRQ
1 A Fig.C2ACfractionC44 K0.0117459 1343.790649 448.9375 1343.802368 448.9414063 3 15 1.1.1.2751.8 19.1789 12689 19.2522
VD_sup3_seq44
MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCGWEIRMAVNNTLPLASYYLS
VLSSVELYDQTTEMS
1 A Fig.C2ACfractionC43 K0.0150174 1455.862305 486.2947 1455.877319 486.2997131 3 14 1.1.1.2895.6 18.8895 2944 18.782
VD_sup3_seq46 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCWLFRSHRLQIFL
1 A Fig.C2ACfractionC43 K0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2902.4 19.2076 19576 19.333
VD_sup3_seq56 MGMRMMFTVFLLVVLATTVVSFTSDRVVGPASDSRKDAA
SGLIALTIKGCCSDPRCNMNNPDYCG
5 A Fig.C2ACfractionC43 K0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2902.4 19.2076 19576 19.333
VD_sup3_seq93
MKLCVTFLLILVILPSVTGEKSSKRTLSGAALRGDWGMCSGI
GQGCGQDSNCCGDMCCYGQICAMTFAACGLLNGRGTLT
VQR
1 I1 Fig.C2ACfractionC34 Deamidated(N)@6 K0.0258295 1446.724243 483.2487 1446.750122 483.2572937 3 14 1.1.1.2266.2 12.4586 2919 12.4752
VD_sup3_seq155
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGGCCHK
SCCRSTCTFPCLIPGKRAKLREFFRQRCYVAQRSAAFLRKW
QITTT
1 I2 Fig.C2ACfractionC37 Amidated@CKterm K0.0115313 1167.555298 584.7849 1167.566772 584.7906494 2 13 1.1.1.3240.2 20.1639 4235 20.0808
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCHK
SCCRSTCTFPCLIPGKRAKLREFFRQRGYVAQRSAAFLRKW
QITQA
I2 Fig.C2ACfractionC37 Amidated@CKterm K0.0115313 1167.555298 584.7849 1167.566772 584.7906494 2 13 1.1.1.3240.2 20.1639 4235 20.0808
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQRGYVAQRSAAFLRKW
QITQA
I2 Fig.C2BCfractionC34 Oxidation(P)@7 0.027557399 2487.981689 623.0027 2487.954102 622.9957886 4 20 1.1.1.2476.3 14.0784 9032 14.0602
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQRGYVAQRSAAFLRKW
QITQA
I2 Fig.C2BCfractionC35 Oxidation(P)@9 K0.170614004 2076.633789 693.2185 2076.804199 693.2753906 3 17 1.1.1.2550.11 15.73 10690 15.6613
VD_sup3_seq216
MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLFNPVKRCCPAAACAMGCKPCCGGAALLSWPHQVS
NE
1 M Fig.C2BCfractionC33 0.091759302 1737.695068 869.8548 1737.603271 869.8088989 2 15 1.1.1.2539.21 16.871 32316 16.9674
VD_sup3_seq290 MKLTCMMIIAVLFLTAWTFVMADDPRDEPEARDEMNPAA
SKLNERGCLAVDYFCGIPFVSNGLCCSGNCVFVCTPQGK
20 O1 Fig.C2FCspotC55 Amidated@CKterm K0.279992014 3556.235107 1186.419 3556.516357 1186.512817 3 16 1.1.1.3727.2 23.2541 6000 23.2128
VD_sup3_seq314
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRDCQEKWEYCIVPILGFVYCCPGLICGPFV
CRLILMSSTPICATPGLIFDRRVPFTGYKPLDPTLWTPRGPNI
QIKQHPKTTEMS
1 O1 Fig.C2ACfractionC33 K0.022351 973.52948 487.772 973.5518188 487.7831726 2 12 1.1.1.3208.3 18.0362 11448 18.0088
VD_sup3_seq434
MKLTCMMIVAVLFLTAWTFATADDPRDGLGNLFSKTQHE
MKNPEASKLNKRCRAENELCDIITQNCCGGMCFLICIEIPEP
SLSSFLRFGRRDMQSPLLSERLRFRALGFRQPSSQKQ
1 O1 Fig.C2ACfractionC44 K0.0127861 1229.664063 615.8393 1229.67688 615.8457031 2 14 1.1.1.2762.14 19.6892 288519 19.6161
VD_sup3_seq167 1
Table S1 (continued) 
 
 
  
VD_sup3_seq841 MCFFPVFVIFLLLIASTPSVDALLKTKDDMPLASFRDDVKRT
LQTLLNKRFCCQYFECC
1 T Fig.>2B>fraction>42 H0.058931898 1887.016846 630.0129 1887.075684 630.0325317 3 15 1.1.1.2319.9 15.54 160158 15.5652
VD_sup3_seq922 MQTIIYLEIPVFVILLLLIASAPSVDARPKTKDDIPQASFQDN
AKRILQVLESKRNCCRLQVCCG
2 T Fig.>2A>fraction>50 Deamidated(N)@13 0.00418436 1677.788818 560.2702 1677.784546 560.2687988 3 18 1.1.1.2466.10 16.8693 13611 16.8928
VD_sup3_seq1177 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRT
VRTLLDIRKCCFDTPGCCPRG
1 T Fig.>2A>fraction>70 H3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1182 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVSLSSFHDDLQRTV
RTLLDIRTCCFDTPGCCPWG
1 T Fig.>2B>fraction>41 0.0473467 1578.633667 790.3241 1578.586304 790.300415 2 16 1.1.1.2940.15 18.7745 7608 18.7831
VD_sup3_seq1364 MRCLPVFVILLLLIASAPRVDVRPKAKDDMPLASFHDNPLQ
IRLVDTRCCPSQPCCRFWIKENDFG
1 T Fig.>2A>fraction>45 2.20EH10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq1454 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQARPKTK
DDIPQASFQDNAKRILQVLESKRNCCRLQVCCG
1 T Fig.>2A>fraction>49 H4.087520123 3355.587158 560.2718 3359.674561 560.953064 6 18 1.1.1.2614.11 16.9201 7223 16.898
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRIL
QVLESKKKLLQTESLLWVILTKGKCACRLWLRPLQTVPGCEI
WRADCSFRTCSWNFEWSLTTRCHLQATICLSFHLWNCMIK
QLKCHRHY
T Fig.>2A>fraction>49 Deamidated(Q)@9;>
Amidated@CHterm
H0.051879 1628.919434 543.9804 1628.971313 543.9976807 3 13 1.1.1.2289.6 15.8414 16657 15.781
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKKKLLQTESLLWVILTKGKCACRLWLRPLQTVPGCEI
WRADCSFRTCSWNFEWSLTTRCHLQATICLSFHLWNCMIK
QLKCHRHY
T Fig.>2A>fraction>49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup3_seq1673 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCGLFEKKENVHANFG
1 T Fig.>2A>fraction>49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup3_seq1701 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCGSPLSVSLTAAFSRPCRHLSAHLK
1 T Fig.>2A>fraction>50 Deamidated(N)@13 0.00418436 1677.788818 560.2702 1677.784546 560.2687988 3 18 1.1.1.2466.10 16.8693 13611 16.8928
VD_sup3_seq1703
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCGSTTRCHLQAAVSLSFHLWNCMIK
QLKCHRNFSVDKHYDHVASNYIIWTF
1 T Fig.>2A>fraction>50 H0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq1727 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCRDLKKRKNVVPTLA
1 T Fig.>2A>fraction>50 Deamidated(N)@13 0.00418436 1677.788818 560.2702 1677.784546 560.2687988 3 18 1.1.1.2466.10 16.8693 13611 16.8928
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRS
FRDNAKRALQTLMDIRECCMGTPGCCPWG
T Fig.>2A>fraction>50 Deamidated(N)@13 0.00418436 1677.788818 560.2702 1677.784546 560.2687988 3 18 1.1.1.2466.10 16.8693 13611 16.8928
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRS
FRDNAKRALQTLMDIRECCMGTPGCCPWG
T Fig.>2F>spot>48 Oxidation(M)@6 H0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq1977 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFGKRNMTLDDTPANRPCMLD
1 T Fig.>2A>fraction>45 2.20EH10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq1981 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFGSRKLTLDETPANCPWM
1 T Fig.>2A>fraction>45 H0.010314 2067.010498 517.7599 2067.020752 517.7624512 4 18 1.1.1.2561.9 19.0826 9059 19.1078
VD_sup3_seq2018 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCSFGKRKMNLDETPANCPWM
1 T Fig.>2A>fraction>45 H0.010314 2067.010498 517.7599 2067.020752 517.7624512 4 18 1.1.1.2561.9 19.0826 9059 19.1078
VD_sup3_seq2036 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTSCCPSQPCCRFGYREMTLDETPTKCPCMYT
1 T Fig.>2A>fraction>45 2.20EH10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq2347
MRCLPVFVILLLLIASTPNVDARPKTKDDMPLASFHDDAKRI
LQILQDRNGCKDDVPLSSFRDNAKRALQTLMDIRECCMGT
PGCCPWG
1 T Fig.>2F>spot>48 Oxidation(M)@6 H0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq2427 MRCLPVFVILLLLIASTPNVDARPKTKDDMPLASFLIASAPSV
DVRPKAKDDMPLASFHDNPLQIRLVDTRCCPSQPCCRFG
3 T Fig.>2A>fraction>45 6.25EH10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq2440 MRCLPVFVILLLLIASTPNVDARPKTKDDMPLRPKAKDDMP
LASFHDNPLQIRLVDTRCCPSQPCCRFG
1 T Fig.>2A>fraction>45 6.25EH10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq2543 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRR
DNAKRALQTLMDIRECCMGTPGCCPWG
1 T Fig.>2F>spot>48 Oxidation(M)@6 H0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq2695
MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTL
QTLLNKRFCCQYFDAKRALQTLMDIRECCMGTPGCCPWG 1 T Fig.>2F>spot>48 Oxidation(M)@6 H0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq2798
MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTL
QTLLNTCFDARPETKDDVPLSSFRDNAKRALQTLMDIRECC
MGTPGCCPWG
1 T Fig.>2F>spot>48 Oxidation(M)@6 H0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq3000 MRCLPVFVILLLLISSAPSVDARPKTKDDIPQASFQDNAKRIL
QILESKRNCCRLQFFFY
1 T Fig.>2A>fraction>50 H0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq3002 MRCLPVFVILLLLISSAPSVDARPKTKDDIPQASFQDNAKRIL
QVLESKRNCFRLQGFCG
1 T Fig.>2B>fraction>49 0.030009 1676.830566 559.9508 1676.800537 559.9407959 3 15 1.1.1.2878.8 16.8471 6099 16.8277
VD_sup3_seq3008 MRCLPVFVILLLLISSIPNVDSRPKTKDDMPLASFHDDAKRIL
QILQDRNGCCIAGDCCG
1 T Fig.>2B>fraction>36 H0.024117099 1086.542847 544.2787 1086.566895 544.2907715 2 12 1.1.1.3001.3 16.4195 9232 16.3571
VD_sup3_seq3272 MRCLPVVVILLLLISSAPSVDARPKTKDDIPQASFQDNAKRV
LQVLESKRNCCRLQVCCG
1 T Fig.>2A>fraction>50 H0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq1549 1
VD_sup3_seq1836 1
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VD_sup3_seq3 MFTVFLLVVLATTVVPFTSDRASDSRKDAASGLIALTIKGCC
SDPRCNMNNPDYCG
1 A Fig.;2A;fraction;47 F0.00377501 1171.67749 586.846 1171.681274 586.8479004 2 13 1.1.1.2761.2 19.3266 1307 19.288
VD_sup3_seq8 MFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIALTIKGCC
SDPRCNMNNPDYCSIIRKAKDK
1 A Fig.;2A;fraction;44 F0.032125399 985.585083 493.7998 985.6171875 493.8158569 2 13 1.1.1.2755.8 19.3629 2941 19.3898
VD_sup3_seq12 MGMRMMFTVFLLGVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2B;fraction;43 0.0109955 1171.692261 586.8534 1171.681274 586.8479004 2 13 1.1.1.2788.6 19.4747 4710 19.3707
VD_sup3_seq22 MGMRMMFTVFLLVVLATTVVPFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2A;fraction;47 F0.00377501 1171.67749 586.846 1171.681274 586.8479004 2 13 1.1.1.2761.2 19.3266 1307 19.288
VD_sup3_seq25 MGMRMMFTVFLLVVLATTVVSFTLDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2B;fraction;43 0.0109955 1171.692261 586.8534 1171.681274 586.8479004 2 13 1.1.1.2788.6 19.4747 4710 19.3707
VD_sup3_seq26 MGMRMMFTVFLLVVLATTVVSFTPDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2A;fraction;47 F0.00377501 1171.67749 586.846 1171.681274 586.8479004 2 13 1.1.1.2761.2 19.3266 1307 19.288
VD_sup3_seq32 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSAPRCNMHNPDYCG
1 A Fig.;2A;fraction;46 F0.008406 1299.767822 650.8912 1299.776245 650.8953857 2 14 1.1.1.2630.13 19.1966 3297 19.1689
VD_sup3_seq34 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCKMNNQDYCG
1 A Fig.;2A;fraction;43 F0.0150174 1455.862305 486.2947 1455.877319 486.2997131 3 14 1.1.1.2895.6 18.8895 2944 18.782
VD_sup3_seq40
MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCASYYLSALSSVELYDQTTEMS 1 A Fig.;2A;fraction;45 F0.00545909 1299.770752 434.2642 1299.776245 434.2660217 3 13 1.1.1.2564.7 19.2171 9136 19.1538
VD_sup3_seq43 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCGQNLNKNMRSVCSNKIRQ
1 A Fig.;2A;fraction;44 F0.0117459 1343.790649 448.9375 1343.802368 448.9414063 3 15 1.1.1.2751.8 19.1789 12689 19.2522
VD_sup3_seq44
MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCGWEIRMAVNNTLPLASYYLS
VLSSVELYDQTTEMS
1 A Fig.;2A;fraction;43 F0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2908.3 19.4818 19576 19.333
VD_sup3_seq45
MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCGWENRMVLNNTLPLASYYLS
VLSSVELYDQTTEMS
1 A Fig.;2A;fraction;44 F0.0117459 1343.790649 448.9375 1343.802368 448.9414063 3 15 1.1.1.2751.8 19.1789 12689 19.2522
VD_sup3_seq46 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCWLFRSHRLQIFL
1 A Fig.;2A;fraction;43 F0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2902.4 19.2076 19576 19.333
VD_sup3_seq53 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSEPRCNMNNPDYCG
5 A Fig.;2A;fraction;46 F0.00853575 1171.672729 586.8436 1171.681274 586.8479004 2 17 1.1.1.2641.4 19.6862 13522 19.674
VD_sup3_seq54 MGMRMMFTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKVCCSDPRCNMNNPDYCG
1 A Fig.;2B;fraction;43 0.0109955 1171.692261 586.8534 1171.681274 586.8479004 2 13 1.1.1.2788.6 19.4747 4710 19.3707
VD_sup3_seq56 MGMRMMFTVFLLVVLATTVVSFTSDRVVGPASDSRKDAA
SGLIALTIKGCCSDPRCNMNNPDYCG
5 A Fig.;2A;fraction;43 F0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2908.3 19.4818 19576 19.333
VD_sup3_seq57 MGMRMMFTVFLLVVLATTVVSFTSDSASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2A;fraction;44 F0.032125399 985.585083 493.7998 985.6171875 493.8158569 2 12 1.1.1.2757.4 19.4468 2941 19.3898
VD_sup3_seq61 MGMRMMFTVFLLVVLATTVVSSTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2A;fraction;47 F0.00377501 1171.67749 586.846 1171.681274 586.8479004 2 13 1.1.1.2761.2 19.3266 1307 19.288
VD_sup3_seq62 MGMRMMFTVFLLVVLATTVVSVTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2A;fraction;43 F0.0121059 985.6051025 493.8098 985.6171875 493.8158569 2 13 1.1.1.2908.3 19.4818 19576 19.333
VD_sup3_seq64 MGMRMMVTVFLLVVLATTVVSFTSDRASDSRKDAASGLIA
LTIKGCCSDPRCNMNNPDYCG
1 A Fig.;2B;fraction;43 0.0109955 1171.692261 586.8534 1171.681274 586.8479004 2 13 1.1.1.2788.6 19.4747 4710 19.3707
VD_sup3_seq103 MKLCVTFLLILVILPSVTGEKSSKRTLSGAALRGDWGMCSGI
GQGCGQDSNCCGDMCCYGQICAMTSAACGP
1 I1 Fig.;2A;fraction;54 Oxidation(M)@5 F0.00981375 1255.514893 628.7647 1255.524658 628.7695923 2 14 1.1.1.2585.4 16.1191 8709 16.1243
VD_sup3_seq922 MQTIIYLEIPVFVILLLLIASAPSVDARPKTKDDIPQASFQDN
AKRILQVLESKRNCCRLQVCCG
2 T Fig.;2A;fraction;50 F0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq998 MRCLPFFVILLLLIASSPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFG
1 T Fig.;2A;fraction;46 0.0294296 855.4744873 428.7445 855.4450073 428.7297974 2 12 1.1.1.2595.5 17.599 32920 17.5872
VD_sup3_seq1071 MRCLPVFIVLLLLIASAPCLAALPKTEGDVPLSSFHDNLKRTR
RTHLNLRECCPDGWCCPAG
1 T Fig.;2A;fraction;55 F0.000525173 1328.719116 665.3668 1328.719604 665.3670654 2 15 1.1.1.2612.3 20.0844 19538 20.1558
VD_sup3_seq1143 MRCLPVFIVLLLLIASAPCLDALPKTEGDVPLSSFHDNLKRTR
RTRLNIRECCSDGWCCPAG
1 T Fig.;2E;spot;7 0.000813833 670.4246826 336.2196 670.4238281 336.2192078 2 7 1.1.1.742.2 4.0934 3474 4.0635
VD_sup3_seq1151 MRCLPVFIVLLLLIASAPCLDTLPKTEGDVPLSSFHDNLKRTR
RTHLNIRECCSDGRCCPAG
1 T Fig.;2A;fraction;45 Oxidation(P)@10 0.063529298 1174.653931 588.3342 1174.590332 588.3024902 2 14 1.1.1.2361.3 16.8598 1425 16.8361
VD_sup3_seq1152 MRCLPVFIVLLLLIASAPCLDTLPKTEGDVPLSSFHDNLKRTR
RTHLNIRECCSDGWCCPAG
2 T Fig.;2A;fraction;45 Oxidation(P)@10 0.063529298 1174.653931 588.3342 1174.590332 588.3024902 2 14 1.1.1.2361.3 16.8598 1425 16.8361
VD_sup3_seq1157 MRCLPVFIVLLLLIASAPCLNALPKTEGDVPLSSFHDNLKRTR
RTHLNIRECCSDGWCCPAG
1 T Fig.;2A;fraction;45 Amidated@CFterm F0.030601 1356.676514 453.2328 1356.707153 453.242981 3 13 1.1.1.2552.4 18.6617 18319 18.6497
VD_sup3_seq1168 MRCLPVFIVLLLLIATAPCLDALPKTEGDVPLSSFHDNLKRTR
RTHLNIRECCSDGWCCPAG
1 T Fig.;2A;fraction;45 0.0100947 1598.869019 533.9636 1598.858887 533.9602661 3 13 1.1.1.2456.9 16.3307 5117 16.31
VD_sup3_seq1174 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRA
VRTLLDIRTCCFDTPGCCPWG
40 T Fig.;2A;fraction;70 F3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1175 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRA
VRTLLDIRTCCFDTPRCCPWG
2 T Fig.;2A;fraction;70 F3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
CCFCFC;(I)
CCFCC;(V)
Tale S1 (continued) 
 
  
VD_sup3_seq1176 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRA
VRTLLDIRTCCFDTTGCCPWG
1 T Fig.=2A=fraction=70 G3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1177 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRT
VRTLLDIRKCCFDTPGCCPRG
1 T Fig.=2A=fraction=70 G3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1178 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRT
VRTLLDIRKCCFDTPGCCPWG
45 T Fig.=2A=fraction=70 G3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1179 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHDDLQRT
VRTLLDIRKCCFDTQGCCPWG
2 T Fig.=2A=fraction=70 G3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1181 MRCLPVFIVLLLLIVSAPGFDARPKTEDDVPLSSFHEDLQRTV
RTLLDIRKCCFDTPGCCPWG
1 T Fig.=2B=fraction=41 0.0109612 1578.633667 790.3241 1578.622681 790.3186035 2 15 1.1.1.2940.15 18.7745 7608 18.7831
VD_sup3_seq1183 MRCLPVFIVLLLLIVSAPRFDARPKTEDDVPLSSFHDDLQRT
VRTLLDIRKCCFDTPGCCPWG
1 T Fig.=2A=fraction=70 G3.1354599 1869.713501 624.2451 1872.848999 625.2902832 3 15 1.1.1.2703.16 18.5706 16398 18.5381
VD_sup3_seq1186 MRCLPVFLIFLLLIASTPSVDALLKTKDDMPLASFRDDVKRT
LQTLLNKRFCCQYFECC
1 T Fig.=2A=fraction=66 0.0131892 2300.309814 767.7772 2300.296631 767.7728271 3 16 1.1.1.2327.13 15.9011 66215 15.9197
VD_sup3_seq1340 MRCLPVFVILLLLIASALSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFG
4 T Fig.=2A=fraction=49 G0.00658971 855.4748535 428.7447 855.4814453 428.7479858 2 12 1.1.1.2620.3 17.1747 60933 17.2535
VD_sup3_seq1363 MRCLPVFVILLLLIASAPRVDVRPKAKDDMPLASFHDNPLQ
IRLVDTRCCPSQPCCRFG
11 T Fig.=2A=fraction=45 7.70EG10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq1364 MRCLPVFVILLLLIASAPRVDVRPKAKDDMPLASFHDNPLQ
IRLVDTRCCPSQPCCRFWIKENDFG
1 T Fig.=2A=fraction=45 7.70EG10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq1366 MRCLPVFVILLLLIASAPRVDVRPTAKDDMPLASFHDNPLQ
IRLVDTRCCPSQPCCRFG
1 T Fig.=2A=fraction=45 7.70EG10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq1434 MRCLPVFVILLLLIASAPSVDARAKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCG
3 T Fig.=2A=fraction=50 G0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq1455 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDDAKRI
LQVLESKRNCCRLQVCCG
14 T Fig.=2A=fraction=49 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup3_seq1727 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCRDLKKRKNVVPTLA
1 T Fig.=2A=fraction=50 G0.0137532 1676.786865 559.9362 1676.800537 559.9407959 3 17 1.1.1.2467.10 16.9148 12512 16.8928
VD_sup3_seq1832 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKR
MLQVLESKRNCCRLQVCCG
1 T Fig.=2B=fraction=47 Deamidated(Q)@6 G0.0330212 1458.801025 487.2743 1458.834106 487.2853088 3 13 1.1.1.2336.8 15.6212 6376 15.6031
VD_sup3_seq1836 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRS
FRDNAKRALQTLMDIRECCMGTPGCCPWG
1 T Fig.=2B=fraction=49 0.030009 1676.830566 559.9508 1676.800537 559.9407959 3 15 1.1.1.2878.8 16.8471 6099 16.8277
VD_sup3_seq1837 MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRS
FRDNAKRALQTLMDIRECCMGTPGCCPWG
1 T Fig.=2F=spot=48 Oxidation(M)@6 G0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq1877 MRCLPVFVILLLLIASAPSVDDFSPVRPKAKDDMPLASFHD
NPLQIRLVDTRCCPSQPCCRFG
1 T Fig.=2A=fraction=45 G0.010314 2067.010498 517.7599 2067.020752 517.7624512 4 18 1.1.1.2561.9 19.0826 9059 19.1078
VD_sup3_seq1985 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFGSRKMTLDENPANSP
1 T Fig.=2A=fraction=45 G0.010314 2067.010498 517.7599 2067.020752 517.7624512 4 18 1.1.1.2561.9 19.0826 9059 19.1078
VD_sup3_seq2347
MRCLPVFVILLLLIASTPNVDARPKTKDDMPLASFHDDAKRI
LQILQDRNGCKDDVPLSSFRDNAKRALQTLMDIRECCMGT
PGCCPWG
1 T Fig.=2F=spot=48 Oxidation(M)@6 G0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq2476 MRCLPVFVILLLLIASTPNVDVRPKTKDDMPLASFHDDAKRI
LQILQDRNGCCIAGDCCG
10 T Fig.=2B=fraction=54 G0.065263599 1509.786255 755.9004 1509.85144 755.9330444 2 13 1.1.1.2647.13 18.9875 36150 18.8206
VD_sup3_seq2543 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRR
DNAKRALQTLMDIRECCMGTPGCCPWG
1 T Fig.=2F=spot=48 Oxidation(M)@6 G0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
VD_sup3_seq2546 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTL
ETLLNKRFCCPYFECC
2 T Fig.=2B=fraction=12 G0.067287497 1584.863892 529.2952 1584.931152 529.317627 3 9 1.1.1.890.3 4.5161 2149 4.5552
VD_sup3_seq2599 MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTL
QTLLKNRFCCPYFECC
1 T Fig.=2B=fraction=12 Deamidated(Q)@7 G0.067287497 1584.863892 529.2952 1584.931152 529.317627 3 13 1.1.1.2343.7 15.8825 37922 15.9111
VD_sup3_seq2896 MRCLPVFVILLLLIASTPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFG
7 T Fig.=2B=fraction=10 0.070359103 869.5310669 435.7728 869.4606934 435.7376099 2 12 1.1.1.3032.2 17.6036 3070 17.5808
VD_sup3_seq2897 MRCLPVFVILLLLIATAPSFDVRPKAKEDMPLASFHDNPLQI
RLVDTRCCPSQPCCRFG
7 T Fig.=2A=fraction=57 Amidated@CGterm G0.051286899 2197.141602 733.3878 2197.192871 733.4049072 3 13 1.1.1.2440.3 19.5618 6678 19.4752
VD_sup3_seq3001 MRCLPVFVILLLLISSAPSVDARPKTKDDIPQASFQDNAKRIL
QVLESKRNCCRLQVCCG
6 T Fig.=2B=fraction=49 0.030009 1676.830566 559.9508 1676.800537 559.9407959 3 15 1.1.1.2878.8 16.8471 6099 16.8277
VD_sup3_seq3008 MRCLPVFVILLLLISSIPNVDSRPKTKDDMPLASFHDDAKRIL
QILQDRNGCCIAGDCCG
1 T Fig.=2B=fraction=36 G0.024117099 1086.542847 544.2787 1086.566895 544.2907715 2 12 1.1.1.3001.3 16.4195 9232 16.3571
VD_sup3_seq3035 MRCLPVFVILLLLMASAPSVDARPKTKDDIPQASFQDNAKR
ILQVLESKRNCCGLQVCCG
1 T Fig.=2B=fraction=30 G0.00690579 1244.647827 623.3312 1244.654663 623.3346558 2 15 1.1.1.3096.2 19.87 2330 19.8207
VD_sup3_seq3036 MRCLPVFVILLLLMASAPSVDARPKTKDDIPQASFQDNAKR
ILQVLESKRNCCRLQVCCG
4 T Fig.=2B=fraction=30 G0.00690579 1244.647827 623.3312 1244.654663 623.3346558 2 15 1.1.1.3096.2 19.87 2330 19.8207
VD_sup3_seq3265 MRCLPVVVILLLLIASAPRVDVRPKAKDDMPLASFHDNPLQ
IRLVDTRCCPSQPCCRFG
1 T Fig.=2A=fraction=45 7.70EG10 2067.020996 517.7625 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
VD_sup3_seq3295 MRCLTVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKR
MLQVLESKRNCCRLQVCCG
1 T Fig.=2B=fraction=30 Deamidated(Q)@6 G0.0330212 1458.801025 487.2743 1458.834106 487.2853088 3 13 1.1.1.2336.8 15.6212 6376 15.6031
VD_sup3_seq202 MMSKLGVLFTICLLLFSLTAVPLDGDQHADQPAERLQGDIL
SEKHPLFNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2B=fraction=33 0.055373799 1737.695068 869.8548 1737.639648 869.8270874 2 15 1.1.1.2540.21 16.9168 32316 16.9674
VD_sup3_seq210 MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLCNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq213 MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLFNHVKRCCPAAACAMGCKPCCG
2 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq215 MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLFNPVKRCCPAAACAMGCKPCCG
179 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq216
MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLFNPVKRCCPAAACAMGCKPCCGGAALLSWPHQVS
NE
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq219 MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGYILS
EKHPLFNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq220 MMSKLGVLLTICLLLFSLTAVQLDGDQHADQPAERLQGDIL
SEKHPLFNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq221 MMSKLGVLLTICLLLFSLTSVPLDGDQHADQPAERLQGDILS
EKHPLFNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
VD_sup3_seq223 MSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILSE
KHPLFNPVKRCCPAAACAMGCKPCCG
1 M Fig.=2A=fraction=34 G0.00993299 1547.588501 516.8701 1547.598511 516.8734131 3 12 1.1.1.3138.5 17.4494 14537 17.344
CCGCGCGCC=(III)
CCGCC=(V)
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VD_sup3_seq247 MKLTCMIIIAVLFLTAWTFATADDTRNGLENLFSKAHHEMK
NPEASKLNKRCIPQFDPCDRLRHTCCQGLCVLIACL
1 O1 Fig.C2FCspotC58 Deamidated(Q)@12 0.066058397 1412.810669 707.4126 1412.744629 707.3795776 2 13 1.1.1.2335.14 16.2535 502713 16.0502
VD_sup3_seq250 MKLTCMIIIAVLFLTAWTFATADDTRNGLENLFSKAHHEMK
NSEASKLNKRCIPQFDPCDMLRHTCCQGLCVLIACL
1 O1 Fig.C2FCspotC58 0.039202899 1388.783813 695.3992 1388.744629 695.3795776 2 13 1.1.1.2356.4 13.1379 2307 13.1432
VD_sup3_seq251 MKLTCMIIIAVLFLTAWTFATADDTRNGLENLFSKAHHEM
KNSEASKLNKRCIPQFDPCDMLRHTCCQGLCVLIACL
1 O1 Fig.C2FCspotC58 0.067674197 1446.726318 483.2494 1446.658691 483.2268372 3 14 1.1.1.2209.5 12.3771 11859 12.4259
VD_sup3_seq289 MKLTCMMIIAVLFLTAWTFVMADDPRDEPEARDEMNPAA
SKLNERGCLAVDYFCGIPFVSNGLCCSGNCVFVCTPQG
1 O1 Fig.C2FCspotC55 Amidated@CQterm Q0.279992014 3556.235107 1186.419 3556.516357 1186.512817 3 16 1.1.1.3727.2 23.2541 6000 23.2128
VD_sup3_seq290 MKLTCMMIIAVLFLTAWTFVMADDPRDEPEARDEMNPAA
SKLNERGCLAVDYFCGIPFVSNGLCCSGNCVFVCTPQGK
20 O1 Fig.C2FCspotC55 Amidated@CQterm Q0.279992014 3556.235107 1186.419 3556.516357 1186.512817 3 16 1.1.1.3727.2 23.2541 6000 23.2128
VD_sup3_seq296
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKGRDCQEKWEYCIVPILGFVYCCPGLICGPF
VCV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq316
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRDCQEKWEYCIVPILGFVYCCPGLICGPF
VCVEY
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq324
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRDCQKKWEYCIVPILGFVYCCPGLICGPF
VCV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq325
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRDCREKWEYCIVPILGFVYCCPGLICGPFV
CV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq326
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKSRDCQEKWEYCIVPILGFVYCCPGLICGPFV
CV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq333
MKLTCMMIIAVLFLTAWTFVMADDSNNGLANHSSKSRDE
MEDPEASKLEKRRDCQEKWEYCIVPILGFVYCCPGLICGPF
VCV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq348 MKLTCMMIVAVLFLIAWTFATADDPRDGLGNLFPKTQHE
MKNPEASKLNKRCKAENELCDIITQNCCGGMCFLICIEIPE
1 O1 Fig.C2ACfractionC31 Deamidated(N)@4;C
Deamidated(Q)@10
0.045943901 1940.976196 647.9993 1940.930176 647.9840088 3 14 1.1.1.3260.8 19.6324 3556 19.6128
VD_sup3_seq408 MKLTCMMIVAVLFLTAWTFATADDPRDGLGNLFSKTQHE
MKNPEASKLNKRCKAENELCDIITQNCCGGMCFLMCIEIPE
1 O1 Fig.C2ACfractionC28 Amidated@CQterm 0.050576601 1004.554077 503.2843 1004.503479 503.2590027 2 11 1.1.1.3339.3 17.9652 2596 17.9519
VD_sup3_seq423 MKLTCMMIVAVLFLTAWTFATADDPRDGLGNLFSKTQHE
MKNPEASKLNKRCKAENEPCDIITQNCCGGMCFLICIEIPE
1 O1 Fig.C2ACfractionC41 Deamidated(N)@2;C
Amidated@CQterm
Q0.0299107 1344.6521 673.3333 1344.682007 673.3482666 2 14 1.1.1.2925.16 17.6787 16166 17.6489
VD_sup3_seq434
MKLTCMMIVAVLFLTAWTFATADDPRDGLGNLFSKTQHE
MKNPEASKLNKRCRAENELCDIITQNCCGGMCFLICIEIPEP
SLSSFLRFGRRDMQSPLLSERLRFRALGFRQPSSQKQ
1 O1 Fig.C2ACfractionC44 Q0.0127861 1229.664063 615.8393 1229.67688 615.8457031 2 14 1.1.1.2762.14 19.6892 288519 19.6161
VD_sup3_seq544 MKLTCMMIVAVLFLTAWTFVMADDPRDEPEARDEMNPA
ASKLNERGCLAVDYFCGIPFVSNGLCCSGNCVFVCTPQGK
1 O1 Fig.C2FCspotC55 Amidated@CQterm Q0.279992014 3556.235107 1186.419 3556.516357 1186.512817 3 16 1.1.1.3727.2 23.2541 6000 23.2128
VD_sup3_seq615
MNLTCMMIIAVLFLTAWTFVMADDSNNGLANHFSKSRDE
MEDPEASKLEKRRECQEKWEYCIVPILGFVYCCPGLICGPFV
CV
1 O1 Fig.C2ECspotC17 0.098985396 3177.566406 1060.196 3177.46582 1060.162598 3 9 1.1.1.958.7 6.2879 2428 6.2672
VD_sup3_seq68 MKLCVKFLLILVILPSVTGEKSSKRTLSGAALRGDWGMCSGI
GQGCGQDSNCCGDVCCYGQICAMTFAACGP
1 I1 Fig.C2ACfractionC54 Oxidation(M)@1 Q0.00551978 780.4182739 391.2164 780.4237671 391.2191467 2 9 1.1.1.2603.2 16.8915 5371 16.9723
VD_sup3_seq93
MKLCVTFLLILVILPSVTGEKSSKRTLSGAALRGDWGMCSGI
GQGCGQDSNCCGDMCCYGQICAMTFAACGLLNGRGTLT
VQR
1 I1 Fig.C2ACfractionC34 Deamidated(N)@6 Q0.0258295 1446.724243 483.2487 1446.750122 483.2572937 3 14 1.1.1.2266.2 12.4586 2919 12.4752
VD_sup3_seq146 MVRVTSVGCFLLVILSLNLVVLSNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
1 I2 Fig.C2BCfractionC35 Deamidated(N)@3 Q0.214100003 2902.074951 968.3656 2902.289063 968.4369507 3 15 1.1.1.2567.11 16.49 5326 16.4953
VD_sup3_seq147 MVRVTSVGCFLLVILSLNLVVLTDACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
1 I2 Fig.C2BCfractionC35 Q0.036878899 1935.713623 968.8641 1935.750488 968.8825073 2 16 1.1.1.2564.11 16.3567 6646 16.4519
VD_sup3_seq148 MVRVTSVGCFLLVILSLNLVVLTDACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
2 I2 Fig.C2BCfractionC35 Oxidation(P)@3 0.021765299 2011.781738 671.6012 2011.76001 671.5939331 3 17 1.1.1.2539.9 15.2501 9863 15.2687
VD_sup3_seq151 MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCGMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
2 I2 Fig.C2BCfractionC35 Q0.049968701 1860.668457 621.2301 1860.718506 621.2467651 3 12 1.1.1.2559.9 16.1208 5180 16.146
VD_sup3_seq167
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQRGYVAQRSAAFLRK
WQITQA
1 I2 Fig.C2BCfractionC34 0.0297962 2471.989014 619.0045 2471.959229 618.9970703 4 19 1.1.1.2519.5 15.7894 10106 15.8606
VD_sup3_seq168
MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQRWYVAQRSAAFLRK
WQKTQA
1 I2 Fig.C2BCfractionC34 0.0297962 2471.989014 619.0045 2471.959229 618.9970703 4 19 1.1.1.2519.5 15.7894 10106 15.8606
VD_sup3_seq172 MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCHK
SCCRSTCTFPCLIPGKRATLREFFRQR
1 I2 Fig.C2ACfractionC37 Amidated@CQterm Q0.0115313 1167.555298 584.7849 1167.566772 584.7906494 2 13 1.1.1.3240.2 20.1639 4235 20.0808
VD_sup3_seq185 MVRVTSVGCFLLVILSLNLVVLTNACLSEGSPCSMSGSCCH
RSCCRSTCTFPCLIPGKRAKLREFFRQR
1 I2 Fig.C2BCfractionC34 Oxidation(P)@7;C
Oxidation(R)@17
0.052709501 2487.981689 623.0027 2487.928955 622.989502 4 16 1.1.1.2480.4 14.2676 9032 14.0602
VD_sup3_seq188 MVRVTSVGCFLLVILSLNLVVLTNACRSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
3 I2 Fig.C2BCfractionC35 Deamidated(R)@2;C
Oxidation(P)@7
0.0245416 2531.979736 634.0022 2531.955078 633.9960327 4 20 1.1.1.2532.3 14.9436 47642 15.1808
VD_sup3_seq189 MVRVTSVGCFLLVILSLNLVVLTNACRSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
2 I2 Fig.C2BCfractionC35 Q0.057959199 1972.716797 658.5795 1972.774658 658.598877 3 15 1.1.1.2543.11 15.425 24286 15.4
VD_sup3_seq195 MVRVTSVGCFLLVILSLNVVVLTNACLSEGSPCSMSGSCCH
KSCCRSTCTFPCLIPGKRAKLREFFRQR
1 I2 Fig.C2BCfractionC35 Oxidation(P)@9 Q0.170614004 2076.633789 693.2185 2076.804199 693.2753906 3 17 1.1.1.2550.11 15.73 10690 15.6613
VD_sup3_seq199 MVRVTSVGCLLLVILSLNLVVLTNACLSEGSPCSMSGSCCHK
SCCRSTCTFPCLIPGKRAKLREFFRQR
3 I2 Fig.C2ACfractionC37 Amidated@CQterm Q0.0115313 1167.555298 584.7849 1167.566772 584.7906494 2 13 1.1.1.3240.2 20.1639 4235 20.0808
VD_sup3_seq201 MVRVTSVSCFLLVILSLSLVVLTNACLSEGSPCSMSGSCCHK
SCCRSTCTFPCLIPGKRAKLREFFRQR
1 I2 Fig.C2BCfractionC34 0.0297962 2471.989014 619.0045 2471.959229 618.9970703 4 16 1.1.1.2526.7 16.1066 9825 15.9525
CQCQCQCQCQCQCQCQCQCC(VIII) VD_sup3_seq636 MFVLLLLFTLASSLEKGDVQAGKTQKSDFYRTLTRSARGCT
MSCAFQNNICQGTCHCSGSTNCYCASGHHNTGCGCACTN
1 S Fig.C2BCfractionC43 Amidated@CQterm 0.0313037 1215.677246 608.8459 1215.645874 608.8302612 2 13 1.1.1.2332.11 15.4462 183377 15.3791
CQCQCCQCQCC(VI/VII)
CQCQCCQCCQCQCC(XI)
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Cysteine(Pattern Sequence(Name Sequence cDNA(Frequency Gene(Superfamily Fraction(/(Spot Modification dMass Theor(MW Prec(m/z Prec(MW Theor(m/z Theor(z Sc Spectrum Time Precursor(Signal Precursor(Elution
CC"C"CC"C VD_sup3_seq214 MMSKLGVLLTICLLLFSLTAVPLDGDQHADQPAERLQGDILS
EKHPLFNPVKRCCPAAACAMGCCPFICGTV
1 M Fig.A2BAfractionA33 0.0529548 1647.66748 824.841 1647.614502 824.8145142 2 17 1.1.1.2542.20 17.0045 101615 17.0114
VD_sup3_seq1100 MRCLPVFIVLLLLIASAPCLDALPKTEGDVPLSSFHDNLKRTR
RTHLNIRECCSDGRCCPAGCSTENVHLCP
1 T Fig.A2AAfractionA70 Deamidated(N)@13 "0.028110901 1872.8573 625.293 1872.885376 625.3024292 3 18 1.1.1.2700.19 18.4379 19038 18.4922
VD_sup3_seq1646
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLQVCCGFHLWNCMIKQLKCHRNFSVDKH
YDHVASNYIIWTF
1 T Fig.A2AAfractionA49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup3_seq1802
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLKSKRNCCRLQVCCGLQAAVSLSFHLWNCMIKQLKCH
RNFSVDKHYDHVASNYIIWTF
1 T Fig.A2AAfractionA50 Deamidated(N)@13 0.00418436 1677.788818 560.2702 1677.784546 560.2687988 3 18 1.1.1.2466.10 16.8693 13611 16.8928
VD_sup3_seq2036 MRCLPVFVILLLLIASAPSVDVRPKAKDDMPLASFHDNPLQI
RLVDTSCCPSQPCCRFGYREMTLDETPTKCPCMYT
1 T Fig.A2AAfractionA45 "0.010314 2067.010498 517.7599 2067.020752 517.7624512 4 19 1.1.1.2564.10 19.2221 9059 19.1078
CC"CC"CC VD_sup3_seq2695
MRCLPVFVILLLLIASTPSVDALLKTKDDMPLASFRDDVKRTL
QTLLNKRFCCQYFDAKRALQTLMDIRECCMGTPGCCPWG 1 T Fig.A2FAspotA48 Oxidation(M)@6 "0.0311542 1075.538452 538.7765 1075.56958 538.7920532 2 14 1.1.1.3599.4 20.3407 7558 20.3543
CC"C"C"C"C"C"C VD_sup3_seq1738
MRCLPVFVILLLLIASAPSVDARPKTKDDIPQASFQDNAKRI
LQVLESKRNCCRLWLRPLQTVPGCEIWKADCSFRTCSWNF
EWSLTTRCHLQATISLSFHLWNCMIKQLKCHRHY
1 T Fig.A2AAfractionA49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
E
Sequence(Name Sequence cDNA(Frequency Gene(Superfamily Fraction(/(Spot Modification dMass Theor(MW Prec(m/z Prec(MW Theor(m/z Theor(z Sc Spectrum Time Precursor(Signal Precursor(Elution
MLPFLLFTHQWWLNLVVLTNACLSEGSPCSMSGSCCHKSC
CRSTCTFPCLIPGKRAKLREFFRQR
Fig.A2BAfractionA34 0.0297962 2471.989014 619.0045 2471.959229 618.9970703 4 19 1.1.1.2519.5 15.7894 10106 15.8606
MLPFLLFTHQWWLNLVVLTNACLSEGSPCSMSGSCCHKS
CCRSTCTFPCLIPGKRAKLREFFRQR
Fig.A2BAfractionA35 "0.019081799 3869.48291 645.9211 3869.501953 645.9242554 6 15 1.1.1.2568.7 16.51 48841 16.4953
MLPFLLFTHQWWLNLVVLTNACLSEGSPCSMSGSCCHKSC
CRSTCTFPCLIPGKRAKLREFFRQR
Fig.A2AAfractionA37 Amidated@C"term "0.0115313 1167.555298 584.7849 1167.566772 584.7906494 2 13 1.1.1.3240.2 20.1639 4235 20.0808
VD_sup2_seq346
MADNSSLTFLQFFLPVFFFLSPSHLLSLLLPAPCDPRDGLGN
LFSKTQHEMKNPEASKLNKRCKAENELCDIITQNCCGGMCF
LICIEIPE
1 SF"EpiA1 Fig.A2AAfractionA39 "0.0453889 1276.693726 639.3541 1276.739136 639.3768311 2 16 1.1.1.3236.4 19.8679 3841 19.7797
VD_sup2_seq348 MADNSSLTFLQFFLPVFFFLSPSPSVDARPKTKDDIPQASFQ
DNAKRILQVLESKRNCCRLQVCCG
1 SF"EpiA1 Fig.A2AAfractionA49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup2_seq688 MMMAKTRRISLWLRLLLIASAPSVDARPKTKDDIPQASFQ
DNAKRILQVLESKRNCCRLQVCCG
1 SF"EpiA5 Fig.A2AAfractionA49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
VD_sup2_seq1337 MYNILPLYIKHFVGVILVILPSVTGEKSSKRTLSGAALRGDWG
MCSGIGQGCGQDSNCCGDMCCYGQICAMTFAACGP
1 SF"EpiA8 Fig.A2AAfractionA54 "0.0428284 1255.514893 628.7647 1255.557739 628.7861328 2 14 1.1.1.2585.4 16.1191 8709 16.1243
VD_sup2_seq1344 MIIEDDGHLRNISVGVIVLFTFLHFCLLSIPFVYFSVCFTLNDA
LLKTKDDMPLASFRDDVKRTLQTLLNKRFCCQYFECC
2 SF"EpiA9 Fig.A2AAfractionA44 Deamidated(N)@6 0.00770317 1067.543701 534.7791 1067.536011 534.7752686 2 13 1.1.1.2371.4 14.4877 36708 14.5196
MADNSSLTFLQFFLPVFFFLSPSHLLSLLLPAEIPTVPIYYLAKP
QPRERAWRNQRGKKTLLSLTLVRLCEET
Fig.A2AAfractionA31 0.0182127 1276.746094 639.3803 1276.727905 639.3712158 2 16 1.1.1.2486.2 17.7248 60128 17.5064
MADNSSLTFLQFFLPVFFFLSPSHLLSLLLPAEIPTVPIYYLAK
PQPRERAWRNQRGKKTLLSLTLVRLCEET
Fig.A2AAfractionA31 "0.0372102 1276.701904 639.3582 1276.739136 639.3768311 2 14 1.1.1.3265.2 19.8546 23115 19.9209
VD_sup2_seq1356 MADNSSLTFLQFFLPVFFFLSPSHLLSLLLPAPQCNYDLHLVL 1 SF"EpiA1 Fig.A2AAfractionA56 0.00819998 1276.747314 639.3809 1276.739136 639.3768311 2 14 1.1.1.2398.5 17.3413 108352 17.2355
VD_sup2_seq1357 MADNSSLTFLQFFLPVFFFLSPSHLLSLLLPAPRNAHKLFTRLI
N
1 SF"EpiA1 Fig.A2AAfractionA56 0.0116179 1276.750732 639.3826 1276.739136 639.3768311 2 15 1.1.1.2510.7 17.2351 57736 17.3002
VD_sup2_seq1370
MIILVMIIRLVGYAAVSLILGRYTCRSLVEGQEIELLLLIASAPS
VDARPKTKDDIPQASFQDNAKRILQVLESKRNCCRLQVCC
G
1 SF"EpiA11 Fig.A2AAfractionA49 Deamidated(N)@13 0.00894511 1677.793579 560.2718 1677.784546 560.2687988 3 17 1.1.1.2614.11 16.9201 7223 16.898
CC"CC"C"C
VD_sup2_seq187 2 SF"EpiA4
VD_sup2_seq1348 1 SF"EpiA1
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Cysteine frameworks in human and venom peptides 
The analyses of the cysteine frameworks isolated from human and venom peptides revealed that 
these precise scaffolds are important to stabilize protein folds, discrete domains or structural motifs. 
However, we could observe that they are not directly responsible for the selectivity and potency of 
the fold, motif or discrete ligand, which is precluded by the diversity of the receptors targeted. The 
decisive architectural elements that determine the activity of a peptide depend in most cases on the 
length and the hypervariability of the inter-cysteine sequences that when folded present active 
residues in the right orientation for an optimized interaction with the receptor site. 
 
The investigation of the 53 cysteine frameworks extracted from mature human mini-proteins (378) 
and the 86 cysteine frameworks extracted from venom peptides (2,022) characterized to date 
reflects an obvious conservation among protein families containing EGF-like, Kazal, BPTI/Kunitz, 
or WAP domains, which are often be found across heterologous species. Interestingly, it has been 
observed that all of the cysteine-rich peptides studied to date are directed toward a small class of 
targets including GPCRs, enzyme-coupled receptors or may exert the same type of effect by 
inhibiting transporters, extracellular enzymes, as well as being able to act as antimicrobial agents. 
Nevertheless, despite these common characteristics, no ion channel modulators or the ICK motif 
have been found in human to date. With the rapid development of transcriptome sequencing 
technologies, a potential source of new protein sequences may reside in the untranslated region of 
precursor mRNAs likely to contain information encoding cysteine-rich species.90, 91 
 
It is also surprising to see how such particular protein cysteine frameworks are recruited and 
favored in nature. This selection process becomes clearer if we calculate the theoretical number of 
cysteine scaffolds proteins would be able to form. The number of cysteine arrangements can be 
calculated by using a triangular array of binomial coefficients n and k defined by Blaise Pascal’s 
triangle rule, which says that if 
 
 
 
then 
 
 
for n ≥ 0, 0 ≤ k ≤ n. 
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Therefore, assuming a set of original proteins containing an even number of cysteine residues n 
(where 2 ≤ n ≤ 20, and forming only intra-molecular disulfide bonds) with a k number of loops, the 
number of cysteine patterns would be equal to 699,050 (Figure 1). In addition, the number of 
disulfide connectivities that such patterns would be able to form is given by the double factorial of 
non-negative odd arguments p: 
2𝑝 − 1 ‼ = (2𝑝 − 1)!!!!  
where the number of cysteine bridge is p (p ≥ 1), and the number of cysteine is 2p.92 The theoretical 
number of disulfide connectivities is thus equal to 691,362,124, which leads to 
347,850,813,395,066 possible cysteine frameworks (Figure 1). 
 
Although this supposed diversity of scaffolds does not take into account physicochemical 
limitations such as steric restrictions within the molecules, the experimental number of cysteine 
frameworks observed is remarkably less. Indeed, after searching the SwissProt database (542,258 
entries) for all the mature protein regions with the same characteristics as the one taken into 
consideration for the previous calculations (9,551 molecules), only 205 unique cysteine frameworks 
have been found. This consistent difference pleads in favor of the extraordinary conservation of 
active protein conformations regardless of the existence of complex evolutionary pressure 
mechanisms. 
 
 
Drug discovery step-up using transcriptome/proteome sequencing and matching 
approach	  
While bioassay-guided fractionation still remains the most popular technique for screening toxins 
from venoms, it is time consuming and requires large amounts of material to detect then isolate 
active molecules. As a consequence, studies on large or abundant organisms are usually preferred, 
which marginalizes, for practical or ethical reasons, investigations on small or rare animal species 
often considered as promising source of novelty and innovation. That is why with the recent 
improvements of sensitive high-throughput sequencing and activity monitoring techniques, it is 
now possible to extract substantial volumes of data from only limited amounts of starting material 
in a low-priced, fast and accurate way. 
 
Deciphering the primary structure of proteins and peptides using next generation transcriptome 
sequencing technologies coupled to modern tandem MS/MS techniques has become increasingly 
popular in venomics. In my thesis work, this novel approach has been extended with the analysis of 
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the molluscivorous Conus marmoreus (chapter 4) and Conus episcopatus (chapter 5) venom gland 
transcriptomes/proteomes, which enabled the identification of (i) known precursor and mature 
conotoxins, (ii) new precursor conopeptide sequences containing known or new cysteine patterns, 
and (iii) new cone snail gene superfamilies. Nevertheless, these investigations also pointed out the 
importance of choosing the right transcriptome sequencing strategy, as well as the current 
limitations of the method. 
 
The venom duct transcriptomes of C. marmoreus and C. episcopatus were sequenced using the 
Roche 454 GS FLX Titanium (paired-end)43 and Illumina MiSeq (2 x 300 bp strand specific paired-
end), respectively. These platforms both use the Phred+33 encoding system to measure the quality 
each sequenced nucleotide, which is logarithmically proportional to error probabilities (e.g. Phred 
scores of 10, 20, 30, 40, and 50 correspond to probabilities of 1 incorrect base call in 10, 100, 1,000, 
10,000, and 100,000 respectively – or base call accuracies of 90%, 99%, 99.9%, 99.99%, and 
99.999% respectively).93 Although the Roche pyrosequencer provides longer reads than Illumina, 
the latter offers a larger number of sequences (about 100 times more; Figure 2A) at greatly higher 
quality (Figure 2B). In addition, a drop in sequence quality can be observed with the Roche 454 
device for the longest reads (left panel in Figure 2C). As the majority of sequences longer than 300-
350 bp show intermediate quality scores (≤ 30), long reads are thus more likely to contain 
sequencing errors and should be used with care or discarded from the dataset. Although the reads 
are slightly shorter, Illumina MiSeq provides maximum quality scores no matter the length of the 
sequence (right panel in Figure 2C). As a consequence, Illumina is the method of choice for cDNA 
sequencing as it offers reads of higher quality than Roche 454, at lengths equivalent to the highest 
scores of the latter device. However, the important number of sequences generated by the Illumina 
platform requires more extensive bioinformatics skills and resources for further processing. 
 
The third chapter reports the design of the program ConoSorter and highlights the importance of 
purpose-built bioinformatics tools when conducting large-scale transcriptome and proteome 
analyses. Organism-specific programs dedicated either to the identification of particular molecular 
classes like conopeptides, read assembly, or transcript/peptide matching still need to be developed 
or improved. 
 
Read assembly can be considered as an optional step when searching transcriptomes for short 
precursor conopeptides which are about 300 bp long. However, looking for longer sequences found 
in enzymes or using a different source organism that produces larger toxins requires the assembly of 
read into contigs either by referring to a genome or de novo. Complete genomic data from only a 
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Figure 1 – Theoretical number of cysteine frameworks. Pascal’s triangle (where n and k coefficients represent the number of cysteine -1 and loop respectively) has been used to calculate the 
number of possible cysteine patterns a protein containing an even number of cysteine comprised between 2 and 20 could form. For example, a protein with 4 cysteines (n=3) could be arranged in 1 
pattern without loops (k=0; CCCC), 3 patterns with 1 loop (k=1; C-CCC, CC-CC, CCC-C), 3 patterns with 2 loops (k=2; C-C-CC, CC-C-C, C-CC-C), and 1 pattern with 3 loops (k=3; C-C-C-C). 
The number of disulfide connectivity for has been inferred from the double factorial of odd arguments (i.e. number of cysteine -1). For instance, a protein containing 4 cysteines would be able to 
form (4-1)!! = 3!! = 3 x 1 = 3 combinations of disulfide bridges (I-II, III-IV; I-III, II-IV; I-IV, II-III). 
Conclusion 
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few non-model organisms (or related species) are currently available, however, and therefore most 
of transcriptome assemblies must be preformed de novo. There are two principal obstacle to this 
approach. Firstly, most of the modern short read assembly programs using de Bruijn graph 
algorithms are based on the recognition of overlapping read sequences of length k. The choice of an 
optimal k-mer size parameter (restricted by the available memory of the computer, sequencing 
errors and transcriptome coverage objective) considerably affects the final assembly product and is 
thus crucial.94 Whereas a few genome-specific programs exist for assessing the best k-mer value, 
none have been developed for transcriptomes. Algorithms based on multi-k values that cluster 
homologous sequences from each single-k assembly have been shown to improve the quality of 
Figure 2 – Comparison of Roche 454 and Illumina MiSeq sequencing methods. The distribution of the read lengths 
obtained after sequencing C. marmoreus (Roche 454 in green) and C. episcopatus (Illumina in red) venom gland 
transcriptomes (A). Comparison of the number of cDNA sequences according to their quality score are shown in (B). A score 
of 37 took as a reference represents high quality reads. Quality scores for individual bases depending on their position in the 
read sequences (C: Roche 454 and Illumina statistics are shown in the left and right panels respectively).  
C - Quality scores across all bases
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assemblies but still don’t allow for a complete annotation of all available unique contigs (the 
development of metrics assessing the quality of assemblies is also a focus of several bioinformatics 
groups).95, 96 The second limitation of k-mer based de novo assembly of non-model transcriptomes 
is the presence of repeated sequences. For instance, I show in Chapter X that despite obtaining good 
quality metrics for the assembly of C. episcopatus venom apparatus transcriptomes, only few 
conopeptides have been detected. The high conservation of conopeptide signal regions coupled to a 
significant number of toxin isoforms might be a source of repeat sequences that current de novo 
assemblers cannot overcome. 
 
Another limitation of examining transcriptomes and proteomes is the final matching of the 
translated CDS transcripts to the peptide sequence tags obtained by MS/MS. In all experiments 
conducted on various organisms we observed that this step provides either only few precursor hits 
or very low sequence coverage. The format of the output files specific to the mass spectrometer 
generally restricts the experimenters to only use proprietary mass fingerprinting programs. ABSciex 
ProteinPilot software is one of the few tools available that allows matching MS data to custom 
reference databases (i.e. to a dataset of translated cDNA sequences here). However, the requirement 
for publication purpose of selecting hits only identified at the highest confidence score (≥ 99%) 
insures a low false discovery rate, but at the cost of discarding large populations of isoform 
molecules sharing identical peptide fragments. Moreover, the low number of matches also found its 
origin in the difference of possibilities offered by transcriptome and proteome sample preparations. 
Whereas the PCR amplification of nucleic acid species during the cDNA library construction allows 
detecting transcript expressed at a mono-molecular level, enrichment of proteins remain the main 
difficulty when using small or rare specimen.  
Future prospects: cell culture of cone snail venom duct 
An alternative approach for enriching protein samples isolated from Conus species could be to 
establish a suitable in vitro system for the short-term primary culture of the venom duct epithelium.  
This sustainable system would not only provides higher quantity of material, but would also allows 
an increase in specificity by only targeting venom-producing cells and thus decreasing the amount 
of housekeeping proteins involved in maintaining the organism homeostasis. Access to fresh 
material and better reproducibility of such experiments by limiting intra-specific variability might 
be conceivable as well.97 As demonstrated for the venom glands of the snakes Bitis gabonica98, 
Bothrops jararaca99 and the Brazilian armed spider Phoneutria nigriventer100, a cell culture of the 
cone snail venom gland would be a rich source of bioactive components, and a potent tool for 
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fundamental research in order to study particular aspects such as venom biosynthesis, enzymatic 
folding of conopeptides, and their secretion mechanisms. 
 
Isolated cells from marine invertebrates have been shown to be an effective system for numerous 
applications emanating from three major economical and environmental trends with substantial 
market value: (i) the request for a source of novel marine bioproducts with pharmaceutical, 
cosmetic or nutritional potential; (ii) the need for tools to study diseases of edible marine species; 
and (iii) the development of new biotechnological systems to assess the fate of xenobiotics on 
aquatic ecosystems. However, setting up a cell culture from marine invertebrates remains 
challenging. Contrary to other invertebrates such as insects, and despite many attempts and efforts 
invested for several decades to maintain proliferative cells in vitro, no permanent cell lines from 
marine invertebrates exist to date.101 Moreover, since the 1970’s only a handful of articles reporting 
long-term primary cell cultures for the phylum mollusca (seawater molluscs) have been published 
as most of the cultures have only a life span of some days to weeks.102, 103 Cell cultures of marine 
gastropods that have attracted the most interest focused on myocytes, mantle cells, haemocytes, and 
larvae from the abalone Haliotis104-108 or on the nerve cells of the sea slug Aplysia109-114. In addition, 
the task has become still more ambitious as most of the information reported in the scientific 
literature is usually focused on a few species belonging to only 6 marine invertebrate phyla out of 
more than 20 (Porifera, Cnidaria, Crustacea, Mollusca, Echinodermata, Urochordata) and for 
which the cell physiology and requirements in vitro are poorly described.102, 115 
 
The incredible impact that such a production system could have in the discovery of the future drug 
leads of tomorrow is worth trying to overcome the difficulties described earlier, for which some 
points of support could be found among the extensive knowledge available so far about the cell 
biology of a plethora of organisms. 
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predators. Remarkably, cone snails can rapidly switch between distinct venoms in response to
predatory or defensive stimuli. Here, we show that the defence-evoked venom of Conus
geographus contains high levels of paralytic toxins that potently block neuromuscular
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evoked venom contains prey-specific toxins mostly inactive at human targets. Predation- and
defence-evoked venoms originate from the distal and proximal regions of the venom duct,
respectively, explaining how different stimuli can generate two distinct venoms. A specialized
defensive envenomation strategy is widely evolved across worm, mollusk and fish-hunting
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V
enomous marine gastropods of the genus Conus have
evolved one of the most sophisticated envenomation
strategies known, allowing these slow animals to capture
worms, mollusks and even fish1. Utilizing a hollow, harpoon-like
radula, cone snails inject a complex cocktail of potent venom
peptides (conotoxins) to rapidly immobilize the prey2. This
strategy is underpinned by a remarkable diversity of conotoxins
that target a wide range of membrane proteins, including the
FDA-approved Cav2.2 inhibitor o-MVIIA (Prialt) used to treat
intractable pain3. To maximize venom potency, cone snails
deploy synergistic groups of conotoxins, known as ‘cabals’4. For
example, the ‘lightning-strike cabal’ comprises potassium channel
blocking k-conotoxins and excitatory sodium channel modifying
d-conotoxins that produce immediate tetanic paralysis in fish2.
In contrast, the ‘motor cabal’ developed in particular by
C. geographus comprises inhibitory o-, m- and a-conotoxins
that target neuromuscular receptors and produce flaccid paralysis
in fish5. However, the role of the paralytic motor cabal in
C. geographus predation is unclear, since it mainly uses an
alternate ‘nirvana cabal’ to sedate fish prior to capture using a net
strategy (see Supplementary Fig. 1; Supplementary Movie 1)6.
Molecular and phylogenetic studies have demonstrated that the
evolution of envenomation strategies is typically a predatory
rather than a defensive adaptation7,8, despite the critical
importance of defence for animal survival9. While a shell can
serve as the first line of defence, repair marks commonly observed
in many Conus species indicate they can survive physically
damaging attacks from predators such as octopus or fish (see
Supplementary Fig. 2), possibly by using their venom defensively
(see Supplementary Movie 2). The defensive use of venom can
also result in human injuries, with Conus geographus stings
producing confirmed fatalities5. Such deleterious effects are
currently explained by a unique venom that acts on targets
with conserved pharmacology across prey and predator, and a
separately evolved defensive strategy to deter aggressors has not
been investigated previously.
In this article, we report for the first time the remarkable ability
of cone snails to rapidly and reversibly switch between
functionally and structurally distinct venoms in response to
predatory or threatening stimuli. The defence-evoked venom
typically comprises paralytic toxins, previously thought to
participate in prey capture, that explain the symptoms associated
with human envenomation. In contrast, the predation-evoked
venom appears largely devoid of these paralytic toxins. The
venom duct shows a corresponding regionalization of toxin
production, with high levels of defence-evoked and predation-
evoked venoms in the proximal and distal sections, respectively.
Finally, molecular evolution analyses revealed that both predatory
and defensive toxins are evolving under strong positive selection.
Together, these data suggest that ancestral defensive toxins
originally evolved to protect against fish and cephalopod
predators facilitated a shift from worm-hunting to fish- and
mollusk-hunting strategies.
Results
Distinct predation- and defence-evoked venoms in cone snails.
Fish-hunting C. geographus possesses one of the most fragile
shells (Supplementary Fig. 3) and produces arguably the most
potent venom, suggesting that reduced protection may have co-
evolved with a highly developed defensive strategy in cone snails.
To investigate the evolution of predatory and defensive enveno-
mation strategies in cone snails, we developed a new method that
allowed the sequential collection of injected venom from indivi-
dual C. geographus using alternating predatory and defensive
stimuli (Supplementary Fig. 4). Surprisingly, the defence-evoked
venom was significantly more complex than predation-evoked
venom (Fig. 1a–c), with limited overlap in peptide composition
(o50%), indicating that defence- and predation-evoked venoms
are produced by distinct and independently controlled mechan-
isms (Fig. 1d, Supplementary Fig. 5). The predation-evoked
venom, which was injected only when the proboscis came in close
proximity to appropriate prey tissue, lacked most of the paralytic
peptides thought to enable prey capture but instead contained
high levels of the fish-specific sodium channel inhibitor m-con-
otoxin GS and non-paralytic peptides, including the vasopressin
receptor agonist conopressin-G and the NMDA receptor
antagonist conantokin G (Supplementary Fig. 6). In contrast,
paralytic peptides dominated the defence-evoked venom, which
was injected immediately when the proboscis contacted a solid
surface (Supplementary Movie 3).
Similar predation- and defence-evoked venom profiles were
obtained for several C. geographus specimens (Supplementary
Figs 5–7). To examine how broadly a separate defensive strategy
has evolved in Conus species, we extended these studies to
molluscivorous and vermivorous cone snail species. The mollusci-
vorous Conus marmoreus can inject its prey multiple times during
a single feeding event, allowing predation- and defence-evoked
venoms to be collected over short time-intervals (Fig. 1e–g). The
predatory- and defence-evoked venoms of C. marmoreus were
again distinct, with the first and third injections (both predatory)
being identical (Fig. 1e,g), despite an intervening defensive sting
being collected minutes earlier (Fig. 1f). The occurrence of
only trace amounts of major predatory toxins (for example,
Mr1e) detected in the defence-evoked venom confirmed that there
was minimal venom carryover between stings (Fig. 1h). As
observed for C. geographus, the predation-evoked venom of
C. marmoreus was relatively simple compared with its defence-
evoked venom, which contained several known vertebrate-active
neurotoxins (Fig. 1e). Since C. marmoreus is not known to prey on
vertebrates, these results suggest that these vertebrate-active toxins
have specifically evolved for defence. In contrast, neuro-
toxins previously thought to participate in prey capture are absent
from the predation-evoked venom, including the mO-conotoxins
that inhibit mollusk10 and vertebrate sodium channels11.
Confirming this is a widely evolved strategy on cone snails,
complex defence-evoked venoms were also obtained from
other fish- (Conus obscurus), mollusk- (Conus victoriae) and
worm-hunting species (Conus planorbis and Conus coronatus)
(Supplementary Figs 8–10).
Pharmacological profiles of predation- and defence-evoked
venoms. To further investigate the biological significance of
separate envenomation strategies, we compared the biological
activity of predation- and defence-evoked C. geographus venoms
across human sodium and calcium channels, and nicotinic acet-
ylcholine receptors. Our results confirmed that the defence-
evoked venom contained high levels of paralytic peptides acting
at mammalian ion channels (Fig. 2a–h), which likely account for
the human fatalities associated with C. geographus defensive
stings (up to B6mg venom injected per strike). In contrast, the
predation-evoked venom of C. geographus was inactive at these
human targets, except for calcium channel activity associated with
trace amounts of the highly potent calcium channel blockers
o-GVIA and o-GVIIA. Since C. geographus is a piscivorous
species, a fish bioassay was used to determine the effective dose
(ED50) in vivo of both the predation- and defence-evoked venoms
(Supplementary Fig. 11). Defence-evoked venom was 350-fold
more potent (ED50¼ 10mg kg 1) than the predation-evoked
venom at producing paralysis in fish, consistent with its role in
deterring large predators, although sufficient predation-evoked
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venom (B1mg) was injected to rapidly paralyse fish up to 200 g.
Surprisingly, one of the major and novel components of the
predation-evoked venom (G117, Fig. 1a) did not induce paralysis
when injected in fish, although a role for this peptide in the
‘nirvana cabal’ cannot be excluded.
Origin of predation- and defence-evoked venoms. The long,
convoluted venom duct is the dominant toxin secretory organ in
cone snails, but it is unclear if other embryologically related
organs might also participate in venom production12. Analyses of
the transcriptomes and proteomes of the interconnected venom
gland, salivary gland and radular sac of C. geographus
unequivocally demonstrated that both predation- and defence-
evoked venoms arise from the venom duct and not these other
associated tissues (Supplementary Figs 12 and 13), with 127
conotoxin sequences recovered from the venom duct, including
43 confirmed by tandem mass spectrometry (MS/MS)
(Supplementary Table 1). In contrast, no conotoxin sequences
were found in the salivary gland, and only three rare conotoxin
transcripts were identified in the radula sac transcriptome,
although these were not detected in the injected venoms. To
understand how a single gland can rapidly and reversibly produce
two distinct venoms, we analysed the venom peptide composition
along the venom duct of C. geographus (Fig. 3a–c). Unexpectedly,
the paralytic toxins found in the defence-evoked venom were
abundant in the proximal duct (sections 7–12), whereas the
major toxins found in the predation-evoked venom dominated
the distal sections (sections 1–6 close to the pharynx) (Fig. 3d,
Supplementary Fig. 14). In addition, structural differences within
the venom duct support the distinct partition of the gland
producing toxins (Fig. 3e). These results suggest that stimulus-
dependent spatiotemporal release of toxins from different
segments of the venom duct can generate functionally and
biochemically distinct predation- and defence-evoked venoms
(Fig. 3f).
Defence as a major evolutionary force driving cone snail
venom evolution. To assess the influence of natural selection on
conotoxins, we determined the non-synonymous to synonymous
nucleotide substitution rate ratio (o) and identified sites evolving
under episodic bursts of positive Darwinian selection (Supple-
mentary Tables 2 and 3). Indeed, since the distinct distribution of
toxins along a single venom gland is a unique evolutionary
innovation, it could facilitate the separate evolution of specialized
predatory and defensive venoms, which likely contributed to the
rapid speciation observed in the genus Conus over the last 33
million years13. Our analyses detected a large number of
positively selected sites (o41) in all toxin superfamilies
examined, indicating that both predatory and defensive
conotoxins are rapidly evolving under the influence of positive
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Figure 1 | The predation- and defence-evoked venoms of cone snails. (a–c) LC-MS profiles of venom samples collected from the deadly piscivorous Conus
geographus following alternating predatory (a,c) and defensive (b) stimuli (milkings separated by 1–7 days). The two predation-evoked venom samples
(clear venom), although interrupted by a defensive milking (milky venom with granules), were identical in composition and contained mainly the
non-paralytic contryphan-G, conopressin-G, conophysin-G and a new conotoxin (G117). In contrast, the defence-evoked venom was more complex and
contained paralytic conotoxins, including the presynaptic calcium channel blockers o-GVIA, o-GVIB, o-GVIIA, the postsynaptic muscle nicotinic receptor
antagonists a-GI, a-GIA and a-GII, and the sodium channel inhibitor m-GIIIA, which evidently are used to defend against predators rather than for prey
capture, as previously believed. (d) Overall, o50% of the major predatory toxins are also injected in defence, mostly at significantly lower levels
(the number of previously characterized toxins compared with the total number of major masses detected are shown in parenthesis). (e–g) Show similar
data for the molluscivorous C. marmoreus, which can repeatedly inject venom over much shorter intervals than piscivorous species (minutes versus days).
(h) Remarkably, the predation- and defence-evoked venoms of C. marmoreus are even more divergent compared with the venom of C. geographus.
Again, the defence-evoked venom contained vertebrate-active neurotoxins, including w-MrIA, mO-MrVIA and mO-MrVIB. Examining the number of
previously characterized toxins revealed a bias towards the discovery of defensive toxins in previous studies (d,h).
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Darwinian selection (Fig. 4a). We also detected several lineages in
the phylogenies of Conus defensive and predatory toxins that
were influenced by episodic positive selection (Supplementary
Tables 2 and 3). Assessment of the widely distributed ancestral
plesiotypic (ancestral character state) conotoxin superfamily O1
(ref. 14) highlights the distinct evolutionary trajectories adopted
by C. geographus defensive and predatory toxins (Fig. 4b), with
most of the characterized defensive toxins being found in a
distinct clade separate from the predatory toxins.
Discussion
In this study, we have discovered that the carnivorous gastropods
of the genus Conus were able to rapidly and reversibly alternate
between two distinct venoms in response to predatory or
defensive stimuli. Surprisingly, defence-evoked venoms obtained
from the deadly C. geographus contained high levels of paralytic
conotoxins of the motor cabal, suggesting this cabal has evolved
for defence and not for prey capture as previously suggested5.
Consistent with a prominent defensive role for the motor cabal,
the pharmacology of the defence-evoked venom correlates with
the symptomatology following C. geographus envenomation in
humans, with death typically resulting from respiratory
paralysis15. In contrast, the predation-evoked venom contains
prey-specific toxins that show low activity on human ion
channels, indicating predation- and defence-evoked venoms
have separately evolved for different functions. Expanding our
study on the feeding mode of molluscivorous cone snails that
routinely inject prey multiple times to achieve full paralysis, we
have investigated the most behaviourally relevant milking
sequence, where predatory use of venom is occasionally
interrupted by deployment of defensive venom. The intervening
defensive sting does not alter the composition and quantity of
venom injected next, as the two separate predatory stings were
strictly identical both qualitatively and quantitatively, with no
evidence of depletion. Complex defence-evoked venom could also
be obtained from other fish-hunting species, as well as from
mollusk- and worm-hunting species, demonstrating that a
specialized defensive behaviour and associated defensive venom
has evolved widely across the genus Conus.
Our transcriptomic and proteomic investigation of embryolo-
gically related organs revealed that the venom duct produced all
conotoxins found in both predation- and defence-evoked
venoms, with only three rare conotoxin transcripts retrieved
from the radular sac, and no conotoxin-like sequences found in
the salivary gland. However, while these rare transcripts likely
have no current functional role, we cannot exclude an ancestral
role in conotoxin evolution given they have the canonical
organization of conotoxin precursors (signal peptide, propeptide,
mature toxin) found in the venom gland. Thus, the development
of a specialized venom duct, where different toxin types are
regionally produced, was a key functional innovation to allow
separate venoms to be injected for predation and defence. At this
stage, it is unclear if venom duct specialization arose from
migration of specialized secretory cells from one section of the
venom duct to another, or whether varying transcriptomic
regulation explains the distinct venom peptide expression profiles
in different duct regions. While proximal–distal heterogeneity in
toxin production along the venom duct of Conus textile has been
reported previously16,17, its role was not identified. Our results
now reveal that stimulus-dependent spatiotemporal release of
toxins from different segments of the venom duct can generate
functionally and biochemically distinct predation- and defence-
evoked venoms that are presumably under separate neuronal
control (see Fig. 3f). Stimulus-dependent release of venom likely
explains the occasional ‘dry stings’, which correspond to injection
of venom devoid of peptidic toxins18. Regional specialization of
toxin production also explains early observations that injection of
extracts of distal duct venom had no effect on mice while extracts
of proximal duct venom were lethal19, and is supported by recent
transcriptomic analysis that found distinct messenger RNA
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Figure 2 | Action of predation- and defence-evoked C. geographus
venoms on human receptors. (a–d) Both predation- (blue) and defence-
evoked (green) venoms (1mg each) were separated on RP-HPLC. The
resulting 72 1-min fractions (F1-F72) were screened on SH-SY5Y human
neuroblastoma cells for activity at a7 (a,b) and a3-containing nicotinic
receptors (c,d), Nav1.2 and Nav1.7 voltage-gated sodium channel (e,f) and
Cav2.2 voltage-gated calcium channel (g,h). Active fractions are highlighted
in red on the left panels, with a response ratio41 indicating greater activity
in the defence than the predation-evoked venom, and vice versa (except
F32 and F33, which show minor slowing of the response for Nav1.2/7 in
both predation- and defence-evoked venoms). Specific responses for active
fractions are shown on the right panels (b,d,f and h), and known toxins
detected in these fractions are indicated. Whereas the predation-evoked
venom only shows full inhibition of Cav2.2 response due to trace amount of
o-GVIIA and o-GVIA, the defence-evoked venom shows potent inhibition
of all molecular targets, with several well-characterized toxins identified in
the active fractions. The potent block of these key physiological ion
channels explains the lethal effect of C. geographus defensive envenomation
on humans.
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Figure 3 | Distribution of toxins in C. geographus venom duct and proposed mechanism for venom release. (a) Twelve venom gland sections were
spotted on a MALDI plate together with predation- and defence-evoked venom (O, oesophagus; P, proboscis; RS, radular sac; SG, salivary gland).
(b) The resulting averaged spectrum is highly complex in the range 1,000–4,000 kDa corresponding to the size of most conotoxins (10–30 amino acids).
(c) Gel view representation of MALDI results reveals distinct regionalization of many venom components along the duct. For example, the predatory toxin
at 3,175 kDa and defensive toxin at 1,417 kDa show clear non-overlapping distribution along the duct. (d) Quantification of five major predatory
(including conopressin-G at 1,035 kDa) and defensive (including a-GII at 1,417 kDa, m-GIIIA at 2,610 kDa and o-GVIIA at 3,316 kDa) toxins confirms this
region-specific toxin production. (e) Histology (formaldehyde-fixed animal embedded in paraffin) reveals structural heterogeneity along the venom duct,
including regions with a dense layer of secretory cells and a small lumen and others with a looser cell arrangement and a larger lumen, which could support
such regional specialization. Gomori’s Trichrome stain shows muscle fibres in red, collagen in green and nuclei in blue/black (scale bar, 20 mm). (f) A
simple hypothesis to explain the generation of separate stimulus-evoked venoms is proposed. An initial stimulus (predatory or defensive) is perceived by
mechanical, visual and/or chemical (olfactory) sensors that transmit information to the cerebral ganglia surrounding the oesophagus (O) to activate
two separate neuronal circuits. Predation-evoked stimuli activate neuronal circuit (blue) innervating the distal venom duct, causing the release of predatory
venom peptides into the venom duct lumen. Similarly, threats including larger fish and cephalopods activate a separate defensive neuronal circuit
(green) that innervates the proximal venom duct, causing the release of defensive toxins into the lumen. These lumen contents are then moved to the
proboscis by a synchronized contraction of the muscular venom bulb to generate the injected ‘predation-evoked’ and ‘defence-evoked’ venoms.
This key role of the venom bulb allows the rapid switch between the predation- and defence-evoked venoms observed. This mechanism of stimulus-
dependent release of toxins from different sections of the venom duct explains how distinct predation- and defence-evoked venoms are generated.
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expression patterns in distal and proximal C. geographus venom
duct20.
While venom diversification in cone snails has only been
associated with dietary specialization21, our study reveals that
both predatory and defensive strategies contribute to venom
evolution by rapidly accumulating variations under the influence
of positive Darwinian selection, often in an episodic manner.
From recent studies on the evolutionary relationships of Conus
species, it is now generally accepted that vermivory was the
ancestral feeding mode from which specialized diets (that is,
molluscivory and piscivory) arose. Evidence includes phylogene-
tic analyses of conotoxins expressed by piscivorous species that
were likely derived from a set of loci that was present in the
ancestral vermivorous lineages22, and the observation that some
piscivorous species consume worms as juveniles23. However, no
satisfactory hypothesis has been proposed to explain the shift
from worm to mollusk or fish prey. Our results now suggest an
unexpected evolutionary path to diet diversification in Conidae.
We propose that defence-evoked venom originally evolved in
worm-hunting species to protect against predation by fish and
cephalopods was repurposed in the predatory venom to facilitate
the evolution of piscivorous and molluscivorous feeding strategies
(Fig. 4c). In support, a predation-evoked sting from the non-
piscivorous species C. textile injected into fish was not paralytic
(Supplementary Movie 4), whereas a defensive sting produced
rapid paralysis (Supplementary Movie 5). Similarly, the fish-
hunting C. obscurus rapidly paralyses fish, but using a ‘hook-and-
line’ predatory strategy, which may have evolved from ancestral
defence-evoked venoms (Supplementary Movie 6).
Escape from predation is essential for animal survival. Among
the diverse range of evolved adaptations24, the specific defensive
envenomation strategy employed by cone snails appears among
the most remarkable. It is well known that some venomous
animals can ‘metre’ their venom use based on the size of the prey
or the intensity of the threat25,26. For example, scorpions use a
toxin-poor ‘prevenom’ primarily to subdue small prey or deter
low-level threats and only use their toxin-rich ‘true venom’ for
high-level threats27. Such behavioural adaptations likely evolved
to limit venom expenditure, as the production of venom toxins is
metabolically expensive28. Our results demonstrate that
venomous animals can modify the toxin composition of venom
according to a predatory or defensive stimulus, in an
interchangeable manner.
In conclusion, the separate defensive envenomation strategy
employed by cone snails is a remarkable adaptation, changing our
understanding of the biology, evolution and toxin diversification
mechanisms in Conidae. This knowledge will also rationalize
approaches to discover novel vertebrate-active conotoxins found
preferentially in defence-evoked venom and proximal venom
duct peptides, and prey-specific conotoxins found preferentially
in predation-evoked venoms and distal venom duct peptides.
Moreover, since the defensive use of venom is a general feature of
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most venomous animals, its evolutionary impact on venom
diversification remains to be assessed in phylogenetically
unrelated groups. Indeed, snakes and spiders can control venom
expenditure and produce pain-inducing toxins to deter pre-
dators29,30. Recently, regionalization of toxin production has been
shown in sea anemone31, indicating that deployment of separate
venoms might not be restricted to cone snails. Based on these
observations, the evolution of specialized defensive venoms is
predicted to be more important and widespread in other
venomous animals than previously recognized, especially those
with diversified diets. We propose that this specialization has
allowed cone snails to repurpose conotoxins found in defensive
venom to protect against fish and cephalopod threats to allow
these predatory groups to become prey for piscivorous and
molluscivous cone snails.
Methods
Venom collection. All cone snails used in this study have been collected from
Queensland coastal waters under a research permit issued from the Great Barrier
Reef Marine Park (G10/33243.1). Cone snails were held in aquaria (5 weeks to 2
years) at a temperature maintained between 24–28 C and a 12:12 light–dark cycle.
Following each milking, the collecting tube was briefly centrifuged, lyophilized and
stored at –20 C until use.
Predation-evoked venom samples from the fish-hunting cone snails
C. geographus and C. obscurus were obtained as previously described32. Briefly, a
live fish is used to lure the cone snail and elicit a predatory behaviour with
extension of the proboscis. A microcentrifuge tube covered with parafilm and a
piece of fish tail is then presented at the tip of the proboscis, and upon contact with
fish tissue, predation-evoked venom is forcefully injected through the hollow
harpoon-like radula into the collecting tube. To obtain defensively injected venom
samples, a novel milking procedure was developed to engage the animal in a
defensive mode. The procedure involved removing the cone snail from the tank
and applying light pressure to the shell with long forceps until it was provoked to
extend its proboscis. Once the proboscis was extended, a collecting tube covered
with parafilm was presented to the tip of the proboscis until stinging occurred.
Depending on the cone snail, several attempts were often required to trigger a
stinging response and the delivery of venom into the tube. Owing to the serious
health hazard associated with C. geographus envenomation, this milking procedure
should only be attempted by persons fully aware of and protected from the risk of
an accidental sting (for example, wearing thick gloves and carefully manipulating
the snails with long forceps).
The predation-evoked venom from mollusk-hunting cone snails C. marmoreus
and C. victoriae were collected as previously described14. Like other mollusk
hunters, C. marmoreus and C. victoriae usually inject their prey multiple times with
venom during a single feeding event. Therefore, these species could be challenged
in alternating predatory and defensive modes during a single milking session. The
defence-evoked venom was obtained as outlined for C. geographus, except that
repeated light pinching the foot of the animal was required to induce a similar
defensive behaviour.
For the worm-hunting cone snails C. planorbis and C. coronatus, we used the
predator C. marmoreus to trigger a defensive behaviour and initiate extension of
the proboscis. The defence-evoked venom was then collected as described for
C. geographus.
RNA extraction and transcriptome sequencing. The transcriptome of a pool of
C. geographus venom ducts was recently published20. This study provides
additional support to earlier proteomic and toxicity studies that suggested the
presence of distinct venom-expression patterns along the duct, with disorientating
and paralytic venoms expressed in different regions. To evaluate the possible
contribution of different organs to conotoxin production, a single adult specimen
of C. geographus collected from the Great Barrier Reef (Queensland, Australia) and
measuring 10 cm was dissected on ice to remove the venom duct, salivary gland
and radular sac. Samples were placed separately into 1ml of TRIZOL reagent
(Invitrogen) and total RNA extracted following the manufacturer’s instructions to
yield B400 ng of purified messenger RNA from each tissue (Dynabeads mRNA
DIRECT kit, Invitrogen). A cDNA library was constructed by fragmenting the
RNA, synthesis of double-stranded cDNA, fragment end repair, preparation of
AMPure beads, ligation of adaptors and removal of small fragments, followed by
quantitation and quality assessment. cDNA sequencing was carried out on a Roche
454 GS FLX Titanium sequencer. The three tissue samples were run together on a
full plate, using a unique barcode for each sample.
Transcriptomic analysis. Sorting of raw cDNA reads obtained from tran-
scriptome sequencing was performed with ConoSorter, a standalone programme
developed in house to classify conopeptides into gene superfamilies and classes33.
After translating the nucleic acid sequences in the six reading frames using the
universal genetic code, the algorithm isolates the corresponding CDS regions before
matching the sequences against complementary regular expressions and profile
Hidden Markov Models built from separate signal, pro- and mature conopeptide
regions. The programme then searches the ConoServer database34 for known
precursor sequences and generates additional information relative to the hits
obtained (frequency of sequences in the raw data set, percentage of hydrophobicity
of the amino-terminal region, sequence length, number of cysteines, scores and
bias) in order to sort the reads. C. geographus transcriptomic sequences with at
least duplicate reads (n¼ 2) and 450 amino acids were sorted into superfamilies
and their corresponding template cDNA sequence retrieved for the subsequent
molecular evolution analysis.
Proteomic analyses. Five adult specimens of C. geographus collected from the
Great Barrier Reef (Queensland, Australia) were held in an aquarium for several
weeks for predation- and defence-evoked venom collection. Two specimens were
killed for tissue-based proteomic studies. Dissection was carried out on ice and the
venom duct removed and divided into 12 equal 1.2-cm sections. The content of
each fraction was squeezed from the duct and diluted with 0.1% formic acid. The
salivary glands and radular sac were extracted with 0.1% formic acid and stored at
–20 C prior to use.
Liquid chromatography and electrospray mass spectrometry was performed on
the AB Sciex 5600 TF and AB Sciex QSTAR Pulsar as previously described14,35.
Briefly, the predation- and defence-evoked venom samples, the 12 sections of the
dissected venom, as well as the extracts from the salivary gland and the radular sac
were directly subjected to LC-ESI-MS in order to obtain a complete mass list of
underivatized peptides. Information-dependent acquisition was performed on the
reduced, reduced/alkylated and enzymatically digested venom samples. A sequence
database comprising the entire raw cDNA reads from this transcriptomic project
was used to match MS/MS data with transcriptomic sequences utilizing Protein
Pilot 4 software. The detected peptide fragments (confidence value 499) were
manually inspected and validated.
The extracts of the 12 duct sections were analysed using an Ultraflex III TOF-
TOF (time-of-flight) mass spectrometer (Bruker Daltonics, Bremen, Germany)
equipped with a 200Hz all-solid-state laser (SmartBeam) and controlled by the
FlexControl 2.4 software package. Our analytes have molecular weights between
1,000 kDa and 10,000 kDa and therefore the Ultraflex III was operated in both
linear-positive and reflectron-positive mode using CHCA as a matrix. Spectra
calibration was performed externally using a peptide calibration mixture (206195,
Bruker Daltonics, Bremen, Germany). A CHCA solution was made by the dilution
of acetone saturated with CHCA 1 in 10 with an acetone:acetonitrile:water (6:3:1)
solution. The raw samples were diluted 1 in 100 with 0.1% TFA, and 2 ml of diluted
matrix solution mixed with 1 ml sample and spotted onto a polished steel target. For
all samples, 400 shots were acquired using a random walk function at a laser
frequency of 200Hz and saved, with 10 replicates of each sample averaged. Data
were loaded into Clinprot Tools (Bruker Daltonics, Bremen, Germany) to visualize
the 12 individual duct sections in ‘gel view’ using a colorimetric gradient to show
the abundance of the components in respective fractions.
Histology. Cone snails were fixed with paraformaldehyde, dehydrated using
ethanol and processed using a Sakura Tissue-Tek VIP processor with a programme
of 30min xylene clear, and 4 30min paraffin penetrations. The processed ani-
mals were then prepared into paraffin blocks (Shandon Histocentre 3) and cut at
B5 mm using a Leica RM2235 microtome. Glass slides (Lomb Menzel Glaser) were
used during histological sectioning. Sections of paraformaldehyde-fixed animals
were cut atB5 mm, floated out on a water bath, incubated in a Thermoline hot air
drier at 60 C for 30min and stained according to the following protocol. Sections
were de-paraffinized with xylene, rehydrated from ethanol back to water and then
stained using Weigert haematoxylin for 10min. Following this, the slides were
washed in running water, differentiated in acid alcohol and Scott’s tap water. The
slides were then washed in running water, rinsed in distilled water and stained with
Gomori’s trichrome for 20min. Finally, the slides were rinsed with 0.5% acetic acid,
distilled water and dehydrated with alcohol through to xylene, before being cover-
slipped. The muscle fibres stain red, collagen stains green and the nuclei stain blue/
black.
Bioassay at human Cav, Nav and nAChR in SH-SY5Y cells. Predation- and
defence-evoked venoms (1mg each) were separated on a C18 analytical column
(Grace Vydac) eluted at 1mlmin 1 with an UltiMate 3000 LC system (Dionex)
and 1-min fractions collected using and a FC 204 fraction collector (Gilson). The
activity of each fraction was assessed using high-throughput Ca2þ imaging assays,
as previously described36. In brief, SH-SY5Y cells (European Collection of Cell
Cultures) were maintained in RPMI medium (Invitrogen, Australia) supplemented
with 15% fetal bovine serum and L-glutamine and passaged every 3–5 days using
0.25% trypsin/EDTA (Invitrogen). SH-SY5Y cells were plated at a density of
35,000–50,000 cells per well on 384-well black-walled imaging plates and cultured
for 48 h. Fluorescent responses (excitation 470–495 nm; emission 515–575 nm)
were assessed using the FLIPRTetra fluorescent plate reader (Molecular Devices)
after 30-min incubation with fluorescent Ca2þ dye (Calcium 4 No Wash dye,
Molecular Devices) diluted in physiological salt solution (composition in mM:
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NaCl 140, glucose 11.5, KCl 5.9, MgCl2 1.4, NaH2PO4 1.2, NaHCO3 5, CaCl2 1.8,
HEPES 10). The equivalent of 50 mg crude venom was added 5min prior to
stimulation of endogenously expressed Nav, Cav and nAChR isoforms. To assess
activity at Nav isoforms endogenously expressed in SH-SY5Y cells (Nav1.2 and
Nav1.7), SH-SY5Y cells were stimulated with veratridine (50 mM), while activity at
Cav2.2 channels was assessed in the presence of nifedipine (10 mM) after
stimulation with KCl (90mM) and CaCl2 (5mM). Nicotine (30 mM) was used to
activate endogenously expressed human a3b2 and a3b4 nAChR, while
endogenously expressed human a7 nAChR were activated using the a7 nAChR
agonist choline (30 mM) in the presence of the allosteric modulator PNU120596
(10 mM, Sigma-Aldrich). Responses were normalized to baseline using
ScreenWorks 3.2.0.14 (Molecular Devices) and the maximum increase in
fluorescence for each predation-evoked venom fraction was plotted relative to the
corresponding defence-evoked venom fraction using GraphPad Prism 5.03, in
order to identify fractions with differential activity between both modes.
Fish bioassay. Wild-type zebrafish (Danio rerio) reared in the laboratory for 6–10
months were injected intramuscularly with 5 ml of saline solution (control) or serial
dilutions of C. geographus predation- or defence-evoked venoms using a Hamilton
syringe. Fish were then observed for signs of paralysis over 10min in a 5 l swim
tunnel (Loligo Systems ApS, Denmark) operated at 250 revolutions per minute.
The onset of paralysis was recorded as the time fish drifted to the opposite end of
the tunnel, with unaffected and saline-injected fish able to swim into the current
without signs of exhaustion for more than 1 h. Time of paralysis versus quantity of
venom injected (predatory or defensive) was used to calculate the effective dose
(ED50) in GraphPad Prism 5.03. Ethical approval for zebrafish experiments was
obtained from the University of Queensland animal ethics committee (IMB/066/
12/ARC/NHMRC).
Molecular evolution analyses. To overcome the effects of recombination on the
phylogenetic and evolutionary interpretations, we employed Single Breakpoint
algorithms implemented in the HyPhy package and assessed recombination on all
the toxin forms examined in this study37. When potential breakpoints were
detected using the small sample Akaike information Criterion (AICc), the
sequences were compartmentalized before conducting selection analyses.
The influence of natural selection on various C. geographus and C. marmoreus
toxin types was evaluated using maximum-likelihood models implemented in
CODEML of the PAML package38. We employed site-specific models that estimate
positive selection statistically as a non-synonymous to synonymous nucleotide
substitution rate ratio (o) significantly greater than 1. We compared likelihood
values for three pairs of models with different assumed o distributions as no a
priori expectation exists for the same: M0 (constant o rates across all sites) versus
M3 (allows o to vary across sites within ‘n’ discrete categories, nZ3); M1a (a
model of neutral evolution) where all sites are assumed to be either under negative
(oo1) or neutral selection (o¼ 1) versus M2a (a model of positive selection),
which, in addition to the site classes mentioned for M1a, assumes a third category
of sites; sites with o41 (positive selection) and M7 (Beta) versus M8 (Beta and o)
and models that mirror the evolutionary constraints of M1 and M2 but assume that
o values are drawn from a beta distribution. Only if the alternative models (M3,
M2a and M8: allow sites with o41) show a better fit in Likelihood Ratio Test
relative to their null models (M0, M1a and M7: do not allow sites to have o41),
are their results considered significant. Likelihood Ratio Test is estimated as twice
the difference in maximum-likelihood values between nested models and
compared with the w2 distribution with the appropriate degree of freedom (the
difference in the number of parameters between the two models). The Bayes
empirical Bayes (BEB) approach was used to identify amino acids under positive
selection by calculating the posterior probabilities that a particular amino acid
belongs to a given selection class (neutral, conserved or highly variable). Sites with
greater posterior probability (PPZ95%) of belonging to the ‘o41 class’ were
inferred to be positively selected. Fast, Unconstrained Bayesian AppRoximation39
implemented in HyPhy40 was employed to detect sites evolving under the influence
of pervasive diversifying and purifying selection. Mixed Effects Model Evolution
(MEME)41 was also used to detect episodic burst of selection. To reveal the
proportion of sites under different regimes of selection, an evolutionary fingerprint
analysis was carried out using the evolutionary selection distance algorithm
implemented in datamonkey42. We further utilized branch-site Random Effects
Likelihood43 to identify lineages affected by episodic selection.
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Transcriptomic Messiness in the Venom Duct
of Conus miles Contributes to Conotoxin
Diversity*
Ai-hua Jin‡¶, Se´bastien Dutertre‡¶, Quentin Kaas‡, Vincent Lavergne‡, Petra Kubala‡,
Richard J. Lewis‡, and Paul F. Alewood‡§
Marine cone snails have developed sophisticated chemi-
cal strategies to capture prey and defend themselves
against predators. Among the vast array of bioactive mol-
ecules in their venom, peptide components called cono-
toxins or conopeptides dominate, with many binding with
high affinity and selectivity to a broad range of cellular
targets, including receptors and transporters of the nerv-
ous system. Whereas the conopeptide gene precursor
organization has a conserved topology, the peptides in
the venom duct are highly processed. Indeed, deep
sequencing transcriptomics has uncovered on average
fewer than 100 toxin gene precursors per species,
whereas advanced proteomics has revealed >10-fold
greater diversity at the peptide level. In the present study,
second-generation sequencing technologies coupled to
highly sensitive mass spectrometry methods were applied
to rapidly uncover the conopeptide diversity in the venom
of a worm-hunting species, Conus miles. A total of 662
putative conopeptide encoded sequences were retrieved
from transcriptomic data, comprising 48 validated cono-
toxin sequences that clustered into 10 gene superfami-
lies, including 3 novel superfamilies and a novel cysteine
framework (C-C-C-CCC-C-C) identified at both transcript
and peptide levels. A surprisingly large number of cono-
peptide gene sequences were expressed at low levels, in-
cluding a series of single amino acid variants, as well as
sequences containing deletions and frame and stop codon
shifts. Some of the toxin variants generate alternative cleav-
age sites, interrupted or elongated cysteine frameworks,
and highly variable isoforms within families that could be
identified at the peptide level. Together with the variable
peptide processing identified previously, background ge-
netic and phenotypic levels of biological messiness in ven-
oms contribute to the hypervariability of venom peptides
and their ability to evolve rapidly. Molecular & Cellular Pro-
teomics 12: 10.1074/mcp.M113.030353, 3824–3833, 2013.
Cone snails are predatory marine gastropods that feed on a
variety of prey, including fish and invertebrates. With 700
cone snail species described, Conus represents the largest
genus of all invertebrate marine animals. The current classifi-
cation and phylogeny of cone snails are still a matter of
debate and are being refined using genomic DNA and radula
morphology data (1–3). Cone snails are classified in the tax-
onomic class Neogastropoda, which comprises three super-
families, Muricoidea, Cancellarioidea, and Conoidea (4). The
Conidae family belongs to the Conoidea branch, and the only
genus of this family is Conus (1).
Cone snails have evolved potent venoms that they use for
defense and capturing prey (5). These venoms are highly
complex mixtures of dominant cysteine-rich conotoxins as
well as cysteine-poor conopeptides, enzymes, and proteins
(6–10). Conopeptides are produced as mRNA precursors dis-
playing a mostly conserved topological organization compris-
ing an N-terminus signal sequence followed by an intervening
propeptide region, the mature toxin region, and, for some, an
additional C-terminal propeptide region (11). Based on signal
sequence similarities, conopeptides have been classified into
18 gene superfamilies (12, 13), which reveal evolutionary re-
lationships between different conopeptides. Indeed, the
higher evolution rate of mature peptide regions prevents the
establishment of reliable phylogeny using these regions only,
and only the conservation of signal sequences offers the
possibility of relating conopeptide precursors (14). During
their journey in the endoplasmic reticulum and the export
machinery, conopeptides are excised from the precursors
with proteases (15) and at the same time are heavily post-
translationally modified. Currently, 14 different post-transla-
tional modifications are identified in conopeptides (13).
The most common post-translational modification is the
formation of disulfide bonds, and the conopeptides with more
than one disulfide bond are commonly referred to as cono-
toxins (16). Conotoxins are currently divided into 24 cysteine
frameworks, designated using Roman numerals, according to
the arrangement of cysteines in the mature peptide region (17,
18). The disulfide bond connectivities are usually important for
the folding and activity of conotoxins, although they are not
part of the definition of the cysteine frameworks.
Second-generation transcriptomics has to date uncovered
on average fewer than 100 toxin cDNA precursors per Conus
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species (19–23). A more impressive molecular diversity has
been described at the peptide level in cone snail venoms, with
1000 detected masses observed in a single specimen (19,
24), and even closely related species can display a completely
different set of conopeptides in their venom (24). Phylogenetic
studies of certain gene superfamilies of conopeptides re-
vealed extensive gene turnover, rapid evolution, and diversi-
fication within relatively recent evolutionary time (25), with
conopeptide genes being among the most rapidly evolving
protein-coding genes in Metazoans, a phenomenon thought
to be facilitated by extensive gene duplications (25). An un-
derstanding of how Conus venoms have evolved to generate
this vast number of peptides from a limited set of genes is
expected to shed light on the rapid molecular evolution of
Conus venom peptides (19).
In the present study, a 454 pyrosequencing approach was
applied to uncover the transcriptome of a worm-hunting spe-
cies of cone snail, Conus miles. To date, only a cDNA cloning
strategy using conserved signal peptides has been applied to
the discovery of conotoxins from this species, with three
superfamilies (O1, D, and I2) and 10 conopeptide sequences
currently identified (26–28). To fully characterize the conopep-
tide isoforms, cysteine frameworks, and gene superfamilies
within C. miles venom, we integrated transcriptomic and pro-
teomic data using bioinformatics. This approach revealed
unsuspected messiness at the mRNA level (29), where we
identified a series of single amino acid variants (type I vari-
ants), pre-mature stop codons (type II variants), and frame
shifts (type III variants). These variations produced conopep-
tides with alternative cleavage sites (types I and III), inter-
rupted or elongated cysteine frameworks (types I, II, and III),
and highly variable isoforms including deletions and elonga-
tions (types II and III). Interestingly, most of these unusual
toxin variants were expressed at very low levels, and given the
high rates of evolution of conotoxin genes within families and
the presence of these single read (mRNA) peptides in the
venom, we hypothesize that this “background” genetic noise
or “transcriptomic messiness” contributes to venom peptide
hypervariability and, more broadly, to the rapid evolution of
bioactive peptides.
EXPERIMENTAL PROCEDURES
RNA Extraction, cDNA Library, 454 Sequencing, and Assembly—
One single adult specimen of C. miles collected from the Great Barrier
Reef (Queensland, Australia) and measuring 6 cm was dissected on
ice. The venom duct was removed and directly placed in a 1.5-ml tube
with 1 ml of TRIZOL reagent (Invitrogen). The extraction of total RNA
was carried out following the manufacturer’s instructions. mRNA was
purified from the tRNA using a Qiagen mRNA extraction kit (Qiagen,
Valencia, CA). The Australian Genomic Research Facility conducted
the next-generation sequencing using a Roche GS FLX Titanium
sequencer. The assembly was carried out using Newbler 2.3.
Conopeptide Sequence Analysis—Raw cDNA reads (expressed
sequence tags) and isotigs were up-loaded in a Web-based search-
able database set up by the Australian Genomic Research Facility.
Sorting of raw cDNA reads was performed with ConoSorter, a stand-
alone program developed in-house to classify conopeptides into gene
superfamilies and classes. Briefly, after translating nucleic acid se-
quences in the six reading frames, the algorithm isolates the corre-
sponding coding regions and classifies them into superfamilies and
classes by employing an approach based on the complementarity of
regular expressions and profile hidden Markov models. Finally, the
program searches the ConoServer database for sequences already
characterized and generates additional statistical information about
the matching hits (frequency of identical sequences in the raw data
set, percent hydrophobicity of the signal region, sequence length, and
number of cysteine residues present).
Manual identification of conopeptide sequences was carried out
from the retrieved data. Gene superfamilies, signal peptides, and
cleavage sites were predicted using the ConoPrec tool implemented
in ConoServer. The cut-off value for assigning a signal peptide to a
gene superfamily was set at 75% sequence identity, as extrapo-
lated from a recent analysis of all precursors deposited in ConoServer
(17, 19).
Venom Sample Preparation—The pooled venom obtained from
three adult (6 cm) specimens of C. miles collected from the Great
Barrier Reef (Queensland, Australia) was used for proteomic studies.
Dissection was performed on ice, the venom ducts were squeezed,
and the contents were collected in 1 ml of 0.1% formic acid and
stored at 20° C until further use.
Reduction-Alkylation and Enzyme Digestion—Reduction and alky-
lation of the cysteine bonds was carried out as previously described
(19). Sigma proteomics sequencing-grade trypsin and endoprotein-
ase Glu-C were used to digest the reduced and alkylated venom
samples, and the enzymes were activated in 40 mM NH4HCO3 buffer.
A ratio of 1:100 (w/w) of enzyme to venom peptides was used. The
digestion was carried out in a microwave apparatus for 4 min on the
lowest power setting.
Mass Spectrometry and Proteomic Analysis—Liquid chromatography–
electrospray mass spectrometry (LC-ESI-MS)1 was performed on an
AB Sciex 5600 TF as previously described (19). Briefly, the dissected
venom extracted as described above (8 l supernatant) was directly
subjected to LC-ESI-MS in order to obtain a complete mass list of
underivatized peptides. Information Dependent Acquisition was per-
formed on the reduced, reduced/alkylated, and enzymatically di-
gested venom samples (i.e. four sets of samples for MS/MS). We
used ProteinPilot 4.0 software for peaklist generation and sequence
identification by searching the LC-ESI-MS/MS spectra against the
raw cDNA database (1,534,974 entries) generated by the Roche 454
GS FLX Titanium sequencer. For comparison, the spectra were also
searched against a publicly accessible database extracted from
UniProtKB using “venom protein” as the keyword (3906 entries). With
the alkylated samples, the fixed modification was set as maleimide for
cysteine alkylation. Nine different types of variable modifications that
have been identified on conopeptides were considered: amidation,
deamidation, hydroxylation of proline and valine, oxidation of methi-
onine, carboxylation of glutamic acid, cyclization of N-terminal gluta-
mine (pyroglutamate), bromination of tryptophan, and sulfation of
tyrosine. The mass tolerance was set as 0.05 Da for precursor ions
and 0.1 Da for the fragment ions. Tandem mass spectra were only
acquired to the 2 to 5 charged ions, and the switch criteria were set
to exclude former target ions for 8 s and to exclude isotopes within 4
Da. The threshold score for accepting individual peptide spectra was
99. The detected peptide pieces were manually inspected and
validated.
1 The abbreviations used are: LC-ESI-MS, liquid chromatography–
electrospray mass spectrometry.
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RESULTS
Transcriptomic and Bioinformatic Data Analysis—A single
run on the Roche GS FLX Titanium sequencer (one-quarter of
a plate equivalent for C. miles; see “Experimental Proce-
dures”) generated 255,829 cDNA reads averaging 325 bp
(minimum of 19 bp) after trimming and removal of low-quality
sequences. The raw cDNA reads were assembled using New-
bler 2.3 software. Both the raw cDNA reads and assembled
isotigs (including contigs) were sorted by our in-house pro-
gram ConoSorter. After translation and motif searching using
parameters generated from the ConoServer database, 17,215
and 50 peptide precursors were retrieved from the raw data
and the isotigs, respectively. These peptide precursors were
manually examined according to homology analysis gener-
ated by the ConoSorter program. Interestingly, only a small
fraction of the total number of conopeptide precursors found
in the raw data were retrieved from the assembled isotigs,
indicating that genetic diversity is underestimated if only
isotigs are analyzed. Overall, 662 precursors were character-
ized as putative conopeptide sequences based on the con-
served precursor structures. Because the raw cDNA reads
library was not normalized, the level of mRNA transcription
could be inferred from the number of cDNA reads that coded
for each conopeptide (19).
Dramatic differences at the mRNA level were observed
between the different conopeptide precursors. Isoform
MiEr95, belonging to the O1 gene superfamily, largely domi-
nated the transcriptome with 4128 cDNA reads, whereas 495
putative conopeptide precursors were identified with only 1
cDNA read. These rare transcripts constituted 75% of the
total putative conopeptide precursors retrieved (Fig. 1). In
addition to these sequences, 35 high-level precursors (10
cDNA reads) and 132 low-level precursors (2 to 10 cDNA
reads) were also identified.
Using a 75% signal peptide homology cut-off (17, 19), we
clustered the 662 putative conopeptide precursors into eight
known (i.e. O1, O2, D, M, T, I2, L, and P) and eight putative
new (1 to 8) gene superfamilies. The signal peptides and
cysteine frameworks are listed in Table I. The identification of
known gene superfamilies was confirmed using the ConoPrec
tool in ConoServer. Conopeptide isoforms from all three pre-
viously discovered superfamilies (O1, D, and I2) from C. miles
(26–28) were observed. However, only 3 (MiEr95, MiEr93, and
Ml20.1) of the 10 known sequences described in the literature
were identified in this transcriptome, probably because of the
well-known phenomena of intraspecific variation in cone
snails (24, 30, 31); previous discoveries were made using
venom pooled from 9 to 15 specimens. In addition to these
known sequences, new isoforms from five other gene super-
families (M, O2, L, T, and P) were also found. Finally, eight
putative new gene superfamilies (coded SF-mi1–8) were iden-
tified. SF-mi1 and -2 are closely related to superfamily M
(64% and 57%), whereas SF-mi3 is closely related to super-
family O2 (69%). SF-mi4, -5, and -7 contained only two cys-
teine residues in their mature conopeptides; they all showed
less than 50% homology to the signal peptides of other
FIG. 1. Isoforms and transcription levels of putative conopeptides. A, variations in the level of transcription. Only 5% of the putative
sequences had more than 10 cDNA reads, 20% of the putative sequences had moderate cDNA reads of 2 to 10, and 75% of the putative
sequences were present as rare transcripts with only a single cDNA read discovered for the full-length precursor. B, isoforms of superfamily
O1. C, isoforms of other known superfamilies. D, isoforms of eight putative new superfamilies.
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known superfamilies. In contrast, SF-mi6 and -8 had eight
cysteine residues in their mature peptides, and their signal
peptides were  60% homologous to M and I2, respectively.
The total numbers of isoforms and cDNA reads for each
superfamily are plotted in Fig. 1. Overall, the greatest number
of isoforms was discovered for superfamily O1, accounting for
approximately four times more sequences than the isoforms
from the remaining superfamilies combined, irrespective of
read number (Fig. 1B). Only four other known superfamilies
(O2, M, L, and I2) contain isoforms with high-level cDNA reads
(10 reads). D and T superfamily isoforms display only low-
level cDNA reads (2 to 10 reads and 1 read, respectively). Four
identified isoforms belonged to the P superfamily, all with only
one cDNA read (Fig. 1C). Some isoforms in the three putative
new superfamilies were identified with high cDNA reads (SF-
mi2, -4, and -7). The remaining five putative new superfamilies
had low- or very low-level cDNA read numbers (Fig. 1D).
Proteomic Data Analysis—To interrogate our transcriptomic
sequences at the peptide level, we employed a proteomic
strategy involving LC-ESI-MS and LC-ESI-MS/MS to uncover
the complexity of C. miles dissected venom. To improve
MS/MS fragmentation, the whole venom was reduced and
alkylated prior to digestion (32) by either endo-GluC or trypsin.
The total ion chromatogram (Fig. 2) illustrates the mass profile
of the native venom sample. The pooled dissected venom of
C. miles from three specimens was complex; nevertheless, 9
out of the 10 previously published conopeptide sequences
from C. miles could be identified as major components (see
Fig. 2). MS/MS coverage was obtained across all gene pre-
cursors regardless of their level of transcription; that is, some
mRNA precursors with high-level cDNA reads could be iden-
tified at the peptide level, and surprisingly some mRNA tran-
scripts with low-level and very low-level cDNA reads were
confirmed at the peptide level as well. Specific examples are
illustrated in the following sections.
Conotoxin Precursors, Mature Peptides, and Cysteine
Frameworks—From the 662 putative conopeptide sequences
identified in the venom gland transcriptome of C. miles, only
those that complied with the following four criteria were se-
lected for further analysis: (i) the mature conopeptide region
should contain more than four cysteine residues; (ii) the full
length of the mRNA precursor must be validated by two or
more cDNA reads; (iii) mutations should occur in the mature
region excluding propeptides (identical mature peptides from
different propeptides can complicate the integration process
of the transcriptomics and proteomics); and (iv) the predicted
mature peptides should contain an uninterrupted canonical
cysteine framework (or frameworks) within the gene super-
family (i.e. no odd-number cysteines due to single cysteine
residue mutation). The sequences of 48 conotoxin precursors
selected with these criteria are shown in Fig. 3. ConoPrec was
TABLE I
Representative signal sequence(s) and cysteine framework for C. miles superfamilies
Gene superfamily Signal sequence(s) Cysteine pattern Framework
O1 MKLLCVLIVAMLPLMACHLIIA C-C-CC-C-C VI/VII
MKLTCALIITLLFLSITAG
O2 MEKLTVLILVATVLLTIQVLG C-C-CC-C-C-C-C XV
D MPKLEMMLLVLLILPLSSFSAA C-CC-C-CC-C-C-C-C XX
M MSKLGVVLFIFLVLFTMATLQLDA CC-C-C-CC III
L MKLSVMFIVFLMLTMPMTDG C-CC-C XXIV
T MCCLPVFIILLLLIPSAS CC-CC V
I2 MMCRLTSLCCLLVIVLLNSAVDG C-C-CC-CC-C-C XI
P MHLSLAGSAVLVLLLLFALGNFAGVQP C-C-C-C-C-C IX
SF-mi1 MSKTGLVLVVLYLLSSPVNL C-C-C-CC-C-C-C XIII
SF-mi2 MRFFFLLLTVALFLTSITG C-C-C-CCC-C-C Novel
SF-mi3 MGILTVLLPLVAVLVLT C-C-CC-C-C VI/VII
SF-mi4 MTPRMNLLLMTFVVMTVPLLLA C-C –
SF-mi5 MGLLPLQTSVLLLAPVVHQ C-C –
SF-mi6 MSTLGKVLLLLLLLLPLGNP C-C-CC-C-C-C-C XV
SF-mi7 MSTLNPLTRIYWRASLVPAAAVIPAPIAYT C-C –
SF-mi8 MMYRLTLFCCLLLVIVPLNMA C-C-C-CC-C-C-C XIII
FIG. 2. Total ion chromatogram of C. miles. LC-MS run on the
TripleTOF 5600 revealed the complexity of the dissected venom of C.
miles. Detected masses corresponding to the previously identified
conotoxins are indicated.
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used to predict the mature peptides, and the mature se-
quences that could be identified with an MS/MS confidence
value of more than 99% are listed in Table II.
Superfamily O1—The numbers of cDNA reads and cono-
toxin variants were greatest in this superfamily, with a total of
5912 cDNA reads and 33 isoforms that clustered into two
subfamilies (Fig. 3). The first subfamily contained 22 isoforms
(Mi001–Mi022), including the known MiEr95 (Mi001). The full
precursor of this subfamily contained a pre-sequence cleav-
age site (ER or KR), resulting in predicted mature peptides
containing between 31 and 52 amino acids and a Type VI/VII
framework. MiEr95 was the most highly expressed isoform in
the whole transcriptome, with 4128 cDNA reads for the full
precursor and 7667 for the mature peptide alone. In addition
to MiEr95, 14 variants were also unambiguously identified via
MS/MS within this subfamily (Table II).
The second subfamily (Mi023–Mi033) had a different signal
sequence than the first subfamily. The full precursor of this
subfamily had a presequence cleavage site (KR, ER, and RR),
resulting in predicted mature peptides comprising 30 to 40
amino acids, three disulfide bonds, and a classic Type VI/VII
(C-C-CC-C-C) framework. Remarkably, isoforms in this sub-
family were enriched in acidic residues (24%) and contained
more than twice as many aspartic acid residues (17%) as
glutamic acid residues (7%). Such high levels of negatively
charged residues appear remarkable, as the average frequen-
cies of aspartic acid and glutamic acid residues in mature
conopeptides are only 4.4% and 3.7%, respectively (13).
Although the known MiEr93 (Mi023) has smaller loop sizes
and contains more basic residues than other precursors, it
was included in this subfamily based upon its conserved
signal peptide. MiEr93, along with three other sequences
FIG. 3. Alignment of 48 conotoxin precursors. Sequences are clustered by gene superfamily according to their signal peptide, with gaps
introduced to optimize alignment. Color-coding has been applied using the following scheme: cysteine residues are in yellow, negatively
charged residues are in red, and positively charged residues are in blue.
The Venom of C. miles
3828 Molecular & Cellular Proteomics 12.12
within this subfamily, was identified via MS/MS analysis
(Table II).
Superfamily O2—Three precursors (Mi035–037) with 100%
signal sequence homology and one precursor (Mi034) with
82% homology to the O2 superfamily were identified. All the
full-length precursors contained an obvious presequence
cleavage site (K/R-R), resulting in predicted mature peptides
containing 29 to 39 amino acids. Two cysteine frameworks
exist in the O2 superfamily, including three precursors
(Mi035–037) with a Type XV (C-C-CC-C-C-C-C) framework
that were identified via MS/MS after enzymatic digestion. In
contrast, the predicted mature peptide for Mi034 contained
only six cysteine residues within the Type VI/VII (C-C-CC-C-C)
framework. However, despite the abundance of this sequence
at the transcript level (42 cDNA reads), MS/MS support had a
confidence value of 50%.
Superfamily D—Of the two superfamily D precursors (Mi038
and Mi039), Mi038 had been previously discovered (Ml20.1)
(26). Both contain a pre-sequence cleavage site (R-R). Ml20.1
and the novel Mi039 were expressed with four and two cDNA
reads, respectively. MS/MS analysis confirmed both se-
quences at the peptide level with 69% of confidence value.
Superfamily M—No conopeptides from superfamily M had
been previously discovered fromC. miles. One precursor (Mi040),
with a signal peptidewith 96%homology to classicM superfamily
members, was discovered with 32 cDNA reads. It contained an
obvious presequence cleavage site (RR), resulting in a short ma-
ture peptide of 18 amino acids and cysteine framework III (CC-C-
C-CC). The mature sequence was confirmed via MS/MS analysis
and contained three sequential proline residues.
Superfamily L—One precursor (Mi041) from the L super-
family was identified with an L-K cleavage site predicted by
ConoPrec (13, 33). Precursor Mi041 had 18 cDNA reads,
and the predicted mature peptide was identified with good
MS/MS coverage, containing only 11 amino acid residues.
This peptide was a member of the recently reported cys-
teine framework XXIV (C-CC-C) (18) and included three
proline residues in the two loops despite its short sequence.
Superfamily T—One precursor (Mi042) with 100% se-
quence homology to classic T superfamily members was
identified with five cDNA reads and an RR cleavage site. The
sequence of the resulting short mature peptide (13 residues)
had a classic T superfamily cysteine framework V (CC-CC)
that was confirmed by MS/MS.
TABLE II
MS/MS sequences identified at 99% confidence value
Sequence
number MS/MS (99% confidence)
Number of
reads
Cysteine
modification
Post-translational
modifications
Precursor
m/z z
Mi001 ECREKGQGCTNTALCCPGLECEGQSQGGLCVDN 4128 1134.80 3
Mi003 ECREKGQGCTNTALCCPGLECEGRSQGGLCVDN 5 Y 1Hyp 1007.87 4
Mi004 ECRKKGQGCTNTALCCPGLECEGQSQGGLCVDN 3 Y 996.63 4
Mi005 GQGCTNTAFCCPGLECEGQSQGGLCVDN 2 Y 1092.73 3
Mi007 ECREKGQGCTDTALCCPGLECEGQSQGGLCVDN 2 Y 1Hyp 1001.13 4
Mi008 ECREKGQGCTNTALCCPGLECEGQSQGGWCVDN 2 Y 1015.11 4
Mi009 EKGQSCTNTALCCPGLECEGQSQGGLCVDN 2 Y 1177.11 3
Mi010 VCREKGQGCTNTALCCPGLECEGQSQGGLCVDN 21 Y 989.37 4
Mi012 ECKGKGQGCTNTA 2 Y 745.83 2
Mi013 ECREKGQGCTNTALCCPAVECEGQSQGGLCVDN 2 1Hyp 1140.13 3
Mi014 ECREKVQGCTNTALCCPGLECEGQSQGGLCVDN 2 1148.80 3
Mi015 ECREKGQGCNTALCCPG 2 Y 1078.91 2
Mi016 ECREKGQGCTNTALCCPGLECEGQSQGGCA 29 1Hyp,NH2 1016.44 3
Mi018 ECREKGQGCTNAA 2 Y 780.81 2
Mi020 ECREKGQGCTNTALCCPGLECEGQSQGGCAWTI 2 Y 1Hyp,NH2 1008.13 4
Mi023 GGGCSQHPHCCGGTCNK 9 Y 1Hyp 683.91 3
Mi025 PTDHDCCSGNCIDEGGNGVCAFVREDVPKLY 4 829.10 4
Mi026 PTNHDCCSGNCIDEGGNGVCAFVREDVPKLY 2 828.86 4
Mi027 CTDDSQFCNPSNHDCCSGKCIDEGDNGICAIVPENS 31 948.37 4
Mi035 CPNLTCKCSGSPLCTRYRCKT 12 2Hyp 592.27 4
Mi036 CKCTSAPDCNFYKCRT 8 1Hyp 619.26 3
Mi037 CKCSGSPLCTRYSCQA 5 1Hyp 861.86 2
Mi040 DCCSLSACVPPPACECCK 32 1Hyp 922.85 2
Mi041 SSCPPACCPTC 18 534.68 2
Mi042 CCPKKPYCCPG 5 NH2 599.25 2
Mi043 VPCQQGGGK 10 Y 1Hyp 493.73 2
Mi044 DRPECYNCFPNDDGHCVGTCCGEDSCKGGIRGCGCV 3 754.69 5
Mi045 CMPCGGECCCEPNSCIDGTCHHE 8 Y 1036.28 3
Mi046 EDCGSDCAPCGGECCCEPNSCIDGTCHHESSPN 12 1Hyp 1125.70 3
Notes: Cys-mod (Y), cysteine alkylation by maleimide; Hyp, hydroxyproline; NH2, C-terminal amidation. Underlined residues indicate
post-translational modification sites.
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Superfamily I2—One sequence (Mi043) was found in the I2
superfamily with 13 cDNA reads. The I2 superfamily has a
different precursor structure, with the mature sequence
placed between the signal peptide and the propeptide re-
gions. There was a post-cleavage site (ER) for Mi043, leav-
ing the predicted mature peptide with 39 amino acid resi-
dues, including 8 cysteine residues and an amidated C
terminus. The cysteine framework was Type XI (C-C-CC-
CC-C-C), and MS/MS identified a partial sequence of a
tryptic digest (Table II).
Superfamily SF-mi1—One precursor (Mi044) was identified
whose signal peptide was 64% homologous to the M super-
family, though with a different cysteine framework. The full
precursor contained a presequence cleavage site (E-R), re-
sulting in a predicted mature peptide with 35 amino acids and
four disulfide bonds in a Type XIII framework (C-C-C-CC-C-
C-C). The predicted mature sequences contained six acidic
residues and three basic residues. Despite only moderate
transcription at the mRNA level (three cDNA reads), the ma-
ture peptide of Mi044 produced good MS/MS coverage.
Superfamily SF-mi2—This novel superfamily contained two
precursors (Mi045 and Mi046), with signal peptides having
only 57% homology to the M superfamily. Both gave a mod-
erate number of cDNA reads (8 and 12) and contained a novel
cysteine framework with eight cysteine residues (C-C-C-
CCC-C-C). The pre-cleavage sites were predicted after the
first K (position 29) by ConoPrec to generate mature peptides
of 39 amino acids with an eight-residue-long N-terminal tail. A
conserved arginine residue at position 35 produced a second
cleavage site, resulting in mature peptides 33 amino acids in
length with a two-residue-long N-terminal tail. Both the K29
and R35 cleavage sites were confirmed by MS/MS sequenc-
ing, with the shorter peptide dominating the mature products
for Mi045 and Mi046.
Superfamily SF-mi3—Two precursors (Mi047 and Mi048)
contained a signal peptide with 69% homology to the O2
superfamily that was distinct from SF-mi1 and SF-mi2 signal
peptides and their corresponding cysteine frameworks. We
therefore classified these two sequences as belonging to a
new superfamily. The full precursor contained both a prese-
quence cleavage site (RR) and a post-cleavage site (RR) that
resulted in a predicted mature peptide of 33 amino acids and
three disulfide bonds with a classic VI/VII (C-C-CC-C-C)
framework. However, MS/MS coverage was weak for both
peptides, even after Glu-C enzymatic treatment.
Messiness at the mRNA Level—We identified a large num-
ber (600) of putative conopeptides of three distinct types
comprising a series of single amino acid variants (type I),
pre-mature stop codons (type II), and frame shifts (type III)
(see Table III). Some of these variations produced conopep-
tides with alternative cleavage sites (types I and III), inter-
rupted cysteine frameworks (types I, II, and III), and highly
variable isoforms with deletions and elongations (types II
and III).
Interrupted Cysteine Framework—Each of the type I–III vari-
ations can interrupt the normally conserved cysteine frame-
work patterns, as illustrated by the examples from superfamily
O1 listed in Table III. The single mutation of a cysteine residue
(type I) creates an odd number of cysteine residues, allowing
dimers to be formed. Pre-mature stop codons (type II) pro-
duce truncated isoforms as well as truncated frameworks.
Frame shifts (type III) produce highly variable isoforms includ-
ing cysteine deletions/additions or loop sizes that are signifi-
cantly different from those in the canonical cysteine frame-
works. Alternative cleavage sites were also observed and are
shown in Table III. These interrupted cysteine frameworks
gave high cDNA reads, though no MS/MS data were found to
support their expression in the venom. Why such precursors
were not identified at the peptide level is unclear, but it may
have been the result of unidentified heterodimer formation. A
similar phenomenon was observed at the cDNA level by Terrat
et al., and sequences containing five and seven cysteine
residues have been listed in their new scaffolds table (23).
Rare Transcripts—An unusual aspect of the C. miles tran-
scriptome is that 75% of the 662 putative conopeptides
were identified as rare transcripts with only single cDNA reads
retrieved for the full-length precursors (Fig. 2A). Some of these
may result from sequencing artifacts, as the sequencing error
rate for the 454 is reported to reach 1% (34). Therefore, out
of the total of 6271 cDNA reads encoding full-length cono-
peptide precursors, about 63 are estimated to result from
sequencing errors, and as 495 isoforms are detected with a
TABLE III
Interrupted cysteine frameworks from the C. miles O1 superfamily
Variations Sequences Copies
Reference precursor KRECREKGQGCTNTALCCPGLECEGQSQGGLCVDN 4128
Type I single mutant New pre-cleavage site KRERREKGQGCTNTALCCPGLECEGQSQGGLCVDN 3
5-cysteine framework KRECREKGQGCTNTALCYPGLECEGQSQGGLCVDN 2
Type II pre-mature stop
codon
Truncated framework KRECREKGQGCTNTALCCPG 223
Type III frame shift Truncated framework KRECREKGQGCTNTALAAPARM 7
New post-cleavage site KRECREKGQGCTNTALFPCIPSQWNSGKKVRVVLTQLFAAPA 5
Different loop size KRECREKGQGCTNTALCCPGLDVKARVKVVCAWTIKWRLMFPLGALSCAA 3
Notes: Underlined residues indicate sequence changes caused by mutations. N-terminal and post-cleavage sites are shown in italics.
Cysteine residues are in bold to highlight frameworks.
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single cDNA read, the sequencing error accounts for only
one-eighth of these. Importantly, many of these rare reads are
unrelated to common transcripts and thus unlikely to be read
errors. Moreover, a number of these rare transcripts produced
confident MS/MS coverage (see Table IV), with MS/MS vali-
dating the new single cDNA read isoforms from D and SF-mi1
superfamilies and the propeptides for SF-mi4 and SF-mi8
superfamilies. In addition, enzymatic digestion allowed partial
sequence identification for a new isoform from the M super-
family via MS/MS. These proteomic results confirm that the
single cDNA read transcriptomic sequences previously over-
looked contribute to diversity at the mRNA level and that the
majority of this “transcriptomic messiness” does not simply
arise from 454 systematic sequencing errors.
DISCUSSION
Deep sequencing combined with mass spectrometry was
used to discover new peptides and gene families from the
worm-hunting cone snail C. miles. From the 662 putative
conopeptide precursors retrieved from transcriptomic data,
48 conotoxin sequences within seven known superfamilies
and three new superfamilies were analyzed in detail. In addi-
tion, one new cysteine framework and eight other known
cysteine frameworks were revealed (Table I). High-confidence
MS/MS matches (99% of confidence value) within the pro-
teomic data were achieved for 29 peptides. Prior to this work,
only three superfamilies had been identified from the venom
of C. miles (26–28). Our present work confirmed the presence
of these three superfamilies, along with four other known
superfamilies and three novel superfamilies.
We obtained 60% MS/MS coverage for our selected set
of 48 transcriptomic sequences, similar to results obtained in
our previous study of C. marmoreus (66% MS/MS coverage
of 105 transcriptomic sequences) (19). Becasuse the correla-
tion between mRNA and protein levels often deviates from a
simple 1:1 relationship, levels of expression likely differ de-
pending on the nature of the peptide (35, 36), with nuclear
retention potentially suppressing expression even for tran-
scripts with higher copy numbers. Modern MS can provide
unambiguous identification of peptides at the MS/MS level;
however, the efficiency of MS fragmentation depends upon
the abundance, sequence composition, and local chemical
environment (37). Thus, limitations of current MS/MS likely
contribute to incomplete reconciliation between proteomic
and transcriptomic data.
Remarkably, the transcriptome of the C. miles venom duct
was largely dominated by one toxin superfamily, in terms of
both the level of mRNA transcription and the number of cono-
peptide isoforms present. Indeed, superfamily O (including O1
and O2) accounted for more than 90% of all the conopeptide
cDNA reads identified. This high level of transcription for the
superfamily also generated a high number of isoforms (77%).
Interestingly, the O superfamily is also abundant (44%) in the
transcriptome of another worm-hunting cone snail, C. pulica-
rius (22). The O superfamily has diverse pharmacology, with
-, O, , -, and -conotoxins targeting voltage-gated cal-
cium, sodium, and potassium channels (38). Although most
biologically active O-superfamily members characterized so
far are identified from fish-hunting species (17, 39), the prev-
alence of O-superfamily toxins in worm-hunting cone snails
suggests an important role in prey capture across diverse
phyla.
Surprisingly, no precursors from the A superfamily were
discovered in the C. miles transcriptome, despite its being the
most widely distributed gene family (38). Interestingly, al-
though A superfamily isoforms Pu1.1–Pu1.3 were previously
discovered in the venom of C. pulicarius (40), they were not
detected in the venom gland transcriptome (22). At the protein
level, we were also unable to identify A-superfamily-related
peptides when using NCBI cone-snail-related proteins as the
searching database. These results suggest that A-superfamily
conopeptides are not critical for vermivorous cone snails. In
TABLE IV
Rare transcripts with MS/MS coverage
Superfamily Sequence
Cysteine
modification
Post-translational
modifications
Precursor
m/z
z
D MPKLEMMLLVLLILPLSSFSAAGDKVVQGDRRSDGLAR Hyp 597.62 3
YLQRGGRDVQDCQVVTPGSKWGRCCLNRVCGPMCCPAS
HCYCIYHRGKGHGCSC
M MLKVGVVFLVFLVLLSLADSWNGDNPGRQRGEKQSPQR Y Hyp 521.75 2
NVFRSNLRKYNSYQKRRCANSTPCGECTDEGKICQVQP
GGKGTCGECVPNTR
SF-mi1 MSKTGLVLVVLYLLSSPVNLQQNEDDQAFSKIETRDRP 946.61 4
ECYNCFPNDDGHCVGTCCGEDSCKGGIRGCGCL
SF-mi4 MTPRMNLLLMTFVVMTVPLLLTQPNVRCETNDNGDIIC Y Pyro-glu 899.07 3
KKANGQTLHNPDRSDNGTTDLRQEGPLMTALRGPWHR
SF-mi8 MMYRLTLFCCLLLVIVPLNMARKSGMLARWNEVCSTSS Y 1104.87 2
CGCNQDERCCLECPLRIAEKQLSVMCRTFNADTKELTA
CRMLQTDSDS
Notes: 99% confidence regions highlighted in bold. Cys-mod (Y), cysteine alkylation by maleimide; Hyp, hydroxyproline; Pyro-glu,
glutamine to pyroglutamate. Underlined residues indicate post-translational modification sites.
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contrast, sequences belonging to superfamily D, which tar-
gets nicotinic acetylcholine receptors, were found, albeit at
low transcription levels, but they were reasonably abundant at
the peptide level, with several identified via MS/MS analysis.
Interestingly, all the D-superfamily peptides (30 isoforms)
reported so far are from three clades (i.e. Rhizoconus, Rhom-
biconus, and Strategoconus) of worm-hunting cone snails
that include C. miles (41).
Surprisingly, a high density of aspartic and glutamic amino
acid residues was found in the mature sequences of three
groups of C. miles conotoxins: SF-mi2, SF-mi3, and one
subgroup of O1 superfamilies. In SF-mi2, four glutamic and
three aspartic residues are evenly distributed along the se-
quences of these five-loop peptides, indicating that these
residues might be exposed in its novel cysteine framework
that includes three consecutive cysteine residues and very
small loop sizes (3–2-3–4-4). Three sequential cysteine resi-
dues (CCC) have also been found in two other conotoxin
frameworks (II (42) and IXI (43)) and in funnel-web spider
atracotoxins (44). In contrast, SF-mi3 superfamily mature
peptides containing acidic residues are mostly distributed in
loop 1 and loop 2 of the peptides, reminiscent of O1 super-
family subgroup peptides that contain aspartic acids in loop 1,
loop 2, and loop 4. In comparison to these acidic peptide
families, the conantokins have significantly more glutamic
acid than aspartic acid residues (E:D 2.5:1) and are cysteine
poor. In this NMDA antagonist peptide family, the heavily
-carboxylated glutamic acid residues are clustered on one
face of the helical structured N terminus in an arrangement
that might bind calcium (45–49). -Carboxylation has also
been observed in C. miles acidic peptides, but infrequently.
In addition to new superfamilies and cysteine frameworks,
the C. miles transcriptome contained the largest number of
toxin variants yet identified at the mRNA level from a single
Conus species. From the 600 putative conopeptide se-
quences discovered, we found (i) mutations in the propeptide
region only but identical mature peptide, (ii) interrupted cys-
teine frameworks, and (iii) isoforms that appeared at very low
transcription levels. Strikingly, the majority of this mRNA
messiness was also transcribed at low levels, explaining why
these rare sequences have eluded previous studies using
traditional transcriptomic approaches. Nevertheless, the di-
versity discovered here at the genetic level is impressive,
suggesting that it might play an evolutionary role. Previously,
we reported a high level of sequence diversity at the peptide
level in the molluscivorous C. marmoreus, also at background
levels (19). Many of these peptides were N- and C-terminal
truncations of the major mature peptide toxins, likely resulting
from promiscuous enzymatic activity that we describe as
“variable peptide processing” (19). Although not analyzed to
the same extent, variable peptide processing has also been
observed in the venom of C. miles (data not shown). Based on
the results from C. miles, it now appears that both genetic and
post-translational messiness contribute to the overall cono-
toxin diversity. A theory recently developed in the field of
enzymology stipulates that the origins of evolutionary innova-
tions are the results of infidelity and heterogeneity inherent to
most biological processes, leading to genetic and phenotypic
variations (29). We propose that background genetic diversity,
in addition to the peptide diversity arising from variable pep-
tide processing, contributes to venom peptide diversity.
Venom peptide messiness thus provides a nascent pool of
accumulated chemical diversity that could contribute to the
rapid evolution of venom peptides with new functions and
provides a novel mechanism of adaptation in cone snails.
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EFish venoms remain almost completely unstudied despite the large number of species. In
part this is due to the inherent nature of fish venoms, in that they are highly sensitive to
heat, pH, lyophilisation, storage and repeated freeze–thawing. They are also heavily
contaminated with mucus, which makes proteomic study difficult. Here we describe a
novel protein-handling protocol to remove mucus contamination, utilising ammonium
sulphate and acetone precipitation. We validated this approach using barb venom gland
tissue protein extract from the blue-spotted stingray Neotrygon kuhlii. We analysed the
protein extract using 1D and 2D gels with LC–MS/MS sequencing. Protein annotation was
underpinned by a venom gland transcriptome. The composition of our N. kuhlii venom
sample revealed a variety of protein types that are completely novel to animal venom
systems. Notably, none of the detected proteins exhibited similarity to the few toxin
components previously characterised from fish venoms, including those found in other
stingrays. Putative venom toxins identified here included cystatin, peroxiredoxin and
galectin. Our study represents the first combined survey of gene and protein composition
from the venom apparatus of any fish and our novel protein handling method will aid the
future characterisation of toxins from other unstudied venomous fish lineages.C
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1D gel
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• These results show an efficient manner for removing mucus from fish venoms.
• These results are the first insights into the evolution of proteins present on stingray
venom barbs.
© 2014 Published by Elsevier B.V.TE
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Fig. 1 – The blue-spotted stingray Neotrygon kuhlii and its
venom delivery system. A) A photograph of a collected
specimen of N. kuhlii fromMoreton Bay, Australia. The arrow
highlights the location of the venom delivery system (barb)
on the caudal appendage. B) Stereo microscopy photographs
of the retroserrate venom spine of N. kuhlii at different
magnifications. Left— ventral view showing the median
ventral ridge to which the venom glands (not present here)
flank; right— dorsal view.U
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1. Introduction
Venom systems are important ecological innovations that
have evolved independently on many occasions throughout
the animal kingdom [1,2]. Venoms are bioactive secretions
that are utilised for a variety of functions, such as defence,
competitor deterrence or predation [1,2]. Within vertebrates,
reptiles and fishes represent the vast majority of all venom-
ous species [3–6]. In contrast to the considerable research
effort undertaken to elucidate the composition of venoms
from reptiles, in particular snakes due to their medical
importance [7], little is known about the composition of
venoms present in bony and cartilaginous fishes. In contrast
to snakes, fishes appear to primarily use their venom
systems to protect themselves from predation. Interestingly,
this defensive venom system appears to have evolved
independently on many occasions in different cartilaginous
(sharks, chimaeriformes and stingrays) and bony fish (catfish
and teleosts) lineages [3–5]. The majority of venomous fish
species use spines to inject venom into potential predators—
these spines are typically located dorsally, although a
number of species have pectoral, caudal or clitheral venom
apparatuses [3,4].
Fish venoms are inherently difficult to study — they have
been shown to be highly labile and sensitive to heat, pH,
lyophilisation, storage and repeated freezing and thawing [8].
Furthermore, fish venom samples are typically mucus rich,
causing undesirable issues during protein separation steps
typically applied during proteomic methodologies. The
collection of venom itself can also be problematic because the
‘venom gland’ is typically not a well-defined storage structure,
instead often simply a grouping of secretory cells presentwithin/
along a groove in a spine.
Despite these difficulties, some fish venoms have been
partially characterised pharmacologically and a small number
of fish venom toxins have been purified and their toxic
activities characterised [8,9]. Whilst fish venoms are not
typically considered to be capable of causing mortality, the
incidence of envenomings may be high, and such events can
result in significant clinical sequelae in envenomed victims,
such as paralysis, erythema, itching, and persistent local pain
disproportionate to the wound size [4,8–10]. Consistent
with the hypothesis that defensive venoms likely evolve
slowly due to having a conserved biological activity, fish
venoms have been found to produce broadly similar
pathologies despite their apparent independent evolution
[4,9]. Broadly speaking, the biological activity of and the
resulting pathology induced by fish venoms appear to be
intrinsically linked to the presence of cytolytic components
[9], with extreme local pain being the dominant feature of
envenomations.l, A ray of venom: Combi
lue-spot..., J Prot (2014), hO
F
Despite the relative medical importance of fish venoms
and the pharmacological interest in their toxins, as described
above, their toxic composition remain almost completely
uncharacterised at the molecular level. At the time of writing
there are only 21 fish toxin sequences in the UniProt database
(http://www.uniprot.org) and only one transcriptomic study of
a fish venom gland has been published [11]. The absence of
basic proteomic studies on venomous fishes is particularlyned proteomic and transcriptomic investigation of fish venom
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surprising, yet only a few recent studies have attempted to
investigate this subject [12,13].
Here we address this knowledge deficiency by characterising
the composition of venom from the blue-spotted stingray
(Neotrygon kuhlii). Stingrays (Chontrichthyes: Myliobatoidei) are a
groupof cartilaginous fishes that are commonly foundoccupying
the demersal zone of tropical and subtropical marine waters,
although some species are found in freshwater and pelagic
environments. Most rays have retroserrate spines located on
their caudal appendage (Fig. 1) — the spines are layered by
dermis, venom glands and epidermis and then encapsulated by
an integumentary sheath, resulting in a structure termed a ‘barb’
[3]. This venom system is used defensively to protect the animal
from predation and potential aggressors.
Whilst the venoms of most stingrays remain completely
unstudied, the venom activities of the South American freshwa-
ter stingrays of the family Potamotrygonidae have been partially
characterised. Potamotrygon venoms induce oedematogenic and
nociceptive responses in mice, are capable of causing necrosis
and exhibit some proteolytic and hyaluronidase activity [14,15].
Two small peptides, named porflan and orpotrin, have been
isolated and characterised from Potamotrygon venom and they
have been demonstrated to (i) interfere with membrane phos-
pholipids through an as yet uncharacterized mechanism that
results in pro-inflammatory activity and (ii) act on large arterioles
of the microcirculatory network resulting in vasoconstriction,
respectively [16,17].
In contrast to Potamotrygon stingrays, the blue-spotted stingray
(N. kuhlii) (Fig. 1) inhabitsmarineenvironments, and is found in the
tropical and sub-tropical waters of the Indo-Pacific oceans. Here
we apply a combined transcriptomic and proteomic approach to
characterise the composition of venomextracts collected from the
barb of this species. Our study represents the first combined
survey of gene and protein composition from the venom
apparatus of any fish and our analyses reveal a variety of proteins
that are completely novel to animal venom systems. We also
describe a novel protein handling method that will be of great
value to other researchers interested in characterising the protein
composition of toxins found in problematic fish venom samples.210
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2.1. Specimens
N. kuhlii specimens were collected in Moreton Bay, Queens-
land, Australia under collection permit QS2013/MAN143 and
animal ethics approval SBS/345/12/ARC. Spine samples were
collected and immediately snap frozen in liquid nitrogen
before storage at −80 °C until use. A total of five spines were
used for proteomic analyses and five for transcriptomics. In
total this amounted to spines sampled from 10 specimens.
2.2. Transcriptomics225
226
227
228Stingray spines were scraped to collect venom secretory
material, which was then homogenised and the RNA extracted
using the TRIzol Plus RNA Purification Kit (Life Technologies).
RNA quality was assessed using a Bioanalyser (Agilent) andPlease cite this article as: Baumann K, et al, A ray of venom: Combi
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ribosomal RNA removed using the Ribo-Zero rRNA Removal Kit
for Human/Mouse/Rat (epicentre). The RNA-Seq library was
prepared from 50 ng of the enriched RNA material using the
ScriptSeq v2 RNA-Seq Library Preparation Kit (epicentre), follow-
ing 12 cycles of amplification. The sequencing library was
purified using AMPure XP beads (Agencourt), quantified using
the Qubit dsDNA HS Assay Kit (Life Technologies) and the size
distribution assessed using a Bioanalyser (Agilent). The library
was sequenced on a single lane of an Illumina MiSeq machine
housed at the Centre for Genomic Research, Liverpool, UK,
generating ~3 million paired-end 250 bp reads. The ensuring
read data was quality processed, first by removing the presence
of any adapter sequences using Cutadapt [18] and then by
trimming low quality bases using Sickle (https://github.com/
najoshi/sickle). Reads were trimmed if bases at the 3′ end
matched the adapter sequence for 3 bp or more, and further
trimmed with a minimum window quality score of 20. After
trimming, reads shorter than 10 bpwere removed. The sequence
data was assembled using the de novo assembly algorithm in
CLC Genomics Workbench v4.9 (CLCBio), with the paired-end
read criterion and constraining the contig size to >350 bp in
length. The assembled contigs were subsequently annotated
with Blast2GO using standard parameters [19]. The sequence
data has been submitted to the sequence read archive (SRA)
database of GenBank (http://www.ncbi.nlm.nih.gov/sra) with the
BioProject number PRJNA240112 and the SRA accession number
SRX481088. Nucleotides are available in Supplementary file 1.
2.3. Protein extraction
The proteins from stingray spine scrapings were extracted
and cleaned using a novel protein extraction and cleanup
method. A solution was prepared on ice using 3.7 g EDTA,
5 mL 200 mM PMSF, 10 mL Triton X-100, 1 L purified water.
The solution was poured over the spines and placed on a
magnetic stirrer overnight (>12 h) at 4 °C. The solution was
then centrifuged at 4500 RCF, 4 °C for 30 min, before 80%
ammonium sulphate saturation (~43% w/v) was added and
the solution placed on a magnetic stirrer at 4 °C and left
overnight (>12 h). The protein-containing precipitate was
then centrifuged at 4500 RCF, 4 °C for 30 min. The superna-
tant was removed and the protein precipitate brought up in
purified water (ratio of 15 parts water to 1 part supernatant),
vortexed for 2 min followed by centrifugation at 14,000 RCF,
4 °C for 30 min. Subsequently the supernatant was diluted 1:9
with cold 1:4 acetone:methanol. The solutionwas placed at -20 °C
and allowed to precipitate overnight (>12 h). The solution was
subsequently centrifuged at 14,000 RCF, 4 °C for 30 min and the
supernatant was discarded. The pellet was left to evaporate at
roomtemperature for 1 h, then resolubilised inpurifiedwater. The
total protein concentration was then measured using a Thermo
Scientific Nanodrop 2000 Spectrophotometer in A280 mode.
Extracted venom proteins were stored at −80 °C.
2.4. Proteomics
2.4.1. One dimensional (1D) SDS-PAGE
Samples were first analysed using 1D SDS-PAGE as previously
described [20]. 60 μg of lyophilised venom protein extraction
was reconstituted inpurifiedwater and 6 μL of standard loadingned proteomic and transcriptomic investigation of fish venom
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dye buffer (150 mM Tris HCl pH 6.8, 300 mM DTT, 6% SDS, 0.3%
Bromophenol Blue, 30% Glycerol). Venom proteins were
reduced by boiling the sample at 100 °C for 4 min. SDS-PAGE
gels, composed of a 12% acrylamide resolving gel (3.3 mL
purified water, 2.5 mL resolving buffer [1.5 M Tris, pH8.8], 4 mL
30% Acrylamide, 100 μL 10% SDS, 100 μL 10% APS, 4 μL TEMED)
and a 5% acrylamide stacking gel (1.4 mL purified water, 250 μL
stacking buffer [0.5 M Tris, pH 6.8], 330 μL 30% Acrylamide,
20 μL 10% SDS, 20 μL 10% APS, 2 μL TEMED), were polymerised
and submerged in running buffer (2.4 g Tris, 11.52 g Glycine,
0.8 g SDS, 800 mL purifiedwater). The venomprotein extraction
sample and 5 μL protein ladder (Precision Plus Protein All Blue
Standards, Bio-Rad) were loaded and an electrical current of
120 Vapplied for 10 min and then increased to 140 V for 60 min.
The gel was removed and stained with Colloidal Coomassie
Brilliant Blue G250 (34% MeOH, 3% Phosphoric Acid, 170 g/L
Ammonium sulphate, 1 g/L Coomassie Blue G250) on a shaker
overnight, then destained with purified water.
Using protocols previously described [21–23] in-gel digestion
was undertaken to extract proteolytic peptides for mass spec-
trometry analysis. Bandswere cut from the gel anddestainedwith
500 μL 50% acetonitrile (ACN), 50 mM ammonium bicarbonate
(ABC) — this process was repeated twice. Proteins were reduced
using 40 μL 10 mM dithiothreitol (DTT) for 30 min at 60 °C, then
alkylated with 40 μL of 55 mM iodoacetamide (IAA) for 30 min in
the dark. The protein bands were rinsed twice with 50 mM ABC,
then dehydrated with 100 μL 100% ACN and rehydrated with 8 μL
of trypsin solution (Sigma, USA) (10 ng/μL in 50 mM ABC) for
10 minat 4 °C. 16 μLof 50 mMABCwasaddedand then incubated
at 37 °C for 16 h. The solution was then transferred to a new
1.5 mL Eppendorf tube (Tube 2) and 50 μL of 50% ACN/1% formic
Acid (FA) added to Tube 1 and the contents vortexed. This solution
was transferred to Tube 2, and the previous step repeated twice.
The solutions in Tube 2 were lyophilised, then reconstituted in
20 μL 5%ACN/1%FA inpolypropylene inserts in glass sample vials
for sequencing using an AB SCIEX 5600 Triple TOF mass
spectrometer machine (AB SCIEX, USA). Samples were first
desalted on a 0.5 × 3 mm C18 trap (Agilent) for 3 min at a flow
rate of 30 μl/min using buffer A (1% ACN/0.1% FA), followed by
separation on a Vydac Everest C18 column (5 μm, 300 Å,
150 mm × 150μm) at a flow rate of 1 μl/min using a Shimadzu
Prominence nanoLC system using a gradient of 10%–60% buffer B
(0.1% FA in CAN) over 30 min (10–60% buffer B over 14 min for
samples from2Dgel spots). Eluted peptidesweredirectly analysed
on a TripleTof 5600 instrument using a Nanospray III interface.
TOFMSscanswereperformedacrossm/z350–1800 (0.5 s) followed
by data-dependent acquisition of up to 20 peptides acrossm/z 40–
1800 (0.05 s) with intensity above 100 counts using a collision
energy spread of 40 ±15 V. Gas 1 was set to 10 psi, curtain gas to
30 psi, and ion spray floating voltage set to 2700 V. Spectra were
analysed with Proteinpilot V4.0 (ABSciex, USA), then protein/
peptides were identified via a UniProt Blast search and searches
against the translated assembled transcriptome database.
2.4.2. Two dimensional gel electrophoresis (2DE)
The N. kuhlii venom extract (300 μg) was reconstituted with
150 μL of rehydration buffer (8 M Urea, 100 mM DTT, 4% CHAPS,
0.5% ampholytes (Biolytes pH 3–10), 0.01% Bromophenol Blue)
and loaded onto a 7 cm IPG stripwith a non-linear pH gradient of
3–10 overnight (8+ h). Using the preset methods (Step 1: 100 V,Please cite this article as: Baumann K, et al, A ray of venom: Combi
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rapid gradient, 50 μamps, 100 V h; Step 2: 500 V, rapid gradient,
50 μamps, 500 V h; Step 3: 1000 V, rapid gradient, 50 μamps,
1000 V-h; Step 4: 4000 V, rapid gradient, 50 μamps, 14,800 V h)
the IPG stripswere isoelectrically focused for a total of 98,400 V h,
then stored at −20 °C until needed. The IPG stripwas equilibrated
using 5 mL of reducing buffer (150 mg DTT, 10 mL equilibration
buffer [36 g Urea, 4 mL 50% Glycerol], 6.25 mL gel buffer [1.5 M
Tris HCl pH 8.8], 2.5 mL 20% SDS, topped up to 10 mL with
purified water) for 10 min, then 5 mL alkylating buffer (200 mg
IAA, 10 mL equilibration buffer) for 20 min. The IPG strip and
protein ladder (Precision Plus Protein All Blue Standards,
Bio-Rad) were embedded on the top of a 12% SDS-PAGE gel
(7 cm × 7 cm × 1 mm) (3.3 mL purified water, 2.5 mL resolving
buffer [1.5 MTris, pH8.8], 4 mL 30%Acrylamide, 100 μL 10%SDS,
100 μL 10% APS, 4 μL TEMED) with agarose (0.5% agarose in gel
overlay buffer [0.375 M Tris HCl pH 8.8, 0.1% SDS]). The gel cast
was submerged with electrophoresis running buffer (12 g Tris,
57.6 g Glycine, 4 g SDS, 800 mL purified water) and an electrical
current of 20 mA applied for 10 min and then 60 mA for 1 h.
The resulting gels were stained using 0.2% Colloidal Coomassie
Brilliant Blue G250 for approximately two days, then de-stained
with purified water for up to one week.
Using protocols previously described [21–23] in-gel digestion
was undertaken to extract and cleave proteins for mass
spectrometry analyses. Spots were picked and placed in PCR
tubes (Tube 1). Theywerewashedwith 100 μL purifiedwater for
15 min, then destained twice with 150 μL 40 mM ammonium
carbonate (AC)/50% ACN for 30 min. Spots were dehydrated
using 200 μL ACN for 10 min, then digested overnight (8+ h)
with 10 μL of trypsin solution (10 ng/μL in 50 mMABC) at 37 °C.
The trypsin solution was transferred from Tube 1 to a 1.5 mL
Eppendorf tubes (Tube 2). The gel spot in tube 1 was washed
using 20 μL 1% FA for 20 min, then the solution was transferred
to Tube 2. The gel spot in tube 1 was washed with 20 μL of 5%
ACN/ 1% FA for 20 min, then transferred to Tube 2. Tube 2 was
centrifuged 14,000 RCF for 10 min and then the supernatant
collected for sequencing and identification, as described above.
2.4.3. Liquid chromatography–mass spectrometry/mass
spectrometry (LC–MS/MS)
Using protocols previously validated [21–23] mass spectrom-
etry analyseswere conducted in order to ascertain the identity of
proteins present in theN. kuhlii venomextract. Reduced alkylated
(RA) and trypsinised (Tryp) samples were prepared for each
venom protein extract. 6 μg of the extracted proteins was
aliquoted and vacuum-dried. The samples were reconstituted
with 50 μL of 10% ACN, incubated at 37 °C for 2 h with the RA
solution and lyophilised. The sampleswere then reconstituted in
50 μL of 40 mM ABC and separated into two 25 μL aliquots (RA
and Tryp). RA samples were dried overnight whilst Tryp samples
were incubated with 500 ng trypsin at 37 °C overnight and
lyophilised. The samples were reconstituted with 20 μL 2.5%
ACN and 1% FA and sequenced and identified, as described
above. Fullmass spectrometry sequencematch data is presented
in Supplementary File 2.
2.5. Phylogenetics
Proteomic hits identified as cystatins in the transcriptome
database were blasted against GenBank to identify putativened proteomic and transcriptomic investigation of fish venom
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gene homologues. The resulting sequences were supplemented
with (i) previously identified venom and non-venom cystatins
sourced from GenBank and (ii) sequence data from previous
studies that have described cystatin gene family evolution
[24–26]. The resulting amino acid sequence data was aligned
using theMUSCLEalgorithm [27] implemented inMEGA6 [28] and
a model of sequence evolution was selected by ModelGenerator
[29]. The resulting model (WAG + I + Γ) was implemented in
phylogenetic analyses using MrBayes v3.2 [30] on the CIPRES
Science Gateway (http://www.phylo.org/sub_sections/portal).
The cystatin gene tree was generated in duplicate using four
chains for 1 × 107 generations, sampling every 500th cycle from
the chain and using default settings in regard to priors. Tracer
v1.4 [31] was used to estimate effective sample sizes for all
parameters and to verify the point of convergence (burnin), with
trees generated prior to this point discarded. This process was
repeated for the hyaluronidase gene family following the
identification of a hyaluronidase-like gene in the venom gland
transcriptome of N. kuhlii and previous evidence of hyaluroni-
dases (and their enzymatic activity) being identified in fish
venoms [15,32–34].
2.6. Bioactivity testing
Ethical approval for experiments involving animalswas obtained
from the University of Queensland Animal Ethics Committee. All
experiments were conducted in accordance with the Animal
Care and Protection Regulation Qld (2012), the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes,
8th edition (2013) and the International Association for the Study
of Pain Guidelines for the Use of Animals in Research. Male
C57BL/6 mice (23–25 g) received an intraplantar injection of
ammonium sulphate precipitated venom (n = 3) or venom
additionally acetone-precipitated (n = 3) in a volume of 20 μl
under isoflurane (3%) anaesthesia. Paw erythema, swelling and
nocifensive behaviourwerequantifiedbyablindedobserver. Paw
thickness was measured using electronic callipers 1 h after
injection, and the number of paw lifts, licks and flinches were
counted in 5 min intervals immediately after injection for 1 h.Fig. 2 – 1D SDS-PAGE gel profile of N. kuhlii barb venom
protein extract at different stages of the protein cleanup
protocol. AMS = ammonium sulphate and AcOH = acetone.
The gel was stained with Colloidal Coomassie Brilliant Blue
G250.U
N
C
O3. Results and discussion
Despite the abundance of venomous species, the venoms of
fishes have received scant research attention, particularly
when compared with their squamate reptile counterparts
[2,6,25,35]. In part, fish venoms are neglected due to the
inherent nature of such samples, in that fish venoms are heat
labile, mucus rich and difficult to extract. To facilitate future
work on fish venom samples, we describe a novel methodol-
ogy to facilitate the extraction and processing of such samples
for proteomic investigation. Venom protein extractions were
cleaned and mucus removed using a multi-step protocol
consisting primarily of precipitation with ammonium sul-
phate and acetone. Samples of the extracted venom proteins
were taken after each of these steps to monitor the purity of
the sample. We compared the samples collected during the
cleanup process (post-ammonium sulphate precipitation and
post-acetone treatment) on a 1D SDS-PAGE gel (Fig. 2). It was
not possible to compare these samples with the initial proteinPlease cite this article as: Baumann K, et al, A ray of venom: Combi
composition using barb tissue from the blue-spot..., J Prot (2014), hR
O
O
F
extracted sample due to the extent of mucus contamination
initially present preventing protein migration through the gel.
Importantly, whilst the banding on the ammonium sulphate
precipitated sample was identical to the ammonium sulphate
and acetone precipitated sample, the banding on the acetone
precipitation sample was stronger than the sample that was
only ammonium sulphate precipitated, indicating a more
accurate nanodrop reading due to the removal of contami-
nants (Fig. 2).
We confirmed the retention of venom toxins during the
cleanup process by testing the bioactivity of samples in vivo. The
intraplantar injection of ammonium sulphate precipitated
venom (20 μg) elicited immediate erythema and significant paw
swelling (3.33 ± 0.25 mm) compared to the contralateral hind
paw (1.47 ± 0.07 mm). Venom additionally acetone-precipitated
retained activity and elicited edema in the ipsilateral (2.97 ±
0.27 mm) compared to the contralateral (1.50 ± 0.03 mm) paw,
although erythema was less pronounced. Mild nocifensive
responses, including spontaneous flinching, licking or lifting of
the hind paw, were observed for both crude (23.0 ± 6.1 flinches/
5 min) and acetone-precipitated venom (23.7 ± 8.7 flinches/
5 min). These results demonstrate that the acetone precipitatedned proteomic and transcriptomic investigation of fish venom
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venom retains bioactivity, thus indicating that denaturing is not
a significant issue during the cleanup protocol.
We subsequently analysed the venomcomposition ofN. kuhlii
using our cleaned venomprotein extract in a variety of proteomic
analyses, namely 1D and 2D SDS-PAGE gel electrophoresis (Fig. 3)
and shotgun sequencing — all coupled to LC–MS/MS. To
underpin the annotation of venom proteins detected by proteo-
mics, we generated a venom gland transcriptome for N. kuhlii.
Next generation sequencing of this transcriptome resulted in
2.95 million reads, representing 1.47 million read pairs, with a
mean read length of ~160 bp. The transcriptome assembly
resulted in 4584 contigs with an N50 of 602 bp. GO-term
annotations of the assembled transcriptome revealed a variety
of putative functions for the protein-encoding genes detected
(Fig. 4). Level 2 molecular functions were dominated by genes
associated with ‘binding’ and ‘catalytic activity’, with both
categories representing 79% of all annotated contigs (Fig. 4A).
Level 3 molecular functions were inherently more diverse,
although, notably, predicted protein functions such as ‘protein
binding’ and ‘hydrolase activity’ were well-represented (19%
and 7% respectively) (Fig. 4B).
We identified several protein types in the venom barb tissue
of N. kuhlii via the annotation of detected proteins against the
translated transcriptome database and the UniProt database
(Fig. 3 andTable 1). Theseproteins includedhaemoglobin subunit
alpha, cystatins, galectin, ganglioside GM2 activator, glutathione
S-transferase mu, leukocyte elastase inhibitor, transaldolase,
ATP synthase, peroxiredoxin 6, nucleoside diphosphate kinase
and type III intermediate filament. The relative abundance of the
genes encoding these proteins, as detected by the venom gland
transcriptome, are displayed in Fig. 4C. The protein composition
of N. kuhlii venom extract is therefore relatively complex, with
multiple proteins identified within single gel spots and bands in
many cases (Table 1). Notably, the vastmajority of these proteins
were identified by both the 1D and 2D gel methodologies, with
relatively few additional proteins detected by the shotgun
approach (Table 1). Whilst many protein types are clearly
associated with conserved functions related to structure, trans-
port andmetabolism, a number of other proteins likely represent
putative venom toxins.U
N
C
O
Fig. 3 – 1D and 2D SDS-PAGE gel profiles of N. kuhlii barb venom
bands that were selected for in-gel digestion and protein identifi
were selected for in-gel digestion and protein identification. The
The gels were stained with Colloidal Coomassie Brilliant Blue G2
Please cite this article as: Baumann K, et al, A ray of venom: Combi
composition using barb tissue from the blue-spot..., J Prot (2014), hE
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Wedetected the presence of a galectin in the venomextract of
N. kuhlii. The gene encoding this protein was highly expressed in
the venom gland transcriptome (52nd most abundant contig of
4584 and 2nd most abundant of those detected proteomically)
and represents 12% of the N. kuhlii venome (venom protein
composition) based on this transcriptomic data (Fig. 4C).
Galectins are lectins, which are broadly characterised as carbo-
hydrate binding proteins. Other lectin-scaffolds, specifically
C-type lectins, have been identified as toxic components in the
venoms of snakes, Lonomia caterpillars and the bony fish
Thalassophryne nattereri, where they exhibit diverse functions
including anticoagulant, procoagulant, platelet-modulating,
myotoxic and haemagglutination activities [36–38]. Whilst
galectins are structurally unrelated to C-type lectins, a number
of these proteins are apoptotic and pro- or anti-inflammatory
[39,40]. Galectins are one of only two cell death-inducing ligands
and function by binding to specific saccharide ligands located on
the cell surface of gylcoproteins or glycolipids to initiate cell
death [39]. The previously characterised functional activities of
galectins are therefore relevant to a potential toxic venom
function, particularly when considering that cell death is heavily
implicated as the primary cause of pain disproportionate to the
wound that characterises human envenomings by fishes [9].
Peroxiredoxin-6 (PRDX6)was another protein type of interest
identified in the venom extract of N. kuhlii. This protein was
encoded by a highly expressed transcript in the venom gland
(4th most abundant contig of those detected proteomically)
and, based on this expression data, represents 10% of the
N. kuhlii venome (Fig. 4C). Peroxiredoxins are an important family
of antioxidant enzymes that are ubiquitous in all organisms and
are implicated in the control of cytokine-induced peroxide levels
relevant to mediating cellular signal transduction [41]. Interest-
ingly, PRDX6 is a bifunctional protein with one of its main
functions resulting in the hydrolysis of lipids through phospho-
lipase A2 (PLA2) activity [42]. PLA2 enzymes have several known
scaffolds that have been independently recruited into the
venoms of different animals, including cephalopods, jellyfish,
scorpions and snakes, and the derived toxic functions of PLA2s
include antiplatelet,myotoxic andneurotoxic activities [1]. Thus,
similar to the PLA2 activity observed in other venoms, PRDX6protein extract. A) 1D SDS-PAGE gel profile highlighting the
cation. B) 2D SDS-PAGE gel profile highlighting the spots that
numbers in each gel refer to the proteins displayed in Table 1.
50.
ned proteomic and transcriptomic investigation of fish venom
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Fig. 4 – GO-term classification of the assembled and annotated N. kuhlii venom gland transcriptome. A) Level 2 and B) level 3
GO-term analysis of the annotated contigs. C) The relative abundance of proteins present in the N. kuhlii venome (venom
proteome) calculated by transcriptomic expression levels.
7J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 4 ) X X X – X X Xmay contribute to the toxic activity ofN. kuhlii venomand should
therefore be further investigated to characterise its functional
activity and role in stingray envenoming.
Cystatins are a large superfamily of proteins that are
potent inhibitors of cysteine proteinases, including papain
and the cathepsins [43]. Cystatins have previously been
identified in the venom of snakes and the spider Chilobrachys
jingzhao [44,45] and also in the saliva of haematophagus ticks
[46,47]. In snakes, their toxic role is ill defined, although
venom cystatins may inhibit the defensive enzymes of the
envenomed animal, thereby facilitating the toxic activity ofPlease cite this article as: Baumann K, et al, A ray of venom: Combi
composition using barb tissue from the blue-spot..., J Prot (2014), hother venom components [6]. Alternatively, cystatins may
interfere with clotting processes by inhibiting cathepsin
binding to components such as annexin-2, which ultimately
serve as cell surface receptors for tissue plasminogen activa-
tor, plasminogen and plasmin [48–50]. We identified two
cystatins in our proteomic analyses of N. kuhlii barb venom
extract which, when combined, account for 19% of the
venome based on the transcriptomic expression data
(Fig. 4C). Both cystatins were found to exhibit similarities to
cystatin B-like proteins isolated from other animals. Despite
their similar annotation, our phylogenetic analysis of thened proteomic and transcriptomic investigation of fish venom
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Table 1t1:1 – Protein types identified in the barb venom gland extract of N. kuhlii.
t1:23
t1:4 Protein type 1D bands 2D spots Shotgun UniProt match Known functions
t1:5 60S acidic ribosomal protein ✓ K4GJD9 Elongation in protein synthesis (UniProt)
t1:6 ATP synthase 5 1, 2, 3, 4, 6 ✓ Q9PTY0 Generating ATP [58]
t1:7 Coronin ✓ F1QDY7 Actin binding protein [59]
t1:8 Cystatin 9 6 ✓ Q28988, J7FQE8 Cysteine proteinase inhibition [43]
t1:9 Cytochrome C 9 ✓ Q6DKE1 Electron carrier activity (UniProt)
t1:10 Ferritin ✓ Q801J6 Important in iron homeostasis (UniProt)
t1:11 Galectin 1, 4, 5, 6, 7, 8, 9 3, 4, 6, 7 ✓ H2UTD9 Apoptotic, pro-/anti-inflammatory [39,40]
t1:12 Ganglioside GM2 activator 8 2, 3 ✓ K4FYQ1 Unknown activity
t1:13 Glutathione S-transferase mu 4, 5 Q9TSM5 Cellular detoxification [60]
t1:14 Haemoglobin subunit alpha 2, 4, 5, 6, 7, 8, 9 1, 2, 3, 4, 5, 7 ✓ P56691 Antimicrobial [61]
t1:15 Leukocyte elastase inhibitor 2, 3, 9 1 ✓ R0LF52 Inflammation [62]
t1:16 Nucleoside diphosphate kinase 7 ✓ G3HBD3 Regulatory functions [63]
t1:17 Peroxiredoxin 6 1 2, 3, 4 K4FY71 Antioxidant functions [64]
t1:18 Transaldolase 3 1 ✓ Q28H29 Glucose metabolism [65]
t1:19 Type III intermediate filament 9 1 ✓ P23729 Structural [66]
t1:20 Voltage-dependent anion
channel
4 ✓ Q9IA66 Diffusion of small hydrophilic molecules
(UniProt)
8 J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 4 ) X X X – X X Xcystatin gene family revealed that the two cystatins identified
in N. kuhlii venom are non-monophlyetic, and they are also
non-homologous to the cystatins previously recovered from
other venomous animals (Fig. 5). These results suggest that
cystatin genes have been recruited in parallel to the venom
gland ofN. kuhlii and on at least four occasions in all venomous
animals. Additional recruitment events seemingly account forU
N
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R
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T
Fig. 5 – Phylogenetic relationship of the cystatin gene family dem
in venom. Branches highlighted in red indicate cystatins that ha
animals (snake, spider and stingray) or the saliva of haematoph
different cystatins into the venom of N. kuhlii. Black circles repre
and grey circles Bpp of >0.95.
Please cite this article as: Baumann K, et al, A ray of venom: Combi
composition using barb tissue from the blue-spot..., J Prot (2014), hD
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Rthe presence of cystatins in the saliva of haematophagus ticks
(Fig. 5).
Notably, we did not detect any previously characterised fish
venomproteins (e.g. natterin, nattectin, stonustoxin [38,51,52]) in
our proteomic or transcriptomic analyses. These results are
perhaps unsurprising considering (i) the phylogenetic distance
between N. kuhlii and the bony fishes from which these toxinsE
onstrating the parallel recruitment of these proteins for a role
ve been recovered from the venom glands of venomous
agus animals (tick). Note the apparent parallel recruitment of
sent nodes with Bayesian posterior probabilities (Bpp) of 1.00
ned proteomic and transcriptomic investigation of fish venom
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9J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 4 ) X X X – X X Xhave previously been identified and (ii) the likely independent
evolution of the venomsystems of cartilaginous and bony fishes.
Perhaps more surprising was the absence of hyaluronidase and
the small toxic peptides orpotrin and porflan in our N. kuhlii
venom extract. These proteins/peptides were previously molec-
ularly characterised (or in the case of hyaluronidase, its activity
detected) in the venom of freshwater Potamotrygon stingrays
[15–17]. Whilst we did not detect genes encoding orpotrin- or
porflan-like peptides in the N. kuhlii venom gland transcriptome
(or venom proteome), we did identify a hyaluronidase-like gene
expressed in the venom gland of N. kuhlii; although the corre-
spondingproteinwasabsent fromthevenomproteome.However,
phylogenetic analysis of the N. kuhlii hyaluronidase-like gene
revealed that it was non-monophyletic to hyaluronidases previ-
ously molecularly characterised from fish venoms [32–34] (Fig. 6).
These results suggest that thedetectedN. kuhliihyaluronidase-like
gene is not a venomcomponent, and therefore explain its absence
from the venom proteome. Further validating these results is the
previously described absence of hyaluronidase activity in venom
extracts isolated from the marine stingray Dasyatis guttata [53], a
species which, until recently, was viewed as congeneric with
N. kuhlii [54]. This data suggests that inter-specific variation in
toxin composition, as observed in other venomous taxa [55–57]
also exists between different stingrays. Such variationmay be the
result of (i) the unique recruitment of some toxin types into the
venomof some species, (ii) the loss of toxin types from the venom
of some species, or (iii) potentially as the result of the independent
evolution of venom systems in different stingray lineages.U
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Fig. 6 – Phylogenetic relationship of the hyaluronidase gene fami
gland transcript is paralogous to previously characterised hyalru
indicate hyaluronidases that have been recovered from the veno
circles represent nodes with Bayesian posterior probabilities (Bp
Please cite this article as: Baumann K, et al, A ray of venom: Combi
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Our study represents the first broad characterisation of the
venom composition of a cartilaginous fish and the first
combined proteomic and transcriptomic study of the venom
of any fish. We describe and utilise a novel protein extraction
methodology that overcomesmany of the undesirable aspects
of studying fish venom and will hopefully enable research on
such animals to join contemporary scientific circles. The
identification of a variety of proteins that are novel to venom
highlights the untapped potential of fish venoms and their
toxins, and therefore such samples may be valuable for future
biodiscovery projects. We next intend to apply the approach
utilised here to different fish lineages to investigate the
evolutionary history and composition of venom found in
these understudied venomous vertebrates.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jprot.2014.06.004.E
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